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Background: Recombinant human growth hormone 
(rhGH) is licensed for short stature associated with 
growth hormone deficiency (GHD), Turner syndrome 
(TS), Prader–Willi syndrome (PWS), chronic renal 
insufficiency (CRI), short stature homeobox-containing 
gene deficiency (SHOX-D) and being born small for 
gestational age (SGA).
Objectives: To assess the clinical effectiveness and 
cost-effectiveness of rhGH compared with treatment 
strategies without rhGH for children with GHD, TS, 
PWS, CRI, SHOX-D and those born SGA.
Data sources: The systematic review used a 
priori methods. Key databases were searched (e.g. 
MEDLINE, EMBASE, NHS Economic Evaluation 
Database and eight others) for relevant studies from 
their inception to June 2009. A decision-analytical 
model was developed to determine cost-effectiveness 
in the UK.
Study selection: Two reviewers assessed titles and 
abstracts of studies identified by the search strategy, 
obtained the full text of relevant papers, and screened 
them against inclusion criteria. 
Study appraisal: Data from included studies were 
extracted by one reviewer and checked by a second. 
Quality of included studies was assessed using standard 
criteria, applied by one reviewer and checked by a 
second. Clinical effectiveness studies were synthesised 
through a narrative review.
Results: Twenty-eight randomised controlled 
trials (RCTs) in 34 publications were included in the 
systematic review. GHD: Children in the rhGH group 
grew 2.7 cm/year faster than untreated children and 
had a statistically significantly higher height standard 
deviation score (HtSDS) after 1 year: –2.3 ± 0.45 
versus –2.8 ± 0.45. TS: In one study, treated girls 
grew 9.3 cm more than untreated girls. In a study of 
younger children, the difference was 7.6 cm after 2 
years. HtSDS values were statistically significantly 
higher in treated girls. PWS: Infants receiving rhGH 
for 1 year grew significantly taller (6.2 cm more) than 
those untreated. Two studies reported a statistically 
significant difference in HtSDS in favour of rhGH. 
CRI: rhGH-treated children in a 1-year study grew an 
average of 3.6 cm more than untreated children. HtSDS 
was statistically significantly higher in treated children 
in two studies. SGA: Criteria were amended to include 
children of 3+ years with no catch-up growth, with 
no reference to mid-parental height. Only one of the 
RCTs used the licensed dose; the others used higher 
doses. Adult height (AH) was approximately 4 cm 
higher in rhGH-treated patients in the one study 
to report this outcome, and AH-gain SDS was also 
statistically significantly higher in this group. Mean 
HtSDS was higher in treated than untreated patients 
in four other studies (significant in two). SHOX-D: 
After 2 years’ treatment, children were approximately 
6 cm taller than the control group and HtSDS was 
statistically significantly higher in treated children. The 
incremental cost per quality adjusted life-year (QALY) 
estimates of rhGH compared with no treatment were: 
£23,196 for GHD, £39,460 for TS, £135,311 for PWS, 
£39,273 for CRI, £33,079 for SGA and £40,531 for 
SHOX-D. The probability of treatment of each of the 
conditions being cost-effective at £30,000 was: 95% for 
GHD, 19% for TS, 1% for PWS, 16% for CRI, 38% for 
SGA and 15% for SHOX-D.
Limitations: Generally poorly reported studies, 
some of short duration.
Conclusions: Statistically significantly larger HtSDS 
values were reported for rhGH-treated children with 
GHD, TS, PWS, CRI, SGA and SHOX-D. rhGH-
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treated children with PWS also showed statistically 
significant improvements in body composition 
measures. Only treatment of GHD would be 
considered cost-effective at a willingness-to-pay 
threshold of £20,000–30,000 per QALY gained. This 
analysis suggests future research should include studies 
of longer than 2 years reporting near-final height or 
final adult height.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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AE adverse event
AH adult height
AUC area under the curve
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BMC bone mineral content
BMI body mass index (kg/m2)
BNF British National Formulary
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BSPED British Society for Paediatric 
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CA chronological age
CADTH Canadian Agency for Drugs 
and Technologies in Health
CDSR Cochrane Database of 
Systematic Reviews
CEA cost-effectiveness analysis
CEAC cost-effectiveness acceptability 
curve
CGHAC Canadian Growth Hormone 
Advisory Committee
CI confidence interval
CKD chronic kidney disease
CO-GHD childhood-onset growth 
hormone deficiency
CRF chronic renal failure
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CUA cost–utility analysis
DARE Database of Abstracts of 
Reviews of Effectiveness
DEC Development and Evaluation 
Committee
DEXA dual-energy X-ray 
absorptiometry
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GFR glomerular filtration rate
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GV growth velocity (generally cm/
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GVSDS growth velocity standard 
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velocity relative to 
distribution of growth 
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chronological age (or bone 
age if specified)
HDL-C high-density lipoprotein 
cholesterol
HRG Healthcare Resource Group
HRQoL health-related quality of life
HTA Health Technology 
Assessment
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HtSDS height standard deviation 
score – height relative 
to distribution of height 
in children of the same 
chronological age (or bone 
age if specified)
HV height velocity
HVSDS Height Velocity Standard 
Deviation Score
ICER incremental cost-effectiveness 
ratio
IGF insulin-like growth factor
IGFBP insulin-like growth factor 
building proteins
IQR interquartile range
ISPOR International Society for 
Pharmacoeconomics and 
Outcomes Research
ISS idiopathic short stature
ITT intention to treat
IU international unit 
(3 IU = 1 mg)
IUGR intrauterine growth 
restriction/retardation
KDOQI Kidney Disease Outcomes 
Quality Initiative
KIGS Kabi International Growth 
Study Database (now Pfizer)
KIMS Kabi International Metabolic 
Study Database (now Pfizer)
LBM lean body mass
LDL low-density lipoprotein
LWS Léri–Weill syndrome
m2 square metres (in this context 
referring to body surface 
area)
met-GH methionyl growth hormone
mg milligram
MPHD multiple pituitary hormone 
deficiency
MS manufacturer’s submission
MTA multiple technology appraisal
NCHS National Centre for Health 
Statistics
NFH near-final height – height 
measured when growth 
is assumed to be near 
completion
NHS CRD National Health Service 
Centre for Reviews and 
Dissemination
NHS EED National Health Service 
Economic Evaluation 
Database
NICE National Institute for Health 
and Clinical Excellence
NKF National Kidney Foundation
nr not reported
ns not statistically significant
OLS ordinary least squares
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extrapolating adult height 
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Pla placebo
PSA probabilistic sensitivity 
analysis
PSS Personal Social Services
PWS Prader–Willi syndrome
QALY quality-adjusted life-year
QoL quality of life
QoL-AGHDA quality of life assessment of 
growth hormone deficiency in 
adults
QoL-
AGHDAUTILITY
utility-weighted score
RCT randomised controlled trial
rhGH recombinant human growth 
hormone
SAE serious adverse event
SAR-SR Social Adjustment Scale-self 
rating
s.c. subcutaneous
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SD standard deviation
SDS standard deviation score
SF-36 Short Form questionnaire-36 
items
SG standard gamble
SGA small for gestational age
SHOX short stature homeobox-
containing gene
SHOX-D short stature homeobox-
containing gene deficiency
SHTAC Southampton Health 
Technology Assessments 
Centre
SMR standardised mortality rate
TS Turner syndrome
TTO time trade-off
U unit
WtSDS weight standard deviation 
score
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Background
Recombinant human growth hormone (rhGH) 
is licensed for short stature that is associated 
with growth hormone deficiency (GHD), Turner 
syndrome (TS), Prader–Willi syndrome (PWS), 
chronic renal insufficiency (CRI), short stature 
homeobox-containing gene deficiency (SHOX-D) 
and being born small for gestational age (SGA). 
The National Institute for Health and Clinical 
Excellence (NICE) guidance currently recommends 
rhGH treatment for children with GHD, TS, PWS 
or CRI, but does not cover SGA or SHOX-D.
Objectives
The aim of this report was to assess the clinical 
effectiveness and cost-effectiveness of rhGH 
compared with treatment strategies without rhGH 
for children with GHD, TS, PWS, CRI, SHOX-D 
and those born SGA. The report extends the 
previous review by actively searching for studies 
that report growth outcomes, body composition, 
biochemical markers or quality of life (QoL).
Methods
Data sources
The systematic review of clinical effectiveness 
used a priori methods that are described in the 
research protocol. We searched key databases (e.g. 
MEDLINE, EMBASE, NHS Economic Evaluation 
Database and eight others) for relevant studies 
from their inception to June 2009, limiting to 
the English language. Relevant conferences, 
bibliographies of included papers, our expert 
advisory group and manufacturers’ submissions 
(MSs) to NICE were also consulted to identify any 
additional published or unpublished references. 
We developed an economic model using the best 
available evidence to determine cost-effectiveness 
in the UK.
Study selection
Two reviewers assessed titles and abstracts of 
studies identified by the search strategy, obtained 
the full text of relevant papers, and screened 
them against the inclusion criteria as defined in 
the research protocol. Any differences in opinion 
throughout the process were resolved through 
discussion.
Key inclusion criteria were:
•  patients  children with GHD, TS, PWS, CRI, 
SHOX-D or born SGA
•  treatment  rhGH
•  comparator  treatment strategies without 
somatropin
•  outcomes  height, height standard deviation 
score (HtSDS), growth velocity (GV) and SDS, 
body composition, biochemical markers, QoL, 
adverse events (AEs)
•  study type  randomised controlled trials (RCTs), 
systematic reviews.
Data extraction and quality 
assessment
Data from included studies were extracted by one 
reviewer and checked by a second. The quality 
of included studies was assessed using standard 
criteria. Criteria were applied by one reviewer and 
checked by a second, with differences in opinion 
resolved by discussion and involvement of a third 
reviewer where necessary.
Data synthesis
Clinical effectiveness studies were synthesised 
through a narrative review, with tabulation of 
results of included studies. Meta-analysis was not 
appropriate due to heterogeneity of study design 
and participants.
Economic model
A decision-analytical model was developed 
to estimate the cost-effectiveness of rhGH 
treatment compared with no treatment for a 
cohort of children with GHD, TS, PWS, SGA, 
CRI and SHOX-D. The model was based upon 
that developed in a previous Health Technology 
Assessment (HTA) report but was extended by 
including QoL factors. The perspective of the 
Executive summaryExecutive summary
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analysis was that of the UK NHS and Personal 
Social Services (PSS). The model was informed 
by a systematic search of the literature to 
identify parameters on the natural history and 
epidemiology of the indicated conditions, health-
related quality of life (HRQoL) and costs. The 
model estimated the lifetime costs and benefits of 
rhGH with discount rates of 3.5%. The intervention 
effect in terms of improvement of HtSDS was 
derived from the systematic review of effectiveness. 
The outcome of the economic evaluation is 
reported as cost per quality-adjusted life-year 
(QALY) gained and cost per centimetre gained.
Results
Number and quality of studies
Of the 674 references identified, 560 were excluded 
on inspection of their titles and abstracts. The full 
papers of 114 references were retrieved, of which 
28 RCTs in 34 publications were included in the 
systematic review of clinical effectiveness. Overall, 
the studies were generally poorly reported and 
some were of short duration.
Summary of benefits and risks
None of the studies reported QoL measures, and 
reporting of AEs was limited. Only one of the 
included studies reported adult height (AH).
Growth hormone deficiency 
(one RCT)
Children in the rhGH group grew 2.7 cm/year 
faster than children in the untreated group and 
had a statistically significantly higher HtSDS after 
1 year: –2.3 ± 0.45 versus –2.8 ± 0.45.
Turner syndrome (six RCTs)
Girls in one study grew an average of 9.3 cm 
more than untreated girls. In a study of younger 
children, the difference was 7.6 cm after 2 years. 
HtSDS values were statistically significantly higher 
in treated than in untreated girls.
Prader–Willi (eight RCTs)
Infants who received rhGH for 1 year grew 
significantly taller (6.2 cm more) than those in the 
untreated group in the only study to report change 
in height. Two studies reported a statistically 
significant difference in HtSDS in favour of rhGH. 
rhGH-treated patients had statistically significantly 
higher lean body mass (LBM) and lower body fat 
than untreated patients in three studies. Effects on 
body mass index (BMI) were mixed.
Chronic renal insufficiency (six 
RCTs)
Recombinant human growth hormone-treated 
children in a 1-year study grew an average of 
3.6 cm more than untreated children. HtSDS was 
statistically significantly higher in treated than in 
untreated children in two studies.
Small for gestational age (six 
RCTs)
No RCTs met the original inclusion criteria for 
the review, so these were amended to include 
children from the age of 3 years with no catch-up 
growth, with no reference to mid-parental height. 
Only one out of the six included RCTs used the 
licensed dose; the others used doses two or three 
times higher. AH was approximately 4 cm higher 
in rhGH-treated people in the only study to report 
this outcome. AH-gain SDS was also statistically 
significantly higher in this study’s rhGH group. 
Mean HtSDS was higher in treated than untreated 
patients in four other studies, significantly so in two 
of these.
SHOX deficiency (one RCT)
After 2 years of treatment, children were 
approximately 6 cm taller than the control group 
and HtSDS was statistically significantly higher in 
treated than in untreated patients.
Summary of cost-effectiveness
The systematic review of published economic 
evaluations identified two North American studies 
for children with TS and GHD and no studies 
conducted in the UK. The results of the two 
identified studies produced two very different 
estimates of cost-effectiveness, largely due to the 
choice of utility estimates and assumptions on 
effectiveness.
The systematic review of QoL identified only six 
studies, mostly of poor methodological quality and 
for small numbers of individuals. One reasonable 
study was found for GHD. An additional study 
was found, which estimated QoL utilities in the 
general adult population according to height, 
using the Health Survey for England. These studies 
suggested that there is likely to be a small gain in 
utility from rhGH.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Six of the seven manufacturers submitted evidence 
to be considered for this review. Five out of the 
six manufacturers collaborated and submitted 
essentially the same electronic model. The model 
developed was based upon the previous HTA 
report but was extended to consider longer-term 
outcomes in order to estimate cost-effectiveness in 
terms of QALYs. In the manufacturers’ base case, 
the cost-effectiveness results for all conditions were 
less than £30,000 per QALY gained.
From the model we developed for this review, the 
incremental cost per QALY estimates of rhGH 
compared to no treatment were: £23,196 for GHD, 
£39,460 for TS, £135,311 for PWS, £39,273 for 
CRI, £33,079 for SGA and £40,531 for SHOX-D. 
A further analysis was run for PWS, which included 
a lifelong improvement in body composition 
of 1.8 BMI and an associated additional utility 
of 0.031. Under these assumptions, the cost-
effectiveness of PWS reduced to £54,800 per QALY 
gained.
The effects of a range of parameter values for 
the economic model were evaluated in sensitivity 
analyses. The model results were found to be most 
sensitive to the discount rate used. All conditions, 
except PWS, were cost-effective for a willingness-
to-pay threshold of £30,000 per QALY when the 
previous NICE discount rates of 6% for costs and 
1.5% for benefits were used. The model results are 
also sensitive to treatment start age and length, 
compliance and utility gain. The probability 
sensitivity analysis (PSA) estimated the probability 
of each of the conditions to be cost-effective at 
£30,000 to be: 95% for GHD, 19% for TS, 1% 
for PWS, 16% for CRI, 38% for SGA and 15% for 
SHOX-D.
Discussion
The systematic review was restricted to RCTs 
because these provide the highest level of evidence 
for clinical effectiveness. However, very few of 
these reported either final height (FH) or QoL as 
outcome measures, most were only 1 or 2 years in 
length, and some had very few participants. We 
did not identify any RCTs that met the original 
inclusion criteria for children born SGA, so these 
had to be amended. Only one of the included 
trials used the licensed dose, so results from the 
other five could overstate the effectiveness of rhGH 
treatment for this patient group.
The QoL gains were highest for individuals with 
lower starting heights; for those with starting 
height of less than < –2 HtSDS the QoL gain 
was minimal. For example, those with PWS had 
a starting height of –2 HtSDS, and so for this 
group of patients the health gain (in terms of 
height) is small; therefore, rhGH treatment has 
high incremental cost-effectiveness ratio (ICER) 
values compared with no treatment. Patients with 
PWS may experience an improvement in body 
composition due to rhGH treatment, and this is 
often the point of treatment rather than gain in 
height, but this was difficult to quantify, especially 
in the long term.
The cost-effectiveness results in the current report 
varied from those in the MS and the previous 
HTA report. The incremental costs reported are 
generally consistent between the three models. 
In general, the results, presented in terms of 
centimetres gained, are more favourable in the 
current analyses than in those in the previous HTA 
report. The ICERs in the MS are considerably more 
favourable than the current analysis, due to higher 
estimates of utility gain.
The current analysis has not considered other 
benefits in addition to height gain within the 
model, apart from as a scenario analysis for PWS. 
The base case does not include possible benefits 
from changes in body composition, such as 
reduced risk of diabetes or cardiovascular disease, 
which may result in increases in life expectancy. 
At this stage, these health gains would be purely 
speculative due to lack of data, and it is not 
possible to quantify them. It is also possible that 
there may be additional psychological benefits such 
as improved self-esteem.
Conclusions
The included studies reported statistically 
significantly larger HtSDS values for rhGH-
treated children than untreated children with 
GHD, TS, PWS, CRI, SGA and SHOX-D. 
rhGH-treated children with PWS also showed 
statistically significant improvements in body 
composition measures compared with controls. 
The cost-effectiveness estimates from our model 
vary between conditions. Only GHD would be 
considered cost-effective according to a willingness-
to-pay threshold of £20,000–30,000 per QALY 
gained. TS, CRI, SGA and SHOX-D have 
ICERs between £33,000 and £40,500 per QALY 
gained. PWS has an ICER of between £55,000 
and £135,000 per QALY gained, depending on 
assumptions.Executive summary
xiv
Key research priorities
•  Longer studies beyond 2 years, reporting near-
FH or final AH.
•  A standardised QoL assessment specifically 
designed for children and adults, to be used in 
future RCTs and QoL studies.
•  Good-quality trials of rhGH in children born 
SGA, where the children included and the dose 
administered match the licensing criteria.
•  Good-quality studies of the long-term effects 
of rhGH on body composition, psychological 
benefits, long-term morbidities (such as 
diabetes or cardiovascular disease) and life 
expectancy, particularly for individuals with 
PWS.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Description of health 
problem
The first part of the chapter (see sections Growth 
hormone deficiency to Small for gestational age) 
describes the health problem individually for the 
different conditions covered in this review, in terms 
of their aetiology and epidemiology. The second 
part of the chapter (see sections Impact of health 
problem to Current usage in the NHS) covers the 
impact of the health problems and measurement of 
disease for all the conditions combined.
Growth hormone deficiency
Growth hormone deficiency (GHD) occurs when 
the pituitary gland fails to produce sufficient levels 
of growth hormone (GH).
There is some debate about the diagnostic criteria 
for GHD: the diagnosis of GHD includes short 
stature, growth velocity (GV) below the 25th 
percentile for at least 1 year, and delayed bone 
age.1 Rosenfeld2 suggests other criteria: height 
> 3 standard deviations (SDs) below the mean, 
< –2 SD to –3 SD for age and deceleration in 
growth (such as GV < 25th percentile for age), 
GV < 5th percentile where there is no other 
explanation, a predisposing condition along with 
growth deceleration or other signs of pituitary 
dysfunction. Juul and colleagues3 found ‘large 
heterogeneity in the current practice of diagnosis 
and treatment of childhood GHD’. Their survey 
of European paediatricians found that the cut-off 
points of GH peak response used for diagnosis of 
deficiency clustered around 10 ng/ml or 20 mU/l.
The primary goals of recombinant human growth 
hormone (rhGH) treatment for children with 
GHD are to normalise height during childhood, 
for the treated child to reach a ‘normal’ adult 
height (AH) as defined by the parental target and 
for mature somatic development to be reached 
around age 25.4 The British Society for Paediatric 
Endocrinology and Diabetes (BSPED) recommends 
3- or 6-monthly growth monitoring, annual insulin-
like growth factor-1 (IGF-1)/ insulin-like growth 
factor building protein-3 (IGFBP-3) monitoring, 
and compliance assessment at each appointment.5
Aetiology, pathology and prognosis
Growth hormone deficiency can be caused 
by a variety of factors, but in many cases the 
cause is unknown. In some children, failure or 
reduction in GH secretion is congenital, and 
may be accompanied by other pituitary hormone 
deficiencies. In others, GHD is acquired as a result 
of trauma (either at birth or later in childhood), 
histiocytic infiltration (build up of tissue cells), 
lymphoma or leukaemia, tumours involving the 
pituitary gland or hypothalamus or following 
radiotherapy.6 Untreated patients have a final 
height (FH) of 134–146 cm in males and 128–
134 cm in females.1
Incidence and prevalence
The UK Child Growth Foundation estimates 
that GHD of unknown origin occurs in about 
one in every 3800 births,7 but reliable figures are 
difficult to obtain for GHD that is associated with 
radiotherapy and other causes. Figures from a 
study in Belgium8 indicate an overall prevalence 
of GHD of 1 in 5600. The origin of GHD was 
stated to be unknown in 41% of the patients in 
this Belgian study, congenital in 20% and acquired 
in 35%.8 While the authors of this study state that 
these yearly numbers have remained similar across 
the 16 years of the study, these were not collected 
as part of a formal screening study, and, as a result, 
the study authors believe that this figure is an 
underestimation.8
A Danish study calculated incidence rates of 
childhood-onset growth hormone deficiency (CO-
GHD), based on 1823 patients incident during 
1980–99. The average incidences per 100,000 
population were calculated to be 2.58 [95% 
confidence interval (CI) 2.3 to 2.88] for males, 
and 1.70 (95% CI 1.48 to 196) for females. The 
differences between the sexes was statistically 
significant (p < 0.001).9 Other sources suggest that 
the disorder is two to three times more common 
in boys than in girls.7 A hereditary factor may be 
identified in some children; about 3% of children 
with GHD also have an affected sibling.7
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Turner syndrome
Aetiology, pathology and prognosis
Turner syndrome (TS) is caused by the complete 
or partial absence of the second sex chromosome 
in girls, with or without cell line mosaicism 
(the presence of two populations of cells with 
different genotypes in one individual), leading 
to the presence of characteristic physical 
features including, but not limited to, short 
stature.10,11 Other features of TS can include 
skeletal abnormalities, higher risk of scoliosis, 
cardiovascular abnormalities, lymphoedema, 
and higher rates of hearing problems and ear 
malformations.11
While short stature is the most common clinical 
feature of TS,11 in the majority of girls with TS 
the missing or abnormal second chromosome 
causes ovarian failure, leading to lack of pubertal 
progression and sexual maturation. TS girls 
therefore receive estrogen replacement therapy as 
part of their treatment.
Untreated, the average AH deficit in women with 
TS is 20 cm, with the average height being 143 cm 
(4 ft 8 in.).12 Cases of reduced stature are thought to 
be predominantly due to haploinsufficiency of the 
short stature homebox-containing (SHOX) gene.13 
Not all girls with TS will require rhGH treatment 
and the condition does not necessarily involve a 
deficiency in natural GH secretion, although there 
may be a relative lack of sensitivity to GH, and, in 
some cases, diminished secretion.6,14
Incidence and prevalence
The European Surveillance of Congenital 
Abnormalities (EUROCAT) reported in 2003 that 
TS occurred in 2.08 per 10,000 births in the UK 
in 2002,15 which equates to approximately one in 
2500 live-born females.11 A Belgian study analysed 
age at diagnosis of 242 TS girls who were treated 
with rhGH between 1991 and 2002.16 The median 
age at diagnosis was 6.6 (range 0–18.3) years. 
Although the survey found that 22% of girls were 
diagnosed after the age of 12 years, there was a 
general increase in earlier diagnosis in infancy and 
childhood compared with a previous survey.
A study in Denmark17 identified a standardised 
mortality rate (SMR) of 2.89 in their TS 
population, which was increased compared with 
the general population. However, this significantly 
decreased over the 3 years of the study. It is unclear 
if this is due to a real decrease in mortality, better 
care of individuals with TS, or an increase in 
karyotypes with lower mortality.17
Prader–Willi syndrome
Prader–Willi syndrome (PWS) is a genetic disorder 
characterised by short stature, abnormal body 
composition, hypogonadism, obesity, dysmorphic 
features, hyperphagia (compulsive overeating), 
hypotonia (diminished muscle tone), and specific 
learning and behavioural issues.18
Aetiology, pathology and prognosis
The genetic basis of the syndrome is a deletion 
on the long arm of the paternally derived 
chromosome 15 (15q11-q13), which is found in 
approximately 70% of affected individuals.19 Other 
abnormalities have been identified, including 
maternal uniparental disomy (two maternal copies 
of chromosome 15 and no paternal chromosome 
15), imprinting mutations and translocations. 
Abnormalities to chromosome 15 lead to 
disruption of the hypothalamus, which controls 
appetite. The combination of impaired growth, 
abnormal body composition and hypothalamic 
dysfunction (hyperphagia, hypogonadism) is 
suggestive of GHD.
Birth length and weight are normal or just below 
normal in PWS, but growth is slow due to poor 
feeding. The child is noticeably short from around 
the first year of life and remains short throughout 
childhood [mean height standard deviation 
score (HtSDS) –2] despite normal growth rate.20 
Hypotonia at birth improves towards the end of 
the first year of life, and developmental milestones 
are achieved although delayed. By 2 or 3 years of 
age the hyperphagic phase of the condition begins, 
and, unless eating is controlled, the child will 
become obese.18
Behavioural features include food seeking, temper 
tantrums, obsessive–compulsive disorders, high 
pain threshold, sleep disturbances, and skin 
picking. Learning disabilities are always present to 
some degree.20 Hypogonadism causes delayed but 
complete puberty in females, although menses are 
infrequent or absent. Males have cryptorchidism 
(undescended testis) at birth and usually require 
androgen replacement therapy from mid-puberty, 
even after successful orchidopexy.18
During adolescence, the growth rate declines 
as a result of the absence of pubertal growth 
spurt. Reported mean FHs in the UK are 155 cm 
(–3.2 SD) for males and 147 cm (–2.8 SD) for 
females.21 Body composition shows increased fat 
mass (FM) and reduced fat-free mass, resulting 
in a high fat–lean body mass (LBM) ratio, even 
in children with normal weight–height ratios. DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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In addition, bone mineral density is reduced. 
The reduced bone density is multifactorial; in 
older patients this is due to sex steroid deficiency 
(hypogonadism), whereas in younger patients 
this is due to hypotonia, which responds to rhGH 
therapy.22
The prognosis of the condition in adulthood can 
be reasonable if the person can find occupation 
and can live in an environment where access to 
food can be controlled. However, many adults 
with the disorder develop morbid obesity, often 
accompanied by type 2 diabetes, resulting in 
premature death from cardiorespiratory failure.18
Incidence and prevalence
One UK study estimated a birth incidence for PWS 
of 1 : 20,000, with a lower bound of 1 : 29,000.23 
The study gave a population prevalence of 
1 : 52,000, considered the lower bound, with county 
rates varying from 1 : 42,000 to 1 : 67,000.23 The 
overall death rate for the PWS population aged 
3.4–56 years was found to be around 3% in one 
UK study compared with the standard death rate 
of about 0.3% each year for people in England and 
Wales up to the age of 55 years.23
Chronic renal insufficiency
Chronic renal insufficiency (CRI) is defined as a 
persistent elevation of serum creatinine and/or urea 
level. It can be caused by a variety of conditions, 
including congenital disorders, glomerular 
disorders and infections. Growth failure associated 
with CRI can be caused by acidosis, rickets, GH 
resistance, inadequate nutrition and anorexia.24 
Children with CRI experience impaired growth 
once their glomerular filtration rate (GFR) falls 
to 50% of normal, with increasing problems once 
the GFR falls below 25%.25 Following kidney 
transplantation, chronic graft rejection and 
treatment with steroids can restrict growth and 
development.26 Patients undergoing haemodialysis 
or peritoneal dialysis can be considered for rhGH 
treatment, as well as those who have received 
kidney transplantations.
Aetiology, pathology and prognosis
Chronic renal insufficiency is characterised by a 
GFR of < 75 ml/min per 1.73 m2 of body surface 
area (BSA).27 The term chronic kidney disease (CKD) 
is also sometimes used,27 following guidelines 
developed by the National Kidney Foundation 
(NKF) Kidney Disease Outcomes Quality Initiative 
(KDOQI).28
The aetiology of growth failure in children with 
CRI includes abnormalities in the GH-IGF-1 axis, 
together with nutritional and metabolic problems.27 
Nutritional supplementation in malnourished 
children with CRI can improve growth.29–31 
The NKF KDOQI guidelines recommend that 
patients’ existing nutritional deficiencies and 
metabolic abnormalities should be corrected before 
considering treatment with rhGH.32 However, it is 
estimated that growth remains suboptimal, even 
with energy intake above 80% of the recommended 
daily allowance.33
Not all patients with CRI will be shorter than 
average, but figures from the UK Renal Registry 
indicate that 29% of transplant patients and 41% 
of dialysis patients are below the second percentile 
for height.34 Children with congenital disorders 
(approximately 60% of children with CRI)26 are 
usually of normal length at birth, but are below the 
3rd percentile for height within their first year and 
remain parallel to normal percentiles throughout 
childhood.26 A cohort study of CRI patients who 
grew up before rhGH treatment was available 
reported that more than two-thirds remained 
shorter than the average population.35 One study 
reported a mean height from birth to age 10, which 
was –2.37 SD ± 1.6 below the mean.26 Similarly, 
FH is reported to be reduced to below the 3rd 
percentile in patients who developed end-stage 
renal failure (ESRF) in childhood.26 Adult FH was 
more than 2 SDs below the mean for approximately 
60% of boys and 41% of girls who started renal 
replacement therapy before they were 15 years 
old.36
Incidence and prevalence
It is difficult to find accurate figures for CRI, and 
these do not appear to be available nationally. 
The UK Renal Registry reports an incidence of 
established renal failure (ERF) of 8.0 per million 
of the population who are under the age of 
15 years.37 However, ERF is more severe than CRI, 
so can really serve only as a guide to the minimum 
number of patients for whom rhGH might be 
appropriate.
The UK Renal Registry reported that in 2005 
there were 748 patients under the age of 18 years 
who were on renal replacement therapy in the 
UK’s 13 paediatric renal centres,34 corresponding 
to a prevalence of 47.7 per million.37 However, 
the number of patients with CRI will be higher 
than this, as not all will require renal replacement Background
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therapy. ERF is reported to be more common 
in males than in females (ratio 1.54 : 1), due to 
the prevalence of males with renal dysplasia and 
obstructive uropathy causing ERF.37
Small for gestational age
There are various thresholds for defining a child 
as being born ‘small for gestational age’ (SGA), the 
most commonly used being where the birth height 
or weight is ≤ 2 SDs below the population average, 
or is below the 10th centile for birthweight.38 
However, this group is heterogeneous in 
composition. Between 50% and 70% of these babies 
are ‘constitutionally small’ but otherwise healthy. 
The other babies in the group are those who have 
not reached their height or weight potential, 
having possibly experienced fetal growth restriction 
(FGR).38 For this reason, the terms intrauterine 
growth restriction/retardation (IUGR) and SGA 
are not synonymous: a child born SGA has not 
necessarily undergone IUGR or FGR, and a child 
who has IUGR or FGR may not necessarily be born 
SGA.
Aetiology, pathology and prognosis
There are several possible causes for children being 
born SGA. These include maternal factors (such 
as age, ethnicity, weight, height, parity, medical 
conditions, smoking, malnutrition and alcohol 
abuse), placental factors, and fetal factors (such as 
chromosomal abnormalities and genetic defects).39 
Children classified as SGA may have concurrent 
diagnoses, such as familial short stature, TS, GHD 
or skeletal dysplasia.39
More than 80% of babies born SGA will achieve 
catch-up growth (GV greater than the median 
for chronological age and gender39) during their 
first 6 months,40 with catch-up growth completed 
within 2 years for most SGA infants.41,42 However, 
babies born prematurely who are SGA may take 
around 4 years to achieve catch-up growth.43 
Around 50% of the children who do not experience 
catch-up growth at this stage will go on to achieve 
their target height. It has been estimated that 
approximately 10% of SGA children remain at a 
height below –2 SD throughout their childhood.44,45 
Children who are born SGA with low birth weight 
and who do not achieve catch-up growth by the 
age of 2 years face a relative risk of short stature 
(< –2 SDs) of 5.2 at the age of 18 years.
Incidence and prevalence
A study of US births estimated an annual incidence 
of 91,000 infants born SGA, using a definition of 
SGA as –2 SDs, or equivalent to the 2.3 percentile.39 
A Swedish study of full-term births in 1973–5 found 
that 5.4% of neonates were SGA, defined as being 
< –2 SD for birth length and/or height.46 However, 
other studies have cited an incidence of around 3% 
of babies being born SGA.47,48
SHOX deficiency
Aetiology, pathology and prognosis
The SHOX gene is located on the distal ends 
of the X and Y chromosomes. This gene plays 
a significant role in long bone growth, and 
normal growth requires two functional copies.49,50 
Growth impairment can result from having a 
haploinsufficiency of SHOX, or from mutations.49 
Clinical features associated with short stature 
homeobox-containing gene deficiency (SHOX-D) 
include disproportionate shortening of the middle 
sections of the limbs (mesomelia), bowing of the 
forearms and lower legs, cubitus valgus (increased 
carrying angle of elbow) and Madelung deformity 
of the wrist.49 However, not all people with 
SHOX-D will have these physical characteristics. 
Langer syndrome is a rare homozygous (or 
compound heterozygous) form of SHOX-D. It 
is characterised by extreme dwarfism, profound 
mesomelia and severe limb deformity.49,51,52
Incidence and prevalence
Short stature homeobox-containing gene deficiency 
could be the underlying cause of restricted height 
in some children whose short stature cannot be 
explained by an underlying pathology. Estimates 
of the prevalence of SHOX haploinsufficiency 
in children with short stature of unknown origin 
range from 1% to 12.5%.13,53–59 Rappold and 
colleagues56 studied 900 short children and found 
SHOX mutations in 2.4% of the patients with short 
stature of unknown origin, implying a prevalence 
of at least 1 in 2000 children. Binder and 
colleagues57 reported a lower prevalence of SHOX 
haploinsufficiency, estimating it to be 1 : 4000.
Short stature homeobox-containing gene deficiency 
also causes short stature in people with concurrent 
diagnoses. Huber and colleagues59 reported that 
68% of 56 children with dyschondrosteosis (a rare 
form of dwarfism) had SHOX anomalies. Other 
screening studies have reported it as the cause of 
short stature in approximately 70% of patients 
with Léri–Weill syndrome (LWS).60 Girls with TS 
have only one copy of the SHOX gene, and this 
haploinsufficiency causes short stature in some girls 
and women with the condition.49DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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A small study61 that compared 26 SHOX-
haploinsufficient people with 45 of their relatives 
and general population standards found that 
the SHOX haploinsufficient cohort was 2.14 SDs 
(3.8 cm) shorter at birth and 2.1 SDs shorter 
throughout childhood. Females were more severely 
affected than males, with women’s FH being 
2.4 SDs (14.4 cm) shorter than unaffected siblings, 
and men’s FH being 0.8 SDs (5.3 cm) shorter. 
SHOX haploinsufficiency led to short stature 
in 54% of the cohort, short arms in 92% and 
Madelung deformity in 73%. It is not clear whether 
the SHOX haploinsufficient cohort in this study 
had concurrent diagnoses.61
Impact of health problem
Severe short stature may be physically debilitating 
in untreated children,62 with children being 
at greater risk of bullying at school and social 
isolation.63 Some children with short stature may 
also have difficulties with emotionally immature 
behaviour, anxiety and poor school performance.64 
However, not all children who are shorter 
than their peers will experience problems. For 
example, the Royal College of Obstetricians and 
Gynaecologists states that the majority of children 
born SGA do not have any appreciable morbidity 
or mortality.38 However, others indicate that 
children born SGA who remain short may suffer 
from alienation, low self-esteem, impaired social 
dynamics, behavioural problems, lower educational 
achievement and professional success.39,43
Children with short stature can also be at increased 
risk of morbidity and mortality in later life. For 
example, the risk of cardiovascular morbidity is 
increased in patients with GHD,65 TS,66 and PWS,67 
while some patients with growth disorders may 
also be at increased risk of type 2 diabetes and 
metabolic syndrome.67,68 Low birth weight is also 
associated with future increased risk of coronary 
heart rate and stroke.69
Outcome measures
The main parameter used to measure the efficacy 
of rhGH treatment is growth. This reflects the main 
goals of therapy, which are physiological catch-up 
growth if possible, achievement of normal height 
during childhood, timely and normal growth 
during puberty and normal height in adulthood. 
In children with PWS, treatment with rhGH aims 
to improve body composition as well as boosting 
growth.
Measures of growth include:
•  Final height (FH) or adult height (AH)  Measured 
either in centimetres or expressed as a 
standard deviation score (SDS), this is the best 
measure of how rhGH treatment affects growth. 
FH has been achieved when the growth rate 
has slowed to less than some specified amount 
(e.g. 1–2 cm/year), and radiographs of the wrist 
and hand show that the epiphyses have closed 
(often expressed as a bone age of more than 
14–15 years).6 Ideally, FH would be calculated 
in comparison with an untreated control group 
in a randomised controlled trial (RCT). Some 
non-RCT designs use historical controls, 
which may overestimate the effects of rhGH 
treatment. Similarly, database studies may not 
include all relevant factors or be representative 
samples of treated patients.6
•  Near-final height (NFH)  Sometimes reported 
where it is assumed that FH has been reached 
using the above criteria, but it is acknowledged 
that growth may not yet be quite complete.6
•  Height  Usually measured standing, using a 
wall-mounted Harpenden stadiometer or a 
similar device. For very young children, supine 
length is measured.
•  Height standard deviation score (HtSDS)  This 
expresses height relative to norms for children 
of the same age, allowing comparisons that are 
independent of age or gender. The normal 
population mean is zero and a normal SD 
score will lie between –2 and +2 SDs. Increase 
over time in SDS or upward centile crossing 
implies catch-up growth and a decrease implies 
growth failure. Calculation of SDS depends on 
the reference data used, i.e. normal height for 
children in the same country.
•  Growth velocity (GV)  Also referred to as height 
velocity, this is the change in height over 
a specified period, e.g. cm/year. Although 
the overall effectiveness of rhGH in treating 
short stature is to be found in measures of 
FH, velocity may be a better interim growth 
measure than height attained at a particular 
age, as it is independent of growth in previous 
years.
•  Growth velocity standard deviation score 
(GVSDS)  This is the GV relative to norms for 
children of the same age.
•  Bone age (BA)  A measure of skeletal maturity, 
usually determined by examining the relative 
positions of the bones in the left hand and 
wrist from a radiograph. The measurement of 
BA relative to chronological age is important 
in height-prediction models. In addition, BA Background
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assessments are used to evaluate when the 
epiphyses have closed and growth is complete. 
The interim assessment of BA is important in 
determining whether treatment is advancing 
bone maturity, such that short-term GV 
might come at the expense of early closure of 
the epiphyses. Clinical trials often measure 
BA to monitor whether this is accelerating 
undesirably fast in rhGH-treated patients 
compared with control patients. Height for BA 
can also be used as an estimate of improved 
height potential in response to rhGH therapy, 
especially in short-term studies.
Measures of body composition assess obesity and 
the amount of fat relative to other body tissues. 
Body mass index (BMI) calculates the ratio of body 
mass to the square of body height, expressed as kg/
m2. The National Institute for Health and Clinical 
Excellence (NICE) recommends BMI as providing 
a practical estimate of overweight in children, 
although mentions that it needs to be interpreted 
with caution as it is not a direct measure of 
adiposity.70 Dual-energy X-ray absorptiometry 
(DEXA) can be used to measure lean mass (fat-free 
mass) and percentage body fat, which can be used 
to indicate body composition.
Physiological outcomes reported in studies of rhGH 
may include assessments of the concentrations 
of hormones, glucose, cholesterol, and markers 
of bone and general metabolism. Such measures 
are important for assessing the biochemical, 
metabolic and adverse effects of rhGH, and can 
have implications for long-term health. IGF-1 is 
an endocrine hormone that is produced by the 
liver, and its production is stimulated by GH. 
Lower than normal levels are therefore seen in 
people with growth disorders. The insulin-like 
growth factor building proteins (IGFBPs) act as 
carrier proteins for IGF-1. There are six IGFBPs, 
with IGFBP-3 being the most abundant.71 IGF-1 
is monitored during rhGH therapy as there is a 
theoretical concern that persistently elevated levels 
may predispose the patient to other diseases later 
in life. Monitoring levels also helps to tailor the 
dose to the individual. As IGFBP-3 binds IGF-1, 
monitoring this gives an indication of the levels of 
‘free’ IGF-1 in circulation. High levels of IGF-1 with 
low levels of IGFBP-3 may be linked with breast, 
colorectal and prostate cancer.72,73
Current service provision
Management of rhGH therapy
Children who receive rhGH therapy require regular 
review by consultant paediatric endocrinologists. 
Older children and adolescents in need of 
continued rhGH therapy may enter transitional 
care arrangements that involve consultations with 
both paediatric and adult growth specialists.74 A 
system of shared care is sometimes used for rhGH 
therapy in the UK,1 with diagnosis and assessment 
of growth being carried out in hospital outpatient 
consultations and some GPs writing prescriptions 
and possibly monitoring adverse events (AEs). In 
other areas, all care including prescriptions and 
monitoring of compliance and side effects takes 
place in secondary care.
Administration of rhGH is usually carried out 
at home by the patient or a family member, 
after training, by subcutaneous injection, using 
either needled or needle-free devices, usually 
pharmaceutical companies’ devices rather than 
syringe and needle. Termination of rhGH therapy 
is indicated if there is a poor response (< 50% 
increment in GV within the first year) or when 
FH is achieved. In children with CRI, therapy 
with rhGH is stopped at the time of a transplant. 
Therapy would not resume until at least 1 year post 
transplant, and is dependent upon the absence of 
catch-up growth.1
Relevant guidance
Current guidance from NICE on the use of 
rhGH in England and Wales for children with 
growth failure due to GHD, TS, PWS or CRI was 
published in 2002.75 This is discussed further later 
in the chapter (see Place of the intervention in 
the treatment pathway). Since 2002, a range of 
guidance on the use of rhGH in children with short 
stature has been published by various national 
health agencies and clinical expert groups for 
GHD, TS, CRI, PWS and SGA, but guidance for 
children with SHOX-D is lacking.
Guidelines on the use of rhGH for the treatment 
of girls and women with TS (published in 2007, 
relevant to US practice) recommended that 
treatment with rhGH should be considered 
as soon as growth failure has been identified, 
and its potential risks and benefits have been 
discussed with the family. It also provided rhGH 
dosing information and a comprehensive set of 
recommendations for the diagnosis, evaluation, 
monitoring and ongoing care of children with TS.11
Summary guidelines76 and detailed 
recommendations27 on the use of rhGH for 
short stature in children with CRI (published in 
2005–6, relevant to US practice) recommended 
that therapy should not commence unless patients DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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exhibit clearly defined CRI and attain appropriate 
phosphorus and parathyroid hormone status.76 The 
detailed recommendations included rhGH dosing 
information and a treatment algorithm outlining 
appropriate steps to improve growth and overall 
health outcomes.27
Consensus statements on using rhGH therapy in 
children and adults born SGA (published in 200339 
and 2007,77 relevant to European and US practice) 
emphasised the need for accurate diagnosis of SGA 
and recommended that rhGH therapy should be 
considered in children who are SGA and older than 
2 years of age. However, this reflects differences in 
licensing in Europe and America. The Food and 
Drug Administration (FDA) authorisation is for 
children aged 2 years and over with no catch-up 
growth (no criteria specified), and no specified 
HtSDS at start of treatment or reference to mid-
parental height.78 By contrast, the European 
Medicines Agency (EMEA) authorisation is for 
children aged 4 years and over, with a HtSDS of 
–2.5 at start of treatment, with a GV < 0 SDs and 
HtSDS > 1 SD below mid-parental height.79 In 
addition, the licensed dose is 70 µg/kg/day in the 
USA and 35 µg/kg/day in Europe.
For UK populations, guidelines on rhGH therapy 
for children with GHD, TS, CRI, PWS and SGA 
was published in 2006 by BSPED.1 This guidance 
provided recommendations for shared care 
between GPs and specialists, together with dosing 
information and treatment entry and exit criteria.
Description of technology under 
assessment
Somatropin (rhGH) has been available since 1985, 
following the withdrawal of cadaveric human 
pituitary GH due to possible transmission of 
Creutzfeldt–Jakob disease.6 rhGH is a synthetic 
form of human GH, produced by recombinant 
deoxyribonucleic acid (DNA) technology, having 
a sequence identical to that of pituitary-derived 
human GH. Licensed dosages vary for the different 
indications (Table 1), depending on whether the 
treatment is aiming to replace GH to normal 
levels (for children with GHD) or being used 
in supraphysiological doses where there is no 
hormone deficiency but some lack of sensitivity 
to the hormone. It is given as a subcutaneous 
injection, usually at night (to mimic the child’s 
natural fluctuations in GH).6
Seven pharmaceutical companies have UK 
marketing authorisations for various indications, as 
shown in Table 1.
Adverse events (AEs) have been reported in 
patients using rhGH. For example, sleep apnoea 
and sudden death among patients with PWS 
who have one or more of the following risk 
factors: severe obesity, history of upper airway 
obstruction or sleep apnoea, or untreated 
respiratory infection.80,81 There are potential risks 
of acromegaly, hyperglycaemia and glucosuria if 
the recommended dosage is exceeded.81 Patients 
receiving rhGH should be monitored for glucose 
intolerance, as the drug may induce a state of 
insulin resistance.81 It is also recommended that 
thyroid function should be monitored.81 Possible 
side effects mentioned for 1–10% of patients 
include hypersensitivity to solvent, hypothyroidism, 
injection site pain (reaction) and oedema.81 
Treatment should be discontinued in the event 
of intracranial hypertension,81 although it may 
be possible to restart treatment at a lower dose 
for patients who develop benign intracranial 
hypertension. Treatment with rhGH leads to 
increasing sensitivity to GH, expressed as an 
increase in serum IGF-1.81
Omnitrope, marketed by Sandoz, is a biosimilar 
product. This means that it is an active substance 
that is similar, but not identical, to the other drugs 
considered in this review. The issue of rhGH 
therapy and biosimilars in clinical practice was the 
subject of a recent Parliamentary Summit.30 The 
current review assesses the clinical effectiveness and 
cost-effectiveness of rhGH, without reference to 
the brand product or manufacturer. Discussion of 
the comparative safety and efficacy of biosimilars 
compared with reference products is therefore 
beyond the scope of this review.
Place of the intervention in 
the treatment pathway
The place of rhGH in the treatment pathway 
depends on the child’s particular condition or 
syndrome, and age at diagnosis. Appropriate 
timing of treatment with rhGH will depend 
on the underlying pathology. rhGH therapy is 
contraindicated in cases of progressive tumour 
activity and should not be used for growth 
promotion in children with closed epiphyses.
GHD
Treatment with rhGH is currently recommended by 
NICE to help increase the growth of children with 
GHD.75 For children with congenital GHD, rhGH 
therapy is not generally started before the child is 
4 years old.6 However, if there is profound growth Background
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TABLE 1  Indications for the use of rhGH in children
Indication Dosea Licensed drugs (manufacturers)
GHD 23–39 mcg/kg daily, 
or 0.7–1.0 mg/m2 
daily
Humatrope (Eli Lilly & Co. Ltd)
Zomacton (Ferring Pharmaceuticals UK)
NutropinAq (Ipsen Ltd)
Norditropin Simple Xx (Novo Nordisk Ltd)
Genotropin (Pfizer Ltd)
Omnitrope (Sandoz Ltd)
Saizen (Merck Serono)
TS 45–50 mcg/kg daily 
or 1.4 mg/m2 daily
Humatrope (Eli Lilly & Co. Ltd)
Zomacton (Ferring Pharmaceuticals UK)
NutropinAq (Ipsen Ltd)
Norditropin Simple Xx (Novo Nordisk Ltd)
Genotropin (Pfizer Ltd)
Omnitrope (Sandoz Ltd)
Saizen (Merck Serono)
PWS, with GV > 1 cm/year (in combination 
with energy-restricted diet)
35 mcg/kg daily or 
1.0 mg/m2 daily; 
max. 2.7 mg daily
Genotropin (Pfizer Ltd)
Omnitrope (Sandoz Ltd)
CRI in children 45–50 mcg/kg daily 
or 1.4 mg/m2 daily
Humatrope (Eli Lilly & Co. Ltd)
NutropinAq (Ipsen Ltd)
Norditropin Simple Xx (Novo Nordisk Ltd)
Genotropin (Pfizer Ltd)
Omnitrope (Sandoz Ltd)
Saizen (Merck Serono)
SHOX-D 45–50 mcg/kg daily Humatrope (Eli Lilly & Co. Ltd)
Growth disturbance (current HtSDS –2.5 
and parental adjusted HtSDS, –1) in short 
children born SGA, with a birth weight 
and/or length below –2 SDs, who failed to 
show catch-up growth (HV SDS < 0 during 
the last year) by 4 years of age or later
35 mcg/kg daily or 
1.0 mg/m2 daily
Humatrope (Eli Lilly & Co. Ltd)
Norditropin Simple Xx (Novo Nordisk Ltd)
Genotropin (Pfizer Ltd)
Omnitrope (Sandoz Ltd)
Saizen (Merck Serono)
a  Dosing information from the Electronic Medicines Compendium (http://emc.medicines.org.uk/), accessed 30 April 
2008.
failure or evidence of recurrent hypoglycaemia, 
which may occur in infants under the age of 1, 
treatment may be started earlier. For children who 
acquire GHD at an older age, treatment can start 
at a time that is appropriate to their condition and 
stage of growth. Treatment is discontinued after 
the first year if there is a poor response, i.e. < 50% 
increase in growth rate, or if compliance or growth 
rate remains poor thereafter. Otherwise treatment 
can continue until GV is < 2 cm/year, assessed over 
6–12 months, when FH is achieved. Other clinical 
advice suggests that treatment is necessary for the 
patient to attain peak bone mass, which may not be 
until the age of 25 or 26 in some people. A recent 
survey of paediatric endocrinologists (56 responses 
out of 72 questionnaires) found that 56% of 
clinics provide transfer clinics for patients ending 
paediatric treatment and transferring to the care of 
an adult endocrinologist. Of the 56 respondents, 
80% retest for GHD prior to transfer, 55% transfer 
all rhGH-treated patients and the remainder 
transfer only those who are still GH deficient on 
retesting.74
Transition phase
The transition phase in GHD is defined as the 
period from near FH, usually around the mid 
to late teens, until about 25 years of age, or 
when final adult height has been reached. At the 
stage of near FH, it is important to re-evaluate 
whether the patient is still GH deficient, and 
if they need to continue with treatment and DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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monitoring. Some cases, such as isolated GHD 
with a genetically identified mutation or multiple 
pituitary hormone deficiency (MPHD), severe GHD 
due to genetic causes, pituitary abnormalities, 
congenital hypopituitarism or acquired GHD 
from tumours or cranial irradiation, are likely to 
require a continuation of therapy. However, cases 
of unknown origin and isolated cases of GHD 
carry a lower likelihood of requiring continuing 
treatment.4 The BSPED consensus document 
suggests testing IGF-1 levels: if these are lower than 
–2 SD then these patients require GH stimulation 
retests. A peak GHD level of < 5µg/l during the 
transition phase is indicative of severe GHD.5
During the transition phase the authors of the 
consensus paper recommend that monitoring 
of patients should include weight and BMI at 
least 6-monthly, IGF-1, quality of life (QoL), 
waist circumference and fasting glucose annually, 
and body composition and total and low-density 
lipoprotein (LDL) cholesterol every 2–5 years.5
Turner syndrome
Current NICE guidance recommends that rhGH 
treatment for girls with TS should begin at the 
earliest age possible, to boost growth.75 Some 
patients with profound growth retardation and 
failure to thrive may commence treatment earlier 
than those who are diagnosed later. A Belgian 
study16 found that median age at diagnosis of 242 
girls was 6.6 (range 0–18.3) years, although the 
survey found that 22% of girls were diagnosed after 
the age of 12 years. Some clinical expert advice 
suggests that the mean age for starting treatment 
is 8–9 years of age as many girls are not diagnosed 
until later in childhood, although there has been a 
recent trend towards earlier diagnosis.
Prader–Willi syndrome
NICE guidance currently recommends the use of 
rhGH for children with PWS to improve height, 
body composition and bone mineral density. 
For children with PWS, treatment with rhGH 
is intended to improve body composition and 
metabolism as well as increase FH. Its place in the 
treatment pathway depends on age at diagnosis. 
Children with PWS are assessed for obesity, 
potential for obstructive sleep apnoea and ongoing 
respiratory illness before treatment is considered. 
Low muscle tone and its impact on the child’s 
development are also considered.
Chronic renal insufficiency
Treatment with rhGH is currently recommended by 
NICE to help increase the growth of prepubertal 
children with CRI.75 The guidance recommends 
that treatment should be stopped after a renal 
transplantation, and re-established after only 
1 year if it has been ascertained that catch-up 
growth has not occurred.75 The place of rhGH 
in the treatment pathway for children with CRI 
depends on age at diagnosis, and on clinical factors 
related to management of the child’s condition. 
rhGH treatment can take place either before or 
after renal transplant, although allograft rejection 
can be a concern if rhGH treatment is given post 
transplant.
Small for gestational age
Previous NICE guidelines did not consider 
children born SGA, as rhGH was not licensed for 
this indication at the time.82 Children born SGA 
but with no comorbidities may not be diagnosed 
until they fail to achieve catch-up height by the 
age of 2–4 years,39 or when they start school. 
The International SGA Advisory Board indicated 
that SGA children aged 2–4 years who show no 
evidence of catch-up with a height of –2.5 SD 
should be eligible for rhGH treatment. They also 
recommended that treatment should be considered 
in children older than four years who show no 
catch up at a height –2 SD or less.39 The European 
licence for rhGH is for children aged 4 years and 
over.
SHOX deficiency
Currently, there is no NICE guidance available 
for the use of rhGH in children with SHOX-D. 
Initiation of rhGH treatment for children with 
SHOX-D depends on age at diagnosis. Clinical 
evaluation is used to assess growth failure, but GH 
provocation tests are not required once SHOX-D 
has been established via a positive SHOX DNA 
blood test.
Current usage in the NHS
According to a survey of endocrine clinics 
published in 2006 by BSPED,74 4758 patients 
have been receiving rhGH in the UK, of which 
4168 were in England and Wales. Responses to 
the survey gave a breakdown of rhGH use by 
diagnosis for 3951 of the 4758 patients, indicating Background
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that 57.4% of the patients on rhGH were treated 
for GHD, 18.7% for TS, 4.6% for PWS, 5.2% for 
SGA, 2.5% for CRI, and 11.6% for other diagnoses. 
If we assume that these 3951 patients are a 
representative sample of the total population of 
rhGH-treated patients in the UK, the total numbers 
of rhGH-treated patients with each diagnosis would 
be around 2731 with GHD, 890 with TS, 219 with 
PWS, 247 with SGA, 119 with CRI, and 552 with 
other diagnoses. It is possible that the number 
of children with CRI who received rhGH in this 
survey was underestimated, as some patients with 
CRI are managed in nephrology clinics, rather 
than paediatric endocrine clinics.74 The number of 
patients treated with rhGH for SHOX-D was not 
reported in the survey and published figures are 
not available. Expert advice indicates that very few 
SHOX-deficient patients are currently receiving 
rhGH, for example only two of between 350 and 
400 patients in one unit receiving rhGH are being 
treated for this. The level of service provision for 
SHOX-deficient patients would be similar to that 
required for a patient with TS.
Anticipated costs associated 
with intervention
The costs associated with rhGH therapy 
interventions comprise:
•  the drug (dose adjusted for body weight)
•  self-therapy training of the patients and their 
parents (involving home visits by specialist and 
community nurses)
•  monitoring of treatment effectiveness 
(involving paediatric endocrinology outpatient 
visits for blood tests, a test of pituitary function, 
and an assessment of BA by hand radiograph).
The costs of training patients and their parents are 
limited to the first year of treatment. During each 
year of treatment, until they stop growing, patients 
would typically attend two outpatient consultations. 
Estimates of the current costs of these components 
of the rhGH interventions for patients with GHD, 
TS, PWS, CRI and SGA are provided in Chapter 4 
(see Estimation of costs).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Decision problem
Recombinant human growth hormone is currently 
recommended by NICE75 for children with a 
proven clinical diagnosis of GHD, TS or PWS, 
and for prepubertal children with CRI. Since 
the last review, rhGH has received marketing 
authorisation for the treatment of children born 
SGA and for children with growth failure associated 
with SHOX-D. The scope of the current project 
is broader than that for the previous systematic 
review6 in that it covers body composition as an 
outcome measure for all disease areas, and also 
includes biochemical and metabolic markers. 
In addition, evidence for the use of rhGH for 
children born SGA, or with SHOX-D (conditions 
not considered in the original review) are included 
in this report. For these reasons, the current 
systematic review was undertaken as a complete 
review not an update. The aim of this health 
technology assessment (HTA) is to assess the 
clinical effectiveness and cost-effectiveness of rhGH 
for children with GHD, TS, PWS, CRI, SHOX-D 
and those born SGA.
Interventions
The intervention is rhGH, also known as 
somatropin. It is marketed as the following 
products: Humatrope (Eli Lilly & Co.); Zomacton 
(Ferring Pharmaceuticals); NutropinAq (Ipsen); 
Norditropin SimpleXx (Novo Nordisk); 
Genotropin (Pfizer); Omnitrope (Sandoz) and 
Saizen (Merck Serono).
Population, including subgroups
The population consists of children with one 
of the following conditions: GHD, TS, PWS, 
CRI, SHOX-D, being born SGA. No age-specific 
definition of a child was given during the scoping 
process for this review. Possible subgroups could 
be children with different causes of GHD, and 
children with CRI who are either pretransplant 
or post transplant. However, analysis of the 
effectiveness of rhGH treatment for any of these 
subgroups of patients is limited by the available 
data and the statistical power of the identified 
trials.
Transition of care from paediatric to adult 
endocrine services of young people requires 
patients to have repeat testing of their GH axis to 
be sure that they need to continue treatment. This 
transition period is only considered within this 
review where evidence from the identified studies 
allows for patients whose linear growth is not 
complete.
Relevant comparators
The standard comparator for this review is 
management strategies without rhGH. This 
includes placebo injections and no treatment.
Outcomes
Clinical outcomes of interest include: FH 
gained, HtSDS, GV, GVSDS, body composition, 
biochemical/metabolic markers, AEs of treatment; 
health-related quality of life (HRQoL). Direct 
costs include estimates of all health-care resources 
consumed in the provision of the intervention, 
including diagnostic tests, administration and 
monitoring costs – as well as consequences of those 
interventions, such as treatment of adverse effects.
Overall aims and objectives 
of assessment
The aim of this report is to assess the clinical 
effectiveness and cost-effectiveness of rhGH 
treatment for children with GHD, TS, PWS, CRI, 
SHOX-D and those born SGA.
The objectives are to:
•  summarise the evidence of clinical effectiveness 
and cost-effectiveness of rhGH when compared 
with management strategies without rhGH
•  develop, where appropriate, an economic 
model adapting an existing cost-effectiveness 
model6 or constructing a new model using 
best available evidence to determine cost-
effectiveness in the UK
•  identify priorities for future research.
Chapter 2  
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Methodology
The methods for the systematic review of clinical 
effectiveness were described a priori in the research 
protocol (Appendix 1), which was sent to experts 
for comment. We received helpful comments 
relating to the general content of the research 
protocol, but there was none that identified specific 
problems with the methods of the review. The 
methods are summarised below.
Search strategy
An experienced information specialist developed 
and tested search strategies for this review. 
Separate searches were carried out to identify 
studies reporting clinical effectiveness, cost-
effectiveness, HRQoL, resource use and costs, and 
epidemiology/natural history of the conditions. 
The search strategy for MEDLINE, shown in 
Appendix 2, was adapted as appropriate for 
a number of other electronic databases. We 
searched: The Cochrane Database of Systematic 
Reviews (CDSR); The Cochrane Central Register 
of Controlled Trials; NHS Centre for Reviews and 
Dissemination (NHS CRD, University of York) 
Database of Abstracts of Reviews of Effectiveness 
(DARE) and the NHS Economic Evaluation 
Database (NHS EED); MEDLINE (OVID); 
EMBASE (OVID); National Research Register 
(NRR); Current Controlled Trials; ISI Proceedings; 
Web of Science; and BIOSIS. For all disease areas 
we searched the databases from their inception to 
June 2009. This meant there was some duplication 
of earlier work for the previous review, but this was 
necessary as the present review required searches 
for additional outcomes, such as biochemical and 
metabolic markers. Searches were limited to the 
English language.
Relevant conferences (European Society for 
Paediatric Endocrinology, The Endocrine Society, 
American Association of Endocrinologists, 
Paediatric Academic Societies) were searched for 
recent abstracts (up to June 2009) to assess against 
the inclusion criteria. Bibliographies of related 
papers were screened for relevant studies, and 
we contacted experts to identify any additional 
published or unpublished references. We also 
assessed the MSs to NICE for any additional 
studies that met the inclusion criteria.
Inclusion and data extraction 
process
Titles and abstracts of studies identified by 
the search strategy were assessed for potential 
eligibility by two reviewers. The full text of relevant 
papers was then obtained, and inclusion criteria 
were applied by two independent reviewers. 
At both stages of the screening process, any 
differences in opinion on inclusion of a particular 
study were resolved through discussion. Data from 
included studies were extracted by one reviewer 
using a standard data extraction form and checked 
by a second reviewer. Any discrepancies were 
identified and resolved through discussion.
Quality assessment
The quality of included studies was assessed using 
NHS CRD (University of York) criteria.83 Quality 
criteria were applied by one reviewer and checked 
by a second reviewer, with differences in opinion 
resolved by discussion. The criteria used are shown 
in Appendix 3. Publication bias was not assessed.
Inclusion criteria
Patients
The inclusion criteria required the patient group to 
be children with growth disturbance due to one of 
the following licensed conditions:
•  insufficient secretion of GH (GHD)
•  Turner syndrome, confirmed by chromosome 
analysis
•  Prader–Willi syndrome, confirmed by genetic 
testing
•  chronic renal insufficiency (prepubertal 
children only)
•  short stature homeobox-containing gene 
deficiency, confirmed by DNA analysis
•  small for gestational age (see below).
The licensed indication81 for SGA is for growth 
disturbance (current HtSDS –2.5 and parental 
adjusted HtSDS –1) in short children born SGA, 
Chapter 3  
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with a birth weight and/or length below –2 SD, 
who failed to show catch-up growth [height velocity 
(HV) SDS < 0 during the last year] by 4 years of 
age or later. However, the review group could not 
find any RCTs whose inclusion criteria matched 
these criteria exactly. Following discussions with 
NICE, the team amended the criteria to be: 
‘growth disturbance (current HtSDS < –2.5, but 
with no reference to parental height) in short children 
born SGA with a birth weight and/or length below 
–2 SD, who failed to show catch-up growth (with no 
particular criteria specified) by 3 years of age or later.’
Studies that included adolescents and young adults 
who have completed linear growth were excluded 
from the systematic review of effectiveness.
Interventions
Recombinant human growth hormone 
(somatropin).
Comparators
Management strategies without somatropin.
Outcomes
The following outcomes were included in the 
review, where data were available:
•  final height gained
•  height standard deviation score (height relative 
to the distribution of height in children of the 
same chronological age)
•  growth velocity
•  growth velocity standard deviation score 
(GV relative to the distribution of growth in 
children of the same chronological age or bone 
age)
•  body composition
•  biochemical and metabolic markers
•  adverse effects of treatment
•  HRQoL.
Types of studies
•  Fully published RCTs were included in the 
review, and systematic reviews of RCTs were 
included as sources of information. Indicators 
of a systematic review include: explicit search 
strategy, inclusion criteria, data extraction 
and assessment of quality. While important 
information on FH and long-term AEs will only 
be available in longer, observational studies, 
there was a practical limit on the number of 
studies that could be included for this review. A 
pragmatic decision was therefore taken to limit 
study type to RCTs, in an attempt to capture 
the most methodologically robust data for all 
six of the disease areas included in this review.
•  Studies published only as abstracts or 
conference presentations were included in 
the primary analysis of clinical effectiveness 
and cost-effectiveness if sufficient details 
were presented to allow an appraisal of the 
methodology and assessment of results.
•  Non-English language studies were excluded.
•  In an effort to capture all randomised 
evidence, all identified RCTs were included 
with no restriction on length of treatment, 
size of study population, or design (parallel 
group or crossover design). Crossover studies 
could potentially be problematic as children’s 
growth continues without treatment, making 
comparisons between the different arms 
less straightforward than in a parallel-group 
trial. However, we have attempted to include 
discussion of this in the quality assessment of 
studies.
Data synthesis
•  Clinical effectiveness studies were synthesised 
through a narrative review with tabulation 
of results of included studies. Key outcome 
measures are reported in tables in the text, 
and other outcomes are shown in the full 
data extraction forms in Appendix 4. For 
conciseness, where a study reported outcome 
measures after 1 and 2 years, only the final 
year’s outcomes are included in the table, as 
these show the longest duration of treatment 
effect.
•  Where data were of sufficient quality and 
homogeneity, a meta-analysis of the clinical 
effectiveness studies was considered using 
review manager 5.0 software.
•  Quality-of-life studies were synthesised using 
the same methods as above, i.e. narrative 
review and meta-analysis only if feasible.
Results
A brief overview of the results of the searches is 
presented below. Owing to the extensive nature 
of this multiple technology appraisal (MTA), the 
clinical effectiveness results for the six different 
disease areas are presented separately (see sections 
Growth hormone deficiency to SHOX-D). For all 
disease areas throughout the screening and data 
extraction process, differences in opinion were 
generally minor and easily resolved without the 
involvement of a third reviewer.
Identified on searching
(after duplicates removed)
n = 674
Full copies retrieved
n = 114
Papers inspected
n = 114
37 includes:
Systemic reviews n = 3a
RCTs n = 28 in 34 publications
  GHD n = 1 RCT
  TS n = 6 RCTs, n = 2 SR
  PWS n = 8 RCTs
  CRI n = 6 RCTs
  SHOX n = 1 RCT
  SGA n = 6 RCTs
Titles and abstracts
inspected
Excluded
n = 77
Excluded
n = 560DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Quantity and quality of research 
available
The number of references considered at each 
stage of the review is shown in Figure 1. Of the 
674 references identified, 560 were excluded 
on inspection of their titles and abstracts. The 
full papers of 114 references were retrieved and 
assessed against the inclusion criteria. A total of 
77 of the retrieved full papers were rejected at this 
stage, mostly due to the patient group not meeting 
the inclusion criteria (n = 40) or due to a non-RCT 
study design (n = 27). A list of papers excluded at 
this stage is included in Appendix 5, together with 
reasons for exclusion. A total of 28 RCTs in 34 
publications were included in the systematic review 
of clinical effectiveness. Appendix 6 lists conference 
abstracts that were identified as being of interest, 
but which contained insufficient information to be 
included in the review of clinical effectiveness.
An overview of the included studies is given in 
Table 2. Only one SGA paper and one TS paper 
reported FH; none of the other conditions’ studies 
reported FH as an outcome measure. None of the 
papers reported specific QoL measures. All disease 
areas included at least one paper which reported 
Identified on searching
(after duplicates removed)
n = 674
Full copies retrieved
n = 114
Papers inspected
n = 114
37 includes:
Systemic reviews n = 3a
RCTs n = 28 in 34 publications
  GHD n = 1 RCT
  TS n = 6 RCTs, n = 2 SR
  PWS n = 8 RCTs
  CRI n = 6 RCTs
  SHOX n = 1 RCT
  SGA n = 6 RCTs
Titles and abstracts
inspected
Excluded
n = 77
Excluded
n = 560
FIGURE 1  Flow chart of identification of published studies for inclusion in the systematic review of clinical effectiveness. aOne of the 
systematic reviews was the previous Health Technology Assessment report written for the National Institute for Health and Clinical 
Excellence, so this was not data extracted. It is discussed briefly (in Summary of previous systematic reviews).
outcomes on height gained, body composition, 
biochemical markers and AE. The characteristics 
and quality assessment of the included studies are 
discussed in each of the relevant disease-specific 
results chapters.
Comparison with previous review
The previous review by Bryant and colleagues6 
included a number of studies that were excluded 
from the present review. As described above (see 
Inclusion and data extraction process) and in the 
research protocol, the present review included only 
RCTs as these form the highest level of evidence 
in the hierarchy of clinical trial designs.83 The 
previous review included two non-RCT studies 
for GHD,115,116 four for TS,117–120 two for CRI121,122 
and one for PWS.123 In addition, the previous 
review included two RCTs for TS, which have 
been excluded from the present review. The 
first of these, by Rosenfeld and colleagues,124,125 
was excluded from the present review as it used 
methionyl growth hormone (met-GH) rather 
than rhGH. The second TS RCT was by Ross and 
colleagues,126 which reported cognitive function. 
This was not one of the outcome measures listed 
in the inclusion criteria for the present review, Assessment of clinical effectiveness
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TABLE 2  Included RCTs
Author and date Total (n)
Outcomes included in the systematic review
FH
Height 
gained/
HtSDS
GV/
growth 
SDS
Body 
composition
Biochemical/
metabolic 
markers QoL AE
GHD
Soliman84 19   
TS
Davenport 200785 89     
Stephure 200586 and 
Rovet 199387
154    
Quigley 200212 232  
Gravholt 200288 12  
Gravholt 200589 9  
Johnston 200190 58 
PWS
Festen 200791 20   
Festen 200792 29    
de Lind van Wijngaarden 
200993 and Festen 200894
42 infants, 
49 children
  
Carrel 199995 and 
Myers96
54     
Carrel 200422 and 
Myers97 and Whitman98
32     
Hauffa 199799 19    
Lindgren100,101 29     
Haqq 2003102 14     
CRI
Sanchez 2002103 23    
Hokken-Koelega 1991104 20   
Hokken-Koelega 1996105 11   
Powell 1997106 69   
The Pharmacia and 
Upjohn Study Group 
1996107
203  
Fine 1994108 125     
SHOX-D
Blum 200749 52    
SGA
De Schepper 2007109 40   
Lagrou 2008110 40   
Carel 2003111 168   
de Zegher 1996112 54     
de Zegher 2002113 13   
Philip 2009114 151  DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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so this RCT was excluded. The previous review 
also included a PWS RCT by Whitman and 
colleagues,127 which was considered for the current 
review. However, the study reported psychological 
outcomes rather than a measure of HRQoL, so this 
study did not meet our inclusion criteria.
Growth hormone deficiency
Quantity and quality of research 
available
One study met the inclusion criteria for this review, 
and the key characteristics are presented in Table 3. 
The full data extraction form in Appendix 4 has 
further details.
Soliman and Abdul Khadir84 recruited two groups 
of GH-deficient children and one group of children 
who were not GH deficient. These groups were 
then subdivided into treatment groups: group 1a 
received 30 units (U)/m2/week of rhGH and group 
1b received 15 U/m2/week. Group 2a received 15 U/
m2/week and group 2b received no treatment. 
Group 3 (non-GHD short children) was subdivided 
in the same way as group 2. Group 2 was the only 
group in this study with GHD and with children 
randomised to either rhGH or no treatment, and, 
as such, is the only group considered in this report. 
The treatment groups’ baseline characteristics 
were similar. The study used a dose of 15 U/m2/
week, and it is not clear how this corresponds to 
the licensed dose as neither milligrams (mg) nor 
international units (IUs) are used.
Overall the quality of the reporting of the included 
study was mixed (Table 4). No details were given 
on randomisation or allocation to treatment 
groups. For example, Soliman and Abdul Khadir84 
recruited children into specified groups according 
to peak GH response to provocation, and these 
groups were then divided at random into two 
subgroups. No further details were given. The low 
patient numbers will affect interpretation of results 
from this trial.
The comparator group did not receive placebo: 
this could mean that both care providers and 
patients would have been aware of whether they 
were receiving treatment, which, in turn, can affect 
reporting of some outcomes. Soliman and Abdul 
Khadir84 appear to have carried out an intention-
TABLE 3  Characteristics of GHD study
Reference Intervention Control group
Total randomised 
and withdrawals
Duration of randomised 
treatment
Soliman et al. 
199684
GH 15 U/m2/week
n = 9
Overall mean 
age ± SD: 6.8 ± 2.1
No treatment
n = 10
Overall mean 
age ± SD: 6.8 ± 2.1
Total n = 19
No withdrawals 
reported
1 year
TABLE 4  Quality assessment of included GHD study
Soliman84
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Inadequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary outcome measure? Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateAssessment of clinical effectiveness
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to-treat analysis (ITT), which can protect against 
attrition bias.
Growth outcomes
The Soliman84 study reported GV and HtSDS, and 
these are presented in Table 5. The data extraction 
forms in Appendix 4 list further outcome measures, 
such as BA.
Children in the treated group in the Soliman 
study grew an average of 2.7 cm/year faster than 
those receiving no treatment in the 12 months of 
the study, and the difference between groups was 
statistically significant (p < 0.05). Similarly, children 
in the treated group had a statistically significantly 
higher HtSDS: –2.3 ± 0.45 versus –2.8 ± 0.45 in the 
untreated group (p < 0.05).
Body composition outcomes
Soliman and Abdul Khadir84 did not report body 
composition outcomes.
Biochemical markers
The results reported for IGF-1 levels in the Soliman 
study84 are shown in Table 6. Further biochemical 
markers, such as insulin, are included in the data 
extraction tables in Appendix 4.
The IGF-1 levels at 12 months are statistically 
significantly higher in the treated than in the 
untreated group: 91.2 ± 30.4 versus 49.4 ± 19.
Quality of life
Soliman and Abdul Khadir84 did not report QoL 
results.
Adverse events
Adverse events were not reported by Soliman and 
Abdul Khadir.84
Summary
One trial examining the effectiveness of rhGH for 
GHD met the inclusion criteria for the review.
•  The quality of the included study was mixed. 
It was an unblinded study, which can have an 
impact on outcome reporting but did report an 
ITT analysis.
•  Children in the rhGH group grew 2.7 cm/year 
faster than children in the untreated group 
during the 1-year study, and had a statistically 
significantly higher HtSDS: –2.3 ± 0.45 versus 
–2.8 ± 0.45.
•  The IGF-1 levels were statistically significantly 
higher in the treated group than in the 
untreated group.
•  The included study did not report QoL or AE.
Turner syndrome
Quantity and quality of research 
available
Six studies assessing the effectiveness of GH for 
growth restriction in TS met the inclusion criteria 
for the review.12,85,86,88–90 The key characteristics 
of these studies are presented in Tables 7–12. 
Appendix 4 has further details.
Two of the included studies were of a crossover 
design,88,89 and these compared doses of 
0.1 IU/kg/day88 and a mean of 1.3 ± 0.3 mg/day 
(alone or in combination with oestradiol)89 with 
placebo. The group receiving oestradiol is not 
discussed further here. Of the remaining studies, 
TABLE 5  Growth outcomes for GHD
Study Mean (SD) GH No treatment p-value
Soliman84
GH 15 U/m2/week (n = 9) vs no 
treatment (n = 10); 12 months
HtSDS –2.3 ± 0.45 –2.8 ± 0.45 < 0.05
8.4 ± 1.4 5.7 ± 1.8 < 0.05
TABLE 6  Biochemical markers in GHD studies
Study Outcomes GH Control p-value
Soliman84
GH 15 U/m2/week (n = 9) vs no 
treatment (n = 10); 12 months
IGF-1 (ng/ml) 91.2 ± 30.4 49.4 ± 19 < 0.05DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 7  Characteristics of TS studies
Reference Intervention Control group
Total randomised 
and withdrawals
Duration of 
randomised 
treatment
Stephure and 
CGHAC 200586 and 
Rovet et al., 1993 87
rhGH 0.30 mg/kg/week 
(n = 76)
Mean age (± SD): 10.3 ± 1.8
No rhGH treatment 
(n = 78)
Mean age (± SD): 10.9 ± 1.7
Total n = 154
Sample attrition: 
rhGH, n = 15; 
control, n = 35
Until HV < 2 cm/
year and BA 
≥ 14 year
Davenport et al. 
200785
rhGH 50 µg/kg/day (n = 45)
Mean age (± SD): 1.98 
± 1.01
No treatment (n = 44)
Mean age (± SD): 
1.97 ± 1.01
Total n = 89
Sample attrition: 
rhGH, n = 4; control, 
n = 6 
2 years
Gravholt et al. 
200288
rhGH 0.1 IU/kg/day
Overall age range: 9.5–14.8 
years (median 12.9)
Placebo
Overall age range: 9.5–
14.8 years (median 12.9)
Total n = 12
Withdrawals not 
reported
Crossover RCT, 
2 months in each 
arm
Gravholt et al. 
200589
rhGH (1.3 ± 0.3) mg/day
Overall mean age (± SD): 
15.9 ± 1.8
Placebo
Overall mean age (± SD): 
15.9 ± 1.8
Total n = 9
Sample attrition: 
n = 1
Crossover RCT, 
2 months in each 
arm
Johnston et al. 
200190
rhGH 28–30 IU/m2/week 
(n = 22)
Mean age (range): 9.0 
(5.2–15.4)
Ethinyloestradiola 50–
75 ng/kg/day (n = 13)
Mean age (range): 9.1 
(6.0–13.7)
Total n = 58b
Sample attrition: 
n = 12
1 year
Quigley et al. 200212 rhGH 0.27 mg/kg/week 
(n = 45)
Mean age (± SD): 9.7 ± 2.7
rhGH 0.36 mg/kg/week 
(n = 49)
Mean age (± SD): 9.8 ± 2.9
Placebo (n = 41)
Mean age (± SD): 9.4 ± 2.7
Total n = 232b
Sample attrition: 
n = 8
18 months
CGHAC, Canadian Growth Hormone Advisory Committee.
a  Low-dose estrogen.
b  Including additional study arm(s) not relevant here.
TABLE 8  Quality assessment of included TS studies
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1.  Was the assignment to the treatment groups really random? Un Ad Un Un In Un
2.  Was the treatment allocation concealed? Un Ad Un Un Un Un
3.  Were the groups similar at baseline in terms of prognostic factors? Rep Rep Not 
rep
Not 
rep
Rep Rep
4.  Were the eligibility criteria specified? Ad Ad In In In Ad
5.  Were outcome assessors blinded to the treatment allocation? Un Un Un Un Un Un
6.  Was the care provider blinded? In In Un Un Un Un
7.  Was the patient blinded? In In Un Ad Un Par
8.  Were the point estimates and measure of variability presented for 
the primary outcome measure?
Ad Ad Ad Ad Ad In
9.  Did the analyses include an ITT analysis? In In In In In In
10. Were withdrawals and dropouts completely described? Ad Ad In Ad Ad Ad
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown.Assessment of clinical effectiveness
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two compared rhGH with no treatment,85,86 one 
with low-dose estrogen,90 and one with placebo.12 
Stephure and colleagues86 administered a rhGH 
dose of 0.30 mg/kg/week, with a maximum weekly 
dose of 15 mg. The dose of 50 µg in the Davenport 
study85 is comparable with that of Stephure and 
colleagues. Those in the Quigley study12 were 
slightly different: group 1 received 0.27 mg/kg/week 
and group 2 received 0.36 mg/kg/week. Johnston 
and colleagues90 gave a dose of 28–30 IU/m2/week. 
All studies included at least one treatment arm 
with a dose that was broadly comparable with the 
licensed dose of 45–50 µg/kg/day or 1.4 mg/m2/day.
Four of the six included studies reported growth 
outcomes, including height gain and change in 
HtSDS.12,85,86,90 The remaining two studies reported 
body composition and biochemical marker 
outcomes.88,89
The trials varied considerably in size. The two 
crossover trials were small, with 1288 and nine89 
participants. The Stephure86 and Quigley12 
studies were larger, with 154 and 232 participants, 
respectively. Johnston and colleagues90 recruited 58 
patients, and Davenport and colleagues recruited 
89.85 The included trials also ranged in length. 
The groups in Quigley and colleagues12 remained 
randomised for 18 months, the Davenport study85 
for 2 years and the Johnston study lasted for 
1 year.90 Protocol completion in the Stephure86 
study was defined as annualised GV less than 2 cm/
year and BA of 14 years or greater, which we have 
interpreted to mean FH. In contrast, the two 
Gravholt studies88,89 were short crossover trials, with 
rhGH treatment for 2 months.
Five12,86,88–90 of the six trials recruited broadly 
similar age groups, whilst the sixth by Davenport 
and colleagues85 specifically targeted very young 
girls with TS. As a result their girls have much 
younger mean ages of 1.98 ± 1.01 and 1.97 ± 1.01 
for treatment and control groups, respectively.
Four of the included studies reported baseline 
characteristics that were similar between 
groups.12,85,86,90 However, none reported p-values 
for between-group differences, so there may have 
been small differences at baseline. For example, in 
the study by Stephure and the Canadian Growth 
Hormone Advisory Committee (CGHAC) 2005,86 
girls in the rhGH group were on average 3 cm 
shorter than those in the control group. The SD 
values indicate overlapping CI, suggesting there is 
no statistically significant difference between the 
two groups. However, the 3-cm difference could 
have an impact on end of study height. The other 
two studies, reported by Gravholt and colleagues, 
were of crossover design. One reported baseline 
characteristics for the whole study group89 and 
the other did not appear to report any baseline 
conditions.88
The six included trials were generally of poor 
methodological quality, and poorly reported 
(Table 8). Only one reported adequate methods of 
randomisation to treatment groups.85 Davenport 
and colleagues85 stratified their participants by age 
and then randomised them using a blinded phone-
in process. Four of the six trials did not describe 
randomisation techniques.12,86,88,89 Johnston and 
colleagues90 reported that five participants were 
reallocated from the oestrogen group to receive 
rhGH: it is unclear when this occurred and 
therefore method of randomisation was judged 
inadequate.
Concealment of treatment allocation was also 
judged to be adequate in the Davenport trial, 
and ‘unknown’ in the remaining five. In the 
Gravholt89 study it is unclear how allocation to 
treatment groups had taken place. The study had 
only nine participants, and these were simply 
reported to have been given the treatment regimen 
sequentially and in random order.
Blinding of participants, those who provide care 
and those who assess outcomes can protect against 
the reporting of some outcomes being affected 
by the knowledge of which treatment is being 
received. Blinding of outcome assessors, care 
providers and patients was judged ‘unknown’, 
‘inadequate’ or ‘partial’ in five out of the six trials; 
Gravholt and colleagues89 adequately blinded their 
patients by administering placebo in place of both 
rhGH and the oestradiol.
None of the six studies included here used an 
ITT analysis. This kind of analysis can protect 
the study from attrition bias, where, for example, 
participants withdrawing from the treatment arm 
could represent AE or treatment failure.
Growth outcomes
Four out of the six included studies reported 
growth outcomes, and key measures are shown 
in Table 9. Please see Appendix 4 for additional 
outcomes. Neither of the studies by Gravholt and 
colleagues88,89 reported growth outcomes.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 9  Growth outcomes for TS studies
Study Outcomes (mean ± SD) GH Control p-value
Stephure and CGHAC86
Protocol completion, rhGH 
0.30 mg/kg/week (n = 61) vs no 
treatment (n = 43)
Height (cm) 147.5 ± 6.1 141.0 ± 5.4 < 0.001
Change in height (cm) 28.3 ± 8.9 19.0 ± 6.1 < 0.001
HtSDS (age-specific turner) 1.4 ± 1.0 0.2 ± 0.9 < 0.001
HtSDS (adult Turner) 0.7 ± 0.9 –0.3 ± 0.8 < 0.001
Change in HtSDS (age-specific Turner) 1.6 ± 0.6 0.3 ± 0.4 < 0.001
Stephure and CGHAC86
Addendum follow-up, rhGH 
0.30 mg/kg/week (n = 40) vs no 
treatment (n = 19)
Height (cm) 149.0 ± 6.4 142.2 ± 6.6 < 0.001
Change in height (cm) 30.3 ± 8.3 21.6 ± 6.2 < 0.001
HtSDS (age-specific Turner) 0.9 ± 0.9 –0.1 ± 1.0 < 0.001
HtSDS (adult Turner) 0.9 ± 0.9 –0.1 ± 1.0 < 0.001
Change in HtSDS (age-specific Turner) 1.1 ± 0.5 0.0 ± 0.5 < 0.001
Davenport et al.85
GH (n = 41) vs no treatment 
(n = 37); 2 years
Height (cm) 99.5 ± 7.6 91.9 ± 7.2 < 0.0001
HtSDS –0.34 ± 1.10 –2.16 ± 1.22 < 0.0001
GV (cm/year) 8.4 ± 1.6 5.5 ± 1.8 < 0.0001
GV SDS 0.70 ± 1.11 –1.63 ± 1.29 < 0.001
Johnston et al.90
rhGH 28–30 IU/m2/week (n = ?)a 
vs estrogen (n = ?);a 1 year
Change in HSDS in first year +0.7 (0.7) +0.4 (0.9) < 0.05
Quigley et al.12
GH 1, rhGH 0.27 (n = 45); GH 
2, rhGH 0.36 (n = 49) vs placebo 
(n = 41); 1 year
GV 0–18 months (cm/year) 1: 6.6 ± 1.12 
2: 6.8 ± 1.1
4.2 ± 1.1 < 0.001
a  ‘n’ unclear for this outcome.
Two studies reported height at the end of the 
study: both found a statistically significant 
difference between the treated and untreated 
groups (p < 0.0001).85,86
Children in the treated group in the Stephure 
study86 were 6.5 cm taller on average than the 
untreated group at protocol completion. However, 
there was a 3-cm difference between the groups’ 
mean heights at baseline. Mean change from 
baseline was therefore 9.3 cm more in the rhGH 
than in the untreated group at the end of protocol 
completion (28.3 ± 8.9 vs 19.0 ± 6.1).
The Stephure study86 also reported an addendum 
follow-up (approximately 10 years since 
randomisation), which included 66% of rhGH 
patients and 44% of the control group. The treated 
group’s mean FH was 149.0 ± 6.4 cm compared with 
142.2 ± 6.6 cm in the untreated group (p < 0.001), 
i.e. a difference of 6.8 cm. Mean change from 
baseline to FH was 8.7 cm more in the rhGH than 
in the untreated group.
In the Davenport study85 the mean difference was 
7.6 cm (height at study end was 99.5 ± 7.6 cm in 
the treated group vs 91.9 ± 7.2 cm in the untreated 
group, p < 0.0001).
Height standard deviation score is also reported 
by Davenport and colleagues85 and Stephure 
and CGHAC.86 Both authors report statistically 
significant differences between groups for this 
outcome, with the treated groups both achieving 
higher HtSDS. In the Stephure study86 the HtSDS 
is reported for the age-specific Turner population 
and for the adult Turner population.
The difference in change in height was statistically 
significant between groups in the two studies that 
reported it. Stephure and colleagues86 report 
a change in height at protocol completion of 
28.3 ± 8.9 cm versus 19 ± 6.1 in the untreated group, 
p < 0.001. Davenport and colleagues85 reported a 
2-year height gain of 20.4 ± 3.3 cm (treated group) 
versus 13.6 ± 3.5 cm (untreated group), p < 0.001 
(not shown in table). Change in HtSDS in both the Assessment of clinical effectiveness
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Stephure86 and Johnston90 studies was higher in the 
treated than untreated group: 1.6 ± 0.6 (treated) 
versus 0.3 ± 0.4 (untreated), p < 0.001, at protocol 
completion in the Stephure study; 0.7 (0.7) versus 
0.4 (0.9), p < 0.05, in the Johnston study90 after 
1 year.
Growth velocity was statistically significantly 
greater in the treated groups in the Stephure,86 
Davenport85 and Quigley12 studies. Davenport and 
colleagues85 reported GV at the end of the first 
and second year. Although this was greater in the 
treated groups at both times, GV fell in the second 
year in both groups: 8.4 ± 1.6 cm/year (treated 
group) versus 5.5 ± 1.8 (untreated). Additionally, 
Davenport and colleagues85 measured GV SDS 
at the end of the first and second years. Again, 
this was greater in the treated group at the end 
of the first year: 1.75 ± 1.25 versus 0.8 ± 0.95, p 
< 0.001, but was reduced by the end of the second 
year in both groups: 0.70 ± 1.11 (treated) versus 
–1.63 ± 1.29 (untreated), p < 0.001. Quigley and 
colleagues reported GV after 18 months. This was 
broadly similar in both the lower- and higher-
rhGH-dose groups: both were significantly higher 
than that in the placebo (Pla) group: 6.6 ± 1.1 
(GH 0.27/Pla group) versus 6.8 ± 1.1 (GH 0.36/Pla 
group) versus 4.2 ± 1.1 (Pla/Pla group), p < 0.001 
compared with placebo.
Bone age differences for the younger participants 
in the Davenport study were statistically 
significant:85 the GH-treated group at 2 years 
had a mean BA of 4.24 ± 1.35 versus 3.38 ± 1.11 
in the untreated group, p = 0.0033. Davenport 
and colleagues85 also reported BA/chronological 
age; this is lower in the treated group, and the 
difference was statistically significant: 0.64 ± 0.80 
versus 0.21 ± 0.96, p < 0.001.
Body composition outcomes
Three of the TS studies reported body composition 
outcomes, and these are presented in Table 10. One 
of the studies reported weight, weight standard 
deviation score (WtSDS) and BMI,85 whereas the 
remaining two reported FM, bone mineral content 
(BMC) and LBM for arms, legs, trunk and head, 
and as a total.88,89 Please see Appendix 4 for BMC 
results.
Weight and WtSDS were significantly greater in 
the group receiving rhGH than in the untreated 
group in the Davenport study,85 reported as 
16.62 kg ± 2.86 versus 13.81 kg ± 2.50, and 
0.20 ± 1.06 versus –1.37 ± 1.36, respectively 
(p < 0.0001 for both comparisons).
Two studies considered FM, BMC and LBM.88,89 
In both studies the total FM was greater in the 
untreated group than in the treated group, 
and LBM was slightly higher in treated than in 
untreated patients (Table 10). The differences 
between groups were of borderline statistical 
significance in one study88 but no p-values were 
presented in the other study.89
Biochemical markers
Three of the studies85,88,89 reported biochemical 
outcomes. Key results are shown in Table 11 – other 
outcomes are in Appendix 4.
Two studies reported mean levels of IGF-1 at 
end of treatment. In both studies IGF-1 levels 
were statistically significantly higher in the group 
receiving rhGH. One study88 reported values of 
380.5 ± 116.3 versus 179.8 ± 79.4 in the treated and 
untreated groups, respectively (p < 0.0005). The 
other89 reported 661 ± 192 versus 288 ± 69 (p-value 
not reported) for treated and untreated patients, 
respectively.
Davenport and colleagues85 reported that IGF-1 
SDS was significantly greater in the treated group 
(1.26 ± 0.72 vs –0.69 ± 0.84, p < 0.0001). Change in 
IGF-1 SDS from baseline to year 2 was 1.53 ± 0.93 
versus –0.09 ± 0.87 in the treated and untreated 
groups, respectively.
One Gravholt study88 reported that IGFBP-3 levels 
were statistically significantly higher in the treated 
group than in the untreated group (5982 ± 1557 
vs 4344 ± 787, respectively, p = 0.002). The other 
study by Gravholt and colleagues89 reported 
higher IGFBP-3 SDS values in treated patients, 
but no clear p-value was reported.89 Davenport and 
colleagues85 found that IGFBP-3 SDS was higher 
in their treated group (0.97 ± 0.94 vs –1.12 ± 1.13, 
p < 0.0001).
Fasting glucose and fasting insulin were reported in 
the two studies by Gravholt and colleagues,88,89 both 
of which were raised in the groups receiving GH in 
each study. Mean glucose (nmol/l) was 4.28 ± 0.5988 
and 4.46 ± 0.4089 in the treated groups, versus 
4.02 ± 0.4488 and 4.04 ± 0.4789 in the untreated 
groups. This difference reached statistical 
significance in the first study,88 p = 0.046. Mean 
fasting insulin levels in the first Gravholt study88 
were 17.17 ± 8.30 versus 8.58 ± 4.27, p = 0.007.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
23
Quality of life
None of the TS studies reported QoL as an 
outcome.
Adverse events
Adverse events were reported by only four of the 
studies.12,85,86,90 Details presented by three of the 
studies are shown in Table 12 (the fourth study did 
not present figures90).
The group receiving GH in the Stephure study86 
experienced a statistically significantly greater 
level of all AEs (where statistical significance was 
reported), with the exception of goitre, and one 
instance of death from ruptured aortic aneurysm, 
which occurred in the untreated group. The one 
case of elevated transamine levels in the treated 
group led to withdrawal from the study.
Davenport and colleagues85 report the same level of 
serious adverse events (SAEs) for both the treated 
and untreated groups. For treatment-emergent 
AEs, defined as ‘events or conditions that began or 
worsened after study entry’, the results were similar. 
There were 42 (93%) in the treated group and 43 
(98%) in the untreated group. Most treatment-
emergent AEs were ear disorders.
Quigley and colleagues12 found a significant 
difference in levels of occurrence or worsening 
of otitis media between the treated group (29%) 
and the control group (13%), p = 0.037. Ear pain 
and ear disorder were reported as not differing 
between groups. Three girls discontinued rhGH 
due to hypertension, ulcerative colitis and brain 
tumour. The authors stated that these were not 
directly related to GH. Overall, AEs were not 
presented separately for the groups; however, 
TABLE 11  Biochemical markers in TS studies
Study
Outcomes 
(mean ± SD) GH Control p-value
aDavenport et al.85
GH (n = 41) vs no treatment (n = 37); 2 
years
IGF-1 SDS 1.26 ± 0.72 –0.69 ± 0.84 < 0.0001
IGFBP-3 SDS 0.97 ± 0.94 –1.12 ± 1.13 < 0.0001
∆IGF-1 SDS 1.53 ± 0.93 –0.09 ± 0.87 nr
Gravholt et al.88
GH 0.1 IU/kg/day vs placebo; 2 monthsa
IGF-1 (µg/l) 380.5 ± 116.3 179.8 ± 79.4 < 0.0005
IGFBP-3 (µg/l) 5982 ± 1557 4344 ± 787 0.002
Gravholt et al.89
GH 1.3 mg/day vs placebo; 2 months
IGF-1 (µg/l) 661 ± 192 288 ± 69 nr
IGFBP-3 (µg/l) 5157 ± 741 4146 ± 573 Unclear
a  Baseline data missing for eight control subjects and three GH treated subjects; end point data missing for four control 
subjects and seven rhGH subjects.
TABLE 10  Body composition outcomes for TS studies
Study
Outcomes 
(mean ± SD) GH Control p-value
Davenport et al.85
GH (n = 41) vs no treatment (n = 37); 
2 years
Weight (kg) 16.62 ± 2.86 13.81 ± 2.50 < 0.0001
WtSDS 0.20 ± 1.06 –1.37 ± 1.36 < 0.0001
BMI (kg/m2) 16.72 ± 1.70 16.24 ± 1.29 0.1724
Gravholt et al.88
GH 0.1 IU/kg/day vs placebo; 2 
monthsa
FM total (g/kg) 231.0 ± 49.5 247.8 ± 58.1 0.04
LBM total (g/kg) 725.4 ± 44.8 710.5 ± 54.6 0.05
Gravholt et al.89
GH 1.3 mg/day vs placebo; 2 monthsb
FM total (g/kg) 274.5 ± 55.5 312.9 ± 74.7 nr
LBM total (g/kg) 692.8 ± 55.5 655.2 ± 73.7 nr
nr, not reported.
a  Crossover study, total n = 12.
b  Crossover study, total n = 9.Assessment of clinical effectiveness
24
TABLE 12  Adverse events for TS studies
Study AE (n) GH Control p-value
Stephure and CGHAC86
GH (n = 74) vs no treatment 
(n = 64)
Surgical procedures 37 17 0.005
Otitis media 35 17 0.014
Ear disorder 15 4 0.024
Joint disorder 10 2 0.036
Respiratory disorder 8 1 0.037
Sinusitis 14 4 0.041
Goitre 0 4 0.004
Death (ruptured aortic aneurysm) 0 1 nr
Elevated transamine levels 1 0 nr
Intracranial hypertension 1 0 nr
Davenport et al.85
GH (n = 45) vs no treatment 
(n = 44), 2 years
Serious AEs, n (%) 4 (9) 4 (9) nr
Treatment-emergent AEs, n (%) 42 (93) 43 (98) nr
Quigley et al.12 Otitis media (occurrence/worsening), n (%) 54/186 (29%) 6/46 (13%) 0.037
nr, not reported.
five were reported to have accidentally overdosed 
on the study drug. Five further events described 
as possibly related to the study drug were 
hypertension (two), surgical procedures (two) and 
scoliosis (one).
Five participants were reallocated from the group 
receiving estrogen to rhGH after concerns over 
early breast development in the study by Johnston 
and colleagues.90 Seven patients developed 
‘coincidental disorders’ not severe enough to 
warrant treatment discontinuation. The authors 
reported that compliance problems led to the 
withdrawal of four patients, but no details were 
given. It is unclear which treatment groups these 
latter events occurred in.
Summary
Six trials examining the effectiveness of GH for 
growth disturbance in patients with TS met the 
inclusion criteria for the review.
The reporting and methodological quality 
of the studies was poor. Of the six included 
studies, one reported adequate randomisation to 
treatment groups,85 one study described adequate 
concealment of treatment allocation85 and one 
adequately blinded the patient to treatment by 
administering placebo.89 None of the included 
trials used an ITT analysis.
Children in the rhGH group in the Stephure86 
study grew an average of 9.3 cm more from baseline 
than those in the untreated group. In a study of 
younger children85 the difference was 7.6 cm. Both 
of these were statistically significant results. In the 
same two studies85,86 the groups receiving rhGH 
achieved a significantly higher HtSDS.
Change in height and change in HtSDS were 
statistically significantly greater in the groups 
treated with rhGH.85,86,90
Growth velocity was greater in the treated groups 
in three studies that reported this outcome,12,85,86 
although this was greater in the first year and fell 
in the second year in both treatment groups where 
this was reported separately.85
One study86 found a significant difference in 
BA between groups, being higher in the treated 
patients.
Fat mass and LBM were reported in two studies.88,89 
In both, the total FM was at a lower level in the 
treated groups, compared with those untreated, 
and LBM was higher in the treated groups 
compared with untreated. There was no statistically 
significant difference in BMI between treated and 
untreated girls in one study.85
The IGF-1 levels were substantially higher in 
the treated groups in the studies reporting this DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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outcome.88,89 IGF-1 SDS was also significantly 
higher in the group receiving GH.85 Levels of 
IGFBP-3 and IGFBP-3 SDS were also found to be 
higher in children treated with GH.85,88,89
Levels of fasting glucose and fasting insulin were 
both raised in the treated groups in two studies.88,89
There were variable levels of detail in the reporting 
of AEs across the six studies. Two studies did not 
discuss these.88,89 In those studies that did, no clear 
picture emerges. One found greater levels of AEs in 
the treated group,86 one found similar levels across 
groups,85 one found significantly higher levels of or 
worsening of otitis media, and one reported seven 
patients with ‘coincidental disorders’ and four 
withdrawals due to compliance problems, but gave 
no further details.
Prader–Willi syndrome
Quantity and quality of research 
available
Eight RCTs in 13 publications of the clinical 
effectiveness of rhGH in patients with PWS met 
the inclusion criteria for this review.22,91–102 Their 
key characteristics are shown in Table 13 – see 
Appendix 4 for further details.
It was not possible to perform any meta-analysis of 
outcomes from the PWS studies due to variation in 
the trials’ participants’ ages, dosing calculations, 
and methods of presenting results. The included 
studies had well-matched patient groups, whose 
baseline characteristics were generally similar 
in the treated and untreated groups. Median 
baseline HtSDS was lower in the rhGH group 
than in the untreated group in the study reported 
by both Festen and colleagues94 and by de Lind 
van Wijngaarden and colleagues,93 although the 
interquartile ranges (IQRs) were similar [–2.0 (–3.1 
to –1.7) versus –2.5 (–3.3 to –1.9), respectively]. 
Other exceptions were the crossover study by 
Haqq and colleagues,102 which presented baseline 
characteristics for the study population as a whole, 
and the study by Lindgren and colleagues,100,101 
which reported slightly lower baseline GV SDS in 
the rhGH group [–1.9 ± 2.0, range –6.4 to –0.9, vs 
–0.1 (SD not reported) range –1.7 to –2.71].
Five of the studies were RCTs, which compared 
1 mg/m2/day rhGH with no treatment for 
122,92–98 or 291,93,94 years. The study by Haqq and 
colleagues102 was a crossover RCT, which compared 
0.043 mg/kg/day of rhGH with placebo injections, 
with patients spending 6 months in each treatment 
arm. There does not appear to have been a 
washout phase between the two treatment phases, 
which could affect the generalisability of results.
The doses used in the included studies reflect the 
various marketing authorisations for this drug 
(0.035 mg/kg body weight or 1.0 mg/m2 BSA), with 
1 IU of rhGH being equivalent to approximately 
0.33 mg/kg. The study reported by both de Lind 
van Wijngaarden and colleagues93 and Festen and 
colleagues94 reported results separately for infants 
and children. Two RCTs reported results for infants 
and toddlers aged between 1 and 2.5 years.22,92,97,98 
The five remaining trials were in children aged 
between approximately 6 and 10 years old. 
The studies were generally small, randomising 
between 14102 and 5495,96 children. The study 
reported by both de Lind van Wijngaarden and 
colleagues93 and Festen and colleagues94 had a 
total of 91 participants, but as children and infants 
were randomised separately, the randomised 
comparisons were of rhGH versus no treatment 
within two smaller groups (42 infants and 49 
children). This was the only study to report a 
sample size/power calculation,93,94 and it is not clear 
whether the other studies were adequately powered 
to detect a difference between treatment groups.
With the exception of the two RCTs by Festen and 
colleagues,91,92 the studies did not clearly state 
which of their reported outcomes were primary or 
secondary measures of effect. Seven of the eight 
trials reported measures of body composition. The 
two RCTs by Festen and colleagues91,92 focused 
on body composition and biochemical markers, 
and did not report any measure of change in 
height. The other six studies all reported GV 
SDS or an indicator of linear GV.102 IGF-1 and 
other biochemical markers were reported by five 
RCTs.22,92–99
One RCT was reported in three papers, by Carrel 
and colleagues,22 Myers and colleagues97 and 
Whitman and colleagues.98 The most complete data 
were reported by Carrel and colleagues,22 and these 
data are included in the tables in this section.
The included studies were generally poorly 
reported (Table 14) and lacked information on 
method of randomisation or concealment of 
allocation. It is possible that selection bias could 
have affected the trials if they were not properly 
randomised, but there is insufficient information 
provided on which to make such a judgement. The 
trial by Haqq and colleagues102 was a crossover Assessment of clinical effectiveness
26
TABLE 13  Characteristics of included PWS studies
Reference Intervention Control group
Total randomised 
and withdrawals
Duration of 
randomised 
treatment
Carrel et al. 2004,22 
Myers et al. 2007,97 and 
Whitman et al. 200498
rhGH 1 mg/m2/day
n = 15
Mean age ± SD (months): 
13 ± 8
No treatment
n = 14
Mean age ± SD 
(months):15 ± 0
n = 32
Sample attrition: n = 3a
1 year
Carrel et al. 199995 and 
Myers et al. 199996
GH 1 mg/m2/day
n = 35
Mean age (years): 9.8
No treatment
n = 19
Mean age (y): 10.0
n = 54
No withdrawals
1 year
de Lind van 
Wijngaarden et al. 
200993 and Festen et 
al. 200894
1 mg/m2/day
Infants (< 3.5 years): n = 19
Children (> 3.5 years): 
n = 23
Median (IQR) age: infants 
2.0 (1.6–3.1), children 6.8 
(5.4–8.8)
No treatment
Infants (< 3.5 years): n = 19
Children (> 3.5 years): 
n = 21
Median (IQR) age: infants 
1.3 (1.0–2.8); children 5.9 
(4.7–7.4)
n = 104 enrolled
Sample attrition: 4 
infants and 5 children
1 year for 
infants, 2 years 
for children
Festen et al. 200791 GH 1 mg/m2/day
n = 10
Median age (IQR) (years): 
6.2 (5.1–71)
No treatment
n = 10
Median age (IQR) (years): 
5.8 (4.9–7.8)
n = 20
Withdrawals: none
2 years
Festen et al. 200792 GH 1 mg/m2/day
n = 15
Median (IQR) age, yr: 2.3 
(1.7–3.0)
No treatment
n = 14
Median (IQR) age, year: 
1.5 (1.2–2.7)
n = 43
Sample attrition: n = 14 
12 months
Haqq et al. 2003102 GH 0.043 mg/kg/day
n = 6
Overall mean age ± SD 
(years): 9.7 ± 3.3
Placebo
n = 6
Overall mean age ± SD 
(years): 9.7 ± 3.3
14 randomised
Sample attrition: n = 2 
Crossover 
RCT, 6 months 
in each arm
Hauffa 199799 GH: 0.15 IU/kg/day
n = 8
Mean age ± SD (years): 
8.25 ± 2.4
No treatment
n = 9
Mean age ± SD (years): 
7.56 ± 2.0
N = 19
Sample attrition: n = 3
1 year
Lindgren et al. 1998101 
and 1997100
GH 0.1 IU/kg/day
n = 15
Mean age (range) (years): 
6.8 (3.6–11.9)
No treatment
n = 14
Mean age (range) (years): 
6.4 (3.3–11.7)
Total n = 29
Sample attrition: n = 2
1 year
a  Difference between patient numbers in Whitman97 and Carrel22 = 3.
study, and did not report baseline characteristics 
separately for the two groups. The other studies 
reported baseline characteristics, which indicated 
that patients in the two treatment groups were 
comparable at the start of the study. With the 
exception of the crossover trial by Haqq and 
colleagues,102 which had a placebo-injection group, 
the studies were open label, with the comparator 
groups receiving no treatment. Although this 
could have allowed a degree of bias in reporting 
and assessing results, measurement of objective 
outcomes, such as height gained, is less likely to 
be open to bias. Only two of the studies reported 
results on an ITT basis,91,96 so attrition bias could 
have affected the remaining studies.
The outcome measures for the included studies 
are shown in Tables 15–17. The p-values in the 
tables refer to between-group differences, as this 
is the comparison of interest for this report. Some DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 14  Quality assessment of included PWS studies
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1.  Was the assignment to the 
treatment groups really random?
Un Un Un Un Un Un Un Un
2.  Was the treatment allocation 
concealed?
Un Un Un Un Un Un Un Un
3.  Were the groups similar at baseline 
in terms of prognostic factors?
Rep Rep Rep Rep Rep Not rep Rep Rep
4.  Were the eligibility criteria 
specified?
Ad Ad Ad Ad Ad Ad Ad Ad
5.  Were outcome assessors blinded 
to the treatment allocation?
Un Un Un Un Un Un Un Un
6.  Was the care provider blinded? In In In In In Un In In
7.  Was the patient blinded? In In In In In Ad In In
8.  Were the point estimates and 
measure of variability presented for 
the primary outcome measure?
Ad Ad Ad Ad Ad Ad In Ad
9.  Did the analyses include an ITT 
analysis?
In Ad In Ad In In In In
10. Were withdrawals and dropouts 
completely described?
In Ad Ad Ad In In In Ad
Ad, adequate; In, inadequate; Not rep, not reported; Rep, reported; Un, unknown.
of the studies reported statistical significance in 
change from baseline for each of the treatment 
groups individually, but not for between-group 
comparisons. To avoid confusion with the between-
group comparison p-values, such results have not 
been included in the tables below and are not 
discussed in the text. The full data extraction tables 
in Appendix 4 include any statistical significance 
for change from baseline for individual treatment 
groups without between-group comparisons.
Growth outcomes
Changes in height and other growth outcome 
measures are shown in Table 15. The infants in 
the study by Carrel and colleagues22 who received 
rhGH for a year grew an average of 6.2 cm more 
than those in the untreated group (p < 0.001). 
None of the other studies reported change in 
height as an outcome measure.
Two studies reported a statistically significant 
difference in HtSDS at end of treatment between 
treated and untreated patients.93–96 Treated 
patients in the study reported by both Carrel 
and colleagues95 and Myers and colleagues96 
had a mean HtSDS of –0.6 ± 1.2 compared with 
–1.6 ± 1.2 in the untreated group (p < 0.01). The 
studies reported by de Lind van Wijngaarden and 
colleagues93 and by Festen and colleagues94 also 
reported statistically significant improvements 
in height for rhGH-treated infants and children 
compared with unmatched controls. The rhGH-
treated infants in their study had a median HtSDS 
of –0.9 compared with –1.8 in the untreated 
patients (p = 0.003). This reflected a change from 
baseline HtSDS of +1.2 for treated infants and –0.2 
for untreated infants (p < 0.0001). After 2 years 
of treatment with rhGH, children had a median 
HtSDS of –0.5 compared with –2.6 in untreated 
children (p < 0.001).93Assessment of clinical effectiveness
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TABLE 15  Growth outcomes for PWS studies
Study Outcomes (mean ± SD) GH Control p-value
Carrel et al.22
rhGH 1 mg/m2/day (n = 15) vs. no 
treatment (n = 14); 1 year
Change in height (cm) 15.4 ± 2.3 9.2 ± 3.2 < 0.001
Height SDS –0.2 ± 1.5 –1.5 ± 0.7 nr
GV SDS 5.0 ± 1.8 1.2 ± 1.4 nr
Carrel et al.95 and Myers et 
al.96
GH 1 mg/m2/day (n = 35), vs. no 
treatment (n = 19); 1 year
Height SDS –0.6 ± 1.2 –1.6 ± 1.2 < 0.01
Mean GV (cm/year) 10.1 ± 2.5 5.0 ± 1.8 < 0.01
Mean GV SDS 4.6 ± 2.9 –0.7 ± 1.9 < 0.01
de Lind van Wijngaarden et 
al.,93 Festen et al.94 (infants)
rhGH 1 mg/m2 (n = 19) vs. no 
treatment (n = 19); 1 year
HtSDS median (IQR) –0.9 (–1.6 to –0.1) –1.8 (–3.5 to –1.4) 0.003
∆HtSDS median (IQR) 1.2 (1.0 to 1.6) –0.2 (–0.6 to 0.3) < 0.0001
de Lind van Wijngaarden et 
al.,93 Festen et al.94 (children)
rhGH 1 mg/m2 (n = 23) vs. no 
treatment (n = 21); 2 years
HtSDS median (IQR) –0.5 (–0.8 to 0.0) –2.6 (–3.4 to –2.3) < 0.0001
∆HtSDS median (IQR) 1.4 (1.3 to 1.8) –0.1 (–0.4 to 0.1) < 0.0001
Festen et al.91
rhGH 1 mg/m2/day (n = 10) vs. no 
treatment (n = 10); 2 years
Height SDS median (IQR) –0.6 (–0.9 to –0.3) –3.0 (–3.5 to –1.8) nr
Festen et al.92
rhGH 1 mg/m2/day (n = 15) vs. no 
treatment (n = 14); 1 year
Height SDS median (IQR) –1.6 (–2.1 to –0.8) –2.3 (–3.9 to –1.5) nr
Haqq et al.102
rhGH 0.043 mg/kg/day (n = 12) vs. 
placebo (n = 12); 6 months
HtSDS –1.2 ± 1.1 –1.3 ± 1.3 nr
GV (cm/year) 7.5 ± 3.5 4.5 ± 2.7 < 0.05
Hauffa99
rhGH 0.15 IU/kg/day (n = 7) vs. no 
treatment (n = 9); 1 year
Height SDS 1.07 –0.25 nr
HV SDS 5.5 –2.3 0.0012
Lindgren et al.101 and 
Lindgren et al.100
rhGH 0.1 IU/kg/day (n = 15) vs. no 
treatment (n = 12); 1 year
HtSDS mean (range) –0.4 (–2.7 –1.9) –1.8 (–5.1 –0.2) nr
GV (SDS) mean ± SD (range) 6.0 ± 3.2 (1.4–11.9) –1.4 (–3.2 –0.3) nr
Festen and colleagues91 reported that the difference 
between the two groups was statistically significant 
at year 1 (year 1 HtSDS –1.3 vs –2.8, p < 0.01). 
At year 2, the difference between the two groups 
was even greater (–0.6 compared with –3.0 in the 
treated and untreated groups, respectively), but no 
p-value was reported.91 The other five studies all 
reported that HtSDS values were higher in treated 
than in untreated children, but did not report 
whether or not differences between groups were 
statistically significant.
The five studies that used GV as an outcome 
measure all reported faster growth in the treated 
group than in the untreated group, although 
statistical significance for differences between 
groups was only reported for three of these. The 
mean GV in the studies reported by Carrel and 
colleagues95 and by Myers and colleagues96 was 
twice as fast in the treated children as in the 
untreated children (10.1 vs 5.0, p < 0.01). The 
corresponding mean GV SDS values were 4.6 in the 
treated children and –0.7 in the untreated children 
(p < 0.01), indicating faster than average growth in 
the treated group and slower than average growth 
in the untreated patients. Similarly, Hauffa and 
colleagues99 reported a positive GV SDS for treated 
children and a negative one for untreated children 
(5.5 vs –2.3, p = 0.0012). Haqq and colleagues102 
calculated GV that was 3 cm/year faster in patients 
receiving rhGH than in patients in the placebo arm 
(7.5 vs 4.5, p < 0.05).
Two of the included studies reported BA as an 
outcome measure. There was no statistically 
significant difference in BA at follow-up between DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
29
TABLE 16  Body composition outcomes for PWS studies
Study
Outcomes 
(mean ± SD) GH Control p-value
Carrel et al.22
rhGH 1 mg/m2/day (n = 15) vs no treatment 
(n = 14); 1 year
Mean % body fat 23.2 ± 8.9 32.7 ± 8.8 0.03
Change in body 
fat (%)
–4.8 ± 5.7 +4.1 ± 4.6 0.001
Change in LBM 
(kg)
3.6 ± 0.5 1.8 ± 0.7 < 0.001
Carrel et al.,95 Myers et al.96
GH 1 mg/m2/day (n = 35), vs no treatment 
(n = 19); 1 year
Body fat (%) 38.4 ± 10.7 45.8 ± 8.8 < 0.01
Lean mass (kg) 25.6 ± 4.3 21.7 ± 5.0 < 0.01
BMI (kg/m2) 23.7 ± 6.3 25.2 ± 8.9 n/s
de Lind van Wijngaarden et al.,93 
Festen et al.94 (infants)
rhGH 1 mg/m2 (n = 19) vs no treatment 
(n = 19); 1 year median (IQR)
BMI (kg/m2) 16.3 (15.7 to 18.2) 16.4 (15.4 to 19.8) nr
BMI (SDS) 0.3 (–0.1 to 1.6) 0.3 (–0.6 to 1.6) 0.72
de Lind van Wijngaarden et al.,93 
Festen et al.94 (children)a
rhGH 1 mg/m2 vs no treatment; 2 years 
median (IQR)
BMI (kg/m2) 17.5 (16.1 to 21.1) 19.1 (17.8 to 20.8)
BMI (SDS) 1.1 (–0.2 to 1.7) 1.4 (1.1 to 1.6) 0.19
Fat % (SDS) 1.9 (0.7 to 2.3) 2.4 (2.1 to 2.7) < 0.001
Fat (SDS) 1.1 (0.6 to 2.0) 4.5 (0.9 to 2.0) < 0.01
LBMage (SDS) –0.1 (–1.3 to 0.6) –2.5 (–3.8 to –1.4) < 0.001
LBMHtSDS –1.9 (–2.4 to –1.4) –2.3 (–2.7 to –1.3) < 0.05
Festen et al.91
rhGH 1 mg/m2/day (n = 10) vs no treatment 
(n = 10); 2 years median (IQR)
BMI (kg/m2) 16.3 (15.8 to 19.0) 18.5 (17.5 to 20.6) < 0.05
BMI SDS 0.4 (–0.3 to 1.1) 1.2 (0.9 to 1.5) < 0.05
LBM SDS –1.2 (–1.7 to –1.1) –2.8 (–3. to 1.9) nr
Fat % SDS 1.7 (0.9 to 1.9) 2.1 (1.9 to 2.4) nr
Festen et al.92
rhGH 1 mg/m2/day (n = 15) vs no treatment 
(n = 14); 1 year median (IQR)
BMI (kg/m2) 16.4 (15.2 to 18.5) 15.5 (14.9 to 17.6) nr
BMI SDS 0.3 (–0.9 to 1.8) –0.4 (–0.8 to 1.3) nr
Body fat (%) 22.5 (11.3 to 33.2) 22.8 (19.5 to 32.9) nr
LBM (%) 74.8 (63.7 to 82.3) 73.6 (61.6 to 75.9) nr
Haqq et al.102
rhGH 0.043 mg/kg/day (n = 12) vs placebo 
(n = 12); 6 months
BMI (kg/m2) 31.2 ± 8.9 32.8 ± 9.7 < 0.05
BMI (SDS) 2.4 ± 0.5 2.5 ± 0.6 nr
Body fat (%) 49.7 ± 5.8 54.1 ± 5.6 < 0.05
FM (kg) 26.1 ± 12.8 29.1 ± 14.1 < 0.05
Lean mass (kg) 24.1 ± 8.8 22.4 ± 8.5 < 0.05
Lindgren et al.,101 Lindgren et al.100
rhGH 0.1 IU/kg/day (n = 15) vs. no 
treatment (n = 12)
BMI (SDS) 2.0 (–2.4 to 6.7) 2.5 (0.1 to 6.1) nr
Body fat (%) 30.9 ± 11.4 38.2 ± 9.1 nr
n/s, not significant.
a  ‘n’ is unclear for many of these outcomes.
patients in the treated and untreated groups in 
the study reported by both Carrel and colleagues95 
and by Myers and colleagues.96 Lindgren and 
colleagues100,101 reported similar change from 
baseline in both groups (1.4 in the treated group, 
1.5 in the untreated group), but did not report 
whether or not there was any statistical significance 
to their results.
Body composition
Seven of the trials reported changes in body 
composition, as shown in Table 16.22,91–94,100–102 The 
trial by Hauffa and colleagues99 did not report any 
results but stated that there were no significant 
within- or between-group changes for BMI, 
skinfold thickness, waist or hip circumference.Assessment of clinical effectiveness
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Four of the trials reported a statistically 
significantly lower percentage of body fat in 
patients treated with rhGH than in those with 
no treatment or placebo. In the trial reported by 
Carrel and colleagues22 mean percentage body 
fat was 10% lower for treated patients than for 
untreated patients (p = 0.03). On average, treated 
patients in this trial experienced an approximately 
5% reduction in body fat, compared with an 
average 4% increase in the untreated patients’ body 
fat (p = 0.001). The other two trials that found a 
statistically significant difference reported that 
treated patients had approximately 4% (Haqq 
and colleagues102) or 7% (Carrel95 and Myers96) 
less body fat than those in the comparator group. 
De Lind van Wijngaarden and colleagues93 did 
not report percentage body fat for infants, but 
did report this outcome for the children in their 
study who were over 4 years of age (n = unclear). 
Children who received rhGH for 1 year had a 
median percentage body fat SDS of 1.5, compared 
with 2.3 in the control group (p < 0.001). After 
2 years of treatment, the SDS values were 1.9 
versus 2.4 for the treated and untreated groups. 
respectively (p < 0.001).
Four trials reported that patients treated with rhGH 
had statistically significantly higher LBM93,95,96,102 
or a larger improvement in LBM than untreated 
patients.22 In the trial reported by Carrel and 
colleagues,22 treated patients’ LBM increased by 
1.8 kg more than the improvement seen in the 
untreated group (3.6 vs 1.8 kg, p < 0.001). Treated 
patients in the other two studies had approximately 
2 kg102 or 4 kg95,96 more LBM than their untreated 
counterparts (p < 0.05 and p < 0.01, respectively). 
De Lind van Wijngaarden and colleagues93 
reported that change in trunk LBM was statistically 
significantly better for treated than for untreated 
infants (1.7 vs 0.7, respectively). For children, 
they reported SDS for LBM adjusted for age and 
height, as well as change in trunk LBM. All of these 
outcomes were statistically significantly better for 
treated children than for untreated children after 
both 1 and 2 years of treatment.
Six of the studies reported BMI, with mixed results. 
Festen and colleagues91 reported a BMI of 16.1 at 
year 1 for treated patients and 18.5 for untreated 
patients (p < 0.05), with similar results at year 2. 
Haqq and colleagues102 also reported a statistically 
significant difference of 1.6 in BMI (31.2 vs 32.8 
for treatment phase vs placebo phase in a small 
crossover RCT, p < 0.05). By contrast, the RCTs 
reported by Carrel95 and Myers96 and by de Lind 
van Wijngaarden93 found no statistically significant 
difference between treated and untreated patients. 
Neither of the other RCTs that reported BMI gave 
a value for between-group statistical significance, 
and both treated and untreated patients had 
similar values.92,100,101
There was no statistically significant difference 
in bone mineral density between treated and 
untreated patients in the study reported by Carrel 
and colleagues.22 No statistically significant 
differences in progression of scoliosis or onset of 
scoliosis in either infants or children were reported 
by de Lind van Wijngaarden.93
Biochemical and metabolic 
markers
The included studies reported a range of 
biochemical and metabolic markers, and key 
results are included in Table 17 – see Appendix 4 
for further outcomes. For conciseness, only the key 
outcomes of IGF-1, IGFBP-3, insulin and glucose 
are discussed in the narrative summary below.
All of the RCTs reported IGF-1 values or IGF-1 SDS 
as an outcome measure, and found that levels were 
higher in rhGH-treated patients than in untreated 
children. Three studies reported that IGF-1 values 
were statistically significantly higher in rhGH-
treated patients than in untreated patients.22,95,96,102 
Three studies reported that IGF-1 SDS values were 
statistically significantly higher in treated than in 
untreated patients.91–94
The included studies had well-matched patient 
groups, whose baseline characteristics were 
similar in the treated and untreated groups. The 
only exception was the crossover study by Haqq 
and colleagues,102 which presented baseline 
characteristics for the study population as a whole, 
and the study by Lindgren and colleagues,100,101 
which reported slightly lower baseline GV SDS in 
the rhGH group [–1.9 ± 2.0, range –6.4 to –0.9, vs 
–0.1 (SD not reported) range –1.7 to –2.71].
Three of the RCTs reported IGFBP-3 values,93,95,96 
and these were higher in treated patients than in 
untreated patients. In the trial reported by Carrel95 
and Myers,96 patients treated with rhGH had a 
mean level of 3.5 mg/ml compared with 2.07 in the 
untreated patients (p < 0.01). Haqq and colleagues 
reported mean values of 6029 ng/ml in the treated 
patients and 4247 ng/ml in the untreated patients 
(p < 0.01).102 Treated children and infants in the 
study reported by de Lind van Wijngaarden and 
colleagues93 had higher IGFBP-33 values than DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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untreated children, although no p-values were 
reported for between-group comparisons.
The three studies that reported IGFBP-3 SDS 
found positive values in the treated children, 
with SDS of 0.492,93 and 0.5 (year 1) or 0.6 
(year 2).91,93 In comparison, untreated patients’ 
median scores were between –2.491,93 and –3.192 
in year 1 and between –1.793 to –1.891 in year 2. 
Differences between treated and untreated patients 
were statistically significant in all three studies 
(p < 0.05,92 p < 0.001,93 p < 0.00191).
The RCT reported by Carrel and colleagues22 
reported that there was no statistically significant 
difference in fasting insulin levels between the 
treated and untreated infants in their study (5.6 vs 
5.7 µIU/ml, respectively). Two other studies91,95,96 
reported slightly higher insulin levels in treated 
patients, but did not report p-values. The study by 
Haqq and colleagues102 reported very similar levels 
in both treated and untreated patients. Glucose 
levels appeared to be similar in both treated and 
untreated patients in the two studies that presented 
this as an outcome, but neither study reported any 
p-values.91,102
TABLE 17  Biochemical and metabolic markers for PWS studies
Study
Outcomes 
(mean ± SD) GH Control p-value
Carrel et al.22
rhGH 1 mg/m2/day (n = 15) vs no treatment 
(n = 14); 1 year
IGF-1 (ng/ml) 231 ± 98 51 ± 28 < 0.001
Carrel et al.95 and Myers et al.96
GH 1 mg/m2/day (n = 35), vs no treatment 
(n = 19); 1 year
IGF-1 (ng/ml) 522 ± 127 121 ± 52 < 0.01
IGFBP-3 (mg/l) 3.5 ± 0.73 2.07 ± 0.45 < 0.01
de Lind van Wijngaarden et al.93 and 
Festen et al.94 (infants)
rhGH 1 mg/m2 (n = 19) vs no treatment 
(n = 19); 1-year median (IQR)
IGF-1 (ng/ml) 179.0 (119.5 to 241.0) 
(n = 12)
33.0 (22.5 to 47.8) 
(n = 15)
nr
IGF-1 SDS 2.5 (1.4 to 2.9) –2.6 (–4.1 to –0.7) < 0.0001
IGFBP-3 (ng/ml) 2.2 (1.6 to 2.4) 
(n = 12)
0.9 (0.7 to 1.3) 
(n = 12)
nr
IGFBP-3 SDS 0.5 (0.0 to 1.2) 
(n = 12)
–2.4 (–3.5 to –1.2) 
(n = 12)
nr
de Lind van Wijngaarden et al.93 and 
Festen et al.94 (children)a
rhGH 1 mg/m2 vs no treatment; 2-year 
median (IQR)
IGF-1 (ng/ml) 424.0 (313.0 to 570.0) 
(n = 20)
92.0 (61.8 to 130.0) 
(n = 16)
nr
IGF-1 SDS 2.4 (2.1 to 2.8) –1.6 (–2.5 to –1.0) < 0.0001
IGFBP-3 (ng/ml) 2.8 (2.6 to 3.2) 
(n = 20)
1.5 (1.2 to 1.8) 
(n = 16)
nr
IGFBP-3 SDS 0.6 (0.3 to 1.1) 
(n = 20)
–1.7 (–2.3 to –1.2) 
(n = 16)
< 0.001
Festen et al.91
rhGH 1 mg/m2/day (n = 10) vs no treatment 
(n = 10); 2-year median (IQR)
IGF-1 SDS year 2 2.3 (2.1 to 2.9) –2.0 (–2.7 to 1.0) < 0.001
IGFBP-3 SDS 
year 2
0.6 (0.4 to 1.1) –1.8 (–2.7 to –1.5) < 0.001
Festen et al.92
rhGH 1 mg/m2/day (n = 15) vs no treatment 
(n = 14); 1-year median (IQR)
IGF-1 SDS 1.7 (0.1 to 2.5) –2.6 (–4.1 to –0.4) < 0.001
IGFBP-3 SDS 0.4 (–0.3 to 1.1) –3.1 (–4.0 to –2.2) < 0.05
Haqq et al.102
rhGH 0.043 mg/kg/day (n = 12) vs placebo 
(n = 12); 6 months
IGF-1 (ng/ml) 720 ± 379 232 ± 182 < 0.001
IGFBP-3 (ng/ml) 6029 ± 1311 4247 ± 1209 < 0.01
Lindgren et al.101 and Lindgren et al.100
rhGH 0.1 IU/kg/day (n = 15) vs no treatment 
(n = 12); 1 year
IGF-1 SDS 1.8 (–0.1 to 4.1) –1.4 (–2.9 to –0.3) nr
a  n = unclear for IGF-1 SDS.Assessment of clinical effectiveness
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Quality of life
None of the included studies reported a measure of 
HRQoL.
Adverse events
None of the studies reported AEs in any detail. 
Neither of the studies reported by de Lind van 
Wijngaarden and colleagues93 and by Festen 
and colleagues94 nor the one reported by 
Festen and colleagues91 reported on AEs at all. 
In the other study by Festen and colleagues,92 
the paper stated that rhGH treatment did not 
induce disadvantageous effects on carbohydrate 
metabolism, sleep-related breathing disorders or 
thyroid hormone levels. Hauffa and colleagues99 
reported that one patient in the rhGH group 
developed pseudotumour cerebri after increasing 
the starting dose to the final dose, but their 
symptoms resolved on discontinuation. No 
abnormalities of glucose regulation were observed 
in either group. None of the patients in the study 
reported by Carrel and others95,96 experienced 
pseudotumour cerebri. Two of their patients who 
received rhGH experienced headaches within the 
first 3 weeks, but these resolved with temporary 
stoppage and gradual reinstitution of treatment.
Carrel and colleagues22 commented that there 
was no evidence of changes in the prevalence of 
scoliosis with rhGH treatment, although another 
paper reporting the same study reported that 
there was progression of scoliosis in one patient.97 
Lindgren and colleagues100,101 and Haqq and 
colleagues102 reported that there was no severe 
progression of scoliosis (angle ≥ 20°) during their 
RCTs.
Lindgren and colleagues100,101 noted that one child 
in their study developed low levels of thyroxine 
without any change in TSH levels. He received 
substitution with l-thyroxine during the rhGH 
treatment. Carrel and colleagues22 commented that 
no child in their RCT required thyroid hormone 
therapy. Haqq and colleagues102 reported that only 
one patient required thyroid hormone replacement 
while receiving rhGH treatment.
Summary
The evidence for the clinical effectiveness of HGH 
as a treatment for PWS comes from eight small 
RCTs (one crossover trial and seven parallel group 
trials), reported in 13 publications. The included 
studies were generally poorly reported and only 
two91,96 presented results on an ITT basis.
Only one of the studies reported changes in height. 
Infants who received rhGH for 1 year grew an 
average of 6.2 cm more than those in the untreated 
group (p < 0.001).22 Two studies reported a 
statistically significant difference in HtSDS between 
treated and untreated patients. The difference was 
1 SDS (favouring rhGH treatment) in one study,95,96 
and > 2 (year 2) in the other.93
Treated patients grew 3 cm/year faster than 
untreated patients in one RCT102 and 5 cm/year 
faster in another.95,96 Another study reported 
a positive GV SDS for treated patients and a 
negative one for untreated children (5.5 vs –2.3).99 
The differences between groups were statistically 
significant in all three studies.
Two of the included studies reported BA as an 
outcome measure, and this was similar in both 
treatment groups.95,96,100,101
Four trials reported a statistically significantly lower 
percentage of body fat (between 1%93 and 10%22 
lower) in patients treated with rhGH than in those 
with no treatment or who were given placebo.
Three trials reported that patients treated 
with rhGH had statistically significantly higher 
LBM,95,96,102 or a larger improvement in LBM, 
than untreated patients.22 One study reported that 
LBM SDS was significantly better in treated than in 
untreated children.93
Two studies found that BMI was statistically 
significantly lower in treated patients than in 
untreated patients.91,102 However, another RCT95,96 
found no statistically significant difference between 
the two groups, and three more studies did not 
report a p-value for between-group statistical 
significance.92,93,100,101
Insulin-like growth factor-1 values were statistically 
significantly higher in patients treated with rhGH 
than in untreated patients in three studies.
Two RCTs reported IGFBP-3 values that were 
statistically significantly higher in treated patients 
than in untreated patients.95,96,102 Three studies91–93 
reported positive IGFBP-3 SDS values in treated 
patients and negative values in untreated children; 
differences between the groups were statistically 
significant.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Four of the studies reported insulin levels, with 
varying results. One study22 reported that there 
was no statistically significant difference between 
treated and untreated infants. Insulin levels in 
another study95,96 appeared to be considerably 
higher in treated patients than in untreated 
patients. Another study91 reported higher insulin 
levels in treated patients at year 1 but lower levels 
than in untreated patients at year 2. Similar values 
in both groups were also reported.102
None of the included studies reported a measure of 
HRQoL.
None of the studies reported AEs in any detail.
Chronic renal insufficiency
Quantity and quality of research 
available
Six RCTs of patients with CRI met the inclusion 
criteria for this review,103–108 and their key 
characteristics are shown in Table 18 – further 
details are shown in Appendix 4. The inclusion 
criteria for this systematic review specified that 
children should be prepubertal. Five of the 
studies stated in their inclusion criteria that 
patients should be prepubertal/Tanner stage 1, 
but one study included both prepubertal and 
pubertal patients.107 However, we have included 
outcome measures from this study where data were 
presented separately for prepubertal children and 
pubertal children.
The included RCTs were of different designs (two 
crossover and four parallel group). Three of the 
parallel-group RCTs were open label, with the 
comparator groups receiving no treatment,103,106,107 
and one was placebo controlled.108 The two 
crossover studies104,105 had placebo and treatment 
phases. There does not appear to have been a 
washout phase in either of the crossover trials, 
so a carry-over effect could have affected results. 
The doses all appeared to correspond to those 
specified in the marketing authorisation, but 
dosages were reported differently, with some using 
IUs and others using mgs, and some using doses 
based on weight, whereas others used surface area. 
Randomised treatment duration was 6 months in 
the two crossover trials,104,105 2 years in one study108 
and 12 months in the other studies.
Three of the studies investigated rhGH treatment 
in children who had received a kidney transplant at 
least 1 year before starting the study103,105,107 and the 
other three studied children who had CRI.104,106,108 
There was considerable variation in the age of 
children in the included studies, ranging from 
5.6106 to 12.6107 years old. Two of the studies were 
relatively large (n = 203107 and n = 125108), one was 
of medium size (n = 69106), and the remaining three 
were rather small (n = 23,103 n = 20104 and n = 11105).
Only one study107 specified a primary outcome. The 
Pharmacia and Upjohn Study Group107 designed 
their study to test GFR, with GV and HtSDS being 
used as secondary outcomes. The other studies 
reported various outcomes relating to growth, body 
composition and biochemical/metabolic markers, 
but did not specify which were primary outcomes. 
Only Sanchez and colleagues103 mentioned a power 
calculation, and this appears to have been based 
on bone formation rates in a previous study, so it 
is not clear what the primary outcome was for the 
included study. The lack of clarity around primary 
outcomes and power calculations, together with the 
small size of three of the studies,103–105 suggests that 
the trials may have been underpowered to detect 
differences in outcomes relating to growth and 
body composition.
The included studies had well-matched patient 
groups, whose baseline characteristics were similar 
in the treated and untreated groups.
None of the included RCTs provided clear 
information on method of randomisation or 
concealment of allocation (Table 19), so it is not 
possible to say whether or not selection bias 
may have affected these studies. The studies all 
reported eligibility criteria, and presented baseline 
characteristics that indicated that groups (within 
trials) were similar at the start of the studies.
The studies gave little information on whether 
or not outcome assessors were blinded to 
patients’ treatment groups, although Sanchez 
and colleagues103 did comment that skeletal 
radiographs were reviewed by a single observer 
who had no information about patients’ clinical 
condition or treatment status. In addition, three of 
the trials gave patients in the comparator group no 
treatment, so it would have been clear to patients 
and their care providers whether or not they were 
receiving rhGH. In three trials, patients in the 
comparator group had placebo injections. It is 
not clear whether or not their care providers were 
also blinded to treatment group. Lack of blinding 
could have led to performance bias in measuring 
treatment effect, but the objective nature of 
outcomes such as height change and GV would 
have protected against bias to a certain degree.Assessment of clinical effectiveness
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TABLE 18  Characteristics of CRI studies
Reference Intervention Control group
Total randomised and 
withdrawals
Duration of 
randomised 
treatment
The Pharmacia 
and Upjohn Study 
Group 1996107
rhGH 1 IU/kg/week
n = 106
Mean ± SD age (years): 
12.6 ± 3.4
No treatment
n = 97
Mean ± SD age (years): 
12.1 ± 3.1
Total n = 203
Sample attrition: n = 49
1 year
Fine et al. 2004108 rhGH 0.05 mg/kg/day
n = 82
Mean ± SD age (years): 
6.0 ± 3.9
Placebo n = 43
Mean ± SD age (years): 
5.7 ± 3.6
Total n = 125
Sample attrition: rhGH 26, 
placebo 15
2 years
Hokken-Koelega 
et al. 1991104
rhGH 4 IU/m2/day then 
placebo
n = 8
Median (range) age 
(years): 8.7 (4.4 to 11.3)
Placebo, then 4 IU/m2/
day rhGH
n = 8
Median (range) age 
(years): 8.6 (4.4 to 16.0)
Total n = 20
Sample attrition: n = 4
6 months in 
each arm
Hokken-Koelega 
et al. 1996105
rhGH/placebo 4 IU/m2 
daily s.c.i.
n = 6
Median (range) age 
(years): 12.1 (9.1 to 18.7)
Placebo/4 IU/m2 rhGH 
daily s.c.i.
n = 5
Median (range) age 
(years): 11.1 (8.3 to 14.9)
Total n = 11
No withdrawals
6 months in 
each arm
Powell et al. 
1997106
rhGH 0.05 mg/kg/day
n = 30
Mean age (years) ± SD: 5.6 
± 2.0
No treatment
n = 14
Mean age (years) ± SD: 
5.7 ± 2.6
Total: n = 69
Sample attrition: 20 
withdrew; 4 rhGH patients 
and 1 control patient 
excluded from analyses
1 year
Sanchez et al. 
2002103
rhGH 0.05 mg/kg/day
n = 12
Mean age (± SD) 9.7 ± 4.5
No treatment
n = 11
Mean age (± SD) 11 ± 1.8
Total: n = 23
Sample attrition: rhGH, 
n = 1; control, n = 1
12 months
s.c.i., subcutaneous injection.
TABLE 19  Quality assessment of CRI studies
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1.  Was the assignment to the treatment groups really random? Un Un Un Un Un Un
2.  Was the treatment allocation concealed? Un Un Un Un Un Un
3.  Were the groups similar at baseline in terms of prognostic 
factors?
Rep Rep Rep Rep Rep Rep
4.  Were the eligibility criteria specified? Ad Ad Ad Ad Ad Ad
5.  Were outcome assessors blinded to the treatment 
allocation?
Un Un Un Un Un Par
6.  Was the care provider blinded? In Un Un Un In In
7.  Was the patient blinded? In Ad Ad Ad In In
8.  Were the point estimates and measure of variability 
presented for the primary outcome measure?
Ad Ad Ad Ad Ad Ad
9.  Did the analyses include an ITT analysis? In In In Ad In In
10. Were withdrawals and dropouts completely described? Ad Ad Ad Ad Ad Ad
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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All the studies presented results as mean values 
with SDs or standard errors to give a measure 
of variability. The studies all provided adequate 
details of any patients who withdrew from the 
study, but only one study105 presented results on an 
ITT basis (no patients withdrew from this study). 
Attrition bias could therefore have affected the 
results of the non-ITT studies, i.e. if there had 
been unbalanced and selective withdrawal from 
different treatment groups within a study, or if 
particular patients were more likely to withdraw or 
be excluded from the analysis.
There was a statistically significant difference 
between treated and untreated children’s birth 
length SDS in one study,111 but baseline height was 
the same in both groups. The very small study by 
de Zegher and colleagues113 reported slightly lower 
baseline GV in treated compared with untreated 
children [5.1 (range 4.0–6.8) vs 6.4 (range 5.3–
7.5) cm/year, respectively]. Otherwise, the studies’ 
treatment groups were generally comparable at 
baseline, with no discernible differences between 
treated and untreated patients.
The outcome measures for the included studies are 
shown in Tables 20–22 below. The p-values in the 
tables refer to between-group differences.
Growth outcomes
Key growth outcome measures are shown in Table 
20 – see Appendix 4 for other outcome measures. 
Only one of the included studies reported height 
gain. Powell and colleagues106 found that treated 
children grew an average of 3.6 cm more than their 
untreated counterparts after 1 year of treatment 
(9.1 cm vs 5.5 cm, p < 0.0001). All children in 
the study by The Pharmacia and Upjohn Study 
Group107 experienced an improvement in HtSDS, 
but this was statistically significantly higher in the 
children treated with rhGH than in the untreated 
children (0.6 vs 0.1, p < 0.0001). RhGH-treated 
children in the study by Powell and colleagues106 
had a statistically significantly higher HtSDS at end 
of 12 months than untreated children (0.8 vs 0.0, 
p < 0.0001).
One of the six studies reported change in GV, 
and this was statistically significantly faster in 
treated than in untreated children.107 Four studies 
reported GV at end of treatment, all reporting 
statistically significantly faster growth in children 
who received rhGH treatment than in untreated 
children.103–105,107,108 The 2-year study by Fine and 
colleagues108 reported that rhGH-treated patients’ 
GV in the first year was 4.2 cm/year faster than the 
untreated patients’ (p < 0.00005). The difference 
between the two groups was less in the second year 
(2.3 cm/year faster in rhGH-treated children) but 
the difference between groups was still statistically 
significant (p < 0.00005) when comparing the 
difference in change from baseline in those 
patients who completed 2 years of the study. A 
statistically significant difference in GV between 
groups of just over 3 cm/year was reported by 
both The Pharmacia and Upjohn Study Group107 
(3.4 cm/year difference, p < 0.0001) and by Sanchez 
and colleagues103 (3.2 cm/year difference, p < 0.01).
The two crossover studies by Hokken-Koelega 
and colleagues104,105 also reported statistically 
significantly faster growth velocities in patients 
during the rhGH phase compared with the 
placebo phase, with an average of 2.9 cm/6 months 
difference in velocity. In the study of children 
with CRI, patients who received rhGH followed 
by placebo grew at an average velocity of 
5.2 cm/6 months during treatment compared 
with 1.5 cm/6 months in the placebo phase. 
Patients who received placebo followed by rhGH 
grew 2.4 cm/6 months during the placebo phase 
compared with 4.4 cm/6 months in the treatment 
phase. The overall mean effect of rhGH was 
statistically significant (p < 0.0001). Statistical 
tests showed that there was no significant carry-
over effect (–0.04 cm/6 months, p = 0.94). The 
crossover study in children who had received a 
renal transplant had similar results. Patients grew, 
on average, 3.8 cm/6 months faster during the 
active treatment phase in the group who received 
rhGH followed by placebo, and 2 cm/6 months 
faster in the active treatment phase for patients 
who received placebo followed by rhGH (p < 0.0001 
for overall effect of rhGH vs placebo).105 Hokken-
Koelega and colleagues reported that there was 
no significant carry-over effect (0.5 cm/6 months, 
p = 0.30).104,105
The two crossover trials,104,105 but none of the 
parallel-group RCTs, reported GVSDS. Both trials 
reported positive SDS values during the active 
treatment phases and negative scores during the 
placebo phases. The reported difference in scores 
between active treatment and placebo phases in the 
trial of children with chronic renal failure (CRF) 
was 7.7 (p < 0.0001),104 and in the trial of children 
who had received a renal transplant the difference 
was 8.0 (p < 0.0001).105
Bone age was reported by five of the six studies. 
The studies by Powell and colleagues106 and 
Sanchez and colleagues103 reported that there 
was no statistically significant difference in BA Assessment of clinical effectiveness
36
TABLE 20  Growth outcomes for CRI studies
Study
Outcomes 
(mean ± SD) rhGH (SD) Control (SD) p-value
The Pharmacia and Upjohn Study Group107
rhGH 1 IU/kg/week (n = 30) vs no treatment 
(n = 28); 1 year
Change in HtSDS +0.6  0.3 +0.1 ± 0.3 < 0.0001
Change in GV (cm/
year)
3.7 ± 1.6 0.3 ± 1.6 < 0.0001
Fine et al.108
rhGH 0.05 mg/kg/day (n = 82) vs placebo (n = 43); 
2 years
HtSDS –1.6 –2.9 nr
GV (cm/year) 7.8 ± 2.1 
(n = 55)
5.5 ± 1.9 (n = 27) < 0.00005
Powell et al.106
rhGH 0.05 mg/kg/day (n = 30) vs no treatment 
(n = 14); 1 year
Height gain (cm) 9.1 ± 2.8 5.5 ± 1.9 < 0.0001
HtSDS change 
from baseline
0.8 ± 0.5 0.0 ± 0.3 < 0.0001
Sanchez et al.103
rhGH 0.05 mg/kg (n = 12) vs no treatment (n = 11); 
1 year
HtSDS –1.1 ± 1.0 nr nr
Annual GV (cm/
year)
8.0 ± 2.1 4.8 ± 1.7 < 0.01
Hokken-Koelega et al.104
1: 4 IU/m2 rhGH then placebo (n = 8)
2: Placebo then 4 IU/m2 rhGH (n = 8); 6 months 
each arm
GV (cm/6 months) 1: 5.2 (1.2) 1: 1.5 (0.4) < 0.0001
2: 4.4 (1.6) 2: 2.4 (1.0)
HV SDS 1: 6.9 (2.4) 1: –3.0 (1.6) < 0.0001
2: 5.0 (4.5) 2: –0.5 (3.2)
Hokken-Koelega et al.105
1: 4 IU/m2 rhGH then placebo (n = 6)
2: Placebo then 4 IU/m2 rhGH (n = 5); 6 months 
each arm
GV (cm/6 months) 1: 5.3 (1.0) 1: 1.5 (0.9) < 0.0001
2: 3.9 (1.3) 2: 1.9 (0.7)
HV SDS 1: 9.1 (2.9) 1: –1.3 (2.9) < 0.0001
2: 5.3 (4.0) 2: –0.4 (1.7)
between the treated and untreated patients. The 
two crossover studies by Hokken-Koelega and 
colleagues reported small differences with slightly 
lower mean ages for rhGH overall compared 
with placebo (mean differences –0.01 years104 and 
–0.5 years105) but did not present any p-values for 
these comparisons. Fine and colleagues108 reported 
that the change in BA between baseline and 2 years 
was greater in patients treated with rhGH than in 
untreated patients for those who completed both 
years of the study (2.3 vs 1.6 years, p = 0.0001).
Body composition
Measures of body composition were reported 
by three of the studies, and selected outcomes 
are shown in Table 21.103,106,108 Other outcomes 
are tabulated in the data extraction forms in 
Appendix 4. Children treated with rhGH gained 
statistically significantly more weight than those 
in the control groups in the studies reported by 
Fine and colleagues108 (2.1 kg more in 2 years, 
p = 0.0004) and by Powell and colleagues106 (1.3 kg 
more in 1 year, p = 0.007). However, there was no 
statistically significant difference between groups 
in change in weight for HtSDS. Sanchez and 
colleagues103 did not report actual weight gain, 
but reported a statistically significant difference in 
change in SDS for weight that favoured treatment 
with rhGH (0.2 vs –0.3, p < 0.01). Although 
Powell and colleagues106 reported a statistically 
significantly greater weight gain in treated patients, 
the weight for HtSDS was the same for both groups 
(0.4, p = 0.8703).
Biochemical markers
The included studies reported a range of 
biochemical and metabolic markers, and these are 
included in Table 22. For conciseness, only the key 
outcomes of IGF-1, IGFBP-3, insulin and glucose 
are discussed in the narrative summary below. In 
addition, the studies reported a range of markers 
related to liver function. These are not reported 
in Table 22 or discussed in the narrative summary 
below, but are included in the data extraction 
forms in Appendix 4. No data from Sanchez and 
colleagues are included in Table 22 as their results 
focussed on liver function and did not report IGF, 
insulin or glucose.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 21  Body composition outcomes for CRI studies
Study
Outcomes 
(mean ± SD) GH Control p-value
Fine et al.108
rhGH 0.05 mg/kg/day (n = 82) vs placebo 
(n = 43)
Weight gain after 2 years 
(kg)
6.7 ± 2.2 4.6 ± 2.7 0.0004
Powell et al.106
rhGH 0.05 mg/kg/day (n = 30) vs no 
treatment (n = 14)
Weight gain (kg) 3.5 ± 1.5 2.2 ± 1.0 0.007
Change in weight for 
HtSDS
0.4 ± 0.7 0.4 ± 0.5 0.8703
Sanchez et al.103
rhGH 0.05 mg/kg (n = 12) vs no 
treatment (n = 11)
Change in SDS for weight 0.2 ± 0.3 –0.3 ± 0.3 < 0.01
TABLE 22  Biochemical and metabolic markers from CRI studies
Study Outcomes (mean ± SD) GH Control p-value
Fine et al.108
rhGH 0.05 mg/kg/day (n = 82) vs placebo 
(n = 43)
IGF-1 (µg/l) 244 ± 128 
(n = 47)
135 ± 80 (n = 20) 0.0001
Powell et al.106
rhGH 0.05 mg/kg/day (n = 30) vs no 
treatment (n = 14)
IGF-1 SDS change from 
baseline
0.2 ± 1.0 nr 0.006
IGFBP-3 SDS change from 
baseline
4.0 ± 3.2 nr 0.011
Hokken-Koelega et al.104
1: 4 IU/m2 rhGH then placebo (n = 8)
2: Placebo then 4 IU/m2 rhGH (n = 8)
IGF-1 ng/ml 1: 264 ± 168 1: 160 (104) nr
2: 268 ± 120 2: 160 (95)
IGF-1 SDS for BA 1: 2.6 ± 2.0 1: –0.2 ± 1.5 < 0.0001
2: 2.9 ± 2.0 2: 0.3 ± 1.6
IGFBP-3 ng/ml 1: 7708 ± 2323 1: 6102 ± 1892 nr
2: 8706 ± 2275 2: 6501 ± 1988
IGFBP-3 SDS for BA 1: 5.0 ± 1.3 1: 3.7 ± 1.3 < 0.0001
2: 5.2 ± 1.4 2: 3.9 ± 1.4
Hokken-Koelega et al.105
1: 4 IU/m2 rhGH then placebo (n = 6)
2: Placebo then 4 IU/m2 rhGH (n = 5)
IGF-1 ng/ml 1: 594 ± 180 1: 240 ± 143 nr
2: 488 ± 237 2: 321 ± 94
IGF-1 SDS for BA 1: 5.4 ± 2.8 1: 1.0 ± 2.5 < 0.0001
2: 3.4 ± 0.5 2: 6.4 ± 1.9
IGFBP-3 ng/ml 1: 7457 ± 2088 1: 5681 ± 1588 nr
2: 8495 ± 2921 2: 6228 ± 2193
IGFBP-3 SDS for BA 1: 4.5 ± 1.5 1: 3.7 ± 2.9 nr
2: 3.9 ± 1.5 2: 5.3 ± 1.5
Four studies reported IGF-1 as an outcome 
measure,104–106,108 and levels were higher in treated 
patients than in untreated patients. IGF-1 values 
were statistically significantly higher in treated 
patients at both years 1 and 2 in the study by 
Fine and colleagues108 (p = 0.0004 and p = 0.0001, 
respectively), but only approximately one-half 
of the randomised patients were included in this 
analysis. Powell and colleagues106 also reported 
that IGF-1 and IGF-1 SDS values were statistically 
significantly higher for treated patients than 
untreated patients (p < 0.006).106 The two crossover 
studies by Hokken-Koelega and colleagues104,105 
reported that IGF-1 SDS for BA was statistically Assessment of clinical effectiveness
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significantly higher for treated than for untreated 
patients (2.7 higher in treated children with CRF104 
and 3.7 higher in treated children who were post 
transplant,105 p < 0.0001 for both).
Three studies reported IGFBP values,104–106 and 
in all three the IGFBP-3 values were higher in 
the treated patients. Powell and colleagues106 
reported that IGFBP-3 and corresponding SDS 
values were statistically significantly higher 
in treated patients than in untreated patients 
(p < 0.011). Hokken-Koelega and colleagues104 
reported that the IGFBP-3 SDS for bone age was 
statistically significantly higher for treated patients 
(p < 0.0001).
Fine and colleagues108 reported that fasting insulin 
levels were statistically significantly higher in 
rhGH patients than in untreated patients after 
2 years (p = 0.03). Similarly, Hokken-Koelega and 
colleagues105 reported slightly higher insulin values 
in treated children, but did not present p-values.
Quality of life
Five of the included studies did not report QoL as 
an outcome measure. One study107 reported QoL 
but did not present data for prepubertal patients 
(the licensed patients) separately from pubertal 
patients, so it is not discussed here.
Adverse events
Hokken-Koelega and colleagues105 reported that 
no patients in their study had an acute rejection 
episode, and that there were no SAEs. Sanchez 
and colleagues103 reported that two patients with 
normal rates of bone formation experienced acute 
rejection episodes after 3 and 12 months of rhGH 
therapy. One of these episodes was associated 
with non-compliance to immunosuppressive 
medications and both reversed after treatment 
with methylprednisolone. There were no rejection 
episodes in untreated patients.
Fine and colleagues108 reported that there were 
no differences between groups in year 1. In the 
second year, eight of 55 rhGH patients experienced 
asthma or wheezing, but all episodes were 
preceded by upper respiratory tract infections. 
Fine and colleagues108 reported that there were 
no clinically significant side effects associated with 
rhGH treatment. Hokken-Koelega and colleagues104 
reported that serum alkaline phosphate was 
significantly increased during rhGH treatment, 
but returned to pretreatment levels when rhGH 
therapy was replaced by placebo (p < 0.0001). 
There was no significant change in parathyroid 
hormone concentration during either treatment 
schedule, and thyroid function was reported to 
have been normal. The Pharmacia and Upjohn 
Study Group107 did not present AEs separately for 
prepubertal and pubertal children, so no data are 
reported here. Powell and colleagues106 did not 
report AEs from their study.106
Summary
The evidence for the clinical effectiveness of rhGH 
as a treatment for short stature owing to CRI comes 
from six RCTs, two of which were crossover trials. 
The trials were generally poorly reported, and only 
one105 presented ITT results. Three of the studies 
had fewer than 25 participants, which suggests that 
the trials may have been underpowered to detect 
differences in outcomes relating to growth and 
body composition.
One study reported that rhGH-treated patients 
grew an average of 3.6 cm more than their 
untreated counterparts after 1 year of treatment. 
Two studies reported that HtSDS was statistically 
significantly better in treated children than in 
untreated children.
Five studies reported that change in GV or GV 
SDS was statistically significantly faster for children 
who received rhGH treatment than for untreated 
children, with between-group differences in velocity 
ranging from 3.2 cm/year103 to 4.2 cm/year108 in the 
parallel-group trials.
Two studies reported that there was no statistically 
different difference in BA between the treated and 
untreated patients. Two reported small differences 
with slightly lower mean ages for rhGH overall 
compared with placebo, but did not present any 
p-values for these comparisons. One study reported 
that the change in BA between baseline and 2 years 
was greater in patients treated with rhGH than in 
untreated patients for those who completed both 
years of the study.
IGF-1 levels were statistically significantly higher in 
treated patients than in untreated patients in two of 
the four studies that reported this outcome.
Three studies reported that IGFBP-3 values were 
higher in the treated patients. Only one of these 
reported that differences between groups were 
statistically significant.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Insulin levels were statistically significantly higher 
in children receiving rhGH than in those receiving 
placebo injections or no treatment.
Four studies presented data on AEs. Two rhGH-
treated patients in one study experienced acute 
rejection episodes (one associated with non-
compliance to immunosuppressive medications) 
but both reversed after treatment with 
methylprednisolone. There were no SAEs reported.
Children born SGA
Quantity and quality of research 
available
In the UK, rhGH is licensed for use in children 
born SGA who are over 4 years of age, have a 
current HtSDS of < 2.5, with a parental adjusted 
HtSDS of –1, had a birth weight and/or length SDS 
of < –2, and have failed to show catch-up growth 
during the previous year (HV SDS < 0). No RCTs 
meeting these criteria were identified. Following 
discussion with NICE, the criteria were amended 
in order to include evidence from RCTs on rhGH. 
As discussed above (see Inclusion criteria), the 
following amended criteria were agreed: growth 
disturbance (current height < –2.5, no reference 
to parental height), birth weight and/or length 
< –2 SD and failure to show catch-up growth (no 
stated criteria) by the age of 3 years.
Six studies109–114 met the amended inclusion criteria 
for this review, and their key characteristics are 
shown in Table 23 – see Appendix 4 for further 
details. In the UK, the licensed dose of rhGH for 
TABLE 23  Characteristics of SGA studies
Reference Intervention Control group
Total randomised  
and withdrawals
Duration of 
randomised treatment
Phillip et al. 
2009114
1: rhGH 0.033 mg/kg/
day (n = 51), mean age 
(± SD): 5.5 ± 1.5
2: rhGH 0.1 mg/kg/
day (n = 51), mean age 
(± SD): 5.5 ± 1.4
No treatment, 
(n = 47)
Mean age (± SD): 
5.6 ± 1.4
Total n = 151
Sample attrition: 2
1 year
Carel et al. 2003111 rhGH: 0.2 IU/kg/day, 
n = 112
Mean age 
(± SD):12.7 ± 1.4
No treatment, 
n = 56
Mean age (± SD): 
12.8 ± 1.6
Total n = 168
Sample attrition:
For treatment: rhGH, 
n = 21; control, n = 23
For analysis: rhGH, n = 10; 
control, n = 9 
Until AH reached 
(mean = 2.7 ± 0.6 years)
De Schepper et al. 
2007 109
High-dose rhGH: 
66 ± 3 µg/kg/day, n = 11
Mean age (± SD): 
5.1 ± 1.6
No treatment, 
n = 14
Mean age (± SD): 
5.1 ± 1.4
Total n = 40
Sample attrition: n = 15
2 years
de Zegher et al. 
1996112
1: rhGH 0.2 IU/kg/day, 
n = 20
2: rhGH 0.3 IU/kg/day, 
n = 21
Mean age (± SD):
1: 5.4 ± 0.5
2: 5.1 ± 0.4
No treatment, 
n = 13
Mean age (± SD): 
4.9 ± 0.5
Total: n = 54
Sample attrition:
rhGH 1: n = 2
rhGH 2: n = 1
Control: n = 1
2 years
de Zegher et al. 
2002113
High-dose rhGH 
100 µg/kg/day, n = 9
Mean age (range): 6.3 
(4.0–8.0)
No treatment, n = 4
Mean age (range): 
4.7 (2.3–6.3)
Total n = 13
Sample attrition: not 
reported
2 years
Lagrou et al. 
2008110
rhGH 0.066 mg/kg/day, 
n = 20
Mean age (± SD): 
5.5 ± 1.6
No treatment, 
n = 20
Mean age (± SD): 
5.1 ± 1.3
Total n = 40
Sample attrition: 1
2 years
Licensed dose = 35 µg/kg/day = 0.035 mg/kg/day = 0.105 IU/kg/day.Assessment of clinical effectiveness
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SGA children is 0.035 mg/kg/day, which equates 
to 0.105 IU/kg/day. Only the study by Phillip 
and colleagues114 included a treatment arm with 
the licensed dose; the other studies all used 
approximately two or three times the UK licensed 
dose.
Treatment duration was comparable across five 
of the six included studies. Four of the trials 
stated a treatment duration of 2 years.109,110,112,113 
Carel and colleagues111 administered GH for an 
average of 2.7 ± 0.6 years, until the participants 
reached AH. The children in the study by Phillip 
and colleagues114 received treatment for 2 years, 
but only the first year allowed a randomised 
comparison between GH and no treatment.
The mean age of participants was similar both 
across groups within studies and across five of the 
six trials included.109,110,112–114 The mean ages of 
groups in these trials ranged from 4.7 (2.3–6.3)113 
to 6.3 (4.0–8.0) years. The Carel study111 included 
older children with mean ages of 12.7 ± 1.4 in the 
rhGH group and 12.8 ± 1.6 in the control group.
The six included trials were generally of poor 
methodological quality (Table 24).
TABLE 24  Quality assessment of included SGA studies
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1.  Was the assignment to the treatment groups really 
random?
Un Un Un Un Un Ad
2.  Was the treatment allocation concealed? In Un Un Un Un Un
3.  Were the groups similar at baseline in terms of 
prognostic factors?
Rep Rep Rep Rep Rep Rep
4.  Were the eligibility criteria specified? Ad Ad Ad Ad Ad Ad
5.  Were outcome assessors blinded to the treatment 
allocation?
Un Un Par Un Un Par
6.  Was the care provider blinded? In Un Un Un Un In
7.  Was the patient blinded? In In In In In In
8.  Were the point estimates and measure of variability 
presented for the primary outcome measure?
Ad Ad Ad Ad Ad Ad
9.  Did the analyses include an ITT analysis? In In In Ad In In
10. Were withdrawals and dropouts completely 
described?
Ad Ad Ad Ad In In
Ad, adequate; In, inadequate; Not rep, not reported; Par, partial; Rep, reported; Un, unknown.
Phillip and colleagues114 reported that a centralised 
computer-controlled system was used to randomly 
assign children to groups. In the other five trials it 
was unclear whether the assignment to treatment 
groups was really random. This was reflected in 
the assessment of whether treatment allocation was 
concealed, with one exception being the study by 
Carel and colleagues,111 which reported that group 
assignment was not masked and this was therefore 
judged to be inadequate.
The blinding of outcome assessors can defend 
against bias affecting the measurement of some 
outcomes. In two trials112,114 outcome assessors 
for BA were blinded to chronological age and 
treatment allocation. It was not stated whether this 
extended to assessors of other outcomes. In the 
remaining four trials it was not stated whether the 
outcome assessors were blinded.
Performance bias, where knowledge of treatment 
can potentially lead to differences in care provided 
can be protected against by blinding care givers 
and patients. The care provider was not blinded to 
treatment in the studies by Carel and colleagues111 
or Phillip and colleagues,114 and in the four 
remaining trials this was unknown. In each of the DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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six trials blinding of the patient was inadequate 
as no placebo was used. Only one of the trials 
conducted an ITT analysis.113 This guards against 
bias arising where for example only the results of 
patients who did not experience AE or compliance 
issues are included in the analysis.
Growth outcomes
All six studies109–114 reported growth outcomes, and 
these are presented in Table 25.
Carel and colleagues111 reported AH for the 70% 
of control patients and 89% of treated patients for 
whom these data were available. They reported a 
mean gain in AH of 26 ± 7 cm in the treated group 
compared with 22 ± 6 cm in their untreated group 
(p = 0.005). They also reported AH SDS, which was 
statistically significantly higher in the rhGH treated 
group (–2.1 ± 1.0) compared with the untreated 
group (–2.7 ± 1.0), p = 0.005. Similarly, the SDS 
for AH total gain was statistically significantly 
higher in treated patients than with untreated 
patients (1.1 ± 0.9 vs 0.5 ± 0.8, p = 0.002). Carel 
and colleagues111 also reported the difference from 
target HtSDS. This was statistically significantly 
lower in the group receiving GH, compared 
with the control group (–0.9 ± 1.2 vs –1.7 ± 1.2, 
p = 0.005).
Children who received the licensed dose of 
0.033 mg/kg/day for 1 year in the study by 
Phillips and colleagues114 gained an average of 
3.3 ± 0.2 cm in height compared with children in 
the untreated control group. Those receiving the 
higher dose of 0.1 mg/kg/day rhGH gained an 
average of 6.5 ± 0.2 cm compared with untreated 
children. No p-values were presented for between-
group comparisons, although the CIs suggest a 
statistically significant difference.
de Zegher and colleagues112 found that gain 
in HtSDS at the end of the study was higher 
in the group receiving a higher dose [2.1 ± 0.1 
(0.2 IU/kg/day) vs 2.5 ± 0.1 1 (0.3 IU/kg/day) vs 
0.2 ± 0.1 (untreated), p < 0.001 treated vs untreated 
groups]. The other study by de Zegher and 
colleagues113 reported higher HtSDS in treated 
patients, but did not present p-values. However, 
there were only four patients in the no-treatment 
group, so between-group comparisons are difficult.
Phillips and colleagues114 found that HtSDS was 
higher in the two rhGH-treated groups than in 
the untreated groups (–2.3 ± 0.6, –1.8 ± 0.8 and 
–3.0 ± 0.6 for the 0.033 mg/kg/day (licensed dose), 
0.1 mg/kg/day and untreated groups, respectively). 
These scores reflected changes of 0.8 and 1.4 
in SDS for the licensed- and high-dose groups, 
respectively, compared with a change of only 0.1 in 
the untreated patients’ mean SDS value.
Three109,110,113 of the included studies that used 
higher doses of rhGH reported that HtSDS was 
higher in the treated groups than in the untreated 
groups. De Schepper and colleagues109 and de 
Zegher and colleagues113 reported HtSDS at the 
end of the first and second years of treatment. 
In each of these studies, at both time points, the 
SDS was higher in the treated group, and this 
difference between groups increased in the second 
year. In De Schepper and colleagues’109 study at 
the end of year 1, HtSDS in the treated group was 
–2.1 ± 0.7 versus –3.1 ± 1 in the untreated group 
(p < 0.0001). In year 2, HtSDS in the treated 
group was –1.7 ± 0.7 compared with 3.1 ± 1 in the 
untreated group (p < 0.0001). At the end of 2 years’ 
treatment, the treated group in the Lagrou110 study 
had a statistically significantly higher mean HtSDS 
(–1.9 ± 0.7) than the untreated group (–3.1 ± 0.9), 
p < 0.001.
Two studies109,110 were suitable for meta-analysis of 
the HtSDS outcome because they were sufficiently 
homogeneous in terms of dose, duration of 
treatment, and the children’s mean age at start of 
treatment. However, both trials were small (≤ 20 
girls in each treatment group), which affects the 
validity of tests for heterogeneity, and both used 
twice the licensed dose, so a meta-analysis of these 
was considered unlikely to add to the evidence 
base.
Growth velocity (cm/year) was greater at the end 
of year 2 in the groups receiving rhGH in the two 
studies that presented results for this outcome.112,113 
de Zegher and colleagues 1996112 found an 
increased GV in their group receiving a higher 
dose of GH, and a greater GV for their treated 
participants overall: 10.2 ± 0.2 (0.2 IU/kg/day) 
versus 11.0 ± 0.4 (0.3 IU/kg/day) versus 5.7 ± 0.3 
(untreated), p < 0.001 untreated versus treated. 
The de Zegher 1996 study112 also found that GV 
SDS was statistically significantly higher at the 
end of treatment in the treated groups [4.3 ± 0.3 
(0.2 IU/kg/day) and. 5.2 ± 0.4 (0.3 IU/kg/day)] 
compared with –0.9 ± 0.3 in the untreated group 
(p < 0.001 for untreated vs treated groups).Assessment of clinical effectiveness
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TABLE 25  Growth outcomes for SGA studies
Study Outcomes (mean ± SD) rhGH Control p-value
Phillip et al.114
1: rhGH 0.033 mg/kg/day (n = 51)
2: rhGH 0.1 mg/kg/day (n = 51) vs 
untreated (n = 47); 1 year
HtSDS 1: –2.3 ± 0.6 –3.0 ± 0.6 nr
2. –1.8 ± 0.8
Change in HtSDS 1: 0.8 ± 0.3 0.1 ± 0.3 nr
2: 1.4 ± 0.4
Additional height gained 
(cm)a
1: 3.3 ± 0.2, 95% CI 
2.9 to 3.7
n/a nr
2: 6.5 ± 0.2, 95% CI 
6.0 to 6.9
Carel et al.111
0.2 IU/kg/day (n = 91) vs untreated 
(n = 33)
AH total height gain (cm) 26 ± 7 22 ± 6 0.005
End of treatment: HtSDS –2.1 ± 1.0 nr nr
AH HtSDS –2.1 ± 1.0 –2.7 ± 1.0 0.005
AH total height gain SDS 1.1 ± 0.9 0.5 ± 0.8 nr
AH difference from target 
HtSDS
–0.9 ± 1.2 –1.7 ± 1.2 0.005
De Schepper et al.109
High-dose rhGH (n = 11) vs untreated 
(n = 14); 2 years
HtSDS year 2 –1.7 ± 0.7 –3 ± 1 < 0.0001
de Zegher et al.112
1: rhGH 0.2 IU/kg/day (n = 20)
2: rhGH 0.3 IU/kg/day (n = 19) vs 
untreated (n = 13); 2 years
Gain in HtSDS 1: 2.1 ± 0.1 0.2 ± 0.1 < 0.001b
2: 2.5 ± 0.1
Gain in HtSDS for BA 1: 1.0 ± 0.2 0.0 ± 0.3 < 0.05b
2: 1.2 ± 0.4
GV (cm/year) 1: 10.2 ± 0.2 5.7 ± 0.3 < 0.001
2: 11.0 ± 0.4
GV SDS 1: 4.3 ± 0.3 –0.9 ± 0.3 < 0.001b
2: 5.2 ± 0.4
de Zegher et al.113
High-dose rhGH (100 µg/kg/day) (n = 9) 
vs no treatment (n = 4); 2 years
HtSDS –1.8 (–3.9 to –0.5) –3.0 (–3.3 to 
–2.5)
nr
GV (cm/year) 8.5 (6.3 to 10.2) 5.6 (4.4 to 
6.8)
nr
Lagrou et al.110
rhGH 0.066 mg/kg/day (n = 20) vs 
untreated (n = 19)
HtSDS –1.9 ± 0.7 –3.1 ± 0.9 < 0.001
a  Compared with untreated controls.
b  Untreated vs treated.
de Zegher and colleagues 1996112 reported BA. 
The gain in BA (years) was statistically significantly 
greater in the groups receiving GH than in those 
who were untreated. The 0.2 IU/kg/day rhGH 
group had a mean gain of 1.35 ± 0.16, compared 
with 1.33 ± 0.24 in the 0.3 IU/kg/day rhGH group 
and 0.84 ± 0.07 in the untreated group (p < 0.001 
treated vs untreated groups). This is reflected in 
the gain in HtSDS for BA: 1.0 ± 0.2 (0.2 IU/kg/day) 
versus 1.2 ± 0.4 (0.3 IU/kg/day) versus 0.0 ± 0.3, 
p < 0.05, treated versus untreated groups.
Body composition outcomes
Four of the included studies reported body 
composition outcomes.109,110,112,113 These results are 
shown in Table 26. It should be noted that all of 
these studies used higher doses of rhGH than the 
UK licensed dose.
De Schepper and colleagues reported a WtSDS 
for treated patients that was almost half that for 
untreated patients (–1.8 vs –3.4; p < 0.0001). 
Lagrou and colleagues110 found that WtSDS at DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 26  Body composition outcomes for SGA studies
Study Outcomes (mean ± SD) rhGH Control p-value
De Schepper et al.109
High-dose rhGH (n = 11)a vs 
untreated (n = 14); 2 years
WtSDS –1.8 ± 1 –3.4 ± 1.6 < 0.0001
Lean mass (kg) 15.5 ± 3.4 12.2 ± 2.5 < 0.0001
FM (kg) 2.9 ± 1 3.1 ± 1.1 n/s
Lean mass (%) 82 ± 3 77 ± 5 < 0.05
FM (%) 15 ± 2 20 ± 5 < 0.05
de Zegher et al.112
1: rhGH 0.2 IU/kg/day (n = 20)
2: rhGH 0.3 IU/kg/day (n = 19) vs 
untreated (n = 13); 2 years
Weight gain (kg) 1: 6.9 ± 0.6
2: 7.8 ± 0.5
3.6 ± 0.4 < 0.001a
Gain in WtSDS 1: 1.3 ± 0.1
2: 1.8 ± 0.1
0.4 ± 0.1 < 0.001a
de Zegher et al.113
High-dose rhGH (100 µg/kg/day) 
(n = 9) vs no treatment (n = 4); 2 
years
WtSDS (mean and range) –2.1 (–3.6 to –0.9) –3.8 (–4.8 to –3.2) nr
BMI SDS(mean and range)  –1.2 (–3.4 to –0.4) –2.1 (–2.9 to –1.4) nr
Lagrou et al.110
rhGH 0.066 mg/kg/day (n = 20) vs 
untreated (n = 19)
WtSDS –2.3 ± 1.2 –3.7 ± 1.5 < 0.01
BMI (SDS) –1.5 ± 1.1 –2.0 ± 1.5 ns
ns, not significant.
a  Untreated vs treated.
the end of year 2 was statistically significantly 
higher in their treated group (–2.3 ± 1.2) than 
in their untreated group (–3.7 ± 1.5; p < 0.01). 
Similar values were reported by de Zegher and 
colleagues,113 although no p-values were given.
de Zegher and colleagues 1996112 also reported 
gain in WtSDS and weight gain (kg). For both 
of these outcomes the difference was statistically 
significant and higher in the groups treated with 
GH. Mean weight gain (kg) was 6.9 ± 0.6 (0.2 IU/kg/
day) versus 7.8 ± 0.5 (0.3 IU/kg/day) versus 3.6 ± 0.4 
in the untreated group (p < 0.001 treated vs 
untreated groups). This pattern was reflected in the 
gain in WtSDS, which was 1.3 ± 0.1 in the 0.2 IU/
kg/day group, 1.8 ± 0.1 in the 0.3 IU/kg/day group 
and 0.4 ± 0.1 in the untreated group (p < 0.001 
untreated vs treated groups).
Lean mass and FM were reported in kilograms 
and as a percentage by De Schepper and 
colleagues.109 Lean mass (kg) increased from year 
1 to year 2 in both groups, and was greater in the 
group receiving GH at both times (13.2 ± 3.4 vs 
10.9 ± 2.4 and 15.5 ± 3.4 vs 12.2 ± 2.5 for years 1 
and 2, respectively). The p-value was reported as 
p < 0.0001, but it is unclear at which time point 
this p-value refers to. Lean mass (%) remained 
virtually unchanged from year 1 to year 2, but was 
higher in the rhGH group (82 ± 3 vs 77 ± 5 at year 
2). The difference between treated and untreated 
groups was statistically significant (p < 0.05), but it 
is unclear whether this refers to the year 1 or year 
2 data.
The difference in FM (%) between the two groups 
was statistically significant: 15 ± 2 versus 20 ± 5, 
p < 0.05.
Two studies reported BMI SDS.110,113 One of these 
reported that there was no statistically significant 
difference between treated and untreated 
children,110 and the other reported similar values 
but gave no p-value.113
Biochemical markers
Two of the included studies, both of which used 
higher doses than the UK licensed dose, reported 
biochemical markers.112,114 These results are shown 
in Table 27.
Serum IGF-1 levels were statistically significantly 
higher in rhGH treated groups at the end of 
treatment. In one study,112 children receiving 
0.2 IU/kg/day rhGH had values of 332 ± 29, 
compared with 655 ± 69 in the 0.3 IU/kg/day group 
and 168 ± 46 in the untreated group (p < 0.01, 
0.2 IU/kg/day vs untreated group) after 2 years’ 
treatment. Phillip and colleagues114 reported Assessment of clinical effectiveness
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TABLE 27  Biochemical markers in SGA studies
Study
Outcomes 
(mean ± SD) rhGH Control p-value
de Zegher et al.112
1: rhGH 0.2 IU/kg/day (n = 20)
2: rhGH 0.3 IU/kg/day (n = 19) vs 
untreated (n = 13)
2 years
Serum IGF-1 (µg/l) 1: 332 ± 29
2: 655 ± 69
168 ± 46 < 0.01 untreated vs 
group 1
Serum IGFBP-3 
(mg/l)
1: 6.10 ± 0.35
2: 6.50 ± 0.52
4.00 ± 0.58 < 0.001 untreated vs 
group 1
Phillip et al. 114
1: rhGH 0.033 mg/kg/day (n = 51)
2: rhGH 0.1 mg/kg/day (n = 51) vs 
untreated (n = 47)
1 year
IGF-1 (ng/ml) 1: 345.6 ± 177
2. 594.3 ± 221
176 ± 107 nr
IGF-1 SDS 1: 0.9 ± 1.9
2. 3.3 ± 2.1
–0.9 ± 1.2 nr
IGFBP-3 (µg/l) 1: 4.8 ± 1.1
2: 6.1 ± 1.4
3.9 ± 1.1 nr
similar IGF-1 values as de Zegher and colleagues112 
after 1 year’s treatment, and, in addition, reported 
that IGF-1 SDS was higher in rhGH treated 
patients than in untreated patients. Values were 
0.9 ± 1.9 and 3.3 ± 2.1 in the low- and high-dose 
groups, respectively, and 0.9 ± 1.2 in the untreated 
group.
Serum IGFBP-3 levels were also greater in the 
groups receiving rhGH. In the 1-year study,114 
values were lowest in untreated patients 
(3.9 ± 1.1 µg/l) and higher in the two rhGH groups 
(4.8 ± 1.1 and 6.1 ± 1.4 for the low- and high-dose 
groups, respectively). No p-values were reported. 
At the end of year 2 in the second study, mean 
values were 6.10 ± 0.35 in the 0.2 IU/kg/day rhGH 
group, 6.50 ± 0.52 in the 0.3 IU/kg/day rhGH group 
and 4.00 ± 0.58 in the untreated group (p < 0.001, 
untreated vs 0.2 IU/kg/day rhGH group).112
Quality of life
None of the included studies reported QoL 
outcomes.
Adverse events
Four of the included studies discussed AEs in 
varying detail.109,111,112,114
Carel and colleagues111 found that 44% of patients 
reported AE, with 10% of these reporting four 
or more. It was not stated whether these patients 
were from the treated or untreated group. The 
authors described two AEs that they believed 
to be causally related to treatment; one slipped 
capital epiphysis after 1.5 years of treatment and 
one simple seizure episode 10 minutes after first 
injection. The authors do not state if these led to 
withdrawal. Sixteen severe AEs in 14 patients were 
reported. These were not thought by the authors 
to be related to treatment, and included trauma, 
psychiatric symptoms, abdominal symptoms, 
otitis, asthma, variocele, striae and migraine. 
De Schepper and colleagues109 stated only that 
no participants ‘had a noteworthy adverse event 
during the two years of study’. No further details 
were given.
de Zegher and colleagues 1996112 reported four 
SAEs. The authors suggested that these might not 
be linked to GH, but gave no further details. The 
authors described two treated children versus one 
untreated child hospitalised as a result of viral 
disease (group/dose not reported). There was one 
case of aggravated cutaneous eczema reported in 
group 1 (0.2 IU/kg/day). Three treated children 
(group/dose not given) reported possible increase 
in size or number of pigmented naevi. Treatment 
was not interrupted in any of these cases.
Phillip and colleagues114 reported AEs only for 
the 2-year study overall, so it was not possible 
to compare the treated and untreated children. 
The majority (349/358) of AEs in the study were 
of mild to moderate severity, the most common 
events (57%) being childhood infections. Of 16 
SAEs reported, three were described as likely to 
be related to rhGH. Two of these (convulsions 
and papilloedema) resolved on discontinuation of 
treatment, and the third (epilepsy) stabilised when 
treatment was withdrawn.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Summary
Six109–113 trials examining the effectiveness of GH 
in children born SGA met the inclusion criteria for 
the review. The quality of the included studies was 
generally poor, and only one undertook an ITT 
analysis.113 All but one114 of the trials used higher 
than licensed doses of rhGH.
One trial reported total gain in AH, and found this 
was approximately 4 cm higher in people who had 
received rhGH. The difference between groups was 
statistically significant (p < 0.005).111 AH gain SDS 
was also statistically significantly higher in people 
who had received rhGH.111 However, the study used 
a dose which was approximately twice the licensed 
dose, and it was carried out in children with a mean 
age of 12.7 years at start of treatment. This may 
limit the generalisability of the trial.
One study114 reported that patients who received 
0.033 mg/kg/day of rhGH (the licensed dose) 
gained an additional 3.3 cm height compared 
with untreated children, and those who received 
0.1 mg/kg/day gained 6.5 cm of additional height 
after 1 year’s treatment.
Height SDS was found to be statistically 
significantly higher in children treated with GH in 
two studies,109,110 and higher, but with no reported 
p-value, in two others.113,114
Growth velocity (cm/year) was greater in the treated 
groups at the end of year 2 in the two studies that 
reported this outcome,112,113 but the difference was 
reported to be statistically significant in only one.112
Weight standard deviation score was statistically 
significantly higher in children treated with 
rhGH in one110 of the three studies reporting this 
outcome.
Lean mass was reported in one study,109 and was 
statistically significantly greater in the treated 
group. Two studies reported BMI SDS.110,113 One 
of these reported that there was no statistically 
significant difference between treated and 
untreated children,110 and the other reported 
similar values but gave no p-value.113
One study112 reported that serum IGF-1 and 
IGFBP-3 levels were statistically significantly higher 
in patients treated with rhGH, and another114 
reported similar results but did not present 
p-values.
Reporting of AEs was limited in detail, and only 
reported by four of the trials.109,111,112 One trial111 
reported two events in treated children that may 
have been linked to GH. They did not discuss 
if these led to discontinuation of the drug. A 
second trial109 reported only that there were ‘no 
noteworthy’ AEs recorded. A third trial112 reported 
four SAEs, which were not linked to the study drug. 
Three of 16 SAE in another trial114 were linked with 
rhGH, and these resolved/stabilised once treatment 
was discontinued.
SHOX deficiency
Quantity and quality of research 
available
Only one study of patients with SHOX met the 
inclusion criteria for this review,49 and its key 
characteristics are shown in Table 28. The 2-year 
multicentre RCT by Blum and colleagues49 
compared a daily injection of 50 µg of rhGH 
with no treatment in 52 prepubertal children 
with confirmed SHOX-D. The manufacturer’s 
recommended dose is 45–50 µg/kg body weight,81 
but as the study did not report mean baseline 
weight of participants it is not possible to comment 
on whether or not the study reflects the licensed 
dose. The study also included a non-randomised 
rhGH-treated group of patients with TS, but this 
group will not be discussed further in this report.
The included study was generally poorly reported 
(Table 29), with little information on method of 
randomisation or concealment of allocation. 
TABLE 28  Characteristics of SHOX-D study
Reference Intervention Control group
Total randomised 
and withdrawals
Duration of randomised 
treatment
Blum et al. 200749 rhGH 50 µg/day, n = 27
Mean age ± SD (years): 
7.5 ± 2.7
No treatment, n = 25
Mean age ± SD 
(years): 7.3 ± 2.1
Total n = 52
Sample attrition: 1
2 yearsAssessment of clinical effectiveness
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TABLE 29  Quality assessment of SHOX-D study
1.  Was the assignment to the treatment groups really random? Un
2.  Was the treatment allocation concealed? Un
3.  Were the groups similar at baseline in terms of prognostic factors? Rep
4.  Were the eligibility criteria specified? Ad
5.  Were outcome assessors blinded to the treatment allocation? Para
6.  Was the care provider blinded? In
7.  Was the patient blinded? In
8.  Were the point estimates and measure of variability presented for the primary outcome measure? Ad
9.  Did the analyses include an ITT analysis? In
10. Were withdrawals and dropouts completely described? In
Ad, adequate; In, inadequate; Par, partial; Rep, reported; Un, unknown.
a  Blood analyses were carried out at a central facility.
Patients in the comparator arm received no 
treatment, so the patients themselves and their care 
providers would have been aware of whether or not 
they were receiving the study drug. The patients in 
the two groups had similar baseline characteristics, 
although target HtSDS was statistically significantly 
lower for the rhGH group (–1.3  ± 1.0 vs –1.5 ± 0.9, 
p = 0.013). Baseline IGFBP-3 SDS was slightly 
higher for the rhGH group (0.6 ± 1.3 vs 0.1 ± 1.1), 
although the difference was not statistically 
significant. The analysis was not reported on 
an ITT basis as one discontinuing patient was 
excluded from the analysis. The study did not 
include discussion of sample size or a power 
calculation, so it is not possible to determine 
whether or not it was adequately powered to detect 
a difference in the primary outcome (first-year GV).
Growth outcomes
Table 30 shows growth outcomes at the end of 
2 years’ treatment. Children treated with rhGH 
gained approximately 6 cm more height than 
those in the control group (p < 0.001). Although 
all children remained below average height, the 
HtSDS was statistically significantly lower in the 
untreated group (–3.0 ± 0.2 vs –2.1 ± 0.2, p < 0.001). 
Blum and colleagues49 also commented that 41% 
of rhGH-treated patients reached a height within 
the normal range for age and gender (> –2.0 SDS), 
compared with only one patient in the untreated 
group. There was no statistically significant 
difference between the groups in catch-up of BA.
The difference in GV (1.9 cm/year) between the 
two groups during the second year of the study 
was statistically significant (p < 0.001). Children 
in the rhGH group had a positive HV SDS, i.e. 
their GV was above average for their age group. 
By comparison, those in the untreated group had 
a negative score, indicating slower growth than 
normal for their age group. Again, the difference 
between the groups was statistically significant 
(p < 0.001).
Body composition
The included study did not report body 
composition as an outcome measure.
Biochemical markers
Blum and colleagues49 did not report biochemical 
outcomes in any detail. However, they did state that 
IGF-1 SDS values were in the low-normal range 
for both groups at baseline, but increased to the 
upper-normal range in the rhGH-treated group. 
In 10 (37%) of the rhGH-treated children, IGF-
1 concentrations exceeded +2 SDS at least once 
during treatment, whereas none of the untreated 
patients experienced this. Similarly, IGFBP-3 SDS 
values were close to the normal mean in both 
groups at baseline, but increased to the upper-
normal range in the treated group.
Quality of life
The included study did not report QoL as an 
outcome measure.
Adverse events
The rate of treatment-emergent AE was higher 
in the rhGH group than in the no-treatment arm DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 30  Growth outcomes for SHOX-D study
Study Outcomes (mean ± SD) rhGH Control p-value
Blum et al.49
rhGH 50 µg (n = 27) vs no 
treatment (n = 24); 2 years
Height gain (cm) 16.4 ± 0.4 10.5 ± 0.4 < 0.001
Ht SDS –2.1 ± 0.2 –3.0 ± 0.2 < 0.001
HV (cm/year) 7.3 ± 0.2 5.4 ± 0.2 < 0.001
HV SDS 2.3 ± 0.3 –0.4 ± 0.1 (n = 22) < 0.001
(Table 31), but these were reported to have mostly 
been common childhood illnesses.
There were no significant changes in thyroid 
function reported during the study, and no SAEs 
occurred in the patients with SHOX-D.
Summary
The evidence for the clinical effectiveness of rhGH 
as a treatment for short stature owing to SHOX-D 
comes from the single RCT that met the inclusion 
criteria for this review. The study was unblinded 
and did not report an ITT analysis.
By the end of the second year, children treated 
with rhGH had gained statistically significantly 
more height than those in the control group 
(approximately 6 cm more), with no statistically 
significant difference in catch-up of BA. HtSDS was 
statistically significantly higher in treated than in 
untreated patients.
Treatment with rhGH led to a statistically 
significantly greater GV in both years 1 and 2 
(3.5 cm/year greater than untreated patients in 
year 1, and 1.9 cm/year greater in year 2). The 
HV SDS was positive, i.e. above the average for 
chronological age, during both years of rhGH 
treatment whereas untreated children had negative 
HV SDS.
Treatment with rhGH raised IGF-1 and IGFBP-3 
levels to the upper normal range.
Treatment of the children with SHOX-D in this 
RCT was not associated with any SAE.
Transition phase in GHD
The scope for this review requested that, if 
evidence allows, the assessment report should 
consider the transition of care from paediatric to 
adult endocrine services of young people whose 
linear growth is not complete. Although a number 
of ‘transition phase’ studies were assessed for 
inclusion in the review of clinical effectiveness, 
these included patients who had completed linear 
growth. Therefore, they did not meet the inclusion 
criteria for this review.
Once a patient’s linear growth has ceased, he or 
she may still not have reached peak bone mass, 
which would increase the risk of osteoporosis 
later in life. Continued rhGH treatment in these 
patients beyond completion of linear growth can be 
beneficial for improving bone mass. For example, 
Conway and colleagues128 randomised 160 18- to 
25-year-olds with severe GHD who had received 
rhGH during childhood to continued treatment 
(n = 109) or no treatment (n = 51). They reported 
that 2 years of continued treatment was associated 
TABLE 31  Adverse events for SHOX-D study
Study Outcomes (mean ± SD) rhGH Control p-value
Blum et al.49
rhGH 50 µg (n = 27) vs no 
treatment (n = 24); 2 years
At least 1 treatment-emergent AE (%) 85 68 nr
Arthralgia 3 2 nr
Increased number of cutaneous naevi 2 0 nr
Recurrent otitis media 1 1 nr
Scoliosis 1 0 nrAssessment of clinical effectiveness
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with approximately 3.5% greater increase in bone 
mineral density of the lumbar spine than in those 
who had discontinued treatment.128
Continued rhGH treatment can also improve body 
composition in young adults whose linear growth 
is complete. Five papers129–133 were identified that 
reported changes in body composition, biochemical 
markers, QoL or AE for this patient group. 
However, as the patients had completed linear 
growth they did not meet the inclusion criteria for 
this review and are therefore beyond the scope of 
this review.
Summary of previous 
systematic reviews
The searches for this systematic review identified 
three systematic reviews. One of these was the 
previous HTA report,6 discussed above (see 
Comparison with previous review), and another 
was a Cochrane review related to that work.134 The 
third reference was a new systematic review of GH 
in TS,135 and this is discussed below.
The new systematic review was conducted in 
Canada in 2007 by the Canadian Agency for 
Drugs and Technologies in Health (CADTH).135 
The quality of the systematic review was good. 
Inclusion and exclusion criteria relating to the 
primary studies were reported. The review included 
RCTs or comparative observational studies that 
compared rhGH with placebo or no treatment, 
included females with TS, measured growth 
(FH, interim height, GV), AE and QoL. Those 
studies that included fewer than 20 patients, or 
administered rhGH for less than 1 year, were 
excluded. The Jadad scale and the Hailey scale 
were used in quality assessment, but no further 
details were reported.
The CADTH included 19 studies, 10 of which 
reported data from six RCTs.135 Three of the 
six RCTs included in the CADTH review were 
excluded from the present systematic review. One 
was excluded as it was a conference abstract from 
1991, another was excluded because its outcome 
measures did not match our inclusion criteria, and 
the third was excluded because it did not compare 
rhGH with a treatment arm that did not contain 
somatropin.
The CADTH authors judged the RCTs to be of 
good quality, and the observational studies of fair 
quality, using the Jadad scale. However, they do not 
describe this in detail in their report. The present 
systematic review used the CRD quality assessment 
criteria83 rather than the Jadad scale. This, along 
with the difference in included studies, may explain 
this discrepancy in judgement of quality between 
the two reports.
The CADTH systematic review found that growth 
was accelerated and height increased in girls taking 
rhGH for TS. There were no SAEs reported in 
the included studies. The cost-effectiveness and 
cost–utility analyses (CUA) in the CADTH study 
are discussed in Chapter 4 (see Description of the 
identified studies). The CADTH study135 concluded 
that the evidence suggested that rhGH is effective 
in improving growth and FH in girls with TS, but 
found no evidence available to suggest that rhGH 
improves QoL.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Introduction
The aim of this section is to assess the cost-
effectiveness of GH treatment in children with 
GHD, TS, PWS, CRI, SGA and SHOX-D compared 
with no treatment. The economic analysis 
comprises the following:
•  a systematic review of the literature on the cost-
effectiveness of GH treatment (see first section: 
Systematic review of existing cost-effectiveness 
evidence)
•  a review of the HRQoL of people with GHD, 
TS, PWS, CRI, SGA, SHOX-D (see second 
section: Review of research on QoL)
•  a review of the MSs to NICE (see third section: 
Review of manufacturers’ submissions)
•  a de novo Southampton Health Technology 
Assessments Centres (SHTAC) economic 
model and cost-effectiveness evaluation (see 
fourth section: SHTAC independent economic 
evaluation).
A previous HTA report has estimated the cost-
effectiveness of GH treatment.6 In that report, a 
cost-effectiveness model, which estimated lifetime 
treatment costs and benefits in terms of cost per 
centimetre gained, was constructed. Those analyses 
are extended in the present report by including 
QoL factors in the economic modelling.
Systematic review of 
existing cost-effectiveness 
evidence
Methods for the systematic 
review of cost-effectiveness
A systematic literature search was undertaken 
to identify economic evaluations for rhGH in 
children. The details of the search strategy for the 
cost-effectiveness studies are in Appendix 2. The 
MSs were reviewed for any additional studies. Titles 
and abstracts of studies identified by the search 
strategy were assessed for potential eligibility 
by two health economists. Full text versions of 
relevant papers were retrieved and checked by two 
health economists. Any differences in judgement 
were resolved through discussion. The quality of 
the cost-effectiveness studies was assessed using 
a critical appraisal checklist based on that by 
Drummond and Jefferson,136 the International 
Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) checklist137 and the NICE 
reference case.138
Results of the systematic review 
of cost-effectiveness
A total of 220 potentially relevant studies were 
identified in the cost-effectiveness searches and one 
in the QoL searches. Five full papers were retrieved 
with only two economic evaluations meeting the 
inclusion criteria. For all disease areas throughout 
the screening and data extraction process, 
differences in opinion were generally minor and 
easily resolved without the involvement of a third 
reviewer. The characteristics and results of the 
evaluations are discussed below.
Description of the identified 
studies
The literature search did not identify any economic 
evaluations conducted across the entire range of 
conditions of interest or any for the population of 
England and Wales. Table 32 provides a summary 
of the characteristics and base-case findings for 
the two published North American economic 
evaluations for human GH for children with TS135 
and GHD.139
The cost-effectiveness studies were assessed against 
the critical appraisal checklist (Table 33). Generally, 
the CADTH study135 was of a higher quality; the 
effectiveness of the treatment had been established 
through a systematic review, and the estimates for 
parameter values are more appropriate than the 
study by Joshi and colleagues.139
Modelling approach
Both economic evaluations presented cost-
effectiveness analyses using simple deterministic 
decision-analytical models. Both assumed that 
the clinical benefit achieved as a result of the 
rhGH treatment in the patients’ early years will 
Chapter 4  
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TABLE 32  Characteristics of economic evaluations of rhGH treatment in children
Study/Details CADTH135 Joshi et al.139
Publication year 2007 2006
Organisation Canadian agency for drugs and technologies in 
health
Novo Nordisk
Country Canada USA
Study type CEA and CUA CEA and CUA
Study perspective Canadian health-care system The US health-care payers’ perspective
Study population Female population aged 10 years at baseline with 
TS, receiving treatment for 5 years until 15 years 
old
1. Cohort 5 years old at baseline with GHD, 
receiving treatment for 11 years until 16 years old
2. Cohort 3 years old at baseline with GHD, 
receiving treatment for 15 years until 18 years old
Intervention rhGH rhGH (Norditropin)
Model type Deterministic decision-analytical model Deterministic decision-analytical model
Time horizon Lifetime (assumed to be until age of 81 years) Lifetime (assumed to be the age of 78 years for 
males and age 80 for females)a
Discounting 5% applied to both costs and benefits (QALYs) 3% applied to both costs and benefits (QALYs)
The primary 
clinical treatment 
effects modelled/
assessed
147.5 cm was the FH in the intervention group, 
141 cm was the FH in the control group 
The ‘success’ of treatment is defined as achieving 
‘normal height’, i.e. FH within two SDs of the 
gender-specific population mean
Source of clinical 
evidence for the 
primary effect
Stephure and colleagues86 Not indicated. Appears to be an assumption. The 
probability of ‘success’ was assumed to be 90% 
if treatment started at age 3 and continued until 
age 18. The probability of ‘success’ was assumed 
to be 75% if treatment started at the age of 5 and 
continued until the age of 16
Health-benefit 
outcome
QALY QALY
QoL gain, per year 0.042 0.189
Results Individuals with rhGH treatment had an 
additional discounted cost of C$153,593 and an 
additional discounted benefit of 0.63 QALY. The 
cost-effectiveness was estimated as C$243,078 
per QALY gained
For the cohort of 5–16 years, individuals 
with rhGH had an additional discounted cost 
of US$155,005 and an additional discounted 
benefit of 4.2 QALY. The cost-effectiveness was 
US$36,995 per QALY gained. For the cohort of 
3–18 years, cost per QALY was US$42,556
CEA, cost-effectiveness analysis; CUA, cost–utility analysis; QALY, quality-adjusted life-year.
a  The authors did not report a gender distribution at baseline and whether all-cause mortality rates were used in the 
calculations.
last through their lifetime. Joshi and colleagues139 
assumed that age-adjusted normal height 
was achieved after the first year of treatment. 
Subsequently, the benefits in terms of ‘normal 
height years’ and associated utility gain were 
assigned from the second year of treatment. 
Conversely, the CADTH study135 did not assume 
that patients experienced any improvement in 
HRQoL during the treatment. The utility gain is 
associated with the completion of treatment rather 
than with achieving normal height, as normal 
height was not achieved in the review of clinical 
effectiveness.
The cohorts differed with respect to age at 
baseline, duration of treatment and probability of 
achieving normal height at the end of treatment 
(see Table 32 above). The CADTH study135 used 
the characteristics and clinical effectiveness data 
from the TS RCT,86 whereas Joshi and colleagues139 
did not provide any clinical evidence for either 
the baseline characteristics of the two cohorts 
of patients with GHD or the assumed clinical 
effectiveness estimates.
Joshi and colleagues139 assumed a 20% dropout 
rate after 12 months of treatment and related it to DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 33  Critical appraisal checklist of economic evaluation
Item CADTH135 Joshi et al.139
1 Is there a well-defined question? Yes Yes
2 Is the patient group in the study similar to those of interest in UK NHS? Yes Yes
3 Is the correct comparator used that is routinely used in the UK NHS? Yes Yes
4 Is the study type and modelling methodology reasonable? Yes Yes
5 Is an appropriate perspective used for the analysis? ? ?
6 Is the health-care system or setting comparable to UK? ? ?
7 Is the effectiveness of the intervention established based on a systematic 
review?
Yes No
8 Is the model structure appropriate and does it fit with the clinical theory of 
the disease process?
Yes Yes
9 Are assumptions reasonable and appropriate? Yes No
10 Are health benefits measured in QALYs using a standardised and validated 
generic instrument from a representative sample of the public?
? No
11 Are the resource costs used reasonable and appropriate for the UK NHS? Yes Yes
12 Are the health states and parameters used in the model described clearly and 
are they reasonable and appropriate for the UK NHS?
Yes No
13 Is an appropriate discount rate used? Yes Yes
14 Has the model been validated appropriately? ? ?
15 Is sensitivity analysis undertaken and presented clearly? ? ?
?, unclear or partially true.
the slight pain experienced by patients, although 
no clinical evidence was presented to support this 
assumption. The CADTH study135 did not adjust 
the final outcomes for the dropout rate, effectively 
assuming it to be zero. As none of the TS patients 
achieved normal height, the CADTH study135 did 
not differentiate between partial and complete 
success of rhGH treatment. In contrast, Joshi and 
colleagues139 assumed that those patients who 
completed treatment but did not achieve normal 
height still acquire a partial utility gain. However, 
no justification for this assumption is provided.
Discounting was appropriately applied to costs and 
benefits in both studies, although the discounting 
rates were different from the 3.5% recommended 
by NICE138 (3% in the study by Joshi and 
colleagues139 and 5% in the CADTH study135).
Estimation of final outcomes 
(QALYs)
Both studies highlighted the difficulty of 
translating intermediate (clinical) outcomes to final 
outcomes (QALYs). There is an apparent paucity of 
utility-based estimates of HRQoL in rhGH patients 
and an absence of such estimates obtained from 
children eligible for rhGH treatment (see below, 
Review of research on quality of life). Therefore, 
the authors chose alternative utility estimates 
that, despite acknowledged shortcomings, were 
judged to meet the requirements of their economic 
models. The utility increment associated with rhGH 
treatment reported in the two studies ranged from 
0.04135 to 0.189.139
Joshi and colleagues139 adapted the QoL indexes 
presented in the Wessex Development and 
Evaluation Committee (DEC) report.140 The 
indexes estimated in the report were not derived 
using one of the methodologically rigorous 
techniques for obtaining utility estimates, such as 
time trade-off (TTO) or standard gamble (SG)141 
and cannot therefore be interpreted as ‘utilities’. 
Furthermore, the utility element of that report 
was a set of scenarios not based on primary or 
secondary data sources and thus could not be 
considered reliable or valid.6 Joshi and colleagues139 
used utility estimates of 0.781 for the pretreatment 
and no treatment groups, although this is different 
to the value 0.884, reported in the DEC report. 
Those patients who achieved success, i.e. normal 
height, had a utility of 0.97 applied from the start 
of the second year of treatment. Patients with 
partial success were assumed to acquire a partial 
utility gain defined as 35% less than the full utility Assessment of cost-effectiveness
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gain associated with achieving normal height. The 
value was stated to be between 0.884 and 0.940.
The CADTH study135 did not use absolute utility 
values associated with each health state but 
applied an incremental utility value of 0.04 for 
patients receiving treatment with rhGH. The utility 
increment was estimated from a TTO survey in 
a small sample of adults with TS142 (see below, 
Review of research on qulity of life). The patients 
in the QoL study were asked how many years they 
would be willing to lose from their life to attain 
an average stature. The answers were translated 
into the incremental utility estimate of 0.04. The 
CADTH study135 stated that TS patients do not 
attain an average stature, and so this estimate is 
likely to be an overestimate and bias the result of 
economic evaluation in favour of rhGH treatment.
Estimation of costs
Joshi and colleagues139 included costs for 
paediatric consultations and rhGH treatment. 
The CADTH study135 also included costs for 
X-ray examination. The unit costs reported in 
the economic evaluations reflect the difference 
in clinical practices in Canada and the USA, the 
price difference of the unit of resources expressed 
in Canadian and US dollars, and the difference 
in methodological approach adopted in the two 
studies. For example, the CADTH study135 excluded 
the specialist visits as these do not differ between 
the intervention and the control groups. The total 
incremental cost reported varies according to the 
length of treatment but is consistent between the 
two studies.
Model results
The cost-effectiveness analysis in the CADTH 
study135 used an incremental difference of 6.5 cm in 
FH between the intervention and control groups, 
based on their clinical review. They calculated the 
undiscounted cost-effectiveness as C$26,529 per 
centimetre of improved FH and the discounted 
incremental cost-effectiveness ratio (ICER) was 
C$23,630 per centimetre of improved FH. They 
estimated an ICER of C$243,078 per QALY 
gained. The authors concluded that for an average 
patient with TS, rhGH treatment is unlikely to be 
cost-effective unless the payer is willing to pay more 
than C$200,000 to obtain a QALY.
Joshi and colleagues139 calculated the difference in 
‘normal height years’ between the intervention and 
the control groups to estimate the incremental cost 
per normal height year. It was assumed that normal 
height was achieved by patients in the intervention 
group, but not in the control group. The 
incremental gain in ‘normal height years’ in the 
cohort of 5- to 16-year-olds was 17.4 (discounted). 
The corresponding value in the cohort of 3- 
to 18-year-olds was 21.1 (discounted), which 
translated into an incremental cost per additional 
year of normal height of $8900 (discounted) in the 
cohort of 5- to 16-year-olds and an incremental 
cost per additional year of normal height of $9300 
(discounted) in the cohort of 3- to 18-year-olds. 
They estimated an ICER of about $37,000 per 
QALY gained for treating children with GHD from 
ages 5 to 16 years and an ICER of about $42,600 
per QALY gained for treating children with GHD 
from ages 3 to 18 years. The authors concluded 
that the cost-effectiveness of rhGH compares 
favourably to accepted threshold values and 
represents reasonable value for money.
In both studies the deterministic one-way analyses 
indicated that the results were sensitive to 
variations in the utility estimate, the starting age 
of treatment, the duration of treatment and the 
daily dosage. The results were also sensitive to 
assumptions about clinical effectiveness139 and to 
variations in the price of rhGH.135
The two economic evaluations arrived at opposite 
conclusions about the value for money of the rhGH 
treatment in children. The economic evaluation 
conducted for the CADTH study135 may provide a 
more reliable estimate of the cost-effectiveness as 
it has used clinical data from a reasonable quality 
RCT and TTO utility estimates. In contrast, the 
assumptions about clinical effectiveness of rhGH 
treatment by Joshi and colleagues139 did not seem 
to be supported by clinical evidence. Furthermore 
they also used indexes, interpreted as utility 
weights, which do not appear to be reliable or 
valid.
Summary and conclusion of 
the systematic review of cost-
effectiveness studies
We undertook a systematic review of the literature 
in order to identify existing models in this area. 
The systematic review of published economic 
evaluations identified two North American studies 
relevant to the target population and no studies 
conducted in the UK. The results of the two 
identified studies produced two very different 
estimates of cost-effectiveness. This difference is 
largely due to the choice of utility estimates and DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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assumptions on the effectiveness. As discussed 
below (see next section, below, Review of research 
on QoL), there is a paucity of reliable estimates 
of utility gains associated with GH treatment. 
Therefore, the results of both studies should be 
treated with caution. In particular, Joshi and 
colleagues139 adapted QoL indexes that were not 
derived according to the NICE reference case 
and could not be considered reliable or valid.6 
The literature study did not identify studies that 
we could use for this review and so a de novo 
independent economic model was required.
Review of research on QoL
Systematic review of HRQoL 
studies
A systematic review was undertaken to identify 
HRQoL studies for rhGH for children. The 
HRQoL searches were undertaken to populate a 
lifetime economic model with utilities to calculate 
QALYs, so studies with adults and children were 
eligible for inclusion. Titles and abstracts of studies 
identified by the search strategy were assessed for 
potential eligibility by two health economists. Full 
text versions of relevant papers were retrieved and 
checked by two health economists. Any differences 
in judgement were resolved through discussion. 
The details of the search strategy for QoL are in 
Appendix 2.
The titles and abstract of the studies identified by 
the search strategy were assessed on the basis of the 
following criteria:
•  disease condition as defined in Table 1 (Chapter 
1) of this report
•  primary research using a preference/utility 
based measure for the conditions interest
•  primary research using a generic measure 
[i.e. Short Form questionnaire-36 items (SF-
36)] that can be translated into a utility-based 
estimate
•  primary research using a condition-/disease-
specific QoL measure and an algorithm that 
allowed disease-specific QoL to be converted 
into utility values.
Exclusion criteria for the systematic literature 
search were:
•  primary research reporting QoL that could 
not be converted into utility values using a 
validated mapping algorithm
•  background or discussion papers that did not 
report a QoL measure for the conditions of 
interest
•  papers reported in language other than 
English.
The search strategy identified 391 articles that were 
potentially relevant. After the abstracts had been 
screened, 24 articles were identified and full papers 
were retrieved for these articles. After checking 
the retrieved studies, six papers met the inclusion 
criteria. These are summarised in Table 34. A 
further targeted search linking height to HRQoL 
is reported below (see Height and health-related 
QoL).
Growth hormone deficiency
Three relevant studies were identified that met 
the inclusion criteria.145,147,148 Sandberg and 
colleagues148 used the SF-36 in participants with 
GHD. The study reported no baseline data, and 
reported SF-36 only after rhGH treatment had 
finished compared with non-GHD siblings and the 
general population. Therefore, the study was of 
no value in investigating the gain in HRQoL from 
rhGH treatment.
The second study, by Busschbach and colleagues,145 
used the TTO method, a preference-based 
approach that asks people to quantify the numbers 
of years of life they would be willing to give up 
to overcome a particular state of health. The 
participants were asked the number of years they 
were willing to trade off at the end of their life 
in order to obtain average stature. The TTO was 
completed by people with GHD, TS and CRI (see 
below for TS and CRI). There were 25 adults with 
isolated GHD included in the study. The sample 
of GHD men made only a negligible trade off (less 
than 2%), whereas the sample of GHD women were 
willing to make a slightly larger trade off of around 
2% of their expected length of life to reach average 
height. The major drawbacks with this study were 
the small sample of between 17 and 25 people 
with each condition of interest, the retrospective 
design and the lack of a control group. Also it is 
unlikely that gaining average stature is a realistic 
possibility for most people with the conditions of 
interest. Furthermore, for one of the conditions 
of interest (GHD) the patients had received rhGH 
treatment, and for another condition (CRI) it was 
unclear whether they had or had not received 
rhGH treatment as children. It is likely that any 
rhGH treatment will underestimate the TTO made 
to gain average stature, as these participants have 
already benefited from an increase in extra height. Assessment of cost-effectiveness
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It was decided that this study did not provide a 
robust enough estimate of preference of health 
states to be used in the model.
The third study, by Koltowska-Haggstrom and 
colleagues,147 mapped European Quality of Life-5 
Dimensions quality of life measure (EQ-5D) values 
to a disease-specific QoL assessment of GHD 
(QoL-AGHDA) instrument from a survey. This was 
then used to transform QoL-AGHDA scores from 
a cohort of patients from the Kabi International 
Metabolic Database (now Pfizer) (KIMS) database 
into utility-weighted QoL-AGHDA scores (QoL-
AGHDAUTILITY). A good response rate of 84% was 
achieved, and 921 individuals from the general 
population of England and Wales responded to the 
survey. A regression model was used to estimate 
utility weights for QoL-AGHDA (R2 = 0.42). The 
EQ-5D responses were used as the dependent 
variable and the QoL-AGHDA responses were used 
as independent dummy variables with age as a 
covariate.
The patient cohort from the KIMS database 
consisted of 894 patients from England and 
Wales. However, only 21.6% had childhood-onset 
(CO)-GHD (applicable to the scope). The study was 
carried out in adults and it is unclear whether the 
CO-GHD group had had prior rhGH treatment. 
This may undervalue gain in HRQoL if this is the 
case. An inclusion criterion for the study was no 
treatment for rhGH for a minimum of 6 months 
prior to entry. The mean age for the whole cohort 
was 40 years old (SD16.5) at diagnosis and 45 years 
old (SD 14.3) at entry into KIMS. The study 
reported that patients with CO-GHD had a QoL-
AGHDAUTILITY value of 0.75 (SD 0.173) at baseline 
compared to the last reported visit score of 0.82 
(SD 0.166). The study reports mean gain in QoL-
AGHDAUTILITY per year of 0.05 (SD 0.117). They 
also reported a total gain of 0.18 (SD 0.488), and 
it is assumed that this is the QALY gain over the 
study duration worked out using trapezoid formula 
compared to the baseline QoL-AGHDAUTILITY 
values. A last observation carried forward (LOCF) 
method was used. The average length of follow-up 
in the study for the CO-GHD was not reported and 
so is not possible to verify the QALY gain or gain 
per year.
In the combined cohort of adult-onset GHD (AO-
GHD) (78%) and CO-GHD (22%) the greatest 
improvement in utility occurred within the first 
year of rhGH treatment. Subsequently, the QoL 
improvement is maintained when compared with 
the general population over a 6-year follow-up. It is 
unclear whether this benefit from rhGH treatment 
is maintained after treatment has stopped.
The limitations of this study were that it was 
observational with no control, and that the EQ-5D 
had not been conducted amongst the participants 
of the KIMS database. Furthermore, the regression 
model used to translate EQ-5D scores to disease 
specific measure explained less than one-half 
of the sample variation of the EQ-5D values. 
Nevertheless, the study provided an estimate of 
utility at baseline and at the last reported visit 
in one of the conditions of interest. The study’s 
generalisability to the other conditions of interest 
is unclear and it was felt that any attempt to link 
utilities in this study to the other conditions of 
interest was difficult due to the difference in height 
outcomes.
Turner’s syndrome
There were three studies that met the inclusion 
criteria for people with TS.143,145,146 Two143,146 of 
these were not useful as they reported SF-36 only 
scores after rhGH treatment had been completed 
compared to a cohort of women from the general 
population. Therefore, they could not be used 
to investigate the gain in HRQoL from rhGH 
treatment. Busschbach and colleagues142 used a 
TTO method (described above) with 25 women 
with TS who had not received rhGH treatment 
as children. Their average TTO was small in the 
region of 4% of their life-years to reach an average 
height for the general population.
Prader–Willi syndrome
One study met the inclusion criteria.144 This was 
potentially useful as it shows the gain in HRQoL 
from rhGH treatment over a 24-month period. 
However, the study had several limitations that 
make its results highly uncertain. It was a small 
study with only 13 Italian adult participants with 
PWS, of whom five had previously undergone 
rhGH treatment. There was no control group. At 
the last recorded observation (24 months) there 
were only nine participants left in the study. A new 
study mapping from SF-36 to a UK based EQ-5D 
preference-based utility index has recently been 
published, which provides an algorithm for this to 
be done.149
However, the PWS QoL study is for adults who have 
received rhGH and it is unclear how this relates to 
the QoL gain for a group of children, and whether 
this QoL benefit would be maintained throughout 
their lifetime.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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CRI
One study was identified that met the inclusion 
criteria.142 Busschbach and colleagues used a TTO 
approach for 17 adults who had childhood-onset 
renal failure. It is unclear whether the participants 
received any rhGH treatment prior to the TTO 
assessment. The participants were asked what 
percentage of the years of their expected life 
they were willing to trade to reach normal height 
and to not experience health states involving 
a kidney transplant and dialysis. The resulting 
TTO associated with renal failure was 4% to reach 
normal height.
SGA
No relevant HRQoL studies that were identified 
met the inclusion criteria.
SHOX-D
No relevant HRQoL studies that were identified 
met the inclusion criteria.
Height and health-related QoL
The NICE reference case clearly states that the 
measure of health outcome used in the cost-
effectiveness analysis should be QALYs calculated 
with utilities derived from a validated, generic, 
preference-based measure of HRQoL.138 The 
clinical effectiveness review in Chapter 3 found 
no RCTs that reported HRQoL measures as an 
outcome and the additional search for HRQoL 
studies (above) located only one relevant study by 
Koltowska-Haggstrom147 in one of the conditions 
of interest (GHD) that was strictly applicable to the 
NICE reference case.138
Therefore, a targeted search was conducted to 
identify publications that reported gains and losses 
in utility in relation to variation in height, as height 
is one of the primary outcome measures of GH 
treatment. Details of the search are in Appendix 
2. One full paper by Christensen and colleagues150 
was identified.
The study used the 2003 Health Survey for 
England, with 14,416 observations for adults (aged 
> 18 years).151 HRQoL was measured using the 
EQ-5D with the UK tariff. Height was converted 
from centimetres to HtSDS using a UK population 
algorithm. Inter-relationships between variables 
were assessed using ordinary least squares (OLS) 
linear regressions, controlling for age, weight 
and gender. All OLS analyses were controlled 
for multicollinearity (close interaction between 
explanatory variables). Where there were any 
highly correlated variables (weight and BMI) then 
one variable was omitted from the regression. The 
regression analyses included two-level categorical 
variables (‘sex’, ‘limiting longstanding illness’ and 
‘social class’) to explore the relationship between 
height and HRQoL while controlling for these 
confounding factors.150
There was a positive correlation between an 
increase in height and a participant’s EQ-5D score. 
The mean EQ-5D scores were lower in the shorter 
compared with taller subjects, as well as lower than 
the overall population mean. The authors’ report 
an analysis of variance (ANOVA) combined with 
post hoc Tukey’s Honestly Significant Difference 
(HSD) test for homogeneous subgroups, which 
showed that the sample could be split into three 
meaningful subgroups, each significantly different 
(p < 0.05) from each other in terms of their EQ-
5D scores. The first subgroup ‘HtSDS ≤ –2.0’ had 
significantly lower EQ-5D scores than the second 
group ‘–2.0 > HtSDS ≤ 0’ and the third group 
‘HtSDS > 0’. The second subgroup had significant 
lower scores than the third group. A multivariate 
linear analysis using the previously identified 
subgroups was undertaken to predict the variation 
in HRQoL. The full model predicted only one-
third of the sample variation in EQ-5D (R2 = 0.318, 
0.343 and 0.290) based on 11,946 observations.150
The model predicted that for those people shorter 
than –2.0 HtSDS, an improvement of 1 HtSDS 
will result in a change in EQ-5D score of 0.061. 
However, for the subgroup between –2.0 and 0 
HtSDS the gain in EQ-5D is much reduced (a 
1-HtSDS improvement increases EQ-5D score by 
only 0.010). One drawback to the Christensen 
study150 is that the population used to elicit QoL 
values are not from the conditions of interest but 
from the general population.
Summary and conclusions of the 
QoL review
The systematic review of QoL identified six 
studies that met the inclusion criteria. None of the 
studies was in a childhood population. This is to 
be expected, given the difficulties in conducting 
preference-based QoL studies in children.152 Three 
studies reported the SF-36 in adults but were not 
useful on further examination, as they reported 
SF-36 scores only after rhGH treatment. One poor-
quality study reported SF-36 at baseline, 6 months, 
12 months and 24 months for a small cohort of 
adult participants with PWS, and the scores from 
this study were mapped to a UK-based EQ-5D Assessment of cost-effectiveness
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preference-based utility index by a subsequent 
study.
There were only two studies that reported change 
in QoL using preference-based measures in the 
conditions of interest.145,147 The first study145 used 
TTO methodology for people with GHD, TS and 
CRI. The number of years that the participants 
were willing to trade to reach average height was 
in the range of 0–4%. However, there were several 
limitations to this study and it was felt that it did 
not generally provide a robust estimate of utility 
gain from rhGH treatment. The second study147 
used a regression model to give utility weights 
(based on the EQ-5D from a UK population) to the 
disease-specific QoL-AGHDA. The KIMS database 
was then used to transform patients QoL-AGHDA 
values into QoL-AGHDAUTILITY values. However, 
it was in an adult population and it is unclear 
whether they had previously had rhGH treatment 
as children. This study was specific to patients with 
GHD and is unlikely to be generalisable to the 
other conditions of interest.
An additional targeted search was undertaken for 
QoL in relation to height. One study was identified 
by Christensen and colleagues,150 which provided 
utility estimates based on the EQ-5D for different 
HtSDS from the Health Survey for England for 
an adult general population. The study provides a 
common utility gain that could be compared across 
all of the conditions of interest that could be used 
with the clinical effectiveness outcomes from the 
RCTs.
Based on the review of the QoL literature, there 
is likely to be a small gain in utility for individuals 
receiving GH treatment. However, this is based on 
a proxy measure of gain in height from shorter 
people in the general population. This excludes 
many relevant potential benefits and disadvantages 
of rhGH treatment that it is not possible to 
capture without good-quality evidence from the 
conditions of interest. This is especially true for 
PWS as additional HRQoL gain from improved 
body composition is unlikely to be captured with 
this method. Furthermore, there is also uncertainty 
over the impact of extrapolating back into 
childhood with adult utility data.
Review of the 
manufacturers’ submissions
Six of the seven manufacturers submitted evidence 
to be considered for this review. Five out of the six 
MSs consisted of a written report and an electronic 
model supporting the cost-effectiveness analyses. 
The sixth MS by Sandoz did not comply with the 
NICE template for the MTA and presented a 
description of the product (Omnitrope) and what 
appears to be a cost-minimisation analysis using 
Genotropin as a comparator (defined as a reference 
product). The collaborative submission is appraised 
below and a critique of the Sandoz submission is 
presented below (see Sandoz submission to NICE).
A de novo economic model has been used by the 
five collaborating manufacturers involved in the 
submission to the MTA of rhGH. Under Pfizer’s 
leadership, a common modelling framework 
was developed and used in the cost-effectiveness 
analysis of treatment in children with GHD, TS, 
PWS, CRI and SGA. Each of the collaborating 
manufacturers presented essentially the same 
model with some minor modifications, for 
example changes in the unit price of rhGH. The 
model developed was based upon the previous 
HTA report6 but has been extended to consider 
longer-term outcomes in order to estimate cost-
effectiveness in terms of QALYs. One manufacturer, 
Merck Serono, produced its own version of the 
model and so the health benefits differ slightly to 
the other models.
The MSs also included a rapid review on QoL 
that was undertaken by Eli Lilly on behalf of the 
collaboration of manufacturers. The aim of the 
main review was to provide a rapid search to 
identify the key papers that explored the impact of 
short stature in childhood, and the impact of short 
stature in transition to adulthood and as adults. 
The overall conclusion from this review highlighted 
the inconsistent findings relating to the role of 
short stature in QoL and psychosocial functioning 
in both childhood and adulthood.
Modelling approach
In the MSs, the base-case analyses estimated 
the incremental cost of rhGH per centimetre of 
height gained relative to no treatment (in order 
to compare with previous HTA report6) and the 
incremental cost of rhGH per QALY gained 
relative to no treatment. The utility scores used 
in the model in children with GHD, TS, CRI and 
children who were SGA were based upon the study 
by Christensen and colleagues,150 discussed above 
(see Description of the identified studies). A gain 
in height was assumed to be associated with QoL 
improvements, which was assessed using the EQ-
5D utility scale. In patients with PWS the QoL gain DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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was based upon a small study of adult patients 
with PWS, together with an estimation of the 
benefits associated with a reduced risk of diabetes. 
The assumptions used to derive QoL utility 
improvements are discussed above (see Review of 
research on QoL).
The economic evaluation of rhGH treatment in 
conditions such as GHD, TS, SGA and CRI is 
based on a single clinical effect of additional height 
gained as a result of treatment. This clinical effect 
and many of the other parameters used in the 
model are estimated from the Kabi International 
Growth Study (KIGS) database,153 which is a large-
scale collaborative database developed by Pfizer 
for the safety and efficacy of treatment with rhGH. 
It includes data from more than 60,000 treated 
patients in over 50 countries for all licensed 
indications, i.e. GHD, TS, PWS, SGA and CRI. 
Table 35 shows the input parameters used in the 
manufacturers’ model that have been derived 
from the KIGS database. The costs used in the 
manufacturers’ model were based upon those used 
in the previous HTA report, and inflated to current 
prices where appropriate.6
The cost-effectiveness analysis of rhGH treatment 
in PWS is based on an alternative structure of the 
model that estimates the utility gain based on a 
small study of 13 adult patients with PWS144 (see 
Review of research on QoL, above) who received 
rhGH for 2 years and a further utility gain for 
reduced diabetes risk. However, the PWS QoL 
study is for adults who have received rhGH and it 
is unclear how this relates to the QoL gain for a 
group of children, and whether this QoL benefit 
would be maintained throughout their lifetime. 
Furthermore, the two methods154,155 used by the 
Pfizer submission to translate SF-36 scores into 
utilities were not based on choice-based methods 
like TTO or SG, which produce utilities more 
rigorously.141 The model assumes that individuals 
with PWS and diabetes would have a 10% lower 
QoL than those without. Based on Pfizer’s 
submission to the Pharmaceutical Benefits Advisory 
Committee in Australia, it was assumed that the 
prevalence of diabetes in patients with PWS would 
reduce from 8% to 2%, although it was not possible 
to verify these assumptions in the reference 
provided.
An alternative model structure that allowed for 
the second clinical effect (a reduction in the risk 
of osteoporosis) was also presented in a scenario 
analysis for GHD. In this model it was assumed that 
a proportion of GHD children continue treatment 
until they reach the age of 25 years.
TABLE 35  Input parameters from MSs from KIGS database (from Pfizer MS)
Parameter GHD TS PWS CRI SGA
No. of patients
Start of treatment 7036 2749 485 806 990
Near adult height 2547 1349 75 157 127
Age
Start 9.14 9.3 7.42 9 8.18
End 16.37 16.45 15.21 13.95 14.18
Dropout rate
Percentage at 1 year 0.04 0.0273 0.02 0.117 0.03
Dose
0–17 years of age (mg/kg/day) 0.03 0.04 0.03 0.04 0.04
Utility
Treated 0.83 0.8 0.76 0.8 0.81
Untreated 0.69 0.69 0.67 0.69 0.69
HtSDS
Treated –1.17 –2.24 –1.36 –2.17 –2.01
Untreated –2.99 –3.18 –2.22 –2.99 –3.23Assessment of cost-effectiveness
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The manufacturers’ model makes the following 
assumptions:
1.  Patients with conditions of interest have the 
same life expectancy as the general population 
of England and Wales in the treated and 
untreated groups.
2.  Patients can continue rhGH treatment or 
discontinue treatment at the end of 1 year.
3.  Untreated children do not gain any utility 
benefit throughout the course of the lifetime of 
the model.
4.  Treatment costs and monitoring costs are 
applied over the treatment years. Health 
benefits, as measured by QoL associated with 
particular attained heights, are maintained 
over patients’ lifetimes. The full utility value is 
applied after 2 years of treatment.
5.  Compliance is assumed to be 90% in the base-
case analysis and this was assumed to not 
impact efficacy.
6.  Adverse events are not considered in the model 
for both the treated and non-treated patients.
7.  In the base case, for all conditions except 
PWS, rhGH treatment affects only FH and 
does not affect the risk of morbidities, such as 
osteoporosis fracture or diabetes.
8.  The MS estimated the average height at the 
end of treatment for the control group from 
the previous HTA report.
TABLE 36  Assessment of MS against NICE reference case requirements 
NICE reference case requirements Included in submission
Decision problem: as per the scope developed by NICE 
Comparator: no treatment alternative 
Perspective on costs: NHS and PSS 
Perspective on outcomes: all health effects on individuals 
Type of economic evaluation: cost-effectiveness analysis 
Synthesis of evidence on outcomes: based on a systematic review No evidence synthesis
Measure of health benefits: QALYs 
Description of health states for QALY calculations: use of a standardised and validated 
generic instrument

Method of preference elicitation for health-state values: choice-based method (e.g. 
TTO, SG, not rating scale)

Source of preference data: representative sample of the public 
Discount rate: 3.5% p.a. for costs and health effects 
 , yes. PSS, Personal Social Services.
Appraisal of the manufacturer 
cost-effectiveness analysis
A summary of the MS compared with the NICE 
reference case requirements138 is given in Table 36 
and indicates that the submission meets most of the 
requirements. See Appendix 9 for a tabulation of 
the critical appraisal of the submission against the 
Drummond and colleagues’ checklist.136
Cost-effectiveness results
The mean daily per-patient cost for each of the 
manufacturer’s GH treatments was based upon the 
unit cost shown in Table 37. Merck Serono stated 
that there will be a reduced cost of £20.87 through 
the use of the Merck Serono Easypod™, which 
they report will reduce vial wastage and increase 
compliance.
The base-case analyses for Pfizer, Eli Lilly, Ipsen 
and Merck Serono are shown in Table 38. Merck 
Serono produced their own version of the model 
and so the health benefits differ slightly from the 
other models.
The base-case results for the Novo Nordisk model 
using KIGS data are shown in Table 39. They also 
reported alternative ICERs using patient level data.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 37  Unit cost of rhGH for different manufacturers
Manufacturer/product Unit cost (£/mg)
Genotropin (Pfizer) 23.19
Humatrope (Eli Lilly) 18.00
NutropinAq (Ipsen) 20.70
Saizen (Merck Serono) 23.19
Norditropin SimpleXx (Novo 
Nordisk)
21.39
TABLE 38  Base-case results for Pfizer, Eli Lilly, Ipsen and Merck Serono
Manufacturer
GHD 
continueda GHD TS PWS CRI SGA
Incremental QALY 3.48 3.48 2.83 2.30 2.53 2.98
Height gain (cm) 32.24 32.24 7.95 25.59 4.48 21.92
Pfizer Incremental cost (£) 72,003 61,124 84,078 74,849 40,325 54,088
ICER (£/QALY) 20,673 17,552 29,757 32,540 15,962 18,167
Cost per cm gain (£) 2233 1896 10,576 2925 9001 2467
Eli Lilly Incremental cost (£) 57,043 65,654 31,574 42,340
ICER (£/QALY) 16,176 36,237 12,498 14,221
Cost per cm gain (£) 1747 8258 7048 1932
Ipsen Incremental cost (£) 65,198 54,779 75,243 36,129
ICER (£/QALY) 18,721 15,730 26,630 14,301
Cost per cm gain (£) 2022 1699 9464 8065
Merck Seronob Incremental cost (£) 72,719 84,077 40,325 54,087
65,711 75,847 36,416 48,839
ICER (£/QALY) 20,881 29,757 15,962 18,167
18,869 26,844 14,414 16,404
Cost per cm gain (£) 2256 10,576 9001 2467
2038 9540 8129 2228
a  GHD continued is the scenario with rhGH treatment during childhood and a transition period.
b  Figures in italics are for the EasyPod device.
TABLE 39  Base-case results for Novo Nordisk using KIGS database
GHD continueda GHD TS CRI SGA
Incremental QALY 3.70 3.70 2.89 2.90 2.77
Height gain (cm) 27.45 27.45 7.95 3.65 5.67
Incremental cost (£) 71,264 58,637 79,976 41,388 51,745
Cost per QALY (£) 19,276 15,861 27,720 14,254 18,655
Cost per cm gain (£) 2596 2136 10,060 11,345 9123
a  GHD continued is the scenario with rhGH treatment during childhood and a transition period.
Manufacturers’ conclusions
The authors suggested that many of the health 
benefits associated with rhGH treatment are not 
quantifiable and cannot be modelled easily. Many 
of these benefits would improve overall patient 
QoL and, possibly, duration of life. These benefits 
include self-esteem, improvements in sleep and 
concentration, and increased appetite as well as 
increases in LBM, total bone mass and muscle 
strength. These benefits may lead to reduced risk 
of diabetes, obesity and cardiovascular diseases.Assessment of cost-effectiveness
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The manufacturers concluded that their economic 
analyses demonstrated that rhGH is cost-effective 
for the treatment of short children with GHD, 
CRI and those born SGA, and borders on cost-
effectiveness for the treatment of TS and PWS. 
They stated that the values for cost/centimetre 
compared favourably to those reported in the 
previous NICE assessment6 and supported the 
recommendation of rhGH for children with GHD, 
TS and CRI, plus its extension to include SGA 
children.
Summary of general concerns
•  Clinical effectiveness estimates for height gain 
were taken from an observational cohort rather 
than an RCT. It is not clear whether the subset 
of the KIGS database chosen was representative 
of the UK patient population or, for example, 
whether the subset chosen may be more severe.
•  For three of the conditions (GHD, PWS 
and SGA) the estimates of height gain, in 
centimetres, were considerably higher than 
those shown in the trials due to the estimates 
used for end height in the control group.
•  All conditions, except PWS, used mortality 
rates from the general population. It is likely 
that individuals with these conditions, in 
particular CRI, will have increased mortality 
compared with the general population.
•  The manufacturers have used the Christensen 
study150 for their HRQoL utility values but 
have not taken these from the regression 
analysis from this study. Instead, they have 
used the relationship between EQ-5D and 
height without controlling for other factors. 
Utility gain attributed to height is likely 
to be capturing the combined effects of 
other (unobserved) variables, such as age, 
longstanding illness and gender. For example, 
older generations generally have lower 
QoL because of their age. Not controlling 
for other factors, in particular age, results 
in the overestimation of the utility values. 
Furthermore, the group with the lowest height 
and QoL (< –3 SDS) had few observations and 
individuals in this group were generally elderly 
(mean age > 70 years).
•  Treatment cost is calculated by rounding up to 
the nearest whole year of treatment.
•  There is high uncertainty associated with the 
assumptions and sources used to estimate QoL 
gain in the PWS model. These were based on 
a small study of adult patients with PWS and 
it is unclear how this relates to the QoL gain 
for a group of children, and whether this QoL 
benefit would be maintained throughout their 
lifetime. The methods used to derive values 
from the SF-36 for utilities were based on 
rating scales and therefore did not use choice-
based methods, such as the SG and TTO. QoL 
gain also estimated utility gain from reduced 
diabetes prevalence but this evidence could not 
be verified. There are considerable difficulties 
extrapolating the benefit from treating children 
with rhGH to their health benefits as adults.
Sandoz submission to NICE
Sandoz presented an analysis comparing 
Omnitrope with Genotropin. The MS contained 
a comparison of the annual cost of treatment with 
Omnitrope and with Genotropin in patients with 
GHD and TS. However, the MS did not comply 
with NICE guidance for a MTA,138 as QALYs were 
not estimated and a cost-effectiveness analysis 
was not presented. The MS attempted a cost-
minimisation analysis, implicitly suggesting that 
treatment with Omnitrope is equally effective 
as treatment with Genotropin (in terms of 
additional height in children with GHD and TS) 
but is associated with less cost to the UK NHS. 
A critical appraisal of the Sandoz MS is given in 
Appendix 10.
SHTAC independent 
economic evaluation
Overview
A comparison of the costs and benefits of rhGH 
compared with no treatment in cohorts of children 
with GHD, TS, PWS, CRI and SHOX-D and 
children who are SGA was made using decision-
analytical models. Models were constructed in 
Microsoft excel according to standard modelling 
methods.138 To identify data to populate the model, 
systematic searches were conducted to locate 
studies on the natural history and epidemiology of 
the indicated conditions, HRQoL and costs.
Costs were derived from published studies (where 
available), and from national and local NHS unit 
costs. The model was from the perspective of 
the NHS and PSS, as only these direct costs were 
included. The model estimates the lifelong costs 
and benefits from rhGH treatment. The costs and 
benefits were discounted at 3.5%, as recommended 
by NICE.138 The base year for the costs was 2008. 
The intervention effect in terms of improvement 
in HtSDS was derived from the systematic review of 
effectiveness reported in Chapter 3. The outcome DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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of the economic evaluation is reported as cost per 
QALY gained and cost per centimetre gained.
Description of the model
A decision-analytical model was designed for the 
economic evaluation of rhGH for treatment of 
GHD, TS, PWS, CRI, SGA and SHOX-D, and was 
based upon one developed in the previous HTA 
report.6 The current model compares a cohort of 
patients receiving rhGH during their childhood 
with a cohort of patients who were not treated 
with rhGH. The state transition Markov model 
has a cycle length of 1 year and a lifetime horizon. 
A Markov model was used as these are suitable 
for lifetime analyses with few health states.156 The 
base-case decision-analytical model includes health 
states for alive and dead. The England and Wales 
population mortality rates are applied in each cycle 
for patients, with an adjustment using the SMRs for 
each of the conditions.
The model assumes that a daily subcutaneous 
injection of rhGH is administered for the duration 
of treatment, unless a patient from the treatment 
cohort drops out of treatment or dies. The 
parameters of the model that determine the age 
at the start of treatment, the duration of treatment 
and the annual dropout rates are estimated from 
the KIGS database described in the MS or based 
upon advice from our clinical advisory group, and 
vary between conditions. A daily dose is calculated 
according to the child’s weight. The dose regimen 
corresponds to the licensed indication of rhGH in 
children (and adults, in a scenario analysis of the 
GHD cohort).
Health-care resources included for the cost of 
patient monitoring apply to both the treatment 
and no treatment cohorts. The cost categories and 
unit costs are consistent with the costs used in the 
previous HTA report for rhGH.6 The discount rate 
of 3.5% is applied to both costs and final outcomes.
Patients from the treatment cohort who stay in 
treatment receive a benefit of an additional height 
gain relative to patients in the no treatment 
cohort. Patients who drop out of treatment 
stop accumulating height gain, so their growth 
progression is no different from the height gain 
in the no treatment cohort. In each yearly cycle, 
individual HRQoL is estimated based upon their 
height gain. Individuals are assumed to maintain 
the same HRQoL after treatment has stopped for 
the rest of their lifetime. In each cycle, the total 
costs and QALYs are calculated by multiplying the 
individual costs and HRQoL by the number of 
people in the cohort still alive for the treatment 
and no treatment cohorts. The total lifetime costs 
and QALYs are calculated for the treated and 
non-treated groups by aggregating the costs and 
QALYs in each cycle. The total discounted QALY 
gain, and cost of treatment for the treatment and 
no treatment cohorts are calculated. Thus, the cost-
effectiveness of rhGH is calculated:
Cost-effectiveness = 
Cost for treatment cohort – Cost for no trea atment cohort
QALYs for treatment cohort – Q QALYs for no treatment cohort
Parameters used in the model and the data sources 
used to derive them are described in more detail 
below (see Model validation).
A list of the model assumptions is given below. 
Assumptions are applied to all conditions unless 
explicitly stated otherwise. All assumptions were 
tested in sensitivity analyses.
•  The diagnostic costs were not included in 
the analysis as they were assumed to be the 
same for both rhGH-treated and no-treatment 
patients.
•  The base case assumes no dropout or 
discontinuation of treatment. This was based 
upon advice from our clinical advisory group 
that this was likely to be a relatively rare 
occurrence. The base-case model therefore 
evaluates just rhGH treatment versus no 
treatment.
•  There are two health states for alive or dead in 
the model, and the transition between them is 
based on age-related mortality data.
•  The mortality rates were assumed to be higher 
than for the England and Wales general 
population estimates for untreated and treated 
cohorts for all conditions.
•  It was assumed that there would be no 
reduction in mortality as a result of rhGH 
treatment. There is a lack of data to assume 
otherwise.
•  The model time horizon is 100 years and all 
individuals are assumed to die by this age.
•  Effectiveness estimates for the conditions 
were based on selection of the best-quality 
evidence from the clinical effectiveness review 
in Chapter 3. RCTs were only selected if the 
follow up length was at least 2 years after 
the start of treatment. Where there were no 
appropriate RCTs, long-term observational Assessment of cost-effectiveness
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studies were considered. In the case of SGA, 
the most appropriate RCT was for only 1 year.
•  Compliance was assumed to be 85% in the 
base case, with no loss of efficacy for rhGH 
treatment.157
•  An additional scenario was undertaken for the 
GHD condition where treatment continued 
for a transition phase into adulthood to age 
25. This was only applicable for 34% of the 
GHD population.158 No additional benefit, in 
terms of height gained, was assumed from this 
additional treatment.
•  In the treatment and no-treatment cohorts, 
all children are monitored until they reach 
adulthood, assumed to be the age of 17 years.
Evaluation of uncertainty
The evaluation of the cost-effectiveness of GH 
treatment is based on uncertain information 
about variables, such as clinical effect, HRQoL 
and resource use. This uncertainty was evaluated 
using deterministic and probabilistic sensitivity 
analyses. One-way deterministic sensitivity analyses 
were conducted to evaluate the influence of 
individual parameters on the model results and to 
test the robustness of the cost-effectiveness results 
to variations in the structural assumptions and 
parameter inputs (see Sensitivity analyses, below).
Multiparameter uncertainty in the model 
was addressed using probabilistic sensitivity 
analysis (PSA) (see below).159 In PSA, probability 
distributions are assigned to the point estimates 
used in the base-case analysis. The model is 
run for 1000 iterations, with a different set of 
parameter values for each iteration, by sampling 
parameter values at random from their probability 
distributions. The uncertainty surrounding 
the cost-effectiveness of the GH treatment is 
represented on a cost-effectiveness acceptability 
curve (CEAC) according to the probability that the 
intervention will be cost-effective at a particular 
willingness-to-pay threshold. Appendix 12 reports 
the parameters included in the PSA, the form of 
distribution used for sampling each parameter, 
and the upper and lower limits assumed for each 
variable.
Model validation
The Southampton Health Technology Assessments 
Centre (SHTAC) model was validated by checking 
the model structure, calculations and data inputs 
for technical correctness. The completed cost-
effectiveness model was verified by another health 
economist. The SHTAC model was checked for 
internal consistency against the MS economic 
models by running the SHTAC model with the 
inputs used in MS models to ensure similar 
results. The robustness of the model to changes in 
input values was tested using sensitivity analyses 
to ensure that any changes to the input values 
produced changes to the results of the expected 
direction and magnitude. Finally, the model results 
were compared with those from previous studies 
including the previous HTA report and this is 
discussed in more detail in Chapter 6.
Data sources
Life expectancy
Several studies have attempted to assess the 
mortality rate of adults with the conditions of 
interest. Nielsen and colleagues160 conducted a 
meta-analysis to assess overall SMR for men and 
women with benign pituitary disease. Six studies 
were included in the meta-analysis of sex-specific 
mortality. Studies (total 5412 patients) reported 
SMR for men of 2.06 (CI 1.94 to 2.2) and women 
2.8 (CI 2.59 to 3.02). However, these analyses were 
for hypopituitarism rather than GHD.
Shoemaker and colleagues161 followed up 3439 
women in the UK, who were diagnosed with TS 
between 1959 and 2002, to the end of 2006. 
Mortality in women with TS is three times higher 
than in the general population, is raised for almost 
all major causes of death, and is raised at all ages. 
SMR was 3.9 in women aged 15–44 years old and 
2.6 in women aged 45–84 years.
Population-based morbidity and mortality data 
for PWS are not available, except from regional 
cross-sectional surveys.162 A recent regional survey 
in England indicates high morbidity and mortality 
rates. Lifetime mortality rates were roughly three 
times higher than the general population. Within 
these studies the data are insufficient to construct 
survival curves.
Mortality and causes of death in treatment for 
children with end-stage renal disease was estimated 
in a Dutch cohort study between 1972 and 1992.163 
Of all 381 patients, 85 had died. The SMR was 31.0 
over this period and 21.0 in the last cohort between 
1992 and 2002.
Kajantie and colleagues164 studied the relationship 
between small size at birth and all-cause and non-
cardiovascular mortality in 13,830 individuals born 
between 1924 and 1944 in Helsinki, Finland. They 
found that small size at birth is associated with 
increased all-cause mortality at all ages among 
adult women but only with premature death in 
adult men.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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We were unable to find any information on 
mortality rates for SHOX-D.
Using UK life tables, we estimated the life 
expectancy of adults with these conditions using 
the SMRs described above. Normal adult life 
expectancy was estimated to be 75 years for men 
and 79 years for women. Life expectancy for 
patients with hypopituitarism was reduced to 
68 years for men and 70 years for females. Life 
expectancy with TS was reduced to 70 years for 
females. We estimated the life expectancy with CRI 
to be reduced to 35 years for men and 42 years for 
females, using the end-stage renal disease mortality 
rates as a proxy in the absence of any available data 
for CRI. This may underestimate life expectancy, as 
not all patients with CRI will go on to develop end-
stage renal disease.
In the base-case model, we assume that for all 
conditions the life expectancy is lower than that of 
the general UK population, and investigate general 
population life expectancy in sensitivity analyses.
Effectiveness data
The start and end age of treatment, and the 
duration of treatment, are shown in Table 40. For 
GHD, CRI, PWS and SGA there are no RCTs 
with a duration of more than 3 years, so we used 
data from the KIGS database.153 SHOX-D was not 
included in the KIGS database and so we assumed 
that these children start treatment at the same age 
as those in the Blum RCT49 and continue treatment 
for the same duration as for children with TS in the 
KIGS database. For the purposes of the model we 
rounded the start age and treatment duration.
For GHD, some children continue to receive 
rhGH treatment into adulthood. This is shown 
as an additional scenario for GHD, for which it 
is assumed that 34% of GHD patients continue 
treatment158 until age 25 years with a dose of 
0.4 mg/day.6 These individuals do not receive any 
additional benefit associated with height gain from 
this treatment in the model.
The clinical effect of rhGH was taken from the 
systematic review in Chapter 3. Where possible the 
clinical effect was taken from the best-quality RCT, 
for which children had treatment for a sufficiently 
long time to capture HtSDS height gain, which 
we assumed would be at least 2 years. For GHD, 
these data were not available, as the only available 
RCT was for only 1 year, and so we have used 
observational data (KIGS database)153 to estimate 
the clinical effect (Table 41). For SGA, there were 
no RCTs available for the licensed dose and so 
we used a study with 1-year treatment.114 For TS, 
height gain was reported in terms of age-specific 
TS HtSDS, but the mean age-specific value was 
not reported. We assumed that the age-specific TS 
HtSDS was that reported in the KIGS database.153 
Several studies have not reported the height gain 
in centimetres, and for these studies we converted 
HtSDS values to centimetres, using the height table 
from the Health Survey for England (HSE) 2003.151
A review of compliance with rhGH was conducted 
by Merck Serono as part of the MSs. It found that 
estimates for compliance ranged from 69% to 95% 
for the studies identified. One study estimated 
concordance in 75 children by using data on GP 
prescriptions over 12 months.157 Between one 
and two injections/week were missed by 16% of 
the children, and 23% missed more than two 
injections/week. Based on this study, we assumed a 
compliance of 85%.
Health-related quality of life
There was a lack of good-quality HRQoL data 
expressed in terms of utility in the RCTs and 
other QoL studies for most of the conditions of 
interest (see Review of research on QoL, above). 
Only one study was found that was appropriate to 
the conditions of interest and this was for GHD.147 
However, it was in an adult population and it was 
uncertain whether the participants had already 
benefited from GH as children; the QoL utility 
gain from this study was similar to that from the 
Christensen and colleagues study150 for GHD. 
For the other studies the most appropriate utility 
TABLE 40  Input parameters used in the SHTAC model
GHD TS PWS CRI SGA SHOX-D
Source KIGS153 CGHAC86 KIGS153 KIGS153 KIGS153 Blum49
Starting age (years) 9 10 7 9 8 7
Age at end of treatment (years) 16 16 15 14 14 14
Treatment duration (years) 7 6 8 5 6 7
Sex (males, %) 70 0 50 71 60 48Assessment of cost-effectiveness
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TABLE 41  Clinical effect for rhGH used in the SHTAC model
Parameter GHD TS PWS CRI SGA SHOX-D
Source KIGS153 CGHAC86 ade Lind van 
Wijngaarden et al.93
Fine et 
al.108
Philip et 
al.114
Blum et al.49
Treatment cohort
Starting HtSDS –2.99 –3.4b –2.0 –2.9 –3.1 –3.3
Final HtSDS –1.17 –1.8b –0.5 –1.6 –2.3 –2.1
Control cohort
Starting HtSDS –2.99 –3.3b –2.5 –2.9 –3.1 –3.3
Final HtSDS –2.99 –3.0b –2.6 –2.9 –3.0 –3
Treatment effect
Treatment height gain (SDS) 1.82 1.3 1.6 1.3 0.7 0.9
Treatment height gain (cm) 12.8c 9.3 11.1c 9.2c 3.3 5.9
QoL gain 0.069 0.069 0.021 0.059 0.043 0.055
a  Results reported as median values.
b  Estimated, based on age-specific turner SDS score, converted to SDS score using KIGS database.153
c  HtSDS gain converted to centimetres using HSE 2003.153
measurement was from the study by Christensen 
and colleagues,150 which measured QoL using 
the EQ-5D in a large sample of the general UK 
population (HSE). The utility values are not 
from the conditions of interest; nevertheless it 
does provide a common utility gain that could be 
compared across all the conditions of interest and 
that could be used with the clinical effectiveness 
outcomes from the RCTs. It was assumed for 
children that the adult gain in utility from 
increased height derived from the Christensen and 
colleagues study would be the same as a utility gain 
in children.
This study assessed HRQoL estimates through 
the use of ordinary least squares (OLS) linear 
regression, which controlled for age, weight and 
gender. More details on the study are reported 
above (see Height and health-related QoL, above). 
We assumed that individuals in the treated and 
untreated cohorts would have no difference in 
terms of age, gender, social class, weight and 
longstanding illness. The differences in HRQoL 
utility estimates between the treated and untreated 
cohorts are therefore derived from their differences 
in height. According to the regression, for those 
people shorter than –2.0 HtSDS an improvement 
of 1 HtSDS will result in a change in HRQoL utility 
of 0.061; for the subgroup between –2.0 and 0 
HtSDS, a 1 HtSDS improvement increases utility 
by 0.01. These values were used in the SHTAC 
estimation of cost-effectiveness.
For patients with PWS there may be an additional 
health benefit associated with improved body 
composition. Any improvements in body 
composition may lead to reduced risk of diabetes 
and cardiovascular disease. However, there is 
considerable difficulty estimating the magnitude of 
this effect and extrapolating short-term treatment 
in childhood to lifelong benefit. There was one 
study of poor quality in adults with PWS but this 
was not considered to be a robust estimate of QoL 
benefit (see Review of research on QoL). The MS 
estimated a QoL benefit from reduced diabetes 
risk but it was not possible to verify this evidence. 
Due to the high uncertainty around the estimates 
of QoL benefit, we assumed no benefit due to body 
composition in the base case and then conducted 
sensitivity analyses using the studies mentioned 
above.
Estimation of costs
The costs used in the SHTAC model were based 
upon those used in the previous HTA report.6 The 
annual cost of monitoring associated with each 
condition was calculated for each arm of the model 
using treatment pathways described in that report. 
Treatment costs are calculated on the basis of mean 
dose of rhGH. Unit costs for drugs were taken 
from the British National Formulary (BNF)165 and, 
for consultations, outpatient visits and procedures, 
from NHS Reference Costs.166 The base year used for 
the analysis was 2008; where necessary, costs were 
inflated to that year.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Based on advice from our clinical advisory 
group, the resource use was the same as for the 
previous HTA report except for nurse visit time 
was assumed to be the same for all conditions and 
patients would have two outpatient visits per year. 
Furthermore, patients would no longer have a hand 
X-ray at the end of treatment. The resource use is 
similar for all conditions, except GHD where 20% 
of treated children have a pituitary test each year. 
The unit costs applied to the resource use estimates 
for monitoring tests were provided by the finance 
department at Southampton University Hospital 
Trust [personal communication, Southampton 
University Hospitals Trust: unit costs (unpublished 
database), 2008]. The hourly cost of community 
nursing is taken from the Unit Costs of Health and 
Social Care.167 All children are monitored until 
they reach adulthood, assumed to be at the age of 
17 years old. The unit costs and resource use are 
shown in Tables 42 and 43, respectively.
TABLE 42  Unit costs used in the SHTAC model
Costs component Cost (£) Source
Cost per outpatient attendance first contact face-to-face paediatric 
endocrinology (HRG code 302F)
206.28 NHS ref costs 2007/8166
Cost per outpatient attendance subsequent contact face-to-face 
paediatric endocrinology (HRG code 302F)
127.97 NHS ref costs 2007/8166
Specialist community nurse per patient contact (1 hour) 73 PSSRU 2008167
Community nurse per patient visit (1 hour) 64 PSSRU 2008167
Blood tests (for full blood count, chemical profile, thyroid and IGF) 51 SUHT 2008
X-ray, hand (BA test) 28.64a NHS ref costs 2006/7166
Pituitary function test (glucagon, insulin stress test), includes 2 hours’ 
nurse time
207.50 SUHT 2008
a  Original cost of £27.71 inflated to 2008 costs.
HRG, Healthcare Resource Group; PSSRU, Personal Social Services Research Unit; SUHT, Southampton University 
Hospitals Trust.
TABLE 43  Administration and monitoring resource use
GHD TS, PWS, CRI, SGA, SHOX-D
No treatment monitoring
Outpatient visit 2 2
Blood test 1 1
Treatment 1st year
Specialist nurse home visit (hours) 1 1
Community nurse home visits (hours) 4 4
Outpatient visit 2 2
Blood test 1 1
Pituitary function test 0.2 0
GH treatment subsequent year
Outpatient visit 2 2
Blood test 1 1
Hand X-ray 1 1
Pituitary function test 0.2 0
End of treatment
Outpatient visit 1 1Assessment of cost-effectiveness
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The unit cost of the drug used in the 
manufacturers’ models varies between £18.00 and 
£23.19 per milligram. As this review is for the 
cost-effectiveness of somatropin, rather than being 
dependent on manufacturers’ different device 
costs, we have assumed an rhGH cost in the base 
case that is the average of the six manufacturers’ 
unit cost of rhGH given in the BNF 58 (Table 
44). This gives an average price of £21.06. This 
was done for consistency between the different 
conditions, despite the average cost of rhGH for 
each condition actually varying depending on 
which and how many manufacturers have a licence 
for the condition of interest. The maximum and 
minimum price of rhGH will be used in a sensitivity 
analysis. Drug costs are calculated according to 
the dosage used (Table 45) and the weight of the 
child.165 The weight of children at different ages 
was taken from a long-term observational database 
(Appendix 13).153
Estimation of cost-
effectiveness
This section reports the cost-effectiveness results 
for a cohort of children for each of the conditions 
of interest who received rhGH treatment. Results 
for costs and QALYs are presented for children in 
the cohort for a treated and untreated cohort, with 
costs and benefits discounted at 3.5%. The cost-
effectiveness of rhGH compared to no treatment 
is presented as incremental cost per QALY and 
incremental cost per centimetre gained. The results 
are shown in Table 46 for each condition. In the 
base-case analysis, all conditions, except GHD, 
used the clinical benefit seen in the best-quality 
RCT for each condition (see Chapter 3). The cost-
effectiveness of rhGH versus no treatment varied 
from £23,196 for GHD to £135,311 for PWS per 
QALY gained.
The incremental cost per QALY gained for PWS is 
very high despite a similar or greater height gain 
compared with the other conditions as a result of 
rhGH treatment. This is due to the PWS cohort 
having a starting HtSDS that is much closer to 
population norms with most of the gain in height 
occurring between –2.0 and 0 HtSDS. Therefore, 
using the Christensen regression estimates, this 
is associated with a lower utility gain (see Health-
related quality of life, above) and a smaller QALY 
gain when compared with the other conditions. 
With the exception of PWS, all conditions have an 
ICER lower than £41,000 per QALY gained.
A further analysis was undertaken to see the effect 
of continuation of rhGH treatment into adulthood 
for 34% of the original cohort until the age of 
25 years. The incremental cost per QALY was 
£28,244 (Table 47).
Sensitivity analyses
Cost-effectiveness of rhGH 
treatment – deterministic 
sensitivity analysis
One-way deterministic sensitivity analyses were 
performed, in which model parameters were 
systematically and independently varied, using 
a realistic minimum and maximum value. The 
sensitivity analysis investigated the effect of 
uncertainty around the model structure and for 
variation in parameters on the cost-effectiveness 
results, in order to highlight the most influential 
parameters. The effects of uncertainty in multiple 
parameters were addressed using PSA, which is 
TABLE 44  Individual prices of rhGH and the average cost used 
in the cost-effectiveness analyses
rhGH
BNF 58 price (£)  
(per mg)
Genotropin 23.19
Humatrope 18.00
Norditropin 21.39
Saizen 23.18
Nutropin 20.70
Zomacton 19.92
Average cost 21.06
TABLE 45  Drug dosage
Condition
GHD TS PWS CRI SGA SHOX-D
Drug dosage 
(mg/kg/day)
0.025 0.045 0.035 0.045 0.035 0.045DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 46  Cost-effectiveness results for the base-case analysis
Condition Treatment Costs (£) QALYs
Inc. costs 
(£)
Inc. 
QALYs
ICER  
(£/QALY)
Gain 
(cm)
ICER  
(£/cm)
GHD No rhGH 2211 16.8
rhGH 38,031 18.4 35,820 1.54 23,196 12.80 2798
TS No rhGH 1965 15.9
rhGH 62,752 17.4 60,787 1.54 39,460 9.30 6536
PWS No rhGH 2646 17.6
rhGH 67,794 18.1 65,148 0.48 135,311 11.10 5869
CRI No rhGH 1876 11.6
rhGH 35,877 12.4 34,001 0.87 39,273 9.20 3696
SGA No rhGH 2432 17.1
rhGH 34,431 18.1 31,999 0.97 33,079 3.30 9697
SHOX-D No rhGH 2646 16.8
rhGH 53,434 18.1 50,788 1.25 40,531 5.90 8608
Inc., incremental.
TABLE 47  Cost-effectiveness results for continuation of rhGH treatment into adulthood for patients with GHD
Condition Treatment Costs (£) QALYs
Inc. costs 
(£)
Inc. 
QALYs
ICER  
(£/QALY)
Gain 
(cm)
ICER  
(£/cm)
GHD 
continuers
No rhGH 2211 16.8
rhGH 45,826 18.4 43,615 1.54 28,244 12.80 3407
Inc., incremental.
reported later in this section. Where possible, the 
parameters were varied according to the ranges 
of the CIs of these parameters, based on the 
published estimate. Where these data were not 
available an alternative suitable range was chosen. 
The same ranges were used in the deterministic 
and probabilistic sensitivity analyses and these are 
described in Appendix 12.
Table 48 shows the results for each of the conditions 
using the KIGS database153 for estimate of the 
clinical benefit. The KIGS database, a large 
observational study of children treated with rhGH, 
was used for the effectiveness of GHD in the base 
case reported above. According to these results, 
an ICER of rhGH versus no treatment varied from 
an ICER of £18,980 per QALY gained for SGA 
to £144,050 per QALY gained for PWS. Results 
are of a similar magnitude to the base case with 
the exception of the SGA analyses. The ICER for 
SGA is much lower in this analysis because the 
incremental clinical height gain is lower in the RCT 
effectiveness data than in the KIGS effectiveness 
data.
The discount rates used for the analyses have 
a large effect on the results, due to the upfront 
costs and the health outcomes stretching over the 
life time of the model. Table 49 shows the results 
using the discount rates used in the previous HTA 
report, i.e. costs 6% and benefits 1.5%. Using 
these discount rates, rhGH treatment is more cost-
effective. For all conditions, except PWS, the ICER 
reduces to less than £30,000 per QALY.
Tables 50–55 report the results of the deterministic 
sensitivity analyses for the conditions for the 
most influential parameters. Other variables 
were varied in sensitivity analyses but were found 
to only have a negligible effect on the results. 
The cost-effectiveness results are fairly sensitive 
to the variation in parameters included in the 
deterministic sensitivity analysis. For all of the 
conditions the model results are most sensitive to Assessment of cost-effectiveness
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TABLE 48  Cost-effectiveness results with clinical benefit from KIGS database
Condition Treatment
Height 
(HtSDS) Costs (£) QALYs
Incremental 
costs (£)
Incremental 
QALYs
ICER 
(£/QALY)
TS No rhGH –3.18 1965 15.8
rhGH –2.24 62,752 17.1 60,787 1.28 47,553
PWS No rhGH –2.22 2646 17.4
rhGH –1.36 67,794 17.9 65,148 0.45 144,050
CRI No rhGH –2.99 1876 11.5
rhGH –2.17 35,877 12.2 34,001 0.74 46,245
SGA No rhGH –3.23 2432 16.8
rhGH –2.01 34,431 18.4 31,999 1.69 18,980
SHOX-D No rhGH –3.18 2646 16.6
rhGH –2.24 53,434 17.9 50,788 1.31 40,531
TABLE 49  Cost-effectiveness results with alternative discount rates
Condition Incremental costs (£) Incremental QALYs ICER (£/QALY) Gain (cm) ICER (£/cm)
GHD 32,407 2.49 12,999 12.80 2532
TS 55,753 2.49 22,358 9.30 5995
PWS 58,075 0.79 73,836 11.10 5232
CRI 31,609 1.22 25,804 9.20 3436
SGA 29,362 1.57 18,690 3.30 8898
SHOX-D 45,937 2.05 22,436 5.90 7786
treatment start age and length, compliance and 
utility gain.
The deterministic sensitivity results for GHD are 
shown in Table 50. The results varied between 
£19,187 and £35,917 per QALY gained and were 
most sensitive to dosage.
The deterministic sensitivity results for TS are 
shown in Table 51. The results varied between 
30,505 and £48,778 per QALY gained and were 
most sensitive to utility gain.
The deterministic sensitivity results for PWS are 
shown in Table 52. The results varied between 
£111,560 and £159,062 per QALY gained and were 
most sensitive to compliance.
The deterministic sensitivity results for CRI are 
shown in Table 53. The results varied between 
£28,080 and £54,105 per QALY gained and were 
most sensitive to the treatment start age and length 
of treatment.
The deterministic sensitivity results for SGA are 
shown in Table 54. The deterministic sensitivity 
results varied between £25,675 and £41,180 per 
QALY gained and were most sensitive to utility 
gain.
The deterministic sensitivity results for SHOX-D 
are shown in Table 55. The deterministic sensitivity 
results varied between £33,406 and £50,457 per 
QALY gained and were most sensitive to utility 
gain.
For patients with PWS there may be an additional 
health benefit associated with improved body 
composition, which may reduce the risk of diabetes 
and other morbidities. In addition, there is 
considerable difficulty estimating the magnitude of 
this effect and extrapolating short-term treatment 
in childhood to lifelong benefit. In the base case 
we have assumed that there is no HRQoL benefit 
associated with changes in body composition. 
In this section we present a scenario analysis for 
additional changes in body composition. However, 
there is a difficulty linking changes in lean FM to 
changes in utility, as there are no utility studies 
for lean FM. For this reason we have focused on 
changes in BMI.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
71
TABLE 50  Deterministic sensitivity analyses for GHD
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Dosage (mg/kg) 0.025 0.039 0.023 35,917 21,379 14,538
Utility gain per HtSDS 0.061 0.073 0.049 19,776 28,047 8271
Compliance (%) 85 100 70 27,205 19,187 8018
Treatment age (years) 9–16 11–16 7–16 19,279 25,659 6380
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 25,493 19,895 5598
Utility benefit spread over 2 years 1 year 7 years 22,732 25,638 2906
SMR 2.4 2.4 1 23,196 22,184 1012
TABLE 51  Deterministic sensitivity analyses for TS
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Utility gain per HtSDS 0.061 0.073 0.049 33,131 48,778 15,647
Treatment age (years) 10–16 12–16 8–16 30,505 45,105 14,600
Compliance 85% 100% 70% 46,376 32,544 13,832
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 43,424 33,766 9658
Dosage (mg/kg) 0.045 0.05 0.4 43,815 35,106 8709
Utility benefit spread over 2 years 1 year 6 years 38,672 42,753 4081
SMR 2.4 2.4 1 39,460 37,308 2152
TABLE 52  Deterministic sensitivity analyses for PWS
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Compliance (%) 85 100 70 159,062 111,560 47,502
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 148,924 115,755 33,169
Treatment age (years) 7–15 9–15 5–15 119,036 144,159 25,123
Utility benefit spread over 
(years)
2 1 8 132,645 152,275 19,630
Dosage (mg/kg) 0.035 0.035 0.03 135,311 116,084 19,227
Utility gain per HtSDS 0.061 0.073 0.049 128,030 143,471 15,441
SMR 2.4 2.4 1 135,311 129,640 5671
Picot and colleagues168 conducted a targeted search 
to identify published utility estimates for the BMI 
values relevant to an adult obese population. The 
search aimed to identify estimates of the change 
in utility scores based on the unit change in BMI 
values. Utility estimates were considered only 
where they used a validated, multiattribute utility 
scale (e.g. EQ-5D) or appropriate methodology 
(e.g. SG or TTO techniques) and provided a clear 
definition of utility scores. They suggest the values 
reported by Hakim and colleagues169 represent the 
most methodologically sound estimates derived 
from subjects across a wide range of obesity 
levels. Hakim and colleagues169 found that a one-
unit decrease in BMI, over a period of 1 year, 
was associated with a gain of 0.017, which was 
independent of age or gender.Assessment of cost-effectiveness
72
TABLE 53  Deterministic sensitivity analyses for CRI
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Treatment age (years) 9–14 11–14 7–14 28,080 46,477 18,397
Utility benefit spread over 2 years 1 year 5 years 38,253 54,105 15,852
Utility gain per HtSDS 0.061 0.073 0.049 33,188 48,091 14,903
Compliance (%) 85 100 70 46,181 32,365 13,816
SMR 21 21 1 39,273 28,820 10,453
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 43,232 33,585 9647
Dosage (mg/kg) 0.045 0.05 0.04 43,623 34,923 8700
TABLE 54  Deterministic sensitivity analyses for SGA
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Utility gain per HtSDS 0.061 0.073 0.049 27,641 41,180 13,539
Treatment age (years) 8–14 10–14 6–14 25,675 37,921 12,246
Compliance (%) 85 100 70 38,888 27,270 11,618
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 36,408 28,296 8112
Dosage (mg/kg) 0.035 0.04 0.035 37,781 33,079 4702
Utility benefit spread over 2 years 1 year 6 years 32,422 35,818 3396
SMR 2.4 2.4 1 33,079 31,657 1422
TABLE 55  Deterministic sensitivity analyses for SHOX-D
Parameter Baseline
Upper 
value
Lower 
value
ICER (£/QALY)
Upper value Lower value Range
Utility gain per HtSDS 0.061 0.073 0.049 33,868 50,457 16,589
Compliance (%) 85 100 70 47,657 33,406 14,251
Treatment age (years) 7–14 9–14 5–14 33,787 44,666 10,879
Cost of rhGH treatment (£/mg) 21.06 23.19 18.00 44,615 34,664 9951
Dosage (mg/kg) 0.045 0.05 0.04 45,018 36,045 8973
Utility benefit spread over 2 years 1 year 7 years 39,733 44,729 4996
SMR 2.4 2.4 1 40,531 38,822 1709
In Chapter 3 (see Body composition), RCTs for 
PWS reported mixed results for changes in BMI 
with a maximum BMI difference of 1.8 kg/m2 
between treated and untreated groups after 
2 years’ treatment. Assuming this change in BMI 
is maintained lifelong, and therefore there is an 
additional utility of 0.031, the cost-effectiveness of 
PWS would be £54,800 per QALY gained.
Probabilistic sensitivity analyses
In the probabilistic sensitivity analyses (PSAs) the 
main parameters were sampled probabilistically 
from an appropriate distribution using similar 
ranges as used in the deterministic sensitivity 
analyses. The parameters sampled were: starting 
age, length of treatment, dose, HtSDS at the start 
and end of treatment for both the rhGH and no DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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treatment cohorts, utility increment for gains in 
height and all costs used in the base case excluding 
the cost of rhGH.
The distribution assigned to each variable included 
in the PSA and the parameters of the distribution 
are reported in Appendix 12. One thousand 
simulations were run for each condition of interest 
in this analysis. Table 56 reports the mean costs and 
outcomes from the PSA and the ICER for rhGH 
compared with no treatment, based on the mean 
values generated in the PSA. Table 57 shows the 
2.5% and 97.5% percentiles for the PSA.
The cost-effectiveness results from the PSA are 
slightly lower than those from the deterministic 
analyses for GHD, TS, CRI, SGA and SHOX-D 
(which were £23,196, £39,460, £39,273, £33,079 
and £40,531, respectively). The cost-effectiveness 
results from the PSA for PWS, however, are much 
lower than the deterministic estimates. This is due 
to non-linearity in the PWS model as a result of 
TABLE 56  Costs and outcomes from the PSA
Condition Treatment QALYs Costs (£) Inc. QALYs Inc. costs (£) ICER (£/QALY)
GHD No rhGH 16.81 2277
rhGH 18.36 37,719 1.543 35,517 23,019
TS No rhGH 15.89 1952
rhGH 17.43 62,128 1.546 60,176 38,931
PWS No rhGH 17.61 2639
rhGH 18.19 67,716 0.576 65,076 113,075
CRI No rhGH 11.57 1874
rhGH 12.44 35,702 0.868 33,828 38,951
SGA No rhGH 17.09 2429
rhGH 18.06 34,283 0.966 31,854 32,963
SHOX-D No rhGH 16.80 2633
rhGH 18.07 53,027 1.267 50,394 39,781
Inc., incremental.
the baseline starting HtSDS for the treated group 
being at –2.0 HtSDS. This is also the height at 
which the utility gain per unit HtSDS changes and 
thus an individual with a starting height slightly 
lower than –2.0 HtSDS will have much higher 
utility gain than one with a starting height slightly 
higher than –2.0 HtSDS. This non-linearity results 
in a higher incremental QALY in the PSA results, 
therefore decreasing the ICER in the PSA.
Scatter plots are shown for the incremental 
cost and incremental QALYs for each of the 
conditions in Figures 2–7. The difference in the 
dispersion of costs and QALY data points between 
the six conditions reflects the different levels of 
uncertainty in each condition. The spread of costs 
and to a greater extent QALYs is more compact in 
GHD than for the other conditions. This is because 
the standard errors are much smaller due to the 
effectiveness data coming from the KIGS database, 
which has a large number of observations. This 
TABLE 57  Range of results from the PSA (2.5% and 97.5% percentiles)
Condition
Incremental QALYs Incremental costs (£) ICERs
Min. Max. Min. Max. Min. Max.
GHD 1.27 1.83 25,306 46,043 15,752 31,309
TS 0.77 2.35 43,478 77,707 21,758 81,026
PWS –0.33 1.43 49,419 78,677 –838,603 1,055,815
CRI 0.43 1.30 21,580 44,294 21,553 77,929
SGA 0.52 1.48 23,179 40,773 19,945 64,614
SHOX-D 0.53 2.12 37,854 62,023 21,524 95,600
Max., maximum; Min., minimum.Assessment of cost-effectiveness
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FIGURE 2  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in growth 
hormone deficiency.
FIGURE 3  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in Turner 
syndrome.
FIGURE 4  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in Prader–Willi 
syndrome.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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FIGURE 5  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in chronic renal 
insufficiency.
FIGURE 6  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment for the condition 
‘small for gestational age’.
FIGURE 7  Cost-effectiveness plane – incremental cost and incremental QALYs for rhGH treatment and no treatment in short stature 
homeobox-containing gene deficiency.Assessment of cost-effectiveness
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creates a tighter probability distribution around the 
mean value.
In addition, a CEAC was also derived, representing 
the proportion of simulations when GH treatment 
is cost-effective for a range of willingness-to-pay 
thresholds, up to £100,000, see Figure 8.
In this analysis, rhGH treatment had the 
probability of being cost-effective at willingness-to-
pay thresholds of £20,000, £30,000 and £50,000 
per QALY as: 22%, 95% and 100% for GHD, 2%, 
19% and 78% for TS, 0%, 1% and 8% for PWS, 2%, 
16% and 80% for CRI, 4%, 38% and 90% for SGA, 
and 1%, 15% and 74% for SHOX-D, respectively.
Summary of cost-
effectiveness
•  A systematic search of the literature found two 
fully published economic evaluations of rhGH 
treatment for TS and GHD. The results from 
the studies varied due to the choice of utility 
estimates and assumptions on the effectiveness.
•  A systematic search for published studies of 
QoL for patients with individuals with the 
conditions of interest who had rhGH identified 
six studies, although none of these was in 
children. These were generally small studies 
of poor quality. One study was considered of 
reasonable quality.147 This study estimated 
HRQoL for adults with GHD.
•  An additional targeted search was undertaken 
for QoL in relation to height, which identified 
one study150 that provided utility estimates 
based on the EQ-5D for different HtSDS from 
HSE.
•  Six of the seven manufacturers submitted 
evidence to be considered for this review. 
One MS by Sandoz did not comply with the 
NICE template for MTA and presented a 
description of the product (Omnitrope) and 
what appears to be a cost-minimisation analysis 
using Genotropin as a comparator (defined 
as a reference product). The other five out 
of the six MSs consisted of a written report 
and an electronic model supporting the cost-
effectiveness analyses. This model was used by 
the five collaborating manufacturers involved 
in the submission to the MTA of rhGH in 
the cost-effectiveness analysis of treatment in 
children with GHD, TS, PWS, CRI and SGA.
•  Each of the collaborating manufacturers 
presented essentially the same model with 
some minor modifications. The model 
developed was based upon the previous HTA 
report6 but has been extended to consider 
longer term outcomes in order to estimate cost-
effectiveness in terms of QALYs.
•  The utility scores used in the MS model in 
children with GHD, TS, CRI and SGA were 
based upon the study by Christensen and 
colleagues,150 which estimates QoL associated 
with height for a general population survey. 
However, they used the utility point estimates, 
based only on height, instead of the regression 
analysis from the study, which controlled for 
other key variables.
•  In the manufacturers’ base case, the cost-
effectiveness results for all conditions were 
less than £30,000 per QALY gained. They 
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estimated ICERs of: £17,552 for GHD, £29,757 
for TS, £32,540 for PWS, £15,962 for CRI, and 
£18,167 for SGA per QALY gained.
•  The authors of this report developed an 
independent model, based upon the previous 
HTA report, and extended to consider longer 
term outcomes in order to estimate cost-
effectiveness in terms of QALYs.
•  From this independent model, the incremental 
cost per QALY estimates of rhGH compared 
to no treatment were: £23,196 for GHD, 
£39,460 for TS, £135,311 for PWS, £39,273 
for CRI, £33,079 for SGA and £40,531 for 
SHOX-D. A further analysis was run for PWS, 
which included a lifelong improvement of 
body composition of 1.8 kg/m2 BMI and an 
associated additional utility of 0.031. Under 
these assumptions there was a more favourable 
ICER of £54,800 per QALY gained.
•  The effect of a range of parameter values 
in the economic model were evaluated in 
sensitivity analyses. The model results were 
found to be most sensitive to the discount rate 
used. When the previous NICE discount rate of 
6% for costs and 1.5% for benefits was used, all 
conditions were cost-effective for a willingness-
to-pay threshold of £30,000 per QALY. The 
model results are also sensitive to treatment 
start age and length, compliance and utility 
gain.
•  The PSA estimated the probability of each of 
the conditions to be cost-effective at £30,000 
to be: 95% for GHD, 19% for TS, 1% for 
PWS, 16% for CRI, 38% for SGA and 15% for 
SHOX-D.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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G
uidance from NICE already recommends 
treatment with rhGH for children who have 
short stature that is associated with GHD, TS, 
PWS and CRI. Prescriptions associated with these 
conditions are therefore already part of primary 
care trusts’ (PCTs’) budgets, and are unlikely to 
increase significantly. However, advice from our 
clinical advisory group indicates that many families 
of children with PWS are now seeking treatment 
in infancy rather than in mid-childhood, and 
there may also be some increase in the number of 
prescriptions for GHD associated with oncology, 
as greater numbers of children are surviving 
childhood cancers. The newly licensed conditions 
SHOX-D and SGA are not covered by NICE 
guidance at the time of writing. Of the estimated 
4758 UK patients currently receiving rhGH,74 a 
breakdown by diagnosis for 3951 of them found 
Chapter 5  
Assessment of factors relevant to 
the NHS and other parties
that only 5.2% (205 patients) were receiving 
treatment for short stature that was associated with 
being born SGA. Advice from our clinical advisory 
group indicates that there is unlikely to be a large 
increase in prescriptions for children who were 
SGA.
The BSPED survey74 did not include patients 
with SHOX-D, and it is not clear how many 
children with this condition are currently receiving 
treatment. Children with short stature due to 
unknown causes, or with other conditions, such 
as LWS, not currently covered by NICE guidance, 
might have an underlying SHOX-D. The 
availability of prescriptions to these new groups of 
patients could therefore have a budgetary impact. 
However, these conditions are very rare, so there is 
unlikely to be a large increase in people requiring 
treatment.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Statement of principal 
findings
Growth hormone deficiency
The use of rhGH as replacement therapy is well 
established in children who have a deficiency of 
the natural hormone. Therefore, most clinicians 
would consider it unethical to withhold treatment 
and there is a corresponding lack of RCT evidence 
in the literature. Only one trial84 met the inclusion 
criteria for the review of rhGH in children with 
GHD, and this did not report FH. No details 
were reported on randomisation or allocation 
to treatment groups or blinding. The included 
patients (n = 19) were part of a larger study, which 
was generally poorly reported. After a year’s 
treatment, HtSDS was statistically significantly 
higher in treated than in untreated children, 
although actual height was not reported. Children 
who received rhGH for 1 year had grown at a 
mean velocity of 2.7 cm/year faster than untreated 
children, which was statistically significantly faster. 
The low patient numbers mean that the evidence 
base for GHD is weak. Thus, there is very limited 
evidence of a slight increase in growth for children 
with GHD treated with GH, based on one study 
of mixed quality. Estimates of height gain in the 
previous HTA report6 suggested FH gains of 
approximately 1.3–1.6 SDS (i.e. within 2 SDs of 
the normal mean) with rhGH treatment. However, 
these figures were from retrospective single-cohort 
studies that were not included in the present 
review.
The cost-effectiveness estimate of rhGH treatment 
in GHD is about £23,200 per QALY gained or 
£2,800 per centimetre gained. As there were no 
appropriate RCTs, the KIGS database was used 
for the estimate of height gain from rhGH.153 
This estimate for height gain was higher than for 
the other conditions. The previous HTA report6 
estimated a cost per centimetre gained of £6000 
using 8 years’ treatment compared to the 7 years 
used in our analysis and a slightly lower height gain 
from the KIGS database.153 The cost-effectiveness 
estimate for the cohort of GHD who continue 
rhGH treatment into adulthood was £28,200 per 
QALY gained and £3400 per centimetre gained.
Turner syndrome
Six trials met the inclusion criteria for the 
review of GH for growth disturbance in patients 
with TS.12,85,86,88–90 There is some evidence of 
effectiveness across all reported growth outcomes 
for girls with TS. However, these results are 
reported in studies of poor reporting and 
methodological quality, and in some cases of short 
duration. Of the six included studies, none of the 
included trials used an ITT analysis, one reported 
adequate randomisation to treatment groups,85 one 
study described adequate concealment of treatment 
allocation,85 and one adequately blinded the 
patient to treatment by administering placebo.89
In a large RCT that followed girls until FH, 
children in the rhGH group grew an average 
of 9.3 cm more from baseline than those in the 
untreated group.86 In a study of younger children 
over 2 years, the difference was 7.6 cm.85 Both of 
these were statistically significant results. Weight 
and WtSDS were found to be significantly greater 
in the treated group in one study of younger girls 
with TS.85
The searches for this study identified a new 
systematic review, conducted in Canada in 2007.135 
The review concluded that rhGH is effective in 
improving growth and FH in girls with TS, but 
found no evidence available in the clinical trials to 
suggest that rhGH improves QoL. The evidence 
discussed in the present review reflects this, as we 
found some evidence for increased height but no 
RCT evidence for improvements in QoL.
In summary, there is some evidence of effectiveness 
across all reported growth outcomes for girls with 
growth disturbance as a result of TS. There is also 
evidence of improved body composition. These 
results are reported in studies of poor reporting 
and methodological quality, and, in some cases, 
short duration, issues that may affect the validity 
of these findings. The previous HTA report6 found 
that treated girls’ FH was approximately 5 cm taller 
than untreated controls. The full publication of 
the large Canadian RCT86 since the earlier HTA 
report6 has shown a slightly larger difference in FH 
of 9.3 cm, as reported in the present review.
Chapter 6  
DiscussionDiscussion
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The cost-effectiveness estimate of rhGH treatment 
in TS is about £39,500 per QALY gained, or £6500 
per centimetre gained. The estimate of cost-
effectiveness compares with the estimate of about 
£130,000 per QALY (at current exchange rates) 
from CADTH,135 which used a lower QoL benefit 
for rhGH of 0.042 than used in our analysis. The 
previous HTA report estimated a less favourable 
cost per centimetre gained of £16,000 as a lower 
estimate for height gain of 3.9 cm (compared with 
9.3 cm) was used.
PWS
Eight small, rather poorly reported RCTs were 
included for PWS.22,91–102 Participants’ average 
ages ranged from 13 months to 10 years. Only 
the crossover study102 used a placebo injection; 
the parallel-group RCTs had no treatment as the 
comparison arm.
Treated patients grew an average of 3–5 cm/year 
faster than untreated patients. Only one22 of the 
studies reported actual change in height, with 
infants treated with rhGH growing an average of 
6.1 cm more than untreated patients during 1 year. 
HtSDS was statistically significantly greater in 
treated patients than in untreated patients after 
1 year (1–1.5 SDS higher) or 2 years of rhGH 
treatment (> 2 SDSs).
Four22,95,96,102 trials reported a statistically 
significantly lower percentage of body fat (between 
1% and 10% lower) in patients treated with rhGH 
than in those receiving placebo or no treatment. 
Three93,95,96,102 trials reported that patients treated 
with rhGH had statistically significantly higher 
LBM or a larger improvement in LBM than 
untreated patients. Clinical advice indicates that 
rhGH characteristically increases LBM and reduces 
FM, although weight and BMI do not always 
change. This is reflected in the RCTs’ findings, 
where changes in BMI were statistically significant 
in two studies,91,102 there were no statistical 
differences in two other studies,93,95,96 and results 
were similar between groups in the other two 
studies.92,100,101
In summary, patients treated with rhGH grew 
faster than untreated patients, and tended to 
have lower body fat percentages. Measurements 
in treated patients were reported to be statistically 
significantly better than in untreated patients 
in several studies, but the included studies were 
rather small and did not report power calculations 
or specify a primary outcome, so it is not clear 
whether they were adequately powered. These 
findings were comparable with growth and body 
composition outcomes reported in the previous 
HTA review.6 However, the previous review also 
reported an uncontrolled, single-cohort study of 
16 children, which suggested that rhGH treatment 
normalised FH.
The cost-effectiveness estimate of rhGH treatment 
in PWS is about £135,300 per QALY gained or 
£5,900 per centimetre gained. The ICER values 
for PWS were higher due to the majority of the 
height gain occurring within –2 HtSDS of average 
height where a lower utility gain is experienced. 
The previous HTA report6 presented a cost per 
HtSDS gained of £40,815 and this compares with 
the current report’s estimate of £44,718.
For PWS patients, there may be an additional 
health benefit associated with improved body 
composition, which may reduce the risk of diabetes 
and other morbidities. There is considerable 
difficulty with extrapolating between childhood 
treatment and adult morbidity and QoL.
In the clinical effectiveness review, RCTs for PWS 
reported mixed results for changes in BMI, with a 
maximum BMI difference of 1.8 between treated 
and untreated groups after 2 years’ treatment. 
Assuming this change in BMI is maintained 
lifelong, and therefore there is an additional utility 
of 0.031, the cost-effectiveness of PWS would be 
£54,800 per QALY gained.
Chronic renal insufficiency
The evidence for rhGH in children with CRI came 
from six RCTs,103–108 three of which had fewer 
than 25 participants,103–105 and these might not 
have been sufficiently powered to test for a real 
difference between groups. Three103,105,107 of the 
studies included children who had received renal 
transplants, and three104,106,108 were for children 
with CRI who had not had a transplant.
One study106 reported that treated children grew an 
average of 3.6 cm more than untreated children in 
1 year, with HtSDS being statistically significantly 
better in treated children than in untreated 
children in two studies. Growth was statistically 
significantly faster in treated children than in 
untreated children, with between-group differences 
in velocity ranging from 3.2 cm/year to 4.2 cm/
year in the parallel-group trials.103,106–108 Children 
treated with rhGH showed statistically significant 
improvements in weight gain or WtSDS compared DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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with untreated children in three studies.103,106,108 
No QoL data were reported for prepubertal 
children with CRI. Two rhGH-treated patients 
in one study91,102 experienced acute rejection 
episodes but both reversed after treatment with 
methylprednisolone. There were no SAEs reported.
In summary, treatment with rhGH led to small but 
statistically significant improvements in growth in 
children with CRI in two trials,106,107 one of which 
included post-transport patients and the other 
included children with CRI who had not received 
a transplant. The previous HTA review6 reported 
differences in HtSDS of approximately 0.8 SD and 
1.3 SD for 1 and 2 years of treatment, respectively. 
The present review found slightly greater 
differences, favouring rhGH, of approximately 1 
SDS for 1 year and just over 2 SDSs for 2 years’ 
treatment.
The cost-effectiveness estimate of rhGH treatment 
in CRI is about £39,300 per QALY gained or 
£3,700 per centimetre gained. The previous HTA 
report estimated a cost per centimetre gained of 
£7,403 and this was based upon treatment for only 
3 years compared with 5 years in this analysis. CRI 
has a lower QALY gain than the other conditions 
as we assumed that children with CRI would have 
a much shorter life expectancy than the general 
population due to their renal failure.
SGA
The licensing criteria for rhGH in children born 
SGA with growth disturbance state that eligible 
children need to have a current HtSDS ≤ –2.5, 
a parental-adjusted HtSDS ≤ –1, a birth weight/
length SDS ≤ –2 SDS, and have failed to show 
catch-up growth, defined as GV SDS < 0 during the 
previous year, by 4 years of age or later. None of 
the RCTs screened for this review met the inclusion 
criteria; these were therefore modified, retaining 
the current height and birth weight/length SDS 
criteria. Studies’ inclusion criteria were required 
to state that no catch-up growth had taken place 
by 3 years of age but no specific criteria were used 
for this. The amended inclusion criteria did not 
require any definition of parental height.
This could affect the generalisability of the results 
as it is possible that the trials included children 
with a genetic factor for short stature. However, 
such children would presumably have a shorter 
target height than children whose parents are 
closer to the population mean. So children who 
meet the marketing authorisation may actually 
have a greater possibility for increased growth than 
those in the clinical trials. The other difference 
between the marketing authorisation criteria and 
the adapted inclusion criteria used in this review 
was that the included trials had children as young 
as 3 years of age, whereas the licensed population 
in the UK is children over the age of 4 years. It is 
possible that an early start for treatment could lead 
to better results than would be generalisable to 
the licensed population. However, in practice, the 
mean age of the children in the included studies 
was over 4 years of age for all the trials, so results 
should be generalisable to the licensed population.
Six trials met the modified inclusion criteria for 
this review of growth disturbance in children born 
SGA.109–114 However, only one of the studies used 
the licensed dose for rhGH;26 the others all used 
two or three times the licensed dose. Several trials 
did not meet the inclusion criteria for this review 
as they included patients with heights of < –2 SDS 
rather than < –2.5 SDS as stated in the marketing 
authorisation. These are listed in Appendix 5, with 
reason for exclusion given as ‘wrong patient group’.
One trial reported AH,111 and patients who had 
received rhGH gained an extra 4 cm of height 
compared with the control group. The difference 
between treated and untreated patients was 
statistically significant, as was the difference in 
adult HtSDS. Another study114 reported that 
patients who received 0.033 mg/kg/day rhGH (the 
licensed dose) gained an additional 3.3 cm height 
compared with untreated children, and those who 
received 0.1 mg/kg/day gained 6.5 cm of additional 
height after 1 year’s treatment. HtSDS was found to 
be greater in children treated with GH in the four 
studies that reported this outcome.110,111,113,114
Weight standard deviation score was higher in 
treated than in untreated groups after both 1 and 
2 years of treatment in three studies reporting this 
outcome.109,110,113 Lean mass was reported in one 
study, being greater in the treated group.
There is very limited evidence of a slight increase 
in AH gained in centimetres and SDS, and some 
evidence of an increase in HtSDS in children 
receiving rhGH in these studies. There is also 
limited evidence of improved body composition 
outcomes, including a statistically significant mean 
difference in WtSDS between treated and untreated 
children. This evidence is from trials that did 
not meet the licensed inclusion criteria exactly, 
used higher than the licensed dose in all but one Discussion
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study, and were generally of poor quality, with few 
participants in many cases.
The cost-effectiveness estimate of rhGH treatment 
in SGA is about £33,000 per QALY gained or 
£9700 per centimetre gained. The height gain 
from the clinical review indicated that the gain for 
SGA was smaller than for the other conditions.
SHOX deficiency
Only one study49 reported the use of rhGH in 
children with SHOX-D, and this was open label 
and generally poorly reported. Treated children 
grew approximately 2 cm/year faster than their 
untreated counterparts after 2 years of treatment, 
with a rate of 3.5 cm/year quicker than untreated 
children during the first year. After 2 years of 
treatment, children were approximately 6 cm taller 
than the control group and HtSDS was statistically 
significantly higher in treated than in untreated 
patients. Treatment with rhGH raised IGF-1 and 
IGFBP-3 levels to the upper-normal range, but 
there were no SAEs reported during the study.
The ICER estimate of rhGH treatment in SHOX-D 
is about £40,500 per QALY gained or £8000 per 
centimetre gained.
General discussion
This review updates a previous assessment 
report.6 The criteria for this extended review were 
broadened to include children with SHOX-D or 
who were born SGA, as well as those with GHD, 
TS, PWS or CRI. In addition, we actively searched 
for all outcome measures including growth, body 
composition, biochemical markers and QoL.
The review focuses on increase in height as 
‘centimetres gained’ and also as HtSDS, i.e. a 
comparison with average heights for the child’s 
peer group. One goal of treatment is to prevent 
future loss of height, i.e. a child may remain 
short compared with their peers, but still be taller 
than they would have been without treatment. 
This is an important outcome, especially where 
attainment of average AH is sometimes an 
unrealistic possibility. Unrealistic expectations of 
height gain have been shown to affect QoL. For 
example, a French survey of young women with 
TS found that higher expectations from treatment 
were associated with lower QoL scores.146 This 
review identified a paucity of evidence for QoL 
data in children receiving rhGH, and as such it is 
difficult to quantify the way in which a child’s life 
can be changed by treatment other than in terms of 
centimetres of height gained.
In the previous HTA report,6 a cost-effectiveness 
model was constructed that estimated lifetime 
treatment costs and benefits in terms of cost per 
centimetre gained. Those analyses are extended 
in the present report by including QoL factors in 
the economic modelling. The cost-effectiveness of 
rhGH has been evaluated by decision-analytical 
models using clinical trial data for the gain in 
height, apart from GHD, which used KIGS data.153 
The analysis presented both cost-per-QALY 
outcomes and cost per centimetre height gained 
for comparison with the previous HTA report, as 
shown in Tables 58–60.
The cost-effectiveness results from the SHTAC 
model for rhGH treatment vary widely between 
conditions, from about £23,000 for GHD to 
£135,000 for PWS per QALY gained. The ICERs 
for TS, CRI and SGA and SHOX-D were between 
about £33,000 and £40,500 per QALY gained. 
This indicates that rhGH is unlikely to be cost-
effective for TS, PWS, CRI, SGA and SHOX-D 
at a willingness-to-pay threshold of £20,000 to 
£30,000. However, the results were sensitive to the 
discount rate used. All conditions, except PWS, 
would be cost-effective at a £30,000 willingness-to-
pay threshold using the previous NICE discount 
rate of 6% for costs and 1.5% for benefits. For all 
the conditions, the model results are most sensitive 
to treatment start age and length, compliance and 
utility gain.
The cost-effectiveness results in the current report 
varied from those in the MS and the previous 
HTA report.6 The incremental costs reported are 
generally consistent between the three models, with 
slight variations due to different dose, cost, and 
treatment start age and duration. In general, the 
results, presented in terms of centimetres gained, 
are more favourable in the current analyses than 
in the previous HTA report.6 This is due to higher 
estimates in height gain and lower incremental 
costs in the current report. The height gains in 
the MS for GHD, PWS and SGA appear extremely 
high and inconsistent with those found in the 
review of clinical effectiveness. The ICERs in the 
MS are considerably more favourable than the 
current analysis, due to higher estimates of utility 
gain. The current analyses and the MS have chosen 
utility estimates from the same study.150 However, 
the manufacturers have not taken these values from 
the regression analysis from this study. Instead they DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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have used the relationship between EQ-5D and 
height without controlling for other factors.
In general, the incremental costs consist primarily 
of the rhGH drug costs, while other costs have little 
effect on model results. For the cost-effectiveness 
results, the key issue is the choice of utility values. 
The utility gain from rhGH is assumed to last over 
the patients’ lifetimes and hence most of the QALY 
gain is in adulthood.
The results were sensitive to the length of 
treatment, for example by treating children from 
an earlier age. Current best practice is usually 
regarded as treating children as early as possible 
and this is likely to mean a longer treatment 
duration, which increases the cost of treatment 
and thus the ICER. It is unclear whether there will 
be an associated extra increase in height as most 
of the RCTs followed up children for a short time 
period, for less than 3 years. The previous HTA 
report suggested that height gains were greatest 
in the first year or two of treatment but stopping 
treatment before achieving FH generally leads to 
loss of growth gains, and so should not be advised.
The results were sensitive to the clinical effect. The 
treatment effect has been obtained, where possible, 
from the best-quality RCT available. However, as 
indicated in Chapter 3 (see Results), these trials 
were generally of poor quality and were not long-
term trials. We also used the clinical treatment 
effect from the KIGS observational study but the 
results were largely similar to those reported from 
the RCTs.
There are limitations to the QoL estimates used in 
the model. There was a lack of good QoL studies 
conducted in the conditions of interest. Therefore, 
evidence based on these studies was not used 
in the main analysis. The utility estimates were 
based upon a study that estimated utility in the 
general adult population according to height. The 
study provides a common utility gain that could 
TABLE 58  Base-case results for the SHTAC cost-effectiveness model
GHD TS PWS CRI SGA SHOX-D
Incremental QALYs 1.54 1.54 0.48 0.87 0.97 1.25
Incremental costs (£) 35,820 60,787 65,148 34,001 31,999 50,788
ICER (£/QALY) 23,196 39,460 135,311 39,273 33,079 40,531
Height gain (cm) 12.8 9.3 11.1 9.2 3.3 6.3
Cost per cm gain (£) 2798 6536 5869 3696 9697 8062
TABLE 59  Base-case results for Pfizer
GHD TS PWS CRI SGA
Incremental QALYs 3.48 2.83 2.3 2.53 2.98
Incremental costs (£) 61,124 84,078 74,849 40,325 54,088
ICER (£/QALY) 17,552 29,757 32,540 15,962 18,167
Height gain (cm) 32.24 7.95 25.59 4.48 21.92
Cost per cm gain (£) 1896 10,576 2925 9001 2467
TABLE 60  Base-case results for the previous GH HTA6
GHD TS PWSa CRI
Incremental costs (£) 53,373 61,770 56,663 54,009
Height gain (cm)b 8.85 3.9 1.36 7.29
Cost per cm gain (£) 6029 15,997 40,815 7403
a  Height gain expressed in terms of HtSDS gained.
b  Discounted and adjusted for dropouts.Discussion
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be compared across all the conditions of interest. 
Furthermore, it also provided the possibility the 
outcomes from the RCTs identified in the clinical 
effectiveness could be used. However, this still 
remains a major source of uncertainty in the 
model.
The QoL gains were highest for individuals with 
lower starting height; for those with starting 
height < –2 HtSDS the QoL gain was minimal. For 
example, those with PWS had a starting height of 
–2 HtSDS, and so for this group of patients the 
health gain is small and therefore rhGH has high 
ICER values compared with no treatment. Patients 
with PWS may experience an improvement in body 
composition due to rhGH but this was difficult to 
quantify, especially in the long term, due to lack of 
long-term data.
The current analysis assumes in the base case 
that all children with the conditions of interest 
will have reduced life expectancy. This was based 
upon some evidence to suggest that these children 
would have a lower life expectancy due to increased 
risk of cardiovascular disease, due to abdominal 
obesity and raised blood pressure. Furthermore, 
those children with CRI have a much reduced 
life expectancy. We have used the end-stage renal 
disease mortality rates as a proxy in the absence of 
any available data for CRI. This may underestimate 
life expectancy and overestimate ICER values, as 
not all patients with CRI will go on to develop 
end-stage renal disease. Bengtsson170 suggests 
that rhGH can rectify most of the cardiovascular 
abnormalities associated with GHD, although there 
appear to be few long-term observational studies 
that confirm this claim. Therefore, we assumed that 
rhGH will not increase life expectancy.
Apart from as a scenario analysis for PWS, the 
current analysis has not considered other benefits 
in addition to height gain within the model. The 
base case does not include possible benefits from 
changes in body composition, such as reduced 
risk of diabetes or cardiovascular disease, which 
may even result in increases in life expectancy. 
At this stage, these health gains would be purely 
speculative and it is not possible to verify if they 
exist or quantify them. It is also possible that there 
may be additional psychological benefits such as 
improved self-esteem.
Strengths and limitations of the 
assessment
Strengths
•  The systematic review and economic evaluation 
were carried out independently, with no 
vested interest, and results are presented in a 
consistent and transparent manner.
•  Evidence for clinical effectiveness came from 
RCT data, considered to be the highest level of 
evidence.
•  The project followed established methodology 
and principles for conducting a systematic 
review. The methods used were defined a 
priori in a research protocol (see Appendix 1), 
and this was circulated to clinical experts and 
agreed with NICE before the project started.
•  A clinical advisory group reviewed and 
commented on drafts of the protocol and the 
final report.
•  A de novo economic model was developed 
following recognised guidelines.
Limitations and uncertainties
As specified in the protocol, the systematic review 
was restricted to RCTs, because these provide the 
highest level of evidence for clinical effectiveness. 
The majority of the studies included in this review 
lasted for between 6 months and 2 years, with 
very few continuing long term or to AH. Many of 
the trials excluded patients from analyses due to 
incomplete follow-up data or patient withdrawal. 
The short duration of the RCTs means it is difficult 
to assess effectiveness of rhGH in the context in 
which it would be prescribed in real life, i.e. for 
many years in some cases.
None of the RCTs included in this review reported 
any assessment of QoL issues, and the literature 
has conflicting conclusions regarding the effect 
of short stature on QoL. It is therefore difficult to 
make any judgement about the impact of rhGH 
on the quality of a person’s daily life. Many of 
the children with the health conditions covered 
in this review will have a variety of other physical 
problems. While rhGH treatment can help to 
improve growth, height and body composition to 
some extent, QoL issues associated with underlying 
health problems will continue to affect some 
children.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Given the lack of QoL data for this patient group, 
it is possible that QALYs do not capture all the 
benefits of treatment for these children.
We did not identify any RCTs that met the original 
inclusion criteria for children born SGA. Following 
discussion with NICE, we therefore amended the 
criteria as detailed in Chapter 3 (Inclusion and 
data extraction process). The main difference was 
that we included studies of children who failed to 
show catch-up growth by 3 years of age (rather 
than 4 years) but did not specify exact criteria 
for this. Although this will have allowed slightly 
younger children to be included, the evidence 
presented in this report is still relevant to the UK 
SGA population. We also removed the reference to 
parental height, so it is possible that children in the 
included trials were naturally shorter than those in 
the general population. Only one of the included 
trials used the licensed dose, so results from the 
other five could overstate the effectiveness of rhGH 
treatment for this patient group.
We found only one RCT of rhGH in children with 
GHD,84 so the evidence base for this condition is 
rather weak. However, the previous HTA report6 
also included observational studies for GHD, TS, 
PWS and CRI. Non-randomised evidence for 
this condition has therefore been summarised 
previously in the literature and is publicly available.
The included trials were generally poorly reported, 
and often had low numbers of participants. 
Primary outcomes were not clearly specified, 
and few studies reported power calculations. 
It is therefore possible that some trials were 
underpowered to detect ‘real’ differences between 
the treatment groups, even where such differences 
were reported to be statistically significant.
The included studies were heterogeneous in terms 
of participants, dosages and study duration. The 
results are therefore presented as a narrative 
summary, and it was not appropriate to meta-
analyse the data.
The review did not assess publication bias or 
selective reporting of outcomes, so it is not possible 
to comment on the degree to which these affect the 
evidence base.
The economic model used the suggested doses 
given in the BNF.165 However, the RCTs used doses 
that were sometimes outside the licensed doses.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Implications for service 
provision
Guidance from NICE already recommends 
treatment with rhGH for children who have short 
stature that is associated with GHD, TS, PWS 
and CRI, so prescriptions associated with these 
conditions are already in place. Advice from our 
clinical advisory group indicates that there may be 
a trend towards earlier prescribing for PWS, and 
many families are now seeking treatment in infancy 
rather than in mid-childhood. There may also be 
an increase in treatment associated with acquired 
GHD as the proportion of children surviving 
cancers and associated treatment increases.
The newly licensed conditions SHOX-D and SGA 
are not covered by NICE guidance at the time 
of writing. Of the estimated 4758 UK patients 
currently receiving rhGH, only approximately 
5% were receiving treatment for short stature 
associated with being born SGA. A recent survey by 
BSPED found that there had been little change in 
the number of prescriptions in recent years.74
It is not clear how many children with SHOX-D are 
currently receiving treatment. The availability of 
prescriptions to these new groups of patients could 
theoretically have a budgetary impact. However, 
the number of children with this condition is 
small so there is unlikely to be a large increase in 
prescriptions.
Suggested research 
priorities
•  There is a lack of RCT evidence for the effects 
of rhGH treatment on FH, as it is impractical 
to run such long studies. However, longer 
studies beyond 2 years would be helpful in 
improving the evidence base for long-term 
treatment, even if near-FH rather than final 
AH were reported.
•  None of the included RCTs reported measures 
of HRQoL. There is a need to develop and 
validate a standardised QoL assessment that is 
specifically designed for children and adults. 
Future RCTs should include this as an outcome 
measure in order to assess the impact of small 
increases in height on daily QoL. This would 
also be helpful for developing utilities for cost-
effectiveness analysis of rhGH treatment for 
these conditions.
•  Good-quality trials of continuation/
discontinuation of rhGH in children who have 
finished growing are required, which report 
consistent and clinically relevant outcomes, and 
which are standardised in terms of dose.
•  Good-quality trials are needed of GH in 
children born SGA, where the children 
included and the dose administered match the 
licensing criteria.
•  It was difficult to establish when treatment is 
initiated for the different disease areas, as this 
depends on age at diagnosis. Further work to 
survey national practices or policies would be 
helpful in terms of providing information for 
future updates of this review and economic 
evaluation.
•  Although figures for the use of renal 
replacement therapy are available, there is little 
epidemiological data available on the incidence 
and prevalence of CRI. Epidemiological studies 
would therefore be useful.
•  Good-quality observational studies are needed, 
which show the long-term effects of rhGH, 
particularly the effect of treatment on body 
composition, psychological benefits (such as 
improved self-esteem), long-term morbidities 
(such as diabetes or cardiovascular disease) and 
life expectancy, particularly for PWS.
•  Further research is also necessary to establish 
the QoL benefits associated with rhGH in 
adults and children with these conditions. Well-
conducted qualitative studies could provide 
data to inform future developments in this 
area.
•  Monitoring of AEs associated with long-term 
rhGH treatment is required, with a central 
register to record the effects of long-term 
elevations in IGF-1 levels.
•  More research is needed to assess the long-
term effect on QoL for individuals who had 
rhGH as children.
Chapter 7  
ConclusionsDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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A 
review of the evidence for the clinical 
effectiveness and cost-effectiveness of 
somatropin will be undertaken systematically 
following standard guidelines from the NHS 
Centre for Reviews and Dissemination (CRD).83 
An expert advisory group of clinical experts and 
service users where appropriate will support the 
review team at key stages of the project.
Search strategy
A search strategy will be developed and tested by 
an experienced information scientist. The strategy 
will be designed to identify studies reporting 
clinical effectiveness, cost-effectiveness, HRQoL, 
resource use and costs, epidemiology and natural 
history.
The draft clinical effectiveness search strategy for 
MEDLINE is shown in Appendix 2. This will be 
adapted for other databases.
A number of electronic databases will be searched 
including: The Cochrane Database of Systematic 
Reviews (CDSR); The Cochrane Central Register of 
Controlled Trials; NHS CRD (University of York) 
Database of Abstracts of Reviews of Effectiveness 
(DARE) and the NHS Economic Evaluation 
Database (NHS EED); MEDLINE (Ovid); EMBASE 
(Ovid); National Research Register; Current 
Controlled Trials; ISI Proceedings; Web of Science; 
and BIOSIS. Bibliographies of related papers will 
be assessed for relevant studies where possible.
The MSs to NICE will be assessed for any 
additional studies that meet the inclusion criteria.
Experts will be contacted to identify additional 
published and unpublished references.
Searches will be carried out from the inception 
date of the database. Although this will involve 
duplication of searches carried out for the 
previous review, it will be necessary to identify 
trials reporting body composition as an outcome 
measure, as these may not have been identified for 
all conditions in the previous review. For databases 
of abstracts and conference presentations searches 
will only be carried out for the past 2 years to 
capture any research that has not yet been fully 
published. All searches will be limited to the 
English language, and will be updated around 
February 2009.
Inclusion and exclusion criteria
Patients
Children with growth disturbance, as per licensed 
indication for each preparation available.
Interventions
Recombinant human growth hormone 
(somatropin).
Comparators
Management strategies without somatropin.
Outcomes
The following outcomes will be included, where 
data are available:
•  final height gained
•  height standard deviation score
•  growth velocity
•  growth velocity standard deviation score
•  body composition, and biochemical/metabolic 
markers as appropriate
•  adverse effects of treatment
•  HRQoL.
Types of studies
•  Fully published RCTs or systematic reviews 
of RCTs will be included. Indicators of a 
systematic review include: explicit search 
strategy, inclusion criteria, data extraction 
and assessment of quality. Where we judge it 
necessary and appropriate, we will consider 
the inclusion of evidence from other non-
randomised studies. Full economic evaluations 
(cost-effectiveness studies, cost–utility studies, 
cost–benefit studies) and reviews of economic 
evaluations will be included in the review of 
cost-effectiveness.
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•  Studies published only as abstracts or 
conference presentations will be included only 
in the primary analysis of clinical effectiveness 
and cost-effectiveness if sufficient details 
are presented to allow an appraisal of the 
methodology and assessment of results.
•  Non-English language studies will be excluded.
Inclusion and data extraction 
process
•  Two reviewers will assess the titles and abstracts 
of studies identified by the search strategy for 
potential eligibility.
•  The full text of relevant papers will be 
requested for further assessment, and these will 
be screened independently by two reviewers.
•  Data will be extracted by one reviewer using a 
standard data extraction form and checked by 
a second reviewer.
•  At each stage, any discrepancy will be resolved 
by discussion, with involvement of a third 
reviewer where necessary.
Quality assessment
The quality of included clinical effectiveness studies 
will be assessed using NHS CRD (University of 
York) criteria.83 The methodological quality of 
the economic evaluations will be assessed using 
accepted frameworks such as the international 
consensus-developed list of criteria developed 
by Evers and colleagues171 and Drummond and 
colleagues.141 For any studies based on decision 
models we will also make use of the checklist for 
assessing good practice in decision-analytical 
modelling (Philips and colleagues).172
Quality criteria will be applied by one reviewer and 
checked by a second reviewer, with differences in 
opinion resolved by discussion and involvement of 
a third reviewer where necessary.
Methods of analysis/synthesis
•  Clinical effectiveness and cost-effectiveness 
studies will be synthesised through a narrative 
review with tabulation of results of included 
studies.
•  Where data are of sufficient quality and 
homogeneity, a meta-analysis of the clinical 
effectiveness studies will be performed using 
appropriate software.
•  Quality-of-life studies will be synthesised using 
the same methods as above, i.e. narrative 
review and meta-analysis as appropriate.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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S
earch strategies for MEDLINE are shown below. 
Strategies for other databases are available from 
the authors.
rhGH clinical effectiveness
MEDLINE: all years 1950–2008, search date: 23 
June 2009.
1.  growth disorders/
2.  growth failure.ti,ab.
3.  growth deficien*.ti,ab.
4.  Prader-Willi Syndrome/
5.  prader-willi.ti,ab.
6.  turner syndrome/
7.  (Turner*2 adj syndrome).ti,ab.
8.  growth hormone deficien*.ti,ab.
9.  GH deficien*.ti,ab.
10. GHD.ti,ab.
11. exp renal insufficiency chronic/
12. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab.
13. (CRI or CRF).ti,ab.
14. “small for gestational age”.ti,ab.
15. “short for gestational age”.ti,ab.
16. infant small for gestational age/
17. “short stature homeobox-containing gene”.
ti,ab.
18. “short stature homeobox”.ti,ab.
19. SGA.ti,ab.
20. SHOX.ti,ab.
21. PHOG.ti,ab.
22. “Pseudoautosomal homeobox-containing 
osteogenic gene”.ti,ab.
23. or/1-22
24. human growth hormone/or growth hormone/
25. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab.
26. 24 or 25
27. exp child/or exp adolescent/or exp infant/
28. child preschool/
29. (child* or infant* or adolescen* or girl* or 
boy* or prepubert* or pre-pubert*).ti,ab.
30. or/27-29
31. 23 and 26 and 30
32. randomized controlled trial.pt.
33. controlled clinical trial.pt.
34. exp Randomized Controlled Trial/
35. exp Randomized Controlled Trials as Topic/
36. exp random allocation/
37. Double-Blind Method/
38. Single-Blind Method/
39. ((singl* or doubl* or trebl*) adj9 (blind* or 
mask*)).ti,ab.
40. placebo*.ti,ab,sh.
41. random*.ti,ab.
42. (medline or medlars or embase or scisearch or 
cinahl).ti,ab,sh.
43. (systematic* adj5 review*).mp.
44. (systematic adj5 overview*).mp.
45. (methodolog* adj5 review).mp.
46. (methodolog* adj5 overview).mp.
47. (methodolog* adj5 research*).mp.
48. meta analysis.pt.
49. meta-analysis.sh.
50. (meta-analys* or meta analys* or metaanalys*).
mp.
51. ((hand adj5 search*) or (manual* adj5 search)).
mp.
52. (electronic* database* or bibliographic* 
database* or computer* database* or online 
database*).mp.
53. (Health Technology Assessment* or Medical 
Technology Assessment*).ti,ab,in.
54. or/32-53
55. 31 and 54
56. limit 55 to (english language and humans)
57. kidney transplantation/
58. (renal or kidney*).ti,ab.
59. 57 or 58
60. 26 and 30 and 54 and 59
61. 60 not 56
62. growth hormone/or human growth hormone/
63. 30 and 54 and 59 and 62
64. 63 not 56
65. 61 or 63
66. limit 65 to (english language and humans)
67. 55 or 66
68. (editorial or letter or comment).pt.
69. 67 not 68
70. from 69 keep 1-13,21-22
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Cost-effectiveness
MEDLINE: all years 1950 to current, search date 
24 June 2009.
1.  exp economics/
2.  exp economics hospital/
3.  exp economics pharmaceutical/
4.  exp economics nursing/
5.  exp economics medical/
6.  exp “Costs and Cost Analysis”/
7.  Cost Benefit Analysis/
8.  value of life/
9.  exp models economic/
10. exp fees/and charges/
11. exp budgets/
12. (value adj2 (money or monetary)).tw.
13. (economic adj2 burden).tw.
14. (expenditure* not energy).tw.
15. budget*.tw.
16. (economic* or price* or pricing or financ* 
or “fee” or “fees” or pharmacoeconomic* or 
pharma economic* or pharmaco-economic*).
tw.
17. (decision adj1 (tree* or analys* or model*)).tw.
18. Resource Allocation/
19. (unit cost or unit-cost or unit-costs or unit costs 
or drug cost or drug costs or hospital costs or 
health-care costs or health care cost or medical 
cost or medical costs).tw.
20. ((value or values or valuation) adj2 (money or 
monetary or life or lives or costs or cost)).tw.
21. (cost adj2 (util* or effective* or efficac* 
or benefit* or consequence* or analys* or 
minimi* or saving* or breakdown* or lowering 
or estimate* or variable* or allocation* 
or control* or illness* or affordable* or 
instrument* or technolog* or fee* or charge* 
or charges)).tw.
22. Markov Chains/
23. Monte Carlo Method/
24. exp Decision Support Techniques/
25. (resource adj2 (use* or utili* or allocat*)).tw.
26. or/1-25
27. growth disorders/
28. growth failure.ti,ab.
29. growth deficien*.ti,ab.
30. Prader-Willi Syndrome/
31. prader-willi.ti,ab.
32. turner syndrome/
33. (Turner*2 adj syndrome).ti,ab.
34. growth hormone deficien*.ti,ab.
35. GH deficien*.ti,ab.
36. GHD.ti,ab.
37. exp renal insufficiency chronic/
38. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab.
39. (CRI or CRF).ti,ab.
40. “small for gestational age”.ti,ab.
41. “short for gestational age”.ti,ab.
42. infant small for gestational age/
43. “short stature homeobox-containing gene”.
ti,ab.
44. “short stature homeobox”.ti,ab.
45. SGA.ti,ab.
46. (SHOX or PHOG).ti,ab.
47. “idiopathic short stature”.ti,ab.
48. “Pseudoautosomal homeobox-containing 
osteogenic gene”.ti,ab.
49. or/27-48
50. human growth hormone/
51. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab.
52. or/50–51
53. 26 and 49 and 52
54. growth disorders/ec or growth hormone/ec
55. 53 or 54
56. limit 55 to (human and english language)
57. (editorial or letter).pt.
58. 56 not 57
59. “growth hormone”.ti,ab.
60. 26 and 49 and 59
61. 58 or 60
62. limit 61 to (english language and humans) 
Quality-of-life searches
Searched 30 September 2008.
1.  “Quality of Life”/
2.  (hql or hqol or “h qol” or hrqol or “hr qol”).
ti,ab.
3.  (“hye” or “hyes”).ti,ab.
4.  (euroqol or “euro qol” or “eq5d” or “eq 5d”).
ti,ab.
5.  Quality-Adjusted Life Year/
6.  “quality adjusted life”.ti,ab.
7.  (qaly$or qald$or qale$or qtime$).ti,ab.
8.  “disability adjusted life”.ti,ab.
9.  “quality of wellbeing”.ti,ab.
10. “quality of well being”.ti,ab.
11. daly$.ti,ab.
12. (SF-36 or SF-36 or short form 36 or shortform 
36 or sf thirtysix or sf thirty six or shortform 
thirtysix or shortform thirty six or short form 
thirty six or short form thirtysix or short form 
thirty six).ti,ab.
13. health$year$equivalent$.tw.
14. disutil*.ti,ab.
15. “Value of Life”/
16. rosser.ti,ab.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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17. willingness to pay.tw.
18. standard gamble$.tw.
19. time trade off.tw.
20. time tradeoff.tw.
21. health utilit*.ab.
22. exp Health Status/
23. exp Health Status Indicators/
24. “Activities of Daily Living”/
25. “Patient Acceptance of Health Care”/
26. “health-related quality of living”.ti,ab.
27. “health-related quality of life”.ti,ab.
28. (patient* adj2 (preference* or satisfaction or 
acceptance)).ti,ab.
29. (health adj (“state” or “status” or “states”)).
ti,ab.
30. or/1-29
31. growth disorders/
32. growth failure.ti,ab.
33. growth deficien*.ti,ab.
34. Prader-Willi Syndrome/
35. prader-willi.ti,ab.
36. turner syndrome/
37. (Turner*2 adj syndrome).ti,ab.
38. growth hormone deficien*.ti,ab.
39. GH deficien*.ti,ab.
40. GHD.ti,ab.
41. exp renal insufficiency chronic/
42. (chronic adj2 (renal or kidney*) adj2 (failure or 
insufficien*)).ti,ab.
43. (CRI or CRF).ti,ab.
44. “small for gestational age”.ti,ab.
45. “short for gestational age”.ti,ab.
46. infant small for gestational age/
47. “short stature homeobox-containing gene”.
ti,ab.
48. “short stature homeobox”.ti,ab.
49. SGA.ti,ab.
50. SHOX.ti,ab.
51. PHOG.ti,ab.
52. “Pseudoautosomal homeobox-containing 
osteogenic gene”.ti,ab.
53. or/31-52
54. human growth hormone/
55. (somatropin* or somatotropin* or 
somatotrophin* or genotropin* or saizen* or 
zomacton* or nutropin* or norditropin* or 
omnitrope* or humatrope*).ti,ab.
56. 54 or 55
57. 30 and 53 and 56
58. limit 57 to (english language and humans)
59. (edtorial or letter or comment).pt.
60. 58 not 59
61. HIV.ti,ab.
62. 60 not 61DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Appendix 3  
Quality assessment
Criteria Judgement
1.  Was the assignment to the treatment groups really random? Adequate/partial/inadequate/unknown
2.  Was the treatment allocation concealed? Adequate/inadequate/unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported/unknown
4.  Were the eligibility criteria specified? Adequate/partial/inadequate/unknown
5.  Were outcome assessors blinded to the treatment allocation? Adequate/inadequate/unknown
6.  Was the care provider blinded? Adequate/partial/inadequate/unknown
7.  Was the patient blinded? Adequate/partial/inadequate/unknown
8.  Were the point estimates and measure of variability presented for the 
primary outcome measure?
Adequate/partial/inadequate/unknown
9.  Did the analyses include an ITT analysis? Adequate/inadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Appendix 4  
Data extraction tables
GHD data extraction forms
Reference and 
design Intervention Participants Outcome measures
Soliman et al. 
199684
Country: Egypt
Study design: 
RCT
Number of 
centres: not 
stated
Funding: not 
reported
(Group 1 not data 
extracted as dose–
response arm)
1a. GH 30 U/m2/week as 
a daily s.c. dose
1b. GH 15 U/m2/week as 
a daily s.c. dose
2a. GH 15 U/m2/week as 
a daily s.c. dose
2b. No treatment
(Group 3 not data 
extracted as not GHD)
3a. GH 15 U/m2/week as 
a daily s.c. dose
3b. No treatment
Duration of treatment: 1 
year
Target population: prepubertal children 
with GHD
Number of participants: total 77 (19 in 
group 2)
1. Group I: 34 children with peak GH 
response to provocation < 7 µg (not data 
extracted as dose–response arm)
2. Group 2: 19 children with peak GH 
response to provocation between 7 and 
10 µg/l (2a: 9, 2b: 10)
3. Group 3: 24 children with normal peak 
GH response (not data extracted as not 
GHD)
Sample attrition/dropout: none reported for 
group 2
Inclusion criteria for study entry: Inclusion 
criteria not clearly stated
Subjects were prepubertal, and BA was 
< 10 years at initiation of therapy, and 
< 3rd percentile height for chronological 
age
None of the children had 
haemoglobinopathy, hepatic or renal 
impairment. No child had a reduced 
weight relative to height, other systemic 
disease, history of head trauma or cranial 
irradiation, malnutrition, psychosocial 
dwarfism or hypothyroidism
Primary outcomes: not stated
Secondary outcomes: GV, 
HtSDS, BA delay, IGF-1, 
glucose, FT4, TSH, GH
Method of assessing outcomes: 
height measured on a 
stadiometer, normal population 
data were according to Tanner, 
skeletal age examined yearly 
according to Greulich and 
Pyle, height determined at 
3-month intervals, and height 
GV calculated from height at 
beginning and end of therapy. 
HtSDS calculated using age-
matched population mean 
height and SD
BA, bone age; FT4, free thyroxine; TSH, thyroid-stimulating hormone; s.c., subcutaneous; U, unit.
Characteristics of participants: growth parameters and hormonal data
Characteristic GH 15 U/m2/week (n = 9) No treatment (n = 10) Overall
Age (years) 7.1 ± 1.9 6.6 ± 1.6 6.8 ± 2.1
GV (cm/years) 3.65 ± 1.1 4.3 ± 1 3.9 ± 1.1
HtSDS (–) 3.4 ± 0.8 3.1 ± 0.6 2.8 ± 1
BA delay 2.1 ± 0.8 1.8 ± 0.65 1.9 ± 1
GH peak after clonidine 
(µg/l)
8.4 ± 1.3
GH peak after insulin 
(µg/l)
8.1 ± 1.6
IGF-1 (ng/ml) 58.5 ± 42.5 52.4 ± 21.3 59 ± 33
Glucose (mmol/l) 0 min 3.6 ± 0.6 4.1 ± 0.5
Glucose (mmol/l) 120 min 5.4 ± 0.5 4.9 ± 0.45Appendix 4
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FT4 (pmol/l) 16.5 ± 2.1 14.6 ± 1.4
TSH (µIU/ml) 1.4 ± 0.4 1.6 ± 0.3
Results
Outcomes GH 15 U/m2/week (n = 9) No treatment (n = 10) p-value
GV (cm/years) 8.4 ± 1.4a,b 5.7 ± 1.8
HtSDS (–) 2.3 ± 0.45a,b 2.8 ± 0.45
BA delay 2.25 ± 0.8 1.93 ± 0.75
GH peak after clonidine 
(µg/l)
8.6 ± 1.1 8.2 ± 1
GH peak after insulin 
(µg/l)
8.5 ± 1.4 8.3 ± 1.2
IGF-1 (ng/ml) 91.2 ± 30.4a,b 49.4 ± 19
Glucose (mmol/l) 0 min 4.3 ± 0.6 4.5 ± 0.8
Glucose (mmol/l) 120 min 5.1 ± 0.4 4.4 ± 0.6
FT4 (pmol/l) 17.4 ± 2.2 15.6 ± 1.4
TSH (µIU/ml) 2.4 ± 0.5 2.2 ± 0.5
a  p < 0.05 before vs after 1 year.
b  p < 0.05 ‘a’ vs ‘b’ subgroups.
Methodological comments
Allocation to treatment groups: Three groups of children were identified and recruited according to their peak GH response 
to provocation then subsequently allocated ‘at random’ to two subgroups within that group. No further details on 
randomisation were provided.
Blinding: Blinding is not reported.
Comparability of treatment groups: Treatment groups appear comparable, but no p-value is reported.
Method of data analysis: Data are presented as mean ± SD.
Sample size/power calculation: None reported.
Attrition/dropout: None reported for group 2, although n = 4 excluded from group 1b due to lack of compliance.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Inadequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TS data extraction forms
Reference and 
design Intervention Participants Outcome measures
Quigley et al. 
200212
Country: USA
Study design: 
RCT, dose 
response
Number of 
centres: 50
Funding: author/
group appear to 
be employed by 
Eli Lilly & Co.
1. Growth hormone 
(GH) (Humatrope) 
0.27 mg/kg/week, with 
oral placebo (GH 0.27/
Pla)
2. GH 0.27 mg/kg/week 
with LDE (GH 0.27/LDE)
(not data extracted)
3. GH 0.36 mg/kg/week 
with oral placebo (GH 
0.36/Pla)
4. GH 0.36 mg/kg/week 
with LDE (GH 0.36/LDE) 
(not data extracted)
5. Placebo injection with 
oral placebo (Pla/Pla)
GH/placebo injections: 
s.c., in equally divided 
doses, initially 3 times 
per week; oral placebo 
given daily
Duration of treatment: 
Placebo group for first 
18 months of the study; 
subjects completed the 
full study when HV was 
less than 2 cm/year and 
BA ≥ 15 year
Other interventions used: 
Ethinyl E2 daily, 25–
200 ng/kg/day depending 
on age
Target population: prepubertal girls with 
TS (first 18 months of the study data 
extracted, as placebo group joined group 
3 after this time)
Number of participants: total = 232, 
stratified by age and randomised. 224 
completed 180 days’ active therapy and 
have baseline data reported
1. 45
2. 47
3. 49
4. 42
5. 41
Sample attrition/dropout: No further 
details on withdrawals are given (n = 8)
Inclusion criteria for study entry:
Karyotypically proven TS ≥ 5 years old
BA ≤ 12 years
Prepubertal < 10th percentile for height 
on NCHS standard HV < 6 cm/year
Exclusion criteria for study entry:
Presence of any Y chromosomal 
component in karyotype
Concurrent treatment with agent that 
might influence growth
Clinically significant systemic illness
Primary outcomes: NFH (cm) 
(no placebo group), changes in 
HtSDS from baseline to end 
point (no placebo group)
Secondary outcomes: changes in: 
BA, height (cm), impact of GH 
dose, effect of LDE
Method of assessing outcomes: 
subjects were assessed every 3 
months for first 6 years then 6 
months until study completion: 
height using stadiometer, weight 
and pubertal status. Blood 
chemistry and thyroid function 
tests at every visit. Glucose 
and insulin every 6 months. 
IGF-1 every 3 months for first 
18 months, at 24 months then 
annually. X-ray of the left wrist 
and hand for BA performed 
every 6 months for 24 months 
then annually. HtSDS calculated 
with reference to general 
population and to Lyon TS 
growth data
Length of follow-up: 18 months 
for placebo-controlled study
BA, bone age; LDE, low-dose estrogen; NCHS, National Center for Health Statistics; Pla, placebo.
Characteristics of participants
Baseline (mean ± SD) GH 0.27/Pla (n = 45) GH 0.36/Pla (n = 49) Pla/Pla (n = 41)
Age (years) 9.7 ± 2.7 9.8 ± 2.9 9.4 ± 2.7
BA (years) 7.9 ± 2.3 7.9 ± 2.3 7.9 ± 2.4
Height (cm) 119.2 ± 13.6 118.6 ± 12.5 117.6 ± 13.6
HtSDS (NCHS) –2.7 ± 0.9 –2.9 ± 0.9 –2.9 ± 0.9
HtSDS (NCHS) 0.3 ± 1.0 0.2 ± 0.8 0.2 ± 0.9
Mid-parental height (cm) 164.6 ± 6.1 162.9 ± 5.9 162.4 ± 5.0
Mid-parental height SD 
score
0.27 ± 0.93 0.00 ± 0.91 –0.08 ± 0.77
Prestudy GV 4.1 ± 1.2 4.0 ± 1.2 4.1 ± 1.2
Results
Outcomes GH 0.27/Pla (n = 45) GH 0.36/Pla (n = 49) Pla/Pla (n = 41) p-value
GV 0–18 months (cm/
year)
6.6 ± 1.1 6.8 ± 1.1 4.2 ± 1.1 < 0.001a
a  Compared with placebo.
The 6-monthly GV results are presented on a difficult-to-read graph – could not data extract. Authors state that HV 
declined slightly in all GH groups after the initial peak but was significantly greater than that of the placebo group.Appendix 4
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Adverse effects GH Placebo p-value
Otitis media 
(occurrence/
worsening)
54/186 (29%) 6/46 (13%) 0.037
Comments
Ear pain and ear disorder were not different in frequency between groups. Otitis media was reported in 41% of 
subjects overall, ear pain in 27% and hypothyroidism in 16% and oedema in 3%. There were no disorders that occurred 
significantly more frequently in subjects receiving the higher dose. Serious AEs (defined as death, life-threatening cancer, 
hospitalisation, permanently disabling, drug overdose or resulting in congenital anomaly in an offspring) were reported 
for 47 out of 232 subjects; 31/47 of these were hospitalised for surgical procedures, either for elective management of 
conditions associated with TS or related to accidental injury; 11 were hospitalised for other reasons: infectious illness/
dehydration n = 5, psychosis n = 1, abnormal liver function tests n = 1, vaginal bleeding n = 1, haematuria n = 1, cardiac failure 
n = 1, hypertension n = 1; and the remaining five were reported to have accidentally overdosed on the study drug. AEs that 
were considered unexpected and possibly related to the study drug were reported for 5/232 subjects (2%): hypertension 
n = 2 (in 1 subject this had been present for 11 years), surgical procedures n = 2, scoliosis n = 1. There were no reports of 
deaths, cancer or neoplasia.
Methodological comments
Allocation to treatment groups: Authors state that subjects were randomised in a double blind fashion, but no further details 
are given.
Blinding: States double blind. Placebo is given by injection. BA radiographs were read by a single observer who was blinded 
to treatment status.
Comparability of treatment groups: Treatment groups appear similar at baseline.
Method of data analysis: Data obtained during the initial 18-month placebo-controlled phase are reported for each of the 
five original randomisation groups. ITT performed for all subjects who received 180 days of active treatment.
Sample size/power calculation: Not reported.
Attrition/dropout: Withdrawals not discussed; eight patients were randomised but did not complete treatment.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Partial
8.  Were the point estimates and measure of variability presented for the primary outcome 
measure?
Inadequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
Stephure and 
The Canadian 
Growth 
Hormone 
Advisory 
Committee86 
and Rovet et 
al. 199387 (no 
extractable data, 
so no further 
information 
extracted here)
Year: 2005
Country: Canada
Study design: 
RCT
Number 
of centres: 
multicentre
Funding: Eli Lilly 
Canada Inc.
Intervention: (GH group) 
rhGH (Humatrope, Eli 
Lilly Canada) by daily s.c.i. 
6 times weekly (0.30 mg/
kg/week, maximum 
weekly dose 15 mg)
Control: no GH treatment
Other interventions 
used: girls with primary 
ovarian failure received 
standardised sex 
steroid replacement: 
ethinyloestradiol 2.5 µg/
day at age 13, 5.0 µg/
day at age 14, and 2.0 µg 
on days 1–24 with 
medroxyprogesterone 
acetate 10 mg on days 
15–24 of each month at 
age 15 and thereafter
Target population: prepubertal girls, 
aged 7–13 years, with a diagnosis of 
TS documented by peripheral blood 
karyotype
Number of participants: 154 (95 in Rovet) 
prepubertal girls
Intervention: 76 (51 in Rovet)
Control: 78 (44 in Rovet)
Sample attrition/dropout: Overall, 15 
withdrew from GH; 35 from control:
 addendum follow-up 8 from GH; 9 from 
control
 1997 follow-up only, 5 from GH; 13 
from control
 core protocol data only, 2 from GH; 13 
from control
Sample crossovers: N/A
Inclusion criteria for study entry:
Height less than the 10th percentile for 
chronological age on the growth charts 
of the NCHS of the USA
An annualised GV less than 6.0 cm/year 
during a 6-month prerandomisation 
period
Diagnosis of TS documented by 
peripheral blood karyotype. Phenotypic 
females with identifiable Y chromosome 
eligible to participate if had undergone 
prior gonadectomy
Exclusion criteria for study entry:
Clinically significant chronic systemic 
illness, prior treatment with GH, 
anabolic steroids, estrogens, craniospinal 
radiation or inadequate thyroxine 
replacement for hypothyroidism were 
excluded
A spontaneous or stimulated serum 
GH level was 8.0 µg/l or greater in all 
subjects
Primary outcomes: BA (years), 
height (cm), HtSDS (age specific/
adult Turner), change in height 
(cm), change in HtSDS (age-
specific Turner)
Secondary outcomes:
Method of assessing outcomes: 
routine haematology, 
biochemistry and thyroid 
function studies were monitored 
every 3 months (every 6 in 
control after first year), BA 
interpreted by central reader 
using Greulich and Pyle annually. 
Age-specific and AH SD scores 
(SDS, height SD score) and the 
change in height SD scores at 
protocol completion and follow-
up relative to baseline were 
calculated according to published 
standards for girls with TS
Length of follow-up: subjects 
returned for follow-up every 3 
months until study completion, 
protocol completion criteria 
required annualised GV less than 
2 cm/year and BA 14 years or 
greater
Addendum follow-up = height 
and safety follow-up at least 
1 year following latest core 
protocol visit
Characteristics of participants (mean ± SD)
Baseline 
characteristics GH (n = 61) No treatment (n = 43) p-value
Age 10.3 ± 1.8 10.9 ± 1.7
Baseline BA (years) 8.8 ± 1.4 8.9 ± 1.3
Baseline height (cm) 119.1 ± 8.5 122.0 ± 7.8
Baseline HtSDS (age-
specific Turner)
–0.2 ± 0.9 –0.1 ± 0.8
Adjusted mid-parental 
height (cm)a
160.7 ± 6.2 159.3 ± 5.8
45,X karyotype (%) 62.3 58.1
Comments
a  Adjusted mid-parental height = [(father height – 13 cm) + mother height]/2.
Baseline results for patients who completed the protocol. Baseline data for patients who also had follow-up are very 
similar. No baseline characteristics differed at p < 0.05.Appendix 4
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Results: protocol completion characteristics (mean ± SD)
Primary outcomes GH (n = 61)
No treatment 
(n = 43)
GH effect:b mean 
(95% CI) p-value
Age (years) 16.0 ± 0.8 16.5 ± 0.9
c 0.002
Time since randomisation 
(years)
5.7 ± 1.6 5.7 ± 1.6
BA (years) 14.4 ± 0.8 14.5 ± 0.9 –0.1 (0.5 to 0.3) ns
Height (cm) 147.5 ± 6.1 141.0 ± 5.4 7.2 (6.0 to 8.4) < 0.001
HtSDS (age-specific 
Turner)
1.4 ± 1.0 0.2 ± 0.9 1.2 (1.0 to 1.5) < 0.001
HtSDS (adult Turner) 0.7 ± 0.9 –0.3 ± 0.8 1.1 (0.8 to 1.3) < 0.001
Change in height (cm) 28.3 ± 8.9 19.0 ± 6.1 7.2 (6.0 to 8.3) < 0.001
Change in HtSDS (age-
specific Turner)
1.6 ± 0.6 0.3 ± 0.4 1.3 (1.1 to 1.5) < 0.001
ns, not significant.
b  ANCOVA model with treatment, baseline HtSDS, baseline HtSDS by treatment interaction, baseline age, and baseline 
age by treatment interaction. Explanatory variables were removed from the model when not significant. GH effect is 
estimated by differences of least-squares means for treatment.
c  Age at protocol completion was significantly different between control and GH, p=0.002, this reflects the similar 
numerical difference at baseline and completion, and the lower SD at completion due to the narrower age range.
Protocol completion criteria required an annualised GV of less than 2 cm/year and a BA of 14 years or greater.
Results: addendum follow-up characteristics (mean ± SD)
Primary outcomes GH (n = 40)
No treatment 
(n = 19)
GH effect:b mean 
(95% CI) p-value
Age (years) 20.7 ± 2.5 21.2 ± 2.0
Time since randomisation 
(years)
10.6 ± 1.7 10.7 ± 1.4
BA (years) 15.1 ± 1.0 15.2 ± 1.0 0.0 (–0.6 to 0.6) ns
Height (cm) 149.0 ± 6.4 142.2 ± 6.6 73. (5.4 to 9.2) < 0.001
HtSDS (age-specific 
Turner)
0.9 ± 0.9 –0.1 ± 1.0 1.1 (0.8 to1.4) < 0.001
HtSDS (adult Turner) 0.9 ± 0.9 –0.1 ± 1.0 1.1 (0.8 to 1.4) < 0.001
Change in height (cm) 30.3 ± 8.3 21.6 ± 6.2 7.3 (5.4 to 9.1) < 0.001
Change in HtSDS (age-
specific Turner)
1.1 ± 0.5 0.0 ± 0.5 1.1 (0.8 to 1.4) < 0.001
Comments
As for completion characteristics.
Adverse event GH (n = 74) No treatment (n = 64) p-value
Surgical procedures 37 17 0.005
Otitis media 35 17 0.014
Ear disorder 15 4 0.024
Joint disorder 10 2 0.036
Respiratory disorder 8 1 0.037
Sinusitis 14 4 0.041
Goitre 0 4 0.004
Death (ruptured aortic 
aneurysm)
0 1 nr
Elevated transamine 
levelsd
1 0 nr
Intracranial hypertension 1 0 nrDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Comments
d  Leading to withdrawal from study.
After protocol completion there was no significant difference in auditory acuity (conductive or neurosensory) between 
groups (data not shown).
There were no significant between group differences in change from baseline to end point in fasting blood glucose, glycated 
haemoglobin (HbA1c), serum T4 or TSH (data not shown).
Methodological comments
Allocation to treatment groups: Eligible subjects were stratified for height relative to chronological age at entry and randomly 
assigned.
Blinding: Unblinded – control received no treatment. No mention of blinding of assessors.
Comparability of treatment groups: No statistically significant differences between groups at baseline (stated, p-values not 
given).
Method of data analysis: Data are reported as mean ± 1 SD unless stated otherwise. Differences between groups at baseline 
and end point for characteristics such as age and duration of therapy were assessed by one-way ANOVA or Fisher’s exact 
test, as appropriate. No ITT analysis.
Sample size/power calculation: Not calculated.
Attrition/dropout: Dropout is discussed: 15 withdrew from the GH group; 35 from the control. Addendum follow-up: eight 
from GH, nine from control; 1997 follow up only: five from GH, 13 from control; core protocol data only: two from GH, 13 
from control.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate (no treatment)
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Davenport et al. 
200785
Country: USA
Study design: RCT, 
open label
Number of centres: 
11
Setting: US 
paediatric 
endocrine centres
Funding: 
Supported by 
Eli Lilly (EL) & 
Co., along with 
grants from 
universities; four 
of the authors 
are employed 
by EL, most of 
the authors have 
received grant 
support from 
EL, as well as 
consulting and 
lectureship fees 
from EL and other 
pharmaceutical 
companies in the 
past
1. Recombinant growth 
hormone (Humatrope) 
daily s.c.i. of 50 µg/kg/
day
2. No treatment
Duration of treatment: 2 
years
Other interventions used: 
none
Target population: girls with TS, aged 
9 months to 4 years
Number of participants: total: 89 (The 
efficacy data exclude 1 subject who 
was found after study entry to have 
a 46,XX karyotype)
1. 45
2. 44
Sample attrition/dropout: Overall 
dropouts 10, GH group 4, no 
treatment 6
Reasons for discontinuation:
Control:
 Parents’ decision n = 2
 Scheduling problems n = 1
 Request for GH n = 2
 Lost to follow-up n = 1
GH:
 Relocation n = 1
 Lost to follow-up n = 3
Compliance rated as excellent by 
authors: 95% of subjects received 
80% of scheduled injections
Inclusion criteria for study entry:
Aged 9 months to 4 years
Karyotype proven TS
Normal urinalysis, haemoglobin and 
thyroid stimulating hormone
Adequate thyroid hormone 
replacement for at least 6 months in 
those with hypothyroidism
Written informed consent from 
legal guardians
Exclusion criteria for study entry:
Presence of Y-chromosomal 
component in the karyotype in 
subjects with gonads in situ
Autosomal abnormality
Concurrent treatment that might 
influence growth
Clinically relevant systemic illness
No specific eligibility criteria based on 
height or GV
Primary outcomes: change in SDS for 
length or height (depending on age) 
from baseline to 2 years. A height 
gain of at least 0.5 was considered 
clinically significant
Secondary outcomes: serum IGF-I, 
IGFBP-3, bone tumour markers, 
identify factors associated with 
treatment response, determine 
whether outcome could be 
predicted by regression model using 
these factors, assess safety of GH 
treatment in young cohort
Method of assessing outcomes:
Age-appropriate measures were 
obtained at each visit for length 
using infant measuring box (children 
< 2 years or older, children 
for whom accurate standing 
measurements could not be 
obtained)
Standard wall-mounted stadiometer 
(children older than 2 years)
Both length and height measured 
for girls between 2 and 3 years old; 
length measurements in these cases 
were used for the analyses
Length/HtSDS were calculated on 
the basis of data for aged matched 
girls from the US Centers for 
Disease Control
Mid-parental height 
calculated as follows: (father’s 
height – 13 cm + mother’s height)/2 
and converted to SDS using 
normative height data for women at 
20 years of age
Serum IGF-1, IGFBP-3 and bone 
turnover markers were measured 
at baseline, 4 months, 1 year and 2 
years
SDSs were calculated using 
Esoterix’s data for healthy controls
BA radiographs obtained at 
baseline, 1 year, and 2 year and read 
by blinded independent assessors
Safety was assessed on each visit 
based on reported AE, detailed 
history and physical examinations
Length of follow-up: 4-monthly 
intervals for the 2 years of 
treatmentDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Baseline characteristics of participants (mean ± SD)
Variable GH (n = 45) No treatment (n = 43) p-value
Chronological age (years) 1.98 ± 1.01 1.97 ± 1.01 nr
BA (years)a 1.95 ± 0.89 1.88 ± 0.96 nr
BA–CA –0.06 ± 0.56 –0.14 ± 0.42 nr
Length/height (cm) 78.9 ± 8.6 77.6 ± 8.7 nr
Length/HtSDS –1.42 ± 1.00 –1.76 ± 1.07 nr
MPH (cm)b 164.4 ± 5.0 164.4 ± 4.7 nr
MPH SDSb 0.17 ± 0.77 0.16 ± 0.73 nr
Weight (kg) 10.35 ± 2.28 9.92 ± 2.47 nr
WtSDS –1.31 ± 1.18 –1.77 ± 1.46 nr
BMI (kg/m2) 16.48 ± 1.37 16.24 ± 1.29 nr
Head circumference (cm)c 47.2 ± 2.4 46.7 ± 2.1 nr
Head circumference SDSc 0.09 ± 1.05 –0.14 ± 1.19 nr
Karyotype distribution: 
45,X
27/45 (60%) 29/43 (67%)
Karyotype distribution: 
45,X/46,XX
7/45 (16%) 7/43 (16%)
Karyotype distribution: 
other
11/45 (24%) 7/43 (16%)
IGF-1 SDSd –0.25 ± 0.85 –0.39 ± 0.95 nr
IGFBP-3d –0.66 ± 1.08 –0.83 ± 1.05 nr
CA, chronological age.
a  Baseline BA missing for two subjects in each group.
b  Father’s height missing for one GH subject at both baseline and end point.
c  Baseline data missing for one subject in each group; one control subject had an erroneous value at baseline, so the value 
was not used; end point data missing for two control subjects.
d  Baseline data missing for eight control subjects and three GH-treated subjects; end point data missing for four control 
subjects and seven GH subjects.
Results (mean ± SD)
Outcomes GH (n = 41) No treatment (n = 37) p-value
Chronological age (years) 4.03 ± 1.05 4.03 ± 1.03 0.9944
BA (years)a 4.24 ± 1.35 3.38 ± 1.11 0.0033
BA–CA –0.64 ± 0.80 0.21 ± 0.96 < 0.0001
Length/height (cm) 99.5 ± 7.6 91.9 ± 7.2 < 0.0001
Length/HtSDS –0.34 ± 1.10 –2.16 ± 1.22 < 0.0001
MPH (cm)b 164.7 ± 4.9 164.1 ± 4.9 0.5608
MPH SDSb 0.22 ± 0.76 0.12 ± 0.76 0.5607
Weight (kg) 16.62 ± 2.86 13.81 ± 2.50 < 0.0001
WtSDS 0.20 ± 1.06 –1.37 ± 1.36 < 0.0001
BMI (kg/m2) 16.72 ± 1.70 16.24 ± 1.29 0.1724
Head circumference (cm)c 51.1 ± 1.5 49.9 ± 1.4 0.0004
Head circumference SDSc 1.17 ± 1.03 0.30 ± 0.99 0.0004
IGF-1 SDSd 1.26 ± 0.72 –0.69 ± 0.84 < 0.0001
IGFBP-3d 0.97 ± 0.94 –1.12 ± 1.13 < 0.0001Appendix 4
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Comments
For table footnotes, see corresponding notes above, under Baseline characteristics of participants.
The between group difference for change in HtSDS after 2 years was 1.6 ± 0.6, p < 0.001 – this analysis was performed on 
data from the 78 subjects with karyotype proven TS who completed the 2-year study. The between-group difference was 
significant by 4 months and increased progressively. Total 2-year height gain was 13.6 ± 3.5 cm for the control group, vs 
20.4 ± 3.3 cm for the GH group (p < 0.001). Data are reported as mean ± SD unless noted otherwise.
No treatment (n = 37) GH (n = 41) p-value
First-year GVe (cm/year) 8.0 ± 2.4 11.7 ± 2.4 < 0.0001
Second-year GV (cm/year) 5.5 ± 1.8 8.4 ± 1.6 < 0.0001
First-year GV SDS –0.83 ± 0.95 1.75 ± 1.25 < 0.0001
Second-year GV SDS –1.63 ± 1.29 0.70 ± 1.11 < 0.001
e  Numbers in groups not known for first-year results; data are reported as mean ± SD unless noted otherwise. At the 
2-year time point (when heights of both groups were compared with US standards), only 7% of GH-treated subjects 
remained below –2.0 SDS (~2.3 percentile); in contrast, 57% of the control subjects were below –2.0 SDS at 2 years 
(p < 0.0001).
Outcome GH (n = 41) No treatment (n = 37) p-value
Baseline to 2-year change: 
IGF-I SDS
1.53 ± 0.93 –0.09 ± 0.87 nr
Adverse effects
Adverse effects GH (n = 45) No treatment (n = 44)
Serious AE, n (%)f 4 (9) 4 (9)
Treatment-emergent AEg 42 (93) 43 (98)
f  Control group: one subject each was hospitalised for surgical repair of an atrial septal defect, croup/bronchiolitis, 
gastroenteritis and dehydration. GH: one subject each was hospitalised for gastroenteritis/dehydration, bacterial 
pneumonia, persistent bleeding after tonsillectomy and hypoxaemia after adenoidectomy.
g  Events or conditions that began or worsened after study entry: many of these events were related to ear disorders. 
There was no detrimental effect of GH treatment on frequency of episodes of otitis media, rates of ear tube insertion, 
middle ear function or hearing. Most other events reported with a high frequency were typical childhood illnesses that 
were considered unlikely to have been related to GH treatment. There were no significant changes or between-group 
differences in serum TSH. AEs have been reported for the full group numbers.
Methodological comments
Allocation to treatment groups: Children were stratified by age (9 months to 2.5 years and > 2.5–4 years) and then 
randomised using a blinded phone in process, in a 1 : 1 ratio.
Blinding: Assessors of BA radiographs were blinded; it is not reported if assessors of other outcomes were blinded. 
Control group did not receive placebo injections.
Comparability of treatment groups: The two groups appear broadly similar at baseline. BA–chronological age, length/HtSDS, 
IGF-1 SDS and IGFBP-3 SDS were slightly lower in the GH group at baseline. Weight measures were slightly higher in this 
group. No p-value, so unknown if these differences are minimal.
Method of data analysis: The primary efficacy analysis was conducted on the baseline–2-year change in HtSDS for all 
subjects who had measurements at both time points (not ITT) using an ANOVA model with treatment group and baseline 
age group as explanatory variables. For analyses of changes in HtSDS, 1-sided tests were used, with the significance level 
set at 0.05. All other analyses of efficacy variables were conducted using 2-sided tests, with the significance level set at 
0.05. Serious AEs, treatment-emergent AEs and laboratory data were summarised for all subjects who entered the study. 
Data are reported as mean ± SD unless noted otherwise.
Sample size/power calculation: No calculation.
Attrition/dropout: Overall dropouts 10, GH group 4, no treatment 6.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Adequate
2.  Was the treatment allocation concealed? Adequate
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Gravholt et al. 
200588
Country: Denmark
Study design: 
Randomised, 
placebo-controlled 
crossover study
Number of centres: 
not reported
Funding: Government 
grant to Novo 
Nordisk Centre for 
Research in Growth 
and Regeneration. 
One author recipient 
of honoraria from 
Pharmacia and 
Novo Nordisk, and 
a second author 
is recipient of a 
research grant 
from Eli Lilly, Novo 
Nordisk and Roche
1. GH 0.1 IU/kg/day s.c.
2. Placebo
Age-matched control 
group studied once (not 
data extracted)
Duration of treatment: 2 
months in each arm. No 
washout period between 
the two study periods
Other interventions used: 
At least 6 months before 
inclusion in the study all 
girls had received GH 
(0.1 IU/kg/day)
Target population: girls with TS
Number of participants: total 12; 
numbers allocated to each group not 
given
Sample attrition/dropout: not reported
Inclusion/exclusion criteria for study 
entry: not stated
Primary outcomes: not stated
Secondary outcomes: body 
composition, insulin sensitivity, 
other biochemical/metabolic 
markers, markers of ovarian 
function (not data extracted)
Method of assessing outcomes: 
Participants studied at the end 
of every 2-month period, IGF-1, 
IGFBP-3 and IGFBP-1 and other 
biochemical markers tested at 
the end of every study period. 
Body composition measured by 
whole body DEXA
Length of follow-up: 4 months
DEXA, dual-energy X-ray absorptiometry.
Characteristics of participants: 12 girls with TS, aged 9.5–14.8 years (median 12.9) – not reported
Outcomes GH 0.1 IU/kg/day s.c. Placebo p-value
FM arms (g/kg total body 
weight)
32.9 ± 8.2 36.0 ± 8.6 0.12
FM legs (g/kg total body 
weight)
98.7 ± 18.7 104.9 ± 17.8 0.340
FM trunk (g/kg total body 
weight)
80.7 ± 27.4 88.1 ± 35.4 0.1
FM head (g/kg total body 
weight)
18.7 ± 3.3 18.7 ± 3.1 0.5
FM total (g/kg total body 
weight)
231.0 ± 49.5 247.8 ± 58.1 0.04
BMC arms (g/kg total body 
weight)
3.6 ± 0.8 3.5 ± 0.7 0.6
BMC legs (g/kg total body 
weight)
10.5 ± 1.7 10.6 ± 1.8 0.3
BMC trunk (g/kg total body 
weight)
7.9 ± 1.5 8.0 ± 1.4 0.4
BMC head (g/kg total body 
weight)
7.9 ± 1.1 8.0 ± 1.2 0.9
BMC total (g/kg total body 
weight)
29.6 ± 3.6 30.1 ± 3.6 0.1
LBM arms (g/kg total body 
weight)
62.9 ± 6.4 60.5 ± 6.6 0.1
LBM legs (g/kg total body 
weight)
205.7 ± 23.7 202.0 ± 25.9 0.2
LBM trunk (g/kg total body 
weight)
378.8 ± 17.4 369.3 ± 29.6 0.046
LBM head (g/kg total body 
weight)
78.0 ± 15.2 78.8 ± 13.6 0.5DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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LBM total (g/kg total body 
weight)
725.4 ± 44.8 710.5 ± 54.6 0.05
IGF-1 (µg/l) 380.5 ± 116.3 179.8 ± 79.4 < 0.0005
IGFBP-1 (µg/l) 3.1 ± 2.4 7.3 ± 4.7 0.002
IGFBP-3 (µg/l) 5982 ± 1557 4344 ± 787 0.002
IGF-1/IGFBP-3 ratio 0.065 ± 0.014 0.041 ± 0.013 < 0.0005
Fasting glucose (mmol/l) 4.28 ± 0.59 4.02 ± 0.44 0.046
Fasting insulin (pmol/l) 17.17 ± 8.30 8.58 ± 4.27 0.007a
Fasting glucagon (ng/l) 97.8 ± 43.4 79.2 ± 23.3 0.08
ISIcomp 10.3 ± 9.8 20.9 ± 16.0 0.003
RHOMA 3.34 ± 1.70 1.56 ± 0.87 0.001
AUC insulin (pmol/l/24 h) 61 344 ± 28 547 40 868 ± 16 112 0.006
AUC glucose 6922 ± 570 6707 ± 464 0.3
AUC lactate (mmol/l/540 min) 5255 ± 1224 4589 ± 1165 0.2
AUC alanine (µmol/l/540 min) 2230 ± 548 2081 ± 368 0.4
AUC glycerol 
(µmol/l/540 min)
648 ± 208 527 ± 104 0.1
AUC BOH (µmol/l/540 min) 1215 ± 1486 589 ± 385 0.2
AUC lactate OGTT 
(mmol/l/120 min)
11569 ± 2438 10239 ± 1674 0.09
AUC alanine OGTT 
(µmol/l/120 min)
2848 ± 730 2665 ± 459 0.3
AUC glycerol OGTT 
(µmol/l/120 min)
444 ± 83 408 ± 96 0.2
AUC BOH OGTT 
(µmol/l/120 min)
564 ± 812 319 ± 268 0.3
AUC FFA OGTT 
(µmol/l/120 min)
2.43 ± 0.77 2.06 ± 0.91 0.1
Comments
AUC, area under the curve; BOH, 3-hydroxybutyrate; FFA, free fatty acids; HOMA, homeostasis model assessment  
index; ISIcomp, composite whole-body insulin sensitivity index; OGTT, oral glucose tolerance test; R, fasting insulin 
(22.5 x e–ln fasting glucose).
a  Wilcoxon two-tailed test. Numbers entered into each group unclear.
Adverse effects
Not reported.
Methodological comments
Allocation to treatment groups: States randomised, but no other details. No details of numbers allocated to groups.
Blinding: States placebo used, no other details given.
Comparability of treatment groups: Appear comparable, but unclear if the details are from baseline.
Method of data analysis: Groups were compared using Student’s two-tailed paired t-test, independent t-test, Mann–Whitney 
U-test or Wilcoxon test as appropriate. States that all data were tested for period as well as carry-over effects: authors 
state this did not affect significance. Results expressed as mean ± SD. Statistical significance was assumed for p < 5%.
Sample size/power calculation: Not reported.
Attrition/dropout: Not reported/discussed, no numbers allocated to groups specified.Appendix 4
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Unknown
4.  Were the eligibility criteria specified? Inadequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Unknown
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
Gravholt et al. 
200589
Country: Denmark
Study design: 
randomised, placebo-
controlled, crossover 
trial
Number of centres: not 
reported
Funding: Government 
grant to Novo 
Nordisk Centre for 
Research in Growth 
and Regeneration
All girls were treated with 
placebo + placebo, GH + placebo 
or GH + 17β oestradiol (this 
latter group’s results are not data 
extracted) for a 2-month period 
each completed by a 24-h blood 
sampling period. The treatment 
regimen was given sequentially and 
in random order
Doses:
1. GH [1.3 ± 0.3 (0.7–1.8)] mg/day 
[mean ± SD (range)]
2. 17β oestradiol [0.39 ± 0.16 (0.25–
0.6)] mg/day
A pubertal stage-matched healthy 
control group (n = 10) was studied 
once (not data extracted)
Duration of treatment: 6 months
Other interventions used: At least 
5 months before inclusion in 
the study all TS girls received 
GH [1.3 ± 0.3 (0.7–1.8)] mg/
day [mean ± SD (range)] and 17β 
oestradiol [0.39 ± 0.16 (0.25–
0.6)] mg/day
Target population: girls with TS
Number of participants: total 
9; no numbers given for 
treatment groups
Sample attrition/dropout: 
One girl was excluded for 
non-compliance with study 
protocol
Inclusion/exclusion criteria 
for study entry: all girls with 
TS previously verified by 
chromosomal karyotyping. No 
other criteria stated
Primary outcomes: not 
stated
Secondary outcomes: 
insulin sensitivity, 
glucose tolerance, body 
composition
Method of assessing 
outcomes: participants 
were studied at the 
end of every 2-month 
period. IGF-1, IGFBP-3 
and IGFBP-1 tested at 
each study visit. Body 
composition measured by 
DEXA
Length of follow-up: 8 
months (including initial 
observation period of 2 
months)
Characteristics of participants: baseline data given for Turner participants as 1 group; did not extract data for 
healthy controls
TS p-value
Age (years) 15.9 ± 1.8
Weight (kg) 49.1 ± 11.0
Height (cm) 148.3 ± 4.0
BMI (kg/m2) 22.2 ± 4.0
Results
Outcomes GH Placebo p-value
FM arms 41.2 ± 10.2 46.3 ± 12.9 Unclear which groups 
the p-values in the paper 
are referring to: not data 
extracted here
FM legs 122.4 ± 22.2 135.1 ± 30.2
FM trunk 96.2 ± 27.9 116.6 ± 38.7
FM head 14.7 ± 2.1 14.8 ± 2.5
FM total 274.5 ± 55.5 312.9 ± 74.7
BMC arms 4.5 ± 0.4 4.2 ± 0.3
BMC legs 11.7 ± 0.8 11.9 ± 0.9
BMC trunk 9.0 ± 1.1 8.9 ± 0.7
BMC head 7.3 ± 1.2 7.2 ± 1.2
BMC total 32.5 ± 2.6 32.1 ± 2.0
LBM arms 61.2 ± 6.5 56.5 ± 10.4
LBM legs 213.2 ± 24.1 197.2 ± 29.0
LBM trunk 356.8 ± 20.9 339.9 ± 30.4
LBM head 61.6 ± 10.7 61.3 ± 10.4
LBM total 692.8 ± 55.5 655.2 ± 73.7Appendix 4
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IGF-1 (µg/l) 661 ± 192 288 ± 69
IGFBP-1 (µg/l) 1.8 ± 1.2 4.2 ± 2.8
IGFBP-3 (µg/l) 5157 ± 741 4146 ± 573
Fasting glucose 
(mmol/l)
4.46 ± 0.40 4.04 ± 0.47
Fasting insulin (pmol/l) 147.1 ± 54.0 86.1 ± 41.0
Fasting glucagon (ng/l) 37.4 ± 12.6 43.0 ± 26.1
ISIcomp 7.0 ± 3.7 14.7 ± 8.7
RHOMA 4.12 ± 1.60 2.24 ± 1.31
AUC insulin 
(pmol/l/24 h)
8710 ± 4728 5848 ± 4312
AUC glucose 119 ± 10 111 ± 13
AUC lactate 
(nmol/l/480 min)
4853 ± 1520 5532 ± 2120
AUC alanine 
(µmol/l/480 min)
1864 ± 627 2230 ± 543
AUC glycerol 
(µmol/l/480 min)
516 ± 245 491 ± 220
AUC BOH 
(µmol/l/480 min)
947 ± 1372 338 ± 437
AUC lactate OGTT 
(mmol/l/120 min)
3614 ± 976 3718 ± 948
AUC alanine OGTT 
(µmol/l/120 min)
855 ± 190 840 ± 159
AUC glycerol OGTT 
(µmol/l/120 min)
117 ± 56 99 ± 42
AUC BOH OGTT 
(µmol/l/120 min)
96 ± 96 57 ± 68
AUC FFA OGTT 
(µmol/l/120 min)
0.83 ± 0.18 0.75 ± 0.27
AUC, area under the curve; BOH, 3-hydroxybutyrate; FFA, free fatty acids; HOMA, homeostasis model assessment index; 
ISIcomp, composite whole-body insulin sensitivity index; OGTT, oral glucose tolerance test; R, fasting insulin (22.5 x e–ln 
fasting glucose).
Adverse effects
Not reported/discussed.
Methodological comments
Allocation to treatment groups: Unclear whether allocation to treatment groups has taken place, or whether participants all 
took the same combination of drugs in the same time period.
Blinding: No details given, although is stated that placebo + placebo given and GH + placebo in those groups.
Comparability of treatment groups: Not reported – baseline information given for TS participants as a whole.
Method of data analysis: Groups were compared using Student’s two-tailed paired t-test and an independent t-test when 
normally distributed, Mann–Whitney and Wilcoxon used for non-parametric data. Results expressed as mean ± SD. 
Statistical significance was assumed for p < 5%.
Sample size/power calculation: Not reported.
Attrition/dropout: One patient excluded for non-compliance with study protocol. No further details given.
No washout period. Unclear on whether is randomised or treatment simply given ‘in a random order’ (p. 617).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? nr
4.  Were the eligibility criteria specified? Inadequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Adequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Johnston et al. 
200190
Country: UK
Study design: 
RCT
Number of 
centres: six
Funding: 
Pharmacia & 
Upjohn
1. GH 28–30 IU/m2 surface 
area/week daily s.c.i.
2. Low-dose estrogen: 
ethinyloestradiol 1.0 µg/day 
for < 10 years and 2.0 µg/day 
for > 10 years (approx 50–
75 ng/kg body weight daily)
3. Combined 
ethinyloestradiol and GH 
(not data extracted)
Duration of treatment: 1 year 
in these groups (group 2 
changed to group 3 after the 
first year, not data extracted, 
and treatment continued 
until height increases had 
fallen below 1 cm/year)
Other interventions used: not 
stated for year 1
Target population: girls with TS
Number of participants: total 58
1. 22
2. 13
3. 23
Sample attrition/dropout: 7 
withdrawals, 5 girls reallocated from 
estrogen to GH: it is unclear at what 
point this occurred
Inclusion criteria for study entry: not 
stated
Exclusion criteria for study entry: other 
growth-limiting disorders, prior 
hormone therapy
Primary outcomes: height gain at 
AH
Secondary outcomes: growth-
enhancing effect of LDE (not 
data extracted), change in HSDS
Method of assessing outcomes: 
standing height, sitting height, 
and weight were measured at 
3-month intervals; HtSDSs 
were derived from published 
Turner height standards, BA 
was initially determined at 
yearly intervals and calculated 
using the Tanner–Whitehouse 
RUS method applicable to 
normal female population. 
Various biochemical measures 
performed at study entry and 
annually, including triglycerides, 
cholesterol and TSH
Length of follow-up: 1 year
RUS, radius, ulna and finger (or short) bones.
Characteristics of participants
Characteristic
GH 28–30 IU/m2 surface area/week 
(n = 22)
Low-dose estrogen: 
ethinyloestradiol (n = 13) p-valuea
Age (years) 9.0 (5.2 to 15.4) 9.1 (6.0 to 13.7)
BA (years) 8.0 (3.3 to 13.5) 7.9 (3.0 to 13.7)
Height (cm) 113.2 (93.2 to 135.1) 114.0 (94.6 to 140)
HSDS for CA –0.3 (–2.1 to 1.2) –0.1 (–1.5 to 1.8)
HSDS for BA 0.6 (–0.8 to 3.3) 1.0 (–0.6 to 2.4)
Mid parental HSDS –0.2 (0.8) –0.3 (1.1)
a  Not extracted, as unclear which groups of the three to which this refers.
Results are expressed as mean (range) or (SD).
Results
Outcomes
GH 28–30 IU/m2 surface area/week 
(n = unclear)
Low-dose estrogen: 
ethinyloestradiol (n = unclear) p-value
Change in HSDS in first 
year
+0.7 (0.7) +0.4 (0.9) < 0.05DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Adverse effects
Three of 58 girls ceased GH early because of serious health events not directly related to GH or LDE: one each with 
hypertension, ulcerative colitis and brain tumour. One patient in group 3 died from aortic dissection shortly after 
treatment cessation. Compliance problems led to the withdrawal of four patients. Seven others developed coincidental 
disorders but these were not considered sufficient to invalidate continued participation in the study. Five girls from group 
2 were allocated to LDE were re-allocated to GH due to concerns over early breast development at age range 6.2–8.9 
years.
Methodological comments
Allocation to treatment groups: States randomised, no other details given. Five girls reallocated from estrogen to GH; it is 
unclear at what point this occurred.
Blinding: Unknown, no details given.
Comparability of treatment groups: Authors state that the groups were similar for the main monitoring parameters.
Method of data analysis: Within-group results were compared using the paired Student’s t-test. Between-group results were 
compared using analysis of variance. Parental HtSDS values were calculated using normal population data.
Sample size/power calculation: Not reported.
Attrition/dropout: Seven withdrawals: three out of 58 girls ceased GH early because of serious health events not directly 
related to GH or LDE. Compliance problems led to the withdrawal of four patients. Treatment centres had the option 
of stopping ethinyloestradiol therapy if girls showed unacceptable premature breast development or excessive bone 
maturation: this occurred in five cases. Group numbers for FH data are lower; for the 1-year data they are unclear.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Inadequate
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Inadequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Unknown
8.  Were the point estimates and measure of variability presented for the primary outcome 
measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateAppendix 4
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PWS data extraction forms
Reference and 
design Intervention Participants Outcome measures
Lindgren et al. 
1997,100 1998,101
Countries: 
Sweden and 
Denmark
Study design: 
RCT
Number 
of centres: 
multicentre
Funding: 
Pharmacia & 
Upjohn
1. 0.1 IU/kg/day GH by 
s.c.i.
2. No treatment
Duration of treatment: 2 
years (only year 1 data 
extracted, as no control 
arm in year 2)
Other interventions 
used: special dietary 
instructions more 
than 1 year before 
start of treatment 
and throughout the 
study period to ensure 
constant energy intake 
per kilogram of body 
weight 
Target population: prepubertal children 
aged 3–12 years with PWS
Number of participants: total n = 29
1. n = 15
2. n = 14
An additional group of non-PWS obese 
children was also studied, but data from 
this group were not data extracted
Sample attrition/dropout: Two control 
group patients excluded from analysis
Inclusion criteria for study entry: fulfilled 
diagnostic criteria for PWS and had either 
a paternal deletion or maternal disomy of 
chromosome region 15q11-13; projected 
FH < 165 cm (boys) and 154 cm (girls)
Primary outcomes: not stated
Secondary outcomes: HtSDS; GV 
SDS, BMI SDS, lean mass, % 
body fat
Method of assessing outcomes: 
height and WtSDS calculated 
with reference to the standard 
for healthy Swedish children; 
BA was assessed according 
to Tanner–Whitehouse 2/
RUS; % body fat estimated by 
DEXA QoL questionnaires 
completed (but no extractable 
data reported)
Length of follow-up: 1 year
Characteristics of participants
Mean (range) 0.1 IU/kg/day GH (n = 15) No treatment (n = 12) p-value
Age (years) 6.8 (3.6 to 11.9) 6.4 (3.3 to 11.7)
BA (years) 6.6 (3.3 to 13.0) 5.4 (3.3 to 10.2)
Sex (f/m) 7/8 5/7
Target HtSDS 0.4 (–1.3 to 1.8) –0.1 (–1.5 to 1.0)
HtSDS –1.6 (–4.0 to 0.5) –1.7 (–5.3 to 0.4)
BMI (SDS) 3.0 (–0.7 to 7.6) 2.1 (–1.3 to 5.1)
GV (SDS) mean ± SD 
(range)
–1.9 ± 2.0 (–6.4 to 0.9) –0.1 (–1.7 to 2.71)
IGF-1 (SDS) –1.6 (–3.0 to –0.6) –1.4 (–2.4 to –0.1)
Fat-free mass (kg) by 
DEXA: mean ± SD
14.9 ± 4.1 14.1 ± 3.0
Fat-free mass (kg) by 
BIA: mean ± SD
14.6 ± 3.9 13.6 ± 3.3
Body fat (%) by DEXA: 
mean ± SD
40.0 ± 10.5 34.8 ± 7.9
Body fat (%) by BIA: 
mean ± SD
44.6 ± 9.2 41.3 ± 10.7
Comments
BIA, bioelectrical impedance analyser; DEXA, dual-energy X-ray absorptiometry.
GV SDS was during 12 months before treatment commenced.
Results
Mean (range) 0.1 IU/kg/day GH (n = 15) No treatment (n = 12) p-value
BA (years) 8.0 (5.5 to 13.9)a 6.9 (3.9 to 11.4)
BA (years) change from 
baseline
1.4 (0.0 to 2.8) 1.5 (0.4 to 2.6)
HtSDS –0.4 (–2.7 to 1.9)a –1.8 (–5.1 to –0.2)
BMI (SDS) 2.0 (–2.4 to 6.7)a 2.5 (0.1 to 6.1)
GV (SDS) mean ± SD 
(range)
6.0 ± 3.2 (1.4 to 11.9)a –1.4 (–3.2 to –0.3)DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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IGF-1 (SDS) 1.8 (–0.1 to 4.1)a –1.4 (–2.9 to –0.3)
Fat-free mass (kg) by 
DEXA: mean ± SD
19.8 ± 5.2b 15.2 ± 2.9
Fat-free mass (kg) by 
BIA: mean ± SD
21.7 ± 8.9b 14.8 ± 3.5
Body fat (%) by DEXA: 
mean ± SD
30.9 ± 11.4b 38.2 ± 9.1
Body fat (%) by BIA: 
mean ± SD
30.3 ± 10.5b 43.3 ± 12.9
a  Change from baseline p < 0.05.
b  Change from baseline p < 0.001.
Adverse effects
Intravenous glucose tolerance test was normal and unchanged in all children. Basal fasting insulin levels were significantly 
increased throughout the group in the GH group (from 10.4 mU/I ± 2.7 SD to 19.2 mU/I ± 10.5 SD, p < 0.001). No severe 
progression of scoliosis (angle ≥ 20º) in either group. Bone mineral density did not differ between groups. One child 
developed low levels of thyroxine without any change in TSH levels. He received substitution with l-thyroxine during the 
GH treatment. The increased levels of fasting insulin during the treatment may be regarded as laboratory AE. However, 
both levels of fasting glucose and HbA1c were unchanged and, although increased compared with pretreatment, insulin 
levels were still within the normal range.
Methodological comments
Allocation to treatment groups: States children were randomised, but no further details given.
Blinding: Open label.
Comparability of treatment groups: Baseline age, height, BMI and HVs stated to be similar in both PWS groups.
Method of data analysis: Student’s two-tailed paired and unpaired t-tests were used for normally distributed values, and 
non-parametric tests were used otherwise. Single regression analysis used for statistical comparisons. Not ITT. Data were 
analysed as change from baseline rather than between-group differences.
Sample size/power calculation: Not reported.
Attrition/dropout: One patient excluded at baseline evaluation because she had a severe scoliosis that required surgical 
intervention; one patient was excluded after 6 months in the control arm because she developed central precocious 
puberty.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Carrel et al. 
2004,22 Myers 
et al. 2007,97 
Whitman et al. 
200498
Country: USA
Study design: RCT
Number of centres: 
two
Funding: supported 
by Pharmacia Inc. 
(Pfizer)
1. 1 mg/m2/day GH
2. No treatment
Duration of treatment: 1 
year
Other interventions used: 
0.1 g/kg of deuterium-
labelled water was given 
on day 1 and 0.15 g/kg of 
oxygen-18 water
Target population: infants and toddlers 
with PWS
Number of participants: Total: n = 32 
(Whitman et al.); n = 29 (Carrel et al.); 
n = 25 (Myers et al.)
1. n = 15
2. n = 14
In Whitman paper – 30 patients 
completed first 6 months: n = 18, n = 12
Sample attrition/dropout: none in 
difference in n between Whitman paper 
and others suggests seven patients 
dropped out
Inclusion criteria for study entry: 
confirmed diagnosis of PWS; age 4–37 
months
Primary outcomes: not stated
Secondary outcomes: % body fat, 
LBM, bone mineral density, GV 
SDS, change in height, IGF-1; 
mobility (not data extracted as 
not per protocol)
Method of assessing outcomes: 
Harpenden stadiometer used 
for length/height for children 
> 2, otherwise an infantometer 
was used; body composition 
measured by DEXA
Length of follow-up: 1 year
Characteristics of participants
Mean ± SD 1 mg/m2/day GH (n = 15) No treatment (n = 14) p-value
Age (months) 13 ± 8 15 ± 0 ns
Per cent female 50 42 ns
Length/HtSDSa –1.6 ± 1.2 –1.3 ± 1.1
GV SDS 1.4 ± 1.8 1.2 ± 1.4
Body fat (%)a 28 ± 7 29 ± 12
Lean mass (kg)a 5.8 ± 1.9 6.9 ± 2.0
BMD (g/cm2)a 0.60 ± 0.08 0.64 ± 0.09
Total cholesterol (mg/dl) 163 ± 34 170 ± 30
IGF-1 (ng/dl)a 34 ± 21 nr
Fasting insulin (µIU/ml) 4.8 ± 3.7
Comments
a  From Myers paper, which had unclear patient numbers.
Baseline data are also given by Whitman et al. These have not been data extracted as they differ slightly from the group 
presented here. Whitman’s results were for 6 months, so it is assumed that the Carrel data supersede these.
Results
Mean ± SD 1 mg/m2/day GH (n = 15) No treatment (n = 14) p-value
Mean % body fat 23.2 ± 8.9 32.7 ± 8.8 0.03
Change in body fat –4.8% ± 5.7% 4.1% ± 4.6% 0.001
Change in LBM (kg) 3.6 ± 0.5 1.8 ± 0.7 < 0.001
Change in height (cm) +15.4 ± 2.3 9.2 ± 3.2 < 0.001
GV SDS 5.0 ± 1.8 1.2 ± 1.4
IGF-1 (ng/ml) 231 ± 98 51 ± 28 < 0.001
Fasting insulin (µIU/ml) 5.6 ± 7.1 5.7 ± 7.1 ns
Bone mineral density (%) 14.1 ± 10.4 9.0 ± 6.9 ns
Total cholesterol (mg/dl) 159 ± 40 183 ± 43
Length/HtSDSb –0.2 ± 1.5 –1.5 ± 0.7DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Comments
b  From Myers paper, which had unclear patient numbers.
GVSDS in GH patients, p < 0.001 compared with baseline.
Length/HtSDS change from baseline in GH group, p < 0.005.
Adverse effects
No changes in the prevalence of scoliosis were seen between the treatment and control groups (Carrel et al.) although 
Myers et al. comment on progression of scoliosis in one patient. No other adverse effects were noted during this study, 
and no subject required thyroid hormone therapy. After the first 6 months, two children showed a 3.5 SD increase in head 
circumference. This was monitored, but the later papers do not mention it.
Methodological comments
Allocation to treatment groups: Randomisation following stratification by age (4–18 months and 19–37 months) and sex. No 
further details given. Myers and Whitman papers state that a 60 : 40 ratio was used, but this does not reflect numbers in 
the Carrel study, suggesting that attrition bias may have affected the results.
Blinding: None.
Comparability of treatment groups: Similar at baseline.
Method of data analysis: The t-test for between-group comparisons. Does not appear to be ITT. Data reported by Whitman 
et al. was for 25 patients who completed the first 6 months. All three papers appear to report data for a slightly different 
version of the patient group.
Sample size/power calculation: Not reported.
Attrition/dropout: Difference in n between Whitman paper and others suggests that seven patients dropped out.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Carrel et al. 1999,95 
Myers et al. 199996
Country: USA
Study design: open 
RCT
Number of centres: 
not reported
Funding: Genentech 
Foundation for 
Growth and 
Development
1. GH 1 mg/m2/day
2. No treatment
Duration of treatment: 1 
year
Other interventions used: 
standardised caloric 
intake
Target population: children with PWS 
without prior GH therapy
Number of participants: Total: n = 54
1. n = 35
2. n = 19
Sample attrition/dropout: none
Inclusion criteria for study entry: 
genetically confirmed patients with 
PWS were aged 4–16, with skeletal 
maturation < 13 for girls and < 15 for 
boys
Exclusion criteria for study entry: prior 
GH therapy
Primary outcomes: not clearly 
stated
Secondary outcomes: HtSDS; GV; 
GVSDS; body fat; lean mass; 
BM; IGF-1; IGFBP-3; insulin; 
cholesterol; HDL-C; strength 
and agility (not data extracted 
as not per protocol)
Method of assessing outcomes: 
height measured by Harpenden 
stadiometer; Greulich and Pyle 
method of determining BA; 
body composition assessed 
using DEXA
Length of follow-up: 1 year
HDL-C, high-density lipoprotein cholesterol.
Characteristics of participants
Mean ± SD GH 1 mg/m2/day (n = 35) No treatment (n = 19) p-value
Sex (% female) 42 58
Mean age (years) 9.8 10.0
Prepubertal (n) 34 (97%) 17 (90%)
HtSDS –1.1 ± 1.3 –1.5 ± 0.8
Mean GV (cm/year) 4.72 ± 2.2 5.18 ± 1.5
Mean GV SDS –1.0 ± 2.5 –0.9 ± 1.7
BA 9.1 ± 3.6 8.4 ± 3.1
Body fat (%) 46.3± 8.4 42.6 ± 8.1
Lean mass (kg) 20.5 ± 6.3 20.5 ± 5.0
BMI (kg/m2) 25.0 ± 6.7 24.2 ± 6.5
IGF-1 (ng/ml) 127 ± 67 139 ± 64
IGFBP-3 (ng/ml) 1.73 ± 0.49 1.84 ± 0.64
Insulin-0 hour (mIU/l) 11.2 ± 9.9 9.3 ± 6.2
Insulin-2 hour (mIU/l) 49.5 ± 40.7 41.6 ± 42.5
Total cholesterol (mg/dl) 184 ± 36 190 ± 36
HDL-C (mg/dl) 42 ± 8 44 ± 9
Femoral neck BMD (g/cm3) 0.656 ± 0.19 0.636 ± 0.9
Spine BMD (g/cm3) 0.744 ± 0.14 0.753 ± 0.12
Scoliosis (°) 9.1 ± 6.0 14.7 ± 11.0
Free fatty acids (mmol/I) 0.6 ± 0.4 0.6 ± 0.3
Triglycerides (mg/dl) 91.6 ± 57.9 84.3 ± 39.6
Results
Mean ± SD GH 1 mg/m2/day (n = 35) No treatment (n = 19) p-value
HtSDS –0.6 ± 1.2 –1.6 ± 1.2 < 0.01
Mean GV (cm/year) 10.1 ± 2.5 5.0 ± 1.8 < 0.01
Mean GV SDS 4.6 ± 2.9 –0.7 ± 1.9 < 0.01
BA 10.6 ± 3.5 9.8 ± 3.0 ns
Body fat (%) 38.4 ± 10.7 45.8 ± 8.8 < 0.01
Lean mass (kg) 25.6 ± 4.3 21.7 ± 5.0 < 0.01DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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BMI (kg/m2) 23.7 ± 6.3 25.2 ± 8.9 ns
IGF-1 (ng/ml) 522 ± 127 121 ± 52 < 0.01
IGFBP-3 (ng/ml) 3.5 ± 0.73 2.07 ± 0.45 < 0.01
Insulin-0 hour (mIU/l) 18.6 ± 14.6 8.8 ± 5.4
Insulin-2 hour (mIU/l) 70.2 ± 44.2 47.1 ± 34.1
Total cholesterol (mg/dl) 166 ± 34 193 ± 34 < 0.01
HDL-C (mg/dl) 50 ± 10 44 ± 8 < 0.01
Femoral neck BMD (g/cm3) 0.797 ± 0.09 0.707 ± 0.09 < 0.05
Spine BMD (g/cm3) 0.834 ± 0.15 0.793± 0.13
Scoliosis (°) 12.1 ± 7.0 16.6 ± 10.0
Free fatty acids (mmol/I) 0.72 ± 0.40 0.64 ± 0.30 < 0.01
Triglycerides (mg/dl) 86.0 ± 62.0 94.2 ± 49.0
Comments
The p-values are for paired t-test before and after GH therapy, compared with either baseline values of treated patients or 
12-month values of non-treated patients.
Adverse effects
Headaches in two patients treated with GH within first 3 weeks. Symptoms resolved with temporary cessation and 
gradual re-institution of GH. No pseudotumour cerebri.
Methodological comments
Allocation to treatment groups: reported as randomised 60 : 40. Method not stated.
Blinding: None.
Comparability of treatment groups: Similar at baseline.
Method of data analysis: ITT. Data were analysed using a Student’s t-test for paired samples or two related samples.
Sample size/power calculation: Not reported.
Attrition/dropout: None.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary outcome 
measure?
Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
de Lind van 
Wijngaarden 
et al. 2009,93 
Festen et al. 
200894
Country: The 
Netherlands
Study design: RCT
Number of 
centres: 18
Funding: not 
stated
1. 1 mg/m2 s.c. daily
2. No treatment
Duration of treatment: 1 
year for infants and 2 
years for children
After 1st year, infants 
were all offered a second 
year of GH treatment. 
Not discussed here as no 
control group
Other interventions used: 
caloric intake and activity 
level standardised and 
monitored
Target population: infants and prepubertal 
children with PWS, who were not 
severely overweight, naive to GH 
treatment
Number of participants: total n = 104 
enrolled, n = 91 were available for 
follow-up: 42 infants (< 3.5 years) and 
49 children over 3.5 years. Randomised 
groups not clear
The following are the groups analysed 
at year 1:
Infants:1. n = 19, 2. n = 19
Children:1. n = 23, 2. n = 21
Sample attrition/dropout: four infants and 
five children excluded from analysis
Inclusion criteria: genetically confirmed 
diagnosis of PWS; age 6 months –14 
years; BA < 14 (girls) or 16 (boys); 
prepubertal – Tanner breast stage ≤ 2 
for girls and testicular volume < 4ml for 
boys
Exclusion criteria: non-cooperative 
behaviour; on medication to reduce fat
Primary outcomes: not stated in 
Festen paper, scoliosis in Lind 
van Wijngaarden paper
Secondary outcomes: HtSDS, BMI, 
BMI SDS, head circumference 
SDS, IGF-1, IGF-1 SDS, IGFBP-3, 
IGFBP-3 SDS, IGF-1/BP3 (SDS), 
LBM and scoliosis
Method of assessing outcomes: 
Harpenden stadiometer used to 
measure height, using a mean of 
three values. Anthropometric 
measurements taken at baseline 
and every 3 months; DEXA used 
for fat measurements. FM, fat 
% and LBM were transformed 
into SDS, adjusting for age and 
sex. LBM is related to height, 
so LBM HtSDS were computed 
by comparing LBM of PWS with 
LBM of healthy children with the 
same height and sex. IGF-1 and 
IGFBP-3 were transformed to 
SDS using sex- and age-matched 
Dutch references
Length of follow-up: 1 year 
(infants), 2 years (children)
Characteristics of participants from Festen et al. 200894 (other than scoliosis and trunk LBM/BSA), as this is the 
most complete
Baseline characteristics of infants (6 months to 3 years)
Median (IQR) 1 mg/m2 s.c. daily rhGH (n = 20) No treatment (n = 22) p-value
Sex (m/f) 12/8 16/6
Age (years) 2.0 (1.6 to 3.1) 1.3 (1.0 to 2.8)
HtSDS –2.3 (–2.8 to –0.7) –2.1 (–3.2 to –1.0)
BMI (kg/m2) 16.4 (15.1 to 18.6) 16.1 (14.7 to 18.2)
BMI (SDS) 0.5 (–0.9 to 1.9) –0.8 (–1.7 to 1.6)
Head circumference (SDS) –0.8 (–1.6 to –0.3) –1.1 (–1.8 to –0.5)
IGF-1 (ng/ml) 27.0 (22.0 to 35.0) (n = 11) 47.0 (17.0 to 52.0)
IGF-1 (SDS) –1.9 (–2.8 to –1.3) (n = 11) –1.6 (–2.6 to –0.4) (n = 11)
IGFBP-3 (ng/ml) 0.8 (0.7 to 1.1) (n = 11) 1.1 (0.8 to 1.3) (n = 11)
IGFBP-3 (SDS) –2.6 (–3.3 to –2.0) (n = 11) –1.5 (–2.6 to –0.7) (n = 11)
IGF-1/BP3 (SDS) –0.9 (–2.0 to –0.4) (n = 11) –0.3 (–1.7 to 0.6) (n = 11)
Scoliosis (%) 7 (37) (n = 19) 4 (21) (n = 19)
Trunk LBM/BSA 7.4 (6.9 to 8.0) (n = 19) 7.3 (7.0 to 7.7)(n = 19)
Baseline characteristics of children (3–14 years)
Median (IQR) 1 mg/m2 s.c. daily rhGH (n = 25) No treatment (n = 22) p-value
Sex (m/f) 13/12 8/14
Age (years) 6.8 (5.4 to 8.8) 5.9 (4.7 to 7.4)
HtSDS –2.0 (–3.1 to –1.7) –2.5 (–3.3 to –1.9)
BMI (kg/m2) 17.7 (16.0 to 22.3) 18.1 (17.2 to 19.9)
BMI (SDS) 1.2 (0.1 to 2.2) 1.3 (1.1 to 1.6)DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Head circumference (SDS) –0.8 (–1.5 to –0.2) –0.6 (–1.2 to –0.1)
IGF-1 (ng/ml) 60.0 (46.5 to 96.5) (n = 21) 56.0 (42.0 to 88.0) (n = 18)
IGF-1 (SDS) –1.7 (–2.3 to –1.2) (n = 21) –1.9 (–2.6 to –1.2) (n = 18)
IGFBP-3 (ng/ml) 1.3 (0.9 to 1.5) (n = 21) 1.2 (0.9 to 1.5) (n = 18)
IGFBP-3 (SDS) –1.9 (–2.8 to –1.2) (n = 21) –2.2 (–3.1 to –1.4) (n = 18)
IGF-1/BP3 (SDS) –0.5 (–1.0 to 0.5) (n = 21) –0.6 (–1.6 to 0.3) (n = 18)
Fat% (SDS) 2.1 (1.7 to 2.7) (n = ?) 2.3 (1.9 to 2.6) (n = ?)
Fat (SDS) 1.2 (0.8 to 2.0) (n = ?) 1.2 (0.7 to 1.6) (n = ?)
LBM age (SDS) –1.7 (–3.0 to –1.0) (n = ?) –1.9 (–3.4 to –1.2) (n = ?)
LBM HtSDS –1.7 (–3.8 to –0.6) (n = ?) –1.4 (–2.9 to 0.9) (n = ?)
Trunk fat (%) 36.0 (24.8 to 46.2) (n = ?) 36.0 (29.2 to 41.2) (n = ?)
Scoliosis (%) 7 (30) (n = 23) 9 (43) (n = 21)
Trunk LBM/BSA 8.0 (7.5 to 8.4)(n = 23) 7.6 (7.1 to 8.1) (n = 21)
Comments
n is unclear for body composition measures, as these were only available for children over the age of 4 at the start of the 
study. The p-values are for change in GH group vs control group.
Results: infants (6 months to 3 years), mostly from de Lind van Wijngaarden 2009 et al.93 as this is the most 
complete data
Median (IQR)
1 mg/m2 s.c. daily rhGH 1 year 
(n = 19) No treatment (n = 19) p-value
HtSDS –0.9 (–1.6 to –0.1) –1.8 (–3.5 to –1.4) 0.003
∆HtSDS 1.2 (1.0 to 1.6) –0.2 (–0.6 to 0.3) < 0.0001
BMI (kg/m2) 16.3 (15.7 to 18.2) 16.4 (15.4 to 19.8) (n = 15)
BMI (SDS) 0.3 (–0.1 to 1.6) 0.3 (–0.6 to 1.6) 0.72
∆Trunk LBM 1.7 (1.3 to 2.1) 0.7 (0.4 to 0.9) < 0.0001
∆Trunk LBM/BSA 1.2 (0.7 to 1.8) 0.3 (–0.3 to 0.6) 0.002
Head circumference (SDS) 0.0 (–0.9 to 0.7) (n = 16) –0.8 (–1.6 to –0.3) (n = 15) < 0.001
IGF-1 (ng/ml) 179.0 (119.5 to 241.0) (n = 12) 33.0 (22.5 to 47.8) (n = 15)
IGF-1 (SDS) 2.5 (1.4 to 2.9) –2.6 (–4.1 to –0.7) < 0.0001
IGFBP-3 (ng/ml) 2.2 (1.6 to 2.4) (n = 12) 0.9 (0.7 to 1.3) (n = 12)
IGFBP-3 (SDS) 0.5 (0.0 to 1.2) (n = 12) –2.4 (–3.5 to –1.2) (n = 12)
IGF-1/BP3 (SDS) 2.3 (1.7 to 3.4) (n = 12) –1.1 (–2.1 to 0.0) (n = 12) < 0.001
Onset scoliosis (%) 4 (21) (n = 19) 2 (11) (n = 19) 0.71
Progression of scoliosis –6.0 (–12.5 to 12.8) (n = 19) –7.5 (–7.5 to –5.0) (n = 19) 0.48
Results for children (3–14 years), mostly from de Lind van Wijngaarden 2009 et al.,93 as this is the most complete 
data
Median (IQR) 1 mg/m2 s.c. daily rhGH No treatment p-value
Year 1 results
N = 23 N = 21
HtSDS –1.0 (–1.5 to –0.3) –2.5 (–3.4 to –2.3) < 0.0001
∆HtSDS 0.9 (0.7 to 1.3) –0.1 (–0.2 to 0.1) < 0.0001
BMI (kg/m2) 17.5 (15.3 to 19.8) (n = 21) 18.6 (17.6 to 19.7) (n = 21)
BMI (SDS) 0.8 (–0.1 to 2.1) 1.4 (1.0 to 1.6) 0.05
∆Trunk LBM 1.8 (1.4 to 2.3) 0.7 (0.1 to 0.8) < 0.0001
∆Trunk LBM/BSA 1.3 (0.7 to 1.7) 0.0 (–0.4 to 0.3) < 0.0001
Head circumference (SDS) –0.2 (–1.2 to 0.2) (n = 21) –0.6 (–0.9 to 0.3) (n = 21)Appendix 4
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IGF-1 (ng/ml) 337.0 (274.3 to 474.3) (n = 21) 55.0 (42.5 to 94.8) (n = 12)
IGF-1 (SDS) 2.3 (1.5 to 2.8) –2.5 (–3.1 to –1.5) < 0.0001
IGFBP-3 (ng/ml) 2.5 (2.2 to 2.9) (n = 21) 1.3 (0.8 to 1.5) (n = 12)
IGFBP-3 (SDS) 0.4 (–0.1 to 0.8) (n = 21) –2.4 (–3.5 to –1.8) (n = 12) < 0.001
IGF-1/BP3 (SDS) 2.5 (2.0 to 3.0) (n = 21) –0.8 (–1.4 to –0.2) (n = 12) < 0.001
Fat % (SDS) 1.5 (0.7 to 2.1) (n = ?) 2.3 (2.0 to 2.6) (n = ?) < 0.001
Fat (SDS) 0.9 (0.2 to 1.4) (n = ?) 1.3 (0.7 to 1.9) (n = ?) < 0.001
LBM age (SDS) –0.5 (–1.3 to 0.7) (n = ?) –2.1 (–4.1 to –1.3) (n = ?) < 0.001
LBM HtSDS –1.5 (–2.3 to –0.7) (n = ?) –1.9 (–2.9 to 0.0) (n = ?) < 0.05
Trunk fat (%) 28.0 (16.9 to 36.7) (n = ?) 37.2 (32.0 to 42.5) (n = ?) < 0.001
Onset scoliosis (%) 5 (22) (n = 23) 6 (29) (n = 21) 0.52
Progression of scoliosis –3.5 (–7.3 to 1.8) (n = 23) 0.0 (–1.0 to 1.0) (n = 21) 0.60
Year 2 results
N = 23 N = 21
HtSDS –0.5 (–0.8 to 0.0) –2.6 (–3.4 to –2.3) < 0.0001
∆HtSDS 1.4 (1.3 to 1.8) –0.1 (–0.4 to 0.1) < 0.0001
BMI (kg/m2) 17.5 (16.1 to 21.1) (n = 20) 19.1 (17.8 to 20.8) (n = 20)
BMI (SDS) 1.1 (–0.2 to 1.7) 1.4 (1.1 to 1.6) 0.19
∆Trunk LBM 2.8 (2.6 to 3.5) 0.8 (0.4 to 1.0) < 0.0001
∆Trunk LBM/BSA 1.4 (0.5 to 1.7) –0.2 (–0.5 to –0.1) < 0.0001
Head circumference (SDS) –0.1 (–1.1 to 0.5) (n = 20) –0.6 (–1.1 to 0.3) (n = 20) < 0.05
IGF-1 (ng/ml) 424.0 (313.0 to 570.0) (n = 20) 92.0 (61.8 to 130.0) (n = 16)
IGF-1 (SDS) 2.4 (2.1 to 2.8) –1.6 (–2.5 to –1.0) < 0.0001
IGFBP-3 (ng/ml) 2.8 (2.6 to 3.2) (n = 20) 1.5 (1.2 to 1.8) (n = 16)
IGFBP-3 (SDS) 0.6 (0.3 to 1.1) (n = 20) –1.7 (–2.3 to –1.2) (n = 16) < 0.001
IGF-1/BP3 (SDS) 2.5 (1.8 to 2.9) (n = 20) –0.6 (–1.2 to –0.1) (n = 16) < 0.001
Fat % (SDS) 1.9 (0.7 to 2.3) (n = ?) 2.4 (2.1 to 2.7) (n = ?) < 0.001
Fat (SDS) 1.1 (0.6 to 2.0) (n = ?) 4.5 (0.9 to 2.0) (n = ?) < 0.01
LBM age (SDS) –0.1 (–1.3 to 0.6) (n = ?) –2.5 (–3.8 to –1.4) (n = ?) < 0.001
LBM HtSDS –1.9 (–2.4 to –1.4) (n = ?) –2.3 (–2.7 to –1.3) (n = ?) < 0.05
Trunk fat (%) 33.3 (17.3 to 40.9) (n = ?) 37.9 (35.0 to 45.7) (n = ?) < 0.001
Onset scoliosis (%) 5 (22) (n = 23) 7 (33) (n = 21) 0.14
Progression of scoliosis 3.3 (–4.3 to 11.9) (n = 23) –5.0 (–9.0 to –2.0) (n = 21) 0.27
Comments
n is unclear for body composition measures, as these were only available for children over the age of 4 at the start of the 
study. The p-values are for change in GH group vs control group.
Progression of scoliosis is change in Cobb angle during study
Adverse effects
Not reported – the reader is referred to three other papers by the same author, but two of these appear to be other 
smaller studies.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Methodological comments
Allocation to treatment groups: Prior to randomisation, infants were stratified for age and children (> 3.5 years) for BMI. All 
participants were randomised to GH treatment or no GH treatment.
Blinding: A double-blind placebo-controlled study was considered unethical.
Comparability of treatment groups: Anthropometric parameters were similar in the two groups, although no p-values are 
presented.
Method of data analysis: Reference data for the DEXA were not available for children under the age of 4, so only those 
> 4 years were included in the analysis. Data were expressed as median (IQR) as most were not Gaussian distributed. 
Differences from baseline between groups were calculated using Mann–Whitney U-tests. The p-values are for change in 
GH group vs control group.
Sample size/power calculation: De Lind van Wijngaarden reports that the power calculation estimated a total number of 40 
patients (infants and prepubertal children) to yield a power of 0.80.
Attrition/dropout: Two excluded before treatment (one had a dose reduction due to high IGF-1 levels, another had spinal 
surgery for scoliosis and two other medical problems). In total, four infants and five children excluded from analysis – 
presumably due to incomplete study period for the other patients. Infants with repeated measures were older (p = 0.025), 
possibly reflecting early diagnosis of PWS during recent years.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary outcome 
measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Festen et al. 
200791
Country: The 
Netherlands
Study design: 
RCT
Number of 
centres: not 
stated
Funding: 
supported by 
Pfizer
1. 1 mg/m2/day 
somatropin by s.c.i. 
(restricted to 0.5mg/m2/
day in the first 4 weeks 
to avoid fluid retention).
2. No treatment
Duration of treatment: 2 
years
Other interventions used: 
caloric intake and activity 
levels standardised 3 
months before study
Target population: prepubertal, 
generally not overweight children 
with PWS
Number of participants: Total n = 20
1. n = 10
2. n = 10
Sample attrition/dropout: none
Inclusion criteria for study entry: 
genetically confirmed diagnosis of 
PWS, age 4–9 years, prepubertal
Primary outcomes: adiponectin levels, 
body composition, carbohydrate 
metabolism and triglyceride levels
Secondary outcomes: associations 
between adiponectin and body 
composition, carbohydrate 
metabolism and triglyceride levels; 
effect of GH on these parameters
Method of assessing outcomes: 
anthropometric measurements 
at baseline, year 1 and year 2 
(standing height, weight, BMI); 
body composition assessed using 
DEXA; biochemical marker assays 
performed in the same laboratory. 
HtSDS and BMI SDS calculated 
from age- and sex-specific Dutch 
reference data
Length of follow-up: 2 years
Characteristics of participants: median (IQR)
Characteristic 1 mg/m2/day GH (n = 10) No treatment (n = 10) p-value
N (male/female) 10 (5/5) 10 (3/7)
Age (years) 6.2 (5.1 to 7.1) 5.8 (4.9 to 7.8)
HtSDS –2.2 (–3.1 to –1.8) –2.8 (–3.4 to –2.0)
BMI (kg/m2) 16.9 (15.8 to 17.7) 17.3 (16.4 to 19.3)
BMI SDS 0.8 (0.1 to 1.2) 1.1 (0.6 to 1.5)
Adiponectin (mg/l) 15.9 (13.3 to 23.9) 17.1 (13.1 to 23.1)
Glucose (mmol/l) 4.8 (4.6 to 5.0) 4.4 (4.3 to 4.7)
Insulin (mU/l) 6.0 (3.8 to 10.0) 5.5 (4.8 to 7.3)
Insulin–glucose ratio 1.3 (0.8 to 2.1) 1.3 (1.0 to 1.6)
HOMA index 0.8 (0.5 to1.3) 0.7 (0.6 to 0.9)
Triglycerides (mmol/l) 0.9 (0.7 to 1.7) 0.7 (0.6 to 1.0)
IGF-1 SDS –1.7 (–2.2 to –1.2) –1.7 (–2.9 to –1.0)
IGFBP-3 SDS –2.0 (–3.0 to –1.3) –2.5 (–3.2 to –1.5)
LBM SDS –2.2 (–2.7 to –2.0) –2.3 (–2.8 to –1.8)
FM SDS 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.2)
Per cent fat SDS 1.7 (1.6 to 2.0) 1.8 (1.5 to 2.4)
Trunk fat/total fat 0.44 (0.34 to 0.47) 0.4 (0.35 to 0.46)
Comments
HOMA, Homeostasis Model Assessment index.
Adiponectin levels were compared with healthy matched controlsDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
139
Results (median, IQR)
Outcomes 
1 mg/m2/day GH (n = 10) No treatment (n = 10) p-value change 
from baseline 
group 1 vs 
group 2 Year 1 Year 2 Year 1 Year 2
HtSDS –1.3a (–1.7 to 
–0.8)
–0.6a (–0.9 to 
–0.3)
–2.8 (–3.5 to 
–2.0)
–3.0 (–3.5 to 
–1.8)
< 0.01b
BMI (kg/m2) 16.1c (15.2 to 
17.6)
16.3 (15.8 to 
19.0)
18.5 (17.6 to 
19.3)
18.5 (17.5 to 
20.6)
< 0.05c
BMI SDS 0.2c (–0.2 to 0.8) 0.4 (–0.3 to 1.1) 1.3 (1.0 to 1.6) 1.2 (0.9 to 1.5) < 0.05c
Adiponectin (mg/l) 24.7 (15.0 to 
25.9)a,b
24.6 (15.4 to 
28.2)a,b
13.4 (11.6 to 
21.4)
15.8 (12.5 to 
19.2)
< 0.05b
Glucose (mmol/l) 4.4 (4.2 to 5.0) 4.6 (4.2 to 5.0) 4.6 (4.3 to 4.8) 4.7 (4.3 to 4.9)
Insulin (mU/l) 9.0 (6.5 to 13.5)a 7.5 (6.0 to 11.5) 6.0 (3.3 to 8.3) 11.0 (6.0 to 
24.0)a
Insulin–glucose ratio 2.1 (1.5 to 2.6)a 1.6 (1.5 to 2.2) 1.3 (0.8 to 1.9) 2.3 (1.4 to 2.2)a
HOMA index 1.2 (0.8 to 1.8) 1.0 (0.7 to 1.5) 0.8 (0.4 to 1.0) 1.4 (0.8 to 3.0)a
Triglycerides (mmol/l) 0.8 (0.6 to 1.3) 0.7 (0.6 to 0.8) 0.6 (0.5 to 1.0) 1.0 (0.6 to 1.0)
IGF-1 SDS 2.3 (1.6 to 3.0)a,c 2.3 (2.1 to 2.9)a,c –2.5 (–3.2 to 
–0.8)
–2.0 (–2.7 to 
1.0)
< 0.001c
IGFBP-3 SDS 0.5 (–0.1 to 1.0)a,c 0.6 (0.4 to 1.1)a,c –2.4 (–3.8 to 
–1.9)
–1.8 (–2.7 to 
–1.5)
< 0.001c
LBM SDS –1.6 (–1.9 to 
–1.4)a
–1.2 (–1.7 to 
–1.1)a
–2.5 (–3.0 to 
–1.8)
–2.8 (–3. to 1.9)a
FM SDS 0.5 (0.2 to 1.0) 0.9 (0.4 to 1.4) 1.1 (0.9 to 1.2)a 1.2 (0.9 to 1.4)a
Per cent fat SDS 1.4 (0.9 to 1.7)a 1.7 (0.9 to 1.9)a 2.1 (1.8 to 2.2) 2.1 (1.9 to 2.4)a
Trunk fat/total fat 0.4 (0.33 to 0.42) 0.41 (0.34 to 
0.46)
0.41 (0.40 to 
0.44)
0.41 (0.38 to 
0.45)
Comments
Adiponectin levels were compared with healthy matched controls.
a  p < 0.05 compared with baseline corrected for multiple testing.
b  p < 0.05 change compared with baseline in GH group vs control group corrected for multiple testing.
c  p < 0.001 change compared with baseline in GH group vs control group corrected for multiple testing.
Adverse effects
Not reported.
Methodological comments
Allocation to treatment groups: Stratified by age and BMI prior to randomisation. No further details given.
Blinding: Open-label trial.
Comparability of treatment groups: Similar at baseline. Note: adeponectin levels were compared against healthy controls, not 
the untreated PWS group.
Method of data analysis: Most data not Gaussian distributed, so data expressed as median (IQR) and non-parametric 
tests were used. Mann–Whitney U-tests used for differences between groups. Adiponectin levels of PWS children were 
compared with reference data of healthy sex- and age-matched controls (n = 40) with Wilcoxon signed-rank test.
Sample size/power calculation: Not reported.
Attrition/dropout: None.Appendix 4
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Reference and 
design Intervention Participants Outcome measures
Festen et al. 
200792
Countries: The 
Netherlands and 
Sweden
Study design: 
RCT
Number 
of centres: 
multicentre
Funding: Pfizer
1. GH 1 mg/m2/day
2. No treatment
Duration of treatment: 12 
months
Other interventions used: 
dietary advice given and 
compliance evaluated 
every 3 months
Target population: PWS infants and 
toddlers
Number of participants: Total: 43 
evaluated at baseline, then 29 
entered treatment
1. n = 15
2. n = 14
Sample attrition/dropout: 14 were 
excluded from the study, and this 
appears to have taken place post-
randomisation
Inclusion criteria for study entry: 
Genetically confirmed diagnosis of 
PWS; aged 6 months to 3 years at 
start of protocol
Exclusion criteria for study entry: 
severe scoliosis (> 20°); extremely 
low dietary intake
Primary outcomes: psychomotor 
development (BSID-II) (not data 
extracted as not per protocol)
Secondary outcomes: body 
composition; IGF-1 and IGFBP-3
Method of assessing outcomes: 
height measured with a Harpenden 
stadiometer; Dutch references used 
to calculate age- and sex- specific 
SDS for median height, BMI and head 
circumference; body composition 
in Dutch participants measured 
using DEXA; IGF in Dutch children 
measured using an immunometric 
technique, and in Swedish infants 
using a semi-illuminescent technique
Length of follow-up: 12 months
BSID-II, Bayley Scales of Infant Development II.
Characteristics of participants
Median (IQR) GH 1 mg/m2/day (n = 15) No treatment (n = 14) p-value
Sex (m/f) 7/8 8/6
Age (years) 2.3 (1.7 to 3.0) 1.5 (1.2 to 2.7)
HtSDS –2.6 (–3.3 to –1.8) –2.3 (–3.3 to –1.1)
BMI (kg/m2) 16.3 (14.5 to 17.8) 15.9 (14.7 to 16.8)
BMI SDS –0.3 (–1.1 to 1.3) –0.9 (–1.8 to –0.8)
Head circumference SDS –1.0 (–1.7 to –0.3) –1.1 (–1.8 to –0.9)
Body fat (%) 26.2 (22.2 to 28.9) 25.8 (23.1 to 27.7)
LBM (%) 72.1 (69.8 to 75.7) 73.3 (70.9 to 75.2)
IGF-SDS –2.1 (–2.7 to –1.7) –2.0 (–2.6 to –0.3)
IGFBP-3 SDS –2.8 (–3.5 to –2.4) –1.8 (–3.4 to –0.9)
Results
Median (IQR) GH 1 mg/m2/day (n = 15) No treatment (n = 14) p-value
Age (years) 3.3 (2.7 to 4.0) 2.6 (2.3 to 3.8)
HtSDS –1.6b (–2.1 to –0.8) –2.3 (–3.9 to –1.5)
BMI (kg/m2) 16.4 (15.2 to 18.5) 15.5 (14.9 to 17.6)
BMI SDS 0.3 (–0.9 to 1.8) –0.4a (–0.8 to 1.3)
Head circumference SDS –0.2b,c (–1.2 to 0.6) –1.1c (–1.6 to –0.6)
Body fat (%) 22.5 (11.3–33.2) 22.8 (19.5 to 32.9)
LBM (%) 74.8 (63.7 to 82.3) 73.6 (61.6 to 75.9)
IGF-SDS 1.7b,d (0.1 to 2.5) –2.6d (–4.1 to –0.4)
IGFBP-3SDS 0.4a,c (–0.3 to 1.1) –3.1c (–4.0 to –2.2)
a  p < 0.05.
b  p < 0.005: 12 vs 0 months.
c  p < 0.05.
d  p < 0.001: GH vs control.Appendix 4
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Adverse effects
No results presented. Paper states that compared to randomised controls, GH did not induce disadvantageous effects on 
carbohydrate metabolism, sleep-related breathing disorders, and thyroid hormone levels. 
Comments
Methodological comments
Allocation to treatment groups: Children were stratified for age before randomisation. No further details given.
Blinding: Open label.
Comparability of treatment groups: Similar at baseline, although GH group had slightly older median age.
Method of data analysis: For repeated measurement analysis, only children with 2 BSID-II scores were included. BSID-II can 
only be used if developmental age is maximally 3–5 years. Non-parametric statistics used as data not Gaussian distributed. 
Mann–Whitney U-tests used for two-tail differences at baseline, one-tailed ANCOVA used for data analysis.
Sample size/power calculation: Not reported.
Attrition/dropout: 14 of the original 43 were excluded from repeated BSID-II analysis, and therefore do not appear to have 
been randomised. However, the paper later states that results of 14 patients were excluded from analysis – not clear if this 
is the same 14, but assumed to be so, i.e. they were excluded post randomisation.
Reasons for exclusion: Five children had not reached 1 year of study, one infant was excluded due to thyroid hormone 
deficiency, eight had already passed the upper limit of BSID-II after 1 year of follow-up (divided equally between the GH 
group and the control group).
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
143
Reference and 
design Intervention Participants Outcome measures
Haqq et al. 
2003102
Country: USA
Study design: 
Double blind 
placebo-
controlled 
crossover
Number of 
centres: one
Funding: grants 
from the 
General Clinical 
Research Center 
and Pharmacia 
Corp. 
1. GH 0.043 mg/kg/day 
plus inactive ingredients, 
by daily s.c.i.
2. Placebo injection of 
inactive ingredients, by 
daily s.c.i.
Duration of treatment: 
6 months in each 
treatment arm, 12 
months overall
Other interventions used: 
none
Target population: children with PWS
Number of participants: total n = 14 
randomised, but data only given for 
n = 12
1. n = 6
2. n = 6
Sample attrition/dropout: n = 2
Inclusion criteria for study entry: PWS; 
naive to GH treatment
Exclusion criteria for study entry: other 
chronic illnesses, taking medications 
that impact on long-term bone 
mineralisation or body composition
Primary outcomes: not stated
Secondary outcomes: linear GV, body 
composition, pulmonary function, 
sleep, behaviour, cognition, resting 
energy expenditure (last five not 
data extracted as not per protocol)
Method of assessing outcomes: 
assessed at 0.6 and 12 months; 
anthropometric measurements, side 
effects and compliance measured at 
3 and 9 months; BA determined at 
0 and 12 months using Greulich and 
Pyle analysis of wrist radiographs; 
height measured at 0.6 and 12 
months using wall-mounted 
stadiometer; body composition 
measured using DEXA
Length of follow-up: 6 months for 
outcomes, 12 months overall
Characteristics of participants
Mean ± SD All patients (n = 12) p-value
Age (years) 9.7 ± 3.3
Sex (m/f) 6/6
BA (years) 10.0 ± 4.2
BMI SDS 2.5 ± 0.7
IGF-1 (ng/ml) 169.3 ± 155.7
IGF-1 SDS –1.10 ± 1.15
IGFBP-3 (ng/ml) 2169 ± 1010
IGFBP-3 SDS –1.67 ± 1.10
Mean height (cm) 128.9 ± 19.7
BMI (kg/m2) 30.8 ± 8.3
BMI (SDS) 2.5 ± 0.7
HtSDS –1.3 ± 1.2
GV (cm/year) 4.2 ± 2.3
Body fat (%) 54 ± 5.3
FM (kg) 29.6 ± 16.7
Lean mass (kg) 22.5 ± 10.9
Lumbar spine BMD (SDS) –0.51 ± 0.30
Total BMC (g) 1263 ± 451
Comments
Mean BA also reported as 10.2 ± 4.1 years later in the paper.Appendix 4
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Results
Outcomes GH 0.043 mg/kg/day (n = 12) Placebo (n = 12) p-value
BMI (kg/m2) 31.2 ± 8.9 32.8 ± 9.7 < 0.05
BMI (SDS) 2.4 ± 0.5 2.5 ± 0.6
HtSDS –1.2 ± 1.1 –1.3 ± 1.3
GV (cm/year) 7.5 ± 3.5 4.5 ± 2.7 < 0.05
Body fat (%) 49.7 ± 5.8 54.1 ± 5.6 < 0.05
FM (kg) 26.1 ± 12.8 29.1 ± 14.1 < 0.05
Lean mass (kg) 24.1 ± 8.8 22.4 ± 8.5 < 0.05
Lumbar spine BMD (SDS) –0.33 ± 1.4 –0.4 ± 1.4
Total BMC (g) 1337 ± 453 1342 ± 453
IGF-1 (ng/ml) 720 ± 379 232 ± 182 < 0.001
IGFBP-3 (ng/ml) 6029 ± 1311 4247 ± 1209 < 0.01
Leptin (ng/ml) 49.7 ± 39.3 54.3 ± 46.2 0.06
Ghrelin (pmol/l) 272 ± 204 361 ± 309 0.11
FT4 (pmol/l) 12.9 ± 1.5 14.8 ± 1.4 < 0.05
TSH (mU/l) 1.81 ± 0.79 2.04 ± 1.13
Insulin (pmol/l) 64.2 ± 42.6 64.2 ± 39
Glucose (mmol/l) 5.0 ± 0.7 4.8 ± 0.5
Osteocalcin (nmol/l) 10.5 ± 5.7 7.8 ± 5.9 0.06
Triglycerides (mmol/l) 0.80 ± 0.52 0.92 ± 0.42
Total cholesterol (mmol/l) 4.7 ± 0.9 4.5 ± 1.7
Comments
Mean BA (in all patients) increased to 11.3 ± 3.7 by the end of 12 months, compared with a chronological age of 9.7 ± 3.3 
years. Mean height increased to 134.6 ± 19.3 cm. Only one patient required thyroid hormone replacement while receiving 
GH treatment.
Adverse effects
No patient developed a significant degree of scoliosis (> 20°). No evidence of impaired fasting glucose concentrations. GH 
treatment resulted in supranormal IGH-I and normal IGFBP-3 concentrations, but the consequences of this are unknown.
Methodological comments
Allocation to treatment groups: Reported to be randomised, but no further details given.
Blinding: Both GH and placebo injections were given using a Genotropin pen.
Comparability of treatment groups: Data only presented for whole group – crossover study design.
Method of data analysis: Not ITT. Differences between groups calculated using paired t-tests. For data not distributed 
normally, Wilcoxon signed-rank tests were used. p < 0.05 considered statistically significant. Weight, height and BMI SDS 
obtained using Epi Info 2000 (www.cdc.gov/epiinfo/).
Sample size/power calculation: Not reported.
Attrition/dropout: Two patients withdrew – one due to relocation, one due to non-compliance with daily injections. Not 
clear which group they belonged to.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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145
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? nr
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Adequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Hauffa 199799
Country: 
Germany
Study design: 
Open RCT
Number of 
centres: one
Funding: 
Pharmacia 
& Upjohn, 
Germany
1. GH 0.075 IU/kg/
day for first month, 
then continued at dose 
of 0.15 IU/kg/day to a 
maximum of 8 IU/day
2. No treatment
Duration of treatment: 
2-year study with 
control arm during 1st 
year
Other interventions used: 
not stated
Target population: children aged 3–12 
with PWS
Number of participants: total n = 19 
randomised, n = 17 included in study, 
n = 16 analysed
1. n = 8
2. n = 9
Sample attrition/dropout: two not 
entered following randomisation, 
one excluded from analysis due to 
AE-related dose reduction
Inclusion/exclusion criteria for study 
entry: prepubertal, 3–12 years old, 
PWS (confirmed by molecular 
genetics), projected FH < 3rd centile 
for German population
Primary outcomes: not stated
Secondary outcomes: changes in 
HtSDS, GV SDS, IGF-1, IGFBP-3
Method of assessing outcomes: nr
Length of follow-up: 1 year
Characteristics of participants
Mean ± SD GH 0.15 IU/kg/day (n = 7) No treatment (n = 9) p-value
Age (years) 8.25 ± 2.4 7.56 ± 2.0
Sex f/m 3/4 4/5
BA (years) 7.91 ± 4.3 6.76 ± 2.4
Height (cm) 120.9 ± 16.3 120.5 ± 11.2
Weight (kg) 35.9 ± 18.2 32.5 ± 8.7
Hip circumference (cm) 78.8 ± 19.6 77.6 ± 11.5
Target height (cm) 172.9 ± 8.5 174.8 ± 8.2
Results
HV SDS 5.5 –2.3 0.0012
HtSDS 1.07 –0.25
IGF-1 Increased significantly (p < 0.008), 
sometimes to above the upper limit 
of the reference range
‘At or slightly below lower limit of 
reference range’
IGFBP-3 Increased significantly (p < 0.008), 
mostly to above the upper limit of 
the reference range
‘Within normal range’
Comments
Height gain (1.02 SD) remained unchanged when analysed in relation to BA. No significant within- or between-group 
changes were detected for sitting height, BMI, skinfold thickness, waist or hip circumference or serum lipids.
Adverse effects
One patient in GH group developed pseudotumour cerebri after increasing the starting dose to the final dose. Symptoms 
resolved on discontinuation. No abnormalities of glucose regulation observed in either group.
Methodological comments
Allocation to treatment groups: Randomised (method not stated).
Blinding: open label.
Comparability of treatment groups: similar at baseline.
Method of data analysis: No details given.
Sample size/power calculation: Not reported.
Attrition/dropout: 19 randomised, two not entered (reasons not stated), one not included in analysis (discontinued after an 
AE then resumed at half of the dose).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Inadequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateAppendix 4
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CRI data extraction forms
Reference and 
design Intervention Participants Outcome measures
Sanchez et al. 
2002103
Country: USA
Study design: 
RCT
Number of 
centres: one
Funding: partly 
funded by 
Genentech 
Foundation for 
Growth and 
Development, 
and the Casey 
Lee Ball 
Foundation
1. 0.05 mg/kg rhGH, daily 
s.c.i
2. No treatment
Duration of treatment: 12 
months
Other interventions used: 
All patients received 
either monoclonal 
or polyclonal anti-T 
cell therapy and were 
maintained on a 3-drug 
immunosuppressive 
regimen. None was given 
vitamin D sterols, oral 
calcium supplements 
or anticonvulsant 
medications
Target population: prepubertal 
paediatric kidney allograft recipients
Number of participants: total 23
1. 12
2. 11
Sample attrition/dropout: group 1, one; 
group 2, one
Inclusion criteria for study entry: 
pre-pubertal children, stable renal 
function for at least 1 year post 
operation, normal bone formation 
rates, patients with adynamic lesions 
who had not previously been treated 
with rhGH were also included
Exclusion criteria for study entry: 
secondary hyperparathyroidism
Primary outcomes: appears to be 
skeletal changes, but not stated 
clearly
Secondary outcomes: HtSDS, WtSDS, 
GV
Method of assessing outcomes: height 
and weight measured at 3-month 
intervals; height measured using 
fixed wall-mounted stadiometer; 
bone biopsy and histomorphometry 
bone mass measured by DEXA; 
blood samples every 3 months; BA 
determined by Greulich and Pyle 
method from radiographs of left 
hand and wrist. WSDS and HSDS 
calculated using values for 50th 
percentile for children of same CA 
and sex
Length of follow-up: 12 months
Characteristics of participants
Characteristic 0.05 mg/kg rhGH (n = 12) No treatment (n = 11) p-value
Mean age ± SD (years) 9.7 ± 4.5 11 ± 1.8 ns
Sex 18 boys, 5 girls (Groups combined)
Mean interval since transplantation 
(years)
3.4 ± 2.5 (Groups combined)
HtSDS –2.0 ± 1.1 Not given, but ‘did not differ’ 
stated
Mean HtSDS 12 months before study –2.2 ± 0.8 –2.6 ± 1.0 ns
Annual GV 12 months before study 
(cm/year)
5 ± 2.0 4 ± 2.0 ns
BA (years) 7.1 ± 3.6 8.8 ± 2.4 ns
Tanner score 1.9 ± 0.8 2.1 ± 1.1 ns
GFR (ml/min) 58 ± 15 58 ± 14
Results (mean ± SE)
Outcomes  0.05 mg/kg rhGH (n = 12) No treatment (n = 11) p-value
HtSDS for height at end 
of study
–1.1 ± 1.0 (p < 0.02 compared with 
baseline)
No change from baseline
Annual GV (cm/year) 8.0 ± 2.1 4.8 ± 1.7 < 0.01
Change in WtSDS 0.2 ± 0.3 –0.3 ± 0.3 < 0.01
BA (years) 8.5 ± 3.4 9.5 ± 2.8 ns
Tanner score 1.9 ± 0.7 2.2 ± 1.0 ns
GFR (ml/min) 61 ± 13 (change from baseline p = ns) 67 ± 19 (change from baseline p = ns)DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Biochemical markers Baseline Final Baseline Final
Serum calcium (mg/dl) 9.8 ± 0.7 10 ± 0.6 9.4 ± 0.5 9.6 ± 0.7
Serum phosphorous (mg/
dl)
4.8 ± 0.8 4.8 ± 0.7 4.5 ± 0.8 4.2 ± 0.7
Serum osteocalcin (ng/
ml)
24 ± 2.7 24 ± 0.3 20 ± 2.3 17 ± 1.7
Serum parathyroid 
hormone (pg/ml)
55 ± 5.0 55 ± 5.3 38 ± 4.0 34 ± 2.5
Serum alkaline phosphate 
(IU/I)
239 ± 9.0 255 ± 9.0 225 ± 9.0 198 ± 6.4
Serum 
1,25-dihydroxyvitamin D 
(pg/ml)
43 ± 4.3 52 ± 4.7 39 ± 3.3 50 ± 3.1
Bone 
histomorphology Baseline Final Baseline Final
Bone area (%) 20 ± 2.6 21 ± 4.0 20 ± 4.8 22 ± 6.4
Osteoid area (%) 8.8 ± 4.0 7.9 ± 1.8 6.1 ± 2.5 8.2 ± 2.3
Eroded perimeter (%) 5.4 ± 4.8 4.0 ± 2.2 2.2 ± 1.7 3.0 ± 1.5
Bone formation rate 
(µm2/mm2/day)
266 ± 212 348 ± 304 262 ± 180 390 ± 232
SDS for bone mass at 
lumbar spine, based on 
CA
–0.1 ± 1.6 –0.1 ± 1.3 (p = ns) –1.7 ± 0.9 –2.1 ± 1.0 
(p < 0.5)
SDS for bone mass 
corrected for height age
1.1 ± 1.3 0.7 ± 0.8 (change 
from baseline 
p = ns)
0.01 ± 1.0 –0.3 ± 1.2 
(p < 0.05 change 
from baseline)
Comments
Baseline serum levels of calcium, phosphorous, parathyroid hormone, alkaline phosphate, osteocalcin, and 
1,25-dihydroxyvitamin D did not differ between patients given rhGH and untreated controls. Values remained unchanged 
after 12 months’ follow-up in both groups. IGF-1 baseline values were similar between groups (actual values not given), and 
did not change from baseline in the untreated group. Change from baseline was significant for the treated group (p < 0.001), 
although subgroup analysis indicated that this was only in the subgroup of patients with normal rates of bone formation, 
who experienced an increase in serum IGF-1 levels of 54 ± 25% after 3 months and 98 ± 35% after 12 months of rhGH 
(p < 0.05). Serum IGF-1 levels remained unchanged in patients with adynamic bone, and values did not differ from those 
obtained in the untreated group. Cumulative dose of prednisone did not differ between groups. Two patients with normal 
rates of bone formation experienced acute rejection episodes after 3 and 12 months of rhGH therapy. One was associated 
with non-compliance to immunosuppressive medications. Both episodes reversed after treatment with methylprednisolone. 
No rejection episodes in untreated patients.
Methodological comments
Allocation to treatment groups: Statistician who had no information about patients’ clinical or biochemical characteristics 
randomised to treatment groups depending on their initial bone histological finding. Details of randomization procedure 
not given. Not stratified by height, etc.
Blinding: Control group did not receive placebo injections.
Comparability of treatment groups: p = ns for difference in age at baseline.
Method of data analysis: Not ITT as two patients who withdrew were excluded from analysis. Unpaired t-tests were used to 
compare changes from baseline.
Sample size/power calculation: Sample size estimated with 80% power to detect differences in group means and a two group 
comparison that required 20 patients per group. Appears to have been based on bone formation rates in a previous study, 
and it is not clear what the primary outcome for the present study is.
Attrition/dropout: Two withdrawals: one in group 1 due to glucose intolerance after 3 months (which resolved in stopping 
treatment); one in group 2 due to being assigned to control group. Two group 1 patients also failed to undergo second 
bone biopsy.Appendix 4
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Adequate
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Partial
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
The 
Pharmacia 
and Upjohn 
Study Group 
1996107
Country: 
international
Study design: 
open-label RCT
Number 
of centres: 
multicentre
Funding: 
Pharmacia & 
Upjohn
1. Daily s.c.i. of GH 
(1 IU/kg/week)
2. No treatment
Duration of treatment:1 
year of randomised 
treatment, followed by 
1 year of GH treatment 
for both groups (only 
year 1 randomised data 
included here)
Other interventions used: 
not reported
Target population: children who had 
received a kidney transplant
Number of participants: Total: n = 203
1. n = 106
2. n = 97
Sample attrition/dropout: 23 excluded from 
analysis of renal function; 49 excluded 
from analysis of growth
Inclusion criteria for study entry: ≥ 12 
months since transplantation; 2 height 
measurements over last 6 months; height 
SDS < –2 or GV below the 25th centile; 
GFR ≥ 20ml/min/1.73m2; normal serum 
thyroid hormone levels; testicular volume 
< 8 ml or breast development < B2
Exclusion criteria for study entry: HV ≥ 75th 
centile, dialysis therapy, any form of 
malignancy or treatment with GH during 
past 12 months
Primary outcomes: GFR
Secondary outcomes: transplant 
rejections; GV; HtSDS
Note: data extracted only 
where reported separately for 
prepubertal children
Method of assessing outcomes: 
auxological and biochemical 
assessments every 3 months. 
GFR measured by insulin 
clearance, or creatinine 
clearance (Morris method)
Length of follow-up: 1 year (later 
follow-up not data extracted as 
not randomised)
Characteristics of participants
Mean ± SD 1 IU/kg/week GH No treatment p-value
Boys/girls 71/35 72/25
Age (years) 12.6 ± 3.4 12.1 ± 3.1
Proportion prepubertal (%) 53 63
Years since transplantation 3.6 ± 2.3 3.2 ± 2.4
Proportion cadaver donors (%) 81 86
HtSDS –3.2 ± 1.4 –3.1 ± 1.1
GV before treatment (cm/year) 3.6 ± 2.2 4.0 ± 2.1
GFR (insulin)(ml/min/1.73 m2) 48 ± 27 48 ± 26
GF (Morris) (ml/min/1.73 m2) 51 ± 21 51 ± 2.1
Rejection episodes prior to study (n)
0–1 episode 69 63
2–4 episodes 30 32
5–8 episodes 7 1
Comments
N not clear for patient groups at baseline.
Results
Mean ± SD change from baseline 1 IU/kg/week GH (n = 28) No treatment (n = 30) p-value
Change in GV (cm/year) 3.7 ± 1.6 0.3 ± 1.6 < 0.0001
Change in HtSDS +0.6 ± 0.3 +0.1 ± 0.3 < 0.0001
Comments
Primary outcome (GFR) and other outcomes not data extracted as not reportedly separately for prepubertal children.Appendix 4
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Methodological comments
Allocation to treatment groups: Randomised centrally, but no further details given.
Blinding: Open label.
Comparability of treatment groups: No p-values given. Appear to be similar, although control group contained 10% more 
prepubertal patients than treatment group and no. of patients with a high no. of acute rejections was higher in the GH-
treated patients (seven vs one).
Method of data analysis: No information given.
Sample size/power calculation: Not stated.
Attrition/dropout: 23 excluded from analysis of renal function (treatment occurred without randomisation, GFR < 20 ml/
min/1.73 m2; transplantation < 12 months before study entry; non-compliance); 49 excluded from analysis of growth 
[abnormal thyroid function, growing too well (or not being short enough) before the study, previous growth not 
documented].
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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153
Reference and 
design Intervention Participants Outcome measures
Fine et al. 
1994108
Country: USA
Study design: 
RCT
Number of 
centres: 17
Funding: 
Genentech
1. GH 0.05 mg/kg/day s.c.
2. Placebo in equivalent 
volume.
Dose adjusted every 3 
months for change in weight
Duration of treatment: 2 years’ 
treatment was discontinued 
at renal transplantation, 
significant adverse event, or 
when BA > 15 years for boys 
and > 14 years for girls and 
growth rate was < 2 cm/year. 
Treatment was paused if a 
patient’s height percentile 
exceeded the Tanner target 
percentile for mid-parental 
height (4/82 group 1, 11/42 
group 2)
Other interventions used: 
dialysis was permitted as 
required; multivitamins, 
vitamin D analogue and 
various other therapies were 
permitted as required
Target population: prepubertal 
growth-retarded children with CRF
Number of participants: Total: n = 125
1. n = 82
2. n = 43
Sample attrition/dropout: group 1 – 13 
in year 1, 13 in year 2; group 2 – 12 in 
year 1, 3 in year 
Inclusion criteria for study entry: 
irreversible renal insufficiency, 
creatinine clearance > 5 and < 75 ml/
min/1.73 m2, height < 3rd percentile 
for CA, BA < 10 years for girls and 
< 11 years for boys, prepubertal 
status (Tanner stage 1)
Exclusion criteria for study entry: 
evidence of a specific cause for 
growth failure other than CRF 
inability to obtain accurate 
height measurements, use of 
corticosteroids or other medications 
that influence growth, diabetes 
mellitus, active malignant disease 
or treatment of a malignant disease 
within past year, use of any other 
investigational drug therapy within 2 
months of randomisation
Primary outcomes: not stated
Secondary outcomes: GV, HtSDS 
height age, BA, Cumulative 
∆HA – ∆BA, weight gain, triceps 
skinfold thickness, mid-arm 
muscle circumference
Method of assessing outcomes: 
anthropometric measurements 
made by same observer every 3 
months; radiological evaluation 
of BA every 6 months. HSDS 
calculated using age- and sex-
specific norms from the NCHS
Length of follow-up: 2 years
Characteristics of participants
Mean ± SD GH 0.05 mg/kg/day (n = 82) Placebo (n = 43) p-value
Age (years) 6.0 ± 3.9 5.7 ± 3.6
Sex (f/m) 21/61 14/28
Height age 4.0 ± 2.9 3.8 ± 2.8
BA 4.2 ± 3.0 4.2 ± 2.9
HtSDS –2.9 ± 0.9 –2.9 ± 1.0
Standardised height –2.94 ± 0.86 (n = 55) –2.82 ± 0.97 (n = 27)
IGF-1 (µg/ml) 121 ± 73 (n = 55) 141 ± 94 (n = 20)
Fasting insulin (pmol/l) 70.3 ± 43.6 (n = 40) 87.8 ± 71.1 (n = 21)
Postprandial insulin 
(pmol/l)
25.8 ± 26.8 (n = 43) 30.1 ± 14.6 (n = 19)
Fasting glucose (mmol/l) 5.1 ± 1.1 (n = 49) 5.0 ± 0.7 (n = 24)
Postprandial glucose 
(mmol/l)
5.3 ± 1.8 (n = 37) 6.0 ± 1.7 (n = 21)
HbA1c (%) 5.1 ± 0.9 (n = 48) 5.4 ± 1.0 (n = 24)
Creatinine (µmol/l) 174 ± 111 (n = 48) 173 ± 97 (n = 24)
Creatinine (mg/dl) 2.3 ± 1.5 (n = 48) 2.3 ± 1.3 (n = 24)
Creatinine clearance (ml/
sec/1.73 m2)
0.55 ± 0.33 (n = 48) 0.52 ± 0.31 (n = 24)
Creatinine clearance (ml/
min/1.73 m2)
32.8 ± 19.5 (n = 48) 31.1 ± 18.3 (n = 24)
Blood urea nitrogen 
(mmol/l)
15.6 ± 6.6 (n = 48) 16.0 ± 7.3 (n = 24)
Blood urea nitrogen (mg/
dl)
43.6 ± 18.5 (n = 48) 44.9 ± 20.5 (n = 24)Appendix 4
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Results
Mean ± SD GH 0.05 mg/kg/day (n = 82) Placebo (n = 43) p-value
GV year 1 (cm/year) 10.7 ± 3.1 (n = 55) 6.5 ± 2.6 (n = 27) < 0.00005
GV year 2 (cm/year) 7.8 ± 2.1 (n = 55) 5.5 ± 1.9 (n = 27) < 0.00005
HtSDS at year 2 –1.6, p < 0.00005 compared with baseline –2.9, p = 0.52 compared with 
baseline
Roche–Wainer–Thissen 
predicted AH at 2 years 
(cm)
5.4 –0.4 < 0.00005
Weight gain after 2 years 
(kg)
6.7 ± 2.2 4.6 ± 2.7 0.0004
Triceps skinfold thickness 
(mm)
–1.6 ± 2.6 0.6 ± 3.8 0.006
Mid-arm muscle 
circumference (cm)
2.1 ± 1.1 1.3 ± 1.2 0.007
Change in BA at 2 years 
(years)
2.3 ± 0.7 1.6 ± 0.5 0.0001
Standardised height (1 
year)
–1.93 ± 1.01 (n = 55) –2.90 ± 0.95 (n = 27)
Cumulative change in HA 
– change in BA, year 1
0.28 ± 0.45 (n = 43) –0.04 ± 0.36 (n = 21)
Cumulative change in HA 
– change in BA, year 2)
0.15 ± 0.62 (n = 43) –0.12 ± 0.43 (n = 21) 0.08
Standardised height (2 
year)
–1.55 ± 1.16 (n = 55) –2.91 ± 1.04 (n = 27) < 0.00005
Height age (1 year)  4.5 ± 2.7 (n = 43) 5.0 ± 3.2 (n = 21)
Height age (2 year) 5.6 ± 2.9 (n = 43) 5.7 ± 3.3 (n = 21) < 0.00005
BA (1 year) 4.6 ± 2.6 (n = 43) 5.2 ± 3.1 (n = 21)
BA (2 year) 5.8 ± 2.8 (n = 43) 6.0 ± 3.2 (n = 21) 0.0001
IGF-1 (µg/l), year 1 286 ± 158 (n = 47) 167 ± 97 (n = 20) 0.0004
IGF-1 (µg/l), year 2 244 ± 128 (n = 47) 135 ± 80 (n = 20) 0.0001
Fasting insulin (pmol/l) 
year 1
104.9 ± 54.5 (n = 40) 76.9 ± 28.4 (n = 21)
Fasting insulin (pmol/l) 
year 2
80.9 ± 42.8 (n = 40) 59.1 ± 34.6 (n = 21) 0.03
Postprandial insulin 
(pmol/l), year 1
36.6 ± 29.0 (n = 43) 27.7 ± 17.2 (n = 19)
Postprandial insulin 
(pmol/l), year 2
29.0± 20.7 (n = 43) 27.2 ± 16.9 (n = 19) 0.32
Fasting glucose (mmol/l), 
year 1
5.2 ± 0.6 (n = 49) 5.2 ± 1.0 (n = 24)
Fasting glucose (mmol/l), 
year 2
5.0 ± 0.6 (n = 49) 5.1 ± 0.7 (n = 24) 0.70
Postprandial glucose 
(mmol/l), year 1
5.4 ± 1.1 (n = 37) 5.1 ± 1.2 (n = 21)
Postprandial glucose 
(mmol/l), year 2
5.4 ± 1.1 (n = 37) 5.5 ± 1.1 (n = 21) 0.28
HbA1c (%), year 1 5.0 ± 0.8 (n = 48) 5.0 ± 0.8 (n = 24)
HbA1c (%), year 2 4.9 ± 0.7 (n = 48) 5.0 ± 0.8 (n = 24) 0.33
Creatinine (µmol/l), 
year 1
218 ± 163 (n = 48) 192 ± 96 (n = 24)
Creatinine (µmol/l), 
year 2
269 ± 205 (n = 48) 219 ± 114 (n = 24) 0.08DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Creatinine (mg/dl), year 1 2.9 ± 2.1 (n = 48) 2.5 ± 1.3 (n = 24)
Creatinine (mg/dl), year 2 3.5 ± 2.7 (n = 48) 2.9 ± 1.5 (n = 24) 0.08
Creatinine clearance (ml/
sec/1.73 m2), year 1
0.55 ± 0.42 (n = 48) 0.51 ± 0.33 (n = 24)
Creatinine clearance (ml/
sec/1.73 m2), year 2
0.49 ± 0.35 (n = 48) 0.48 ± 0.34 (n = 24) 0.63
Creatinine clearance (ml/
min/1.73 m2), year 1
32.8 ± 25.2 (n = 48) 30.7 ± 19.9 (n = 24)
Creatinine clearance (ml/
min/1.73 m2), year 2
29.3 ± 21.3 (n = 48) 28.9 ± 20.4 (n = 24) 0.63
Blood urea nitrogen 
(mmol/l), year 1
16.1 ± 8.8 (n = 48) 17.7 ± 8.7 (n = 24)
Blood urea nitrogen 
(mmol/l), year 2
17.2 ± 8.7 (n = 48) 15.9 ± 7.1 (n = 24) 0.26
Blood urea nitrogen (mg/
dl), year 1
45.0 ± 24.5 (n = 48) 49.7 ± 24.4 (n = 24)
Blood urea nitrogen (mg/
dl), year 2
48.2 ± 24.5 (n = 48) 44.5 ± 20.0 (n = 24) 0.26
Serum alkaline 
phosphatase level change 
from baseline (IU/l), 
year 1
120.1 ± 130.1 (n = 48) 45.6 ± 90.0 (n = 24) 0.014
Serum alkaline 
phosphatase level change 
from baseline (IU/l), 
year 2
nr ns
Comments
Mean fasting insulin levels changed significantly in patients with GH between baseline and 12 months (p = 0.0005) but not 
between baseline and 24 months. Changes in placebo group were not significant. Postprandial insulin levels also significant 
for GH group between baseline and year 1 (p = 0.0089) but not significant between baseline and 24 months. Changes from 
baseline in placebo group were not significant. No significant change in HbA1c or thyroxine or TSH in either group at either 
time period.
Biochemical measurements: There was no significant difference in the variation in the serum calcium, phosphorous, 
triglyceride or cholesterol levels between the two groups during the first 2 years of treatment.
Adverse effects
No differences between groups in year 1. Year 2 asthma or wheezing in 8 out f 55 GH patients and none of placebo. All 
episodes preceded by upper respiratory tract infections. ‘No clinically significant side effects were associated with rhGH 
treatment.’ During the 1st 12 months, 19 out of 82 patients had low titre GH antibodies (i.e. anti-GH antibody serum 
binding by radioimmunoassay at least twice background values after 10-fold dilution), but over 2 years there was no 
significant difference in growth rate between patients who acquired anti-GH antibodies and those who did not.
Methodological comments
Allocation to treatment groups: No information on randomisation except performed to place 2/3 in treatment and 1/3 in 
placebo and to maintain balance in age, sex, standardised height, degree of renal function and primary renal disease.
Blinding: Placebo used in equivalent volume, but no further detail given.
Comparability of treatment groups: IGF-1 and fasting insulin levels were higher in the placebo group, but were not reported 
to have been significantly different.
Method of data analysis: Between- and within-group comparisons were made with two-tailed t-tests; p < 0.05 was 
considered statistically significant. Many outcome measures are only presented for patients who completed both years of 
the study. Not ITT.
Sample size/power calculation: Not reported.
Attrition/dropout: GH: 13 in year 1, 13 in year 2; placebo: 12 in year 1, 3 in year 2. 41% of total withdrawals were due to 
renal transplant, 24% requested removal, 15% non-compliance.Appendix 4
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Adequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
Hokken-
Koelega et al. 
1991104
Country: 
international
Study design: 
crossover RCT
Number 
of centres: 
multicentre
Funding: Novo 
Nordisk 
A/S Denmark
1. 4 IU/m2 biosynthetic 
human GH daily s.c.i., 
followed by crossover to 
placebo
2. Placebo followed 
by crossover to 
biosynthetic human GH 
daily s.c.i.
Duration of treatment: 6 
months in each arm of 
the study
Other interventions used: 
phosphate-binding 
medication, calcium 
supplements and 
1,25-dihydroxy vitamin 
D
Target population: prepubertal children 
with CRF and severe growth retardation
Number of participants: total 20
1. 8
2. 8
Original assignment not stated
Sample attrition/dropout: Four left due to 
kidney transplantation
Inclusion/exclusion criteria for study entry: 
CRF ≥ 1 year, creatinine clearance 
below 20 ml/min/1.73 m2, HtSDS for age 
< –1.88 and HV for age < 25th percentile, 
prepubertal (Tanner stage I), BA < 10 
years for girls and 12 years for boys, 
no evidence of growth retardation 
cause other than CRF, normal thyroid 
function, no osteodystrophy, no 
previous treatment with anabolic 
steroids, sex steroids or recombinant 
human erythropoietin
Primary outcomes: not stated
Secondary outcomes: GV, GV SDS, 
BA (years), IGF-1 and IFG-II 
plasma concentrations
Method of assessing outcomes: 
height measured with a 
Harpenden stadiometer; BA 
calculated from radiographs 
at start of study and every 
6 months. Baseline height 
expressed as SDS for CA 
compared with Dutch reference 
data. GV expressed as SDS for 
CA compared with references 
derived from Infant–Childhood–
Puberty Model.
Length of follow-up:12 months
Characteristics of participants (median, range)
Characteristic 4 IU/m2 hGH/placebo (n = 8) Placebo/4 IU/m2 hGH (n = 8) p-value
Age (years) 8.7 (4.4 to 11.3) 8.6 (4.4 to 16.0)
Sex (m/f) 6/2 4/4 
BA (years) 7.4 (3.7 to 10.2) 7.5 (3.7 to 10.6)
HtSDS –2.3 (–3.9 to –1.8) –2.7 (–5.6 to –2.0)
GV (cm/6 months) 1.6 (0 to 3.0) 1.4 (0.2 to 2.6)
Weight for height (%) 98.2 (86.7 to 113.5) 101.5 (90.3 to 116.5)
Mean (SD) GV (cm/6 months) 6 
months pre-study
1.5 (0.7) 1.5 (0.5)
Mean (SD) HV SDS 6 months 
prestudy
–3.2 (1.4) –2.9 (2.0)
Mean (SD) BA (years) 6 months 
prestudy
6.9 (2.3) 7.7 (2.6)
Mean (SD) IGF-1 (ng/ml)
SDS for BA
173 (135) 197 (94)
0.8 (2.7) 1.4 (1.6)
Mean (SD) IGF-II (ng/ml)
SDS for BA
1160 (485) 1178 (483)
2.5 (3.0) 3.4 (4.0)
Mean (SD) IGFBP-3 (ng/ml)
SDS for BA
5429 (1352) 6559 (2552)
3.2 (1.1) 4.2 (2.1)
Mean (SD) IGFBP-1 (ng/ml)
SDS for BA
195 (126) 190 (115)
30 (20) 29 (17)Appendix 4
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Results
Outcomes
4 IU/m2 hGH/placebo (n = 8) Placebo/4 IU/m2 hGH (n = 8)
Overall mean 
effect of GH 
minus effect 
of placebo
After 6 
months’ GH
After 6 
months’ 
placebo
After 6 
months’ 
placebo
After 6 months’ 
GH
Mean (SD) GV (cm/6 
months)
5.2 (1.2) 1.5 (0.4) 2.4 (1.0) 4.4 (1.6) 2.9 (95% CI 
2.3 to 3.5) 
(p < 0.0001)
Mean (SD) HV SDS 6.9 (2.4) –3.0 (1.6) –0.5 (3.2) 5.0 (4.5) 7.7 (p < 0.0001)
Mean (SD) BA (years) 7.0 (1.9) 7.6 (1.7) 8.0 (2.6) 8.4 (2.8) –0.01
Mean (SD) IGF-1 (ng/ml) 
SDS for BA
264 (168) 
2.6 (2.0)
160 (104) 
–0.2 (1.5)
160 (95) 
0.3 (1.6)
268 (120) 
2.9 (2.0)
106 
2.7 (p < 0.0001)
Mean (SD) IGF-2 (ng/ml) 
SDS for BA
1174 (361) 
2.8 (2.8)
983 (336) 
0.9 (2.2)
1192 (340) 
3.4 (2.4)
1346 (492) 
4.6 (3.4)
172 
1.6
Mean (SD) IGFBP-3  
(ng/ml) 
SDS for BA
7708 (2323)
5.0 (1.3)
6102 (1892)
3.7 (1.3)
6501 (1988)
3.9 (1.4)
8706 (2275)
5.2 (1.4)
1906
1.3 (p < 0.0001)
Mean (SD) IGFBP-1 
(ng/ml) 
SDS for BA
119 (95)
16.4 (16.8)
185 (119)
27.1 (22.4)
215 (106)
32 (19.5)
140 (90)
20 (16.6)
–70 (p < 0.0001)
–11.2 
(p < 0.0001)
Comments
For GV, there was no significant carry-over effect (–0.04 cm/6 months, p = 0.94). Period check was –0.9 cm/6 months 
(p < 0.06).
Adverse effects
Serum alkaline phosphate was significantly increased during GH treatment, but returned to pretreatment levels when 
GH therapy was replaced by placebo (p < 0.0001). There was no significant change in parathyroid hormone concentration 
during either treatment schedule. Thyroid function was normal.
Methodological comments
Allocation to treatment groups: States randomly and blindly assigned, but no further details given.
Blinding: Stated to be double blind.
Comparability of treatment groups: Similar at baseline, although IGF-1 and IGFBP-3 were higher in group 2 at baseline.
Method of data analysis: Not ITT. Paper states that statistical methods appropriate for crossover trials were used but no 
further details were given. Treatment effects were calculated and tested after taking into account any period effect.
Sample size/power calculation: No information in paper.
Attrition/dropout: Four children left the study to have kidney transplants; 3 at 6 months and 1 at 7 months.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Unknown
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
Hokken-
Koelega et al. 
1996105
Country: 
international
Study design: 
crossover RCT
Number 
of centres: 
multicentre
Funding: Novo 
Nordisk A/S
1. 4 IU/m2 GH/placebo 
daily s.c.i.
2. Placebo/4 IU/m2 GH 
daily s.c.i.
Duration of treatment: 6 
months in each arm
Other interventions used: 
immunosuppressive 
therapy
Target population: prepubertal children 
after renal transplant
Number of participants: total n = 11
1. n = 6
2. n = 5
Sample attrition/dropout: none
Inclusion criteria for study entry: postrenal 
transplant (≥ 12 months), stable condition 
without rejection episodes (≥ 12 months), 
HtSDS for age < –1.88 and HV for age 
< 50th percentile OR HtSDS above –1.88 
with HV < 25th percentile, prepubertal 
(Tanner stage I), BA < 10 years for girls 
and 12 years for boys, prednisone dose 
≤ 0.25 mg/kg/day ≥ 6 months, no evidence 
of growth retardation cause other 
than following renal transplant, normal 
thyroid function and acid–base balance, 
no previous treatment with sex steroids
Primary outcomes: not stated
Secondary outcomes: HV, GVSDS, 
BA, GFR, ERPF, IGF-1 measures, 
insulin and other biochemical 
markers
Method of assessing outcomes: 
same investigator examined 
children at enrolment and every 
3 months; height measured 
with a Harpenden stadiometer 
until three consecutive readings 
within 0.2 cm; GV references 
derived from Infant–Childhood–
Puberty Model; Dutch reference 
data used for baseline HtSDS; 
BA determined from wrist 
radiographs
Length of follow-up: 12 months
Characteristics of participants
Median, range 4 IU/m2 GH/placebo (n = 6) Placebo/4 IU/m2 GH (n = 5) p-value
Age (years) 12.1 (9.1 to 18.7) 11.1 (8.3 to 14.9)
Sex (m/f) 5/1 4/1
HtSDS –3.0 (–7.6 to –1.2) –2.6 (–3.6 to –2.1)
GV (6 months) 1.4 (0.5 to 2.6) 0.8 (0.6 to 1.8)
BMI SDS 3.1 (–1.1 to 4.2) 1.3 (–0.2 to 3.7)
GFR (ml/min/1.73 m2) 62 (56 to 81) 38 (19 to 74)
BA (years) 9.5 (7.9 to 11.5) 7.5 (5.2 to 10.5)
Results (mean, SD)
Outcomes
4 IU/m2 GH/placebo (n = 6) Placebo/4 IU/m2 GH (n = 5)
Overall mean 
effect of GH 
minus effect 
of placebo Prestudy
After 6 
months’ 
GH
After 6 
months’ 
placebo Prestudy
After 6 
months’ 
placebo
After 6 
months’ 
GH
HV (cm/6 months) 1.5 (0.7) 5.3 (1.0) 1.5 (0.9) 1.0 (0.5) 1.9 (0.7) 3.9 (1.3) 2.9 (95% CI 
1.9 to 3.9) 
(p < 0.0001)
GVSDS –1.7 (1.8) 9.1 (2.9) –1.3 (2.9) –3.3 (0.9) –0.4 (1.7) 5.3 (4.0) 8.0 (p < 0.0001)
BA (years) 9.5 (1.7) 9.7 (1.4) 10.5 (2.2) 7.7 (2.2) 8.0 (2.1) 8.1 (1.2) –0.5
GFR (ml/min/1.73 m2) 66 (13) 80 (30) 64 (1) 44 (22) 49 (22) 47 (38) 5.5
ERPF (ml/min/1.73 m2) 261 (75) 254 (87) 264 (77) 173 (79) 191 (62) 184 (86) –15.6
IGF-1 (ng/ml) 
SDSBA
280 (121) 
0.9 (1.6)
594 (180) 
5.4 (2.8)
240 (143) 
1.0 (2.5)
274 (89) 
2.8 (1.8)
321 (94) 
3.4 (0.5)
488 (237) 
6.4 (1.9)
228 
3.7 (p < 0.0001)
IGF-2 (ng/ml) 
SDSBA
759 (114) 
0.5 (0.9)
799 (186) 
1.1 (1.7)
689 (31) 
0.0 (0.4)
728 (349) 
0.9 (3.2)
898 (56) 
2.2 (1.2)
900 (63) 
2.3 (1.0)
73 
0.5
IGFBP-3 (ng/ml)
SDSBA
4902 
(1099) 
2.8 (1.8)
7457 
(2088) 
4.5 (1.5)
5681 
(1588) 
3.7 (2.9)
5787 
(1037) 
3.8 (0.7)
6228  
(2193) 
3.9 (1.5)
8495 
(2921) 
5.3 (1.5)
1698
0.9
IGFBP-1 (ng/ml) 
SDSBA
52 (32) 
4.7 (4.6)
52 (23) 
4.6 (3.5)
71 (43) 
7.5 (6.3)
83 (40) 
9.7 (6.8)
62 (28) 
6.7 (4.9)
43 (35) 
5.1 (5.2)
–19 
–2.1Appendix 4
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Cholesterol (mM/l) 6.4 (1.1)a 6.0 (1.0)a 6.5 (1.8)a 6.3 (0.7)a 6.5 (0.7)a 6.2 (0.6)a –0.3
LDL mM/l 4.0 (1.4) 3.2 (0.6) 4.0 (2.3) 3.7 (1.0) 4.1 (0.9) 3.7 (0.7) –0.5
Apolipoprotein A1 (mg/
dl)
155 (22) 163 (29) 130 (45) 171 (52) 151 (18) 141 (25) 10
Apolipoprotein B (mg/dl) 110 (33) 91 (18) 113 (40) 111 (28) 112 (20) 115 (27) –9
Fructosamine (mM/l) 282 (40) 296 (16) 277 (36) 338 (59) 313 (62) 312 (37) 8
OGTT – glucose (mM/l)
Fasting 4.7 (1.2) 5.3 (0.9) 5.1 (1.1) 5.2 (0.3) 4.5 (0.5) 4.8 (0.3) 0.3
Integrated 738 (163) 784 (165) 691 (79) 943 (249) 846 (143) 854 (168) 55
OGTT – insulin (μU/ml)
Fasting 20 (14) 38 (12) 22 (14) 12 (5) 19 (15) 17 (8) 7
Integrated 2481 
(1006)
4582 
(3042)
3648 
(1643)
2319 
(1019)
2349  
(444)
4267 
(1092)
1532 (p < 0.05 
GH vs placebo)
Comments
ERPF, effective renal plasma flow; GVSDS, chronological age; SDSBA, SDS for BA.
a  p < 0.05 GH vs placebo.
For HV, there was no significant carry-over effect (0.5 cm/6 months, p = 0.30). Period effect was 0.9 cm/6 months (p = 0.06).
Cholesterol and other outcomes above were compared against controls. Not data extracted as not part of randomised 
study.
Adverse effects
None of the patients had an acute rejection episode during the study. No SAEs.
Methodological comments
Allocation to treatment groups: States randomly and blindly assigned to groups, but no further details given.
Blinding: No details provided.
Comparability of treatment groups: Similar at baseline (although BA 2 years higher in group 1).
Method of data analysis: Paper states that statistical methods appropriate for crossover trials were used. Reference cited, 
but no further details given. Treatment effects were calculated and tested after taking into account any period effect. 
ANOVA used to test influence of baseline variables. Correlations were tested by Spearman non-parametric test. ITT 
analysis performed.
Sample size/power calculation: Not stated.
Attrition/dropout: All children completed the study.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Adequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Reference and 
design Intervention Participants Outcome measures
Powell et al. 
1997106
Country: USA
Study design: 
multicentre, 
open-label RCT
Number of 
centres: 26
Funding: 
Genentech Inc.; 
government 
grants
1. 0.05 mg/kg/day 
s.c. rhGH
2. No treatment
Duration of 
treatment: 1 year
Other interventions 
used:
Target population: prepubertal children with 
chronic renal failure
Number of participants: total 69 entered, 44 
analysed
1. n = 30
2. n = 14
Sample attrition/dropout: 20 left (12 ESRF, six 
entered puberty, one allergic to rhGH, one 
drowned); four group 1 and one group 2 
completed study but were excluded as they 
had insufficient serum for the 0- and 12-month 
protein assays
Inclusion criteria for study entry: irreversible renal 
insufficiency (GFR > 10 and < 40 ml/min/1.73 m2), 
height < fifth percentile for age, age > 2.5 years, 
ability to stand for height measurement, BA 
< 10 for girls and 11 for boys, Tanner stage I
Exclusion criteria for study entry: serum albumin 
< 2.5 g/dl, receiving medications that influence 
growth, presence of illness affecting growth, 
diabetes mellitus, presence or past history of 
malignancy
Primary outcomes: not specified
Secondary outcomes: height gain; 
HtSDS; BA; mid-arm muscle 
circumference; triceps skinfold 
thickness; weight gain; various 
IGF measures; insulin; ALS; 
GHBP
Method of assessing outcomes: 
anthropometric measurements 
taken at 0, 3 and 12 months; 
height measured using wall-
mounted stadiometer; BA 
determined by a left hand and 
wrist radiograph at 0 and 12 
months
Length of follow-up: 1 year
Characteristics of participants (mean ± SD)
Characteristic 0.05 mg/kg/day rhGH (n = 30) No treatment (n = 14) p-value
Sex (% male) 83 86
GFR (ml/min/1.73 m2) 27.5 ± 8.9 27.6 ± 8.8
Age (years) 5.6 ± 2.0 5.7 ± 2.6
BA (years) 4.0 ± 1.5 (n = 27) 4.2 ± 1.8
HtSDS –2.7 ± 0.7 –2.7 ± 0.8
Weight for HtSDS 0.0 ± 1.3 –0.2 ± 1.5
MAMC (cm) 14.1 ± 1.6 (n = 29) 14.4 ± 2.8
TSF (mm) 7.9 ± 3.2 (n = 29) 8.5 ± 3.2
IGF-1 (nM) 15 ± 10 10 ± 5
IGF-1 SDS –0.7 ± 1.3 –1.2 ± 1.0
Free IGF-1 (pM) 71 ± 41 (n = 17) 141 ± 94 (n = 9) 0.029
IGF-2 (nM) 100 ± 29 101 ± 41
IGF-2 SDS 1.2 ± 1.2 1.1 ± 1.3
Insulin pM b 19 ± 14 52 ± 66 0.021
Total IGF (nM) 115 ± 34 111 ± 45
IGFBP-1 (nM) 18 ± 9 17 ± 21
IGFBP-1 SDS 2.4 ± 0.6 2.1 ± 1.4
IGFBP-2 (nM)a 50 ± 17 51 ± 26
IGFBP-3 (nM)b 130 ± 50 109 ± 25
IGFBP-3 SDSc 1.7 ± 2.0 0.7 ± 1.1
ALS (nM) 207 ± 81 179 ± 40
GHBP (pM) 183 ± 104 144 ± 104 (n = 12)
GHBP SDS 0.4 ± 1.7 0.0 ± 1.3 (n = 12)
a  Values > normal range (22 ± 11), p < 0.001.
b  Values not different from normal range (98 ± 17).
c  Values > normal range (–0.2 ± 0.7), p = 0.013.Appendix 4
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Results (mean ± SD change from 0–12 months)
Outcome 0.05 mg/kg/day rhGH (n = 30) No treatment (n = 14) p-value
BA (years) 1.0 ± 0.3 (n = 27) 0.9 ± 0.4 (n = 13) 0.5282
Height gain (cm) 9.1 ± 2.8 5.5 ± 1.9 < .0001
Weight gain (kg) 3.5 ± 1.5 2.2 ± 1.0 0.007
HtSDS 0.8 ± 0.5 0.0 ± 0.3 < 0.0001
Weight for HtSDS 0.4 ± 0.7 0.4 ± 0.5 0.8703
MAMC (cm) 1.2 ± 0.9 (n = 29) –0.2 ± 1.7 (n = 13) 0.0015
TSF (mm) –1.9 ± 2.5 (n = 29) 0.9 ± 1.2 (n = 13) 0.0003
IGF-1 (nM) No actual values presented – only small diagram, which is hard to read 
accurately. Not data extracted
< 0.006
IGF-1 (SDS) 0.2 ± 1.0 No change from baseline – no values 
reported
< 0.006
Free IGF-1 (pM) No actual values presented – only small diagram, which is hard to read 
accurately. Not data extracted
< 0.0464
IGF-2 (nM) < 0.006
IGF-2 SDS 2.1 ± 1.3 No change from baseline – no values 
reported
< 0.006
Insulin (pM) No actual values presented – only small diagram which is hard to read 
accurately. Not data extracted
< 0.017
Total IGF (nM) < 0.011
IGFBP-1 (nM) < 0.017
IGFBP-1 SDS < 0.017
IGFBP-2 (nM) ns
IGFBP-3 (nM) < 0.011
IGFBP-3 SDS 4.0 ± 3.2 No change from baseline – no values 
reported
< 0.011
ALS (nM) No actual values presented – only small diagram, which is hard to read 
accurately. Not data extracted
< 0.011
GHBP (pM) ns
GHBP SDS ns
Comments
10 healthy children (80% male; mean age 7.4 ± 2.7 years) provided serum samples for control values for IGFBP-2 and 
IGFBP-3 measurements.
Adverse effects
Not reported.
Methodological comments
Allocation to treatment groups: Randomised 1 : 2, no information on method of randomisation. Groups balanced for age, 
gender, height, GFR at baseline and nature of primary renal disease
Blinding: Open label.
Comparability of treatment groups: Free IGF-1 and insulin were statistically significantly higher in control group, otherwise 
groups were similar. 10 healthy children (80% male; mean age 7.4 ± 2.7 years) provided serum samples for control values 
for IGFBP-2 and IGFBP-3 measurements. Mean age for control children was approximately 2 years older than for the 
randomised children.
Method of data analysis: Not ITT. Data presented as mean ± SD but converted to log10 values for statistical analysis. 
ANCOVA used to test differences between groups; p ≤ 0.05 considered significant. Multiple regression analysis used to 
analyse effect of multiple variables on change in HtSDS, but not data extracted here.
Sample size/power calculation: Not reported, and primary outcome not clearly defined.
Attrition/dropout: 20 left (12 ESRF; six entered puberty; one allergic to rhGH; one drowned); four group 1 and one group 2 
completed study but were excluded as they had insufficient serum for the 0- and 12-month protein assays.
}
}
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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SGA data extraction forms
Reference and 
design Intervention Participants Outcome measures
Lagrou et al. 
2008110
Countries: 
Belgium and 
Luxembourg
Study design: 
RCT
Number of 
centres: 11
Funding: Belgian 
Study Group 
for Paediatric 
Endocrinology/
GH provided by 
Pfizer
1. GH 0.066 mg/kg/day
2. Untreated (did 
not receive placebo 
injections)
Duration of treatment: 2 
years
Other interventions used: 
none stated
Target population: prepubertal children 
born SGA
Number of participants: total: 40
1. 20
2. 20
Sample attrition/dropout: One treated 
patient dropped out due to family 
problems
Inclusion/exclusion criteria for study entry: 
birth weight and or length below –2 SD 
for gestational age, CA between 3 and 8 
years, current height below –2.5 SD, GV 
SDS below +1.0 SD during the last 6–18 
months
Exclusion criteria for study entry: gestational 
age < 34 weeks; endocrine disease, 
including GH deficiency; severe chronic 
disease; Turner, Noonan or Down 
Syndrome or other genetically confirmed 
syndromes; chromosomal abnormalities, 
bone disease, current or previous 
irradiation therapy, current or previous 
(up to 18 months before inclusion) 
treatment with glucocorticoids, severe 
mental retardation (IQ ≤ 50)
Primary outcomes: GV
Secondary outcomes: HtSDS, 
WtSDS, BMI SDS, head 
circumference SDS, perception 
of short stature (not data 
extracted), perception of 
changes in height and physical 
appearance (not data extracted), 
perceptions of changes in 
psychosocial functioning (not 
data extracted)
Method of assessing outcomes: 
standard auxological assessment 
of height, weight and head 
circumference measurements 
every 6 months, SDS calculated 
using British references, 
psychological assessments 
performed at start of study and 
after 2 years of follow-up (not 
data extracted)
Length of follow-up: 2 years
Characteristics of participants
Characteristic GH 0.066 mg/kg/day (n = 20) Untreated (n = 20)  p-value
Birth WtSDS –2.7 ± 0.9 –2.6 ± 0.8 ns
Gestational age 37.3 ± 2.1 38.2 ± 1.6 ns
Age (years) 5.5 ± 1.6 5.1 ± 1.3 ns
HtSDS –3.3 ± 0.6 –3.2 ± 0.9 ns
WtSDS –3.8 ± 1.3 –3.9 ± 1.4 ns
BMI (SDS) –1.7 ± 1.1 –2.0 ± 1.5 ns
Head circumference 
(SDS)
–2.7 ± 1.4 –2.8 ± 1.6 ns
Results (mean ± SD)
Outcomes GH 0.066 mg/kg/day (n = 20) Untreated (n = 19) p-value
HtSDS –1.9 ± 0.7 –3.1 ± 0.9 < 0.001
WtSDS –2.3 ± 1.2 –3.7 ± 1.5 < 0.01
BMI (SDS) –1.5 ± 1.1 –2.0 ± 1.5 ns
Head circumference 
(SDS)
–2.0 ± 1.4 –2.8 ± 1.5 < 0.05DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Adverse effects
Tolerance only discussed in terms of perceptions of the injection by parents and children. No AEs reported or discussed.
Methodological comments
Allocation to treatment groups: States randomised taking into account: gender, chronological age, WtSDS and study centre, 
no further details.
Blinding: No details given, untreated participants not given placebo injections.
Comparability of treatment groups: Authors report no differences in the auxological parameters between groups at baseline.
Method of data analysis: Differences of continuous variables between subgroups were evaluated by Students unpaired t-test 
or by the Mann–Whitney U-test as appropriate. The level of significance of difference was set at p < 0.05.
Sample size/power calculation: Based on 0.8 power to detect a significant difference (p = 0.05). 20 subjects in each group 
were required, assuming a difference of 2 cm/year in GV and a SD of 2.2 cm/year.
Attrition/dropout: One treated patient dropped out due to family problems. Data for untreated group is for 19 after 2 years, 
no explanation of this.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
Carel et al. 
2003111
Country: France
Study design: 
RCT
Number of 
centres: not 
stated
Funding: Sanofi–
Synthélabo
1. Daily GH injections: 
0.2 IU/kg/day (0.067 mg/
kg/day)
2. No treatment
Duration of treatment: 
Until reached AH. 
The mean duration of 
treatment was 2.7 ± 0.6 
years
Other interventions used: 
none stated
Target population: children born SGA
Number of participants: total 168
1. 112
2. 56
Sample attrition/dropout:
For treatment: group 1, n = 21; group 
2, n = 23
For analysis: group 1, n = 10; group 
2, n = 9
Inclusion criteria for study entry: birth 
length < –2 SDS for gestational 
age and term > 30 weeks; at study 
inclusion, height ≤ –2.5 for age or 
less; CA > 10.5 years for girls and 
> 12.5 years for boys; BA ≥ 9 years 
for girls and ≥ 10 years for boys; 
peak plasma GH concentration after 
pharmacological stimulation at least 
10 µg/l to exclude GH deficiency; 
Tanner stage I or II, with testicular 
volume < 8 ml or uterus length 
< 50 mm
Exclusion criteria for study entry: 
chromosomal abnormalities in girls; 
constitutional bone diseases, any 
chronic disease interfering with 
growth; steroid or sex steroid 
treatment; dysmorphic syndromes 
other than Russell–Silver; no catch-
up growth criteria were specified
Primary outcomes: AH SDS
Secondary outcomes: gain in SD units 
between height at inclusion and AH
Method of assessing outcomes: follow-
up visits were every 3 months for 
the treated group, and every 6 
months for the control group and 
the following data recorded: height, 
weight, CA, pubertal stage, dose and 
tolerance. BA analysed yearly. SDS 
calculation appears to be based on 
French registry study
Length of follow-up: criteria for 
stopping treatment/follow-up 
were < 1 cm growth over the last 
6 months, and a BA of ≥ 15 years 
for girls, and ≥ 16 years for boys. 
Only 4% of patients met this criteria 
when treatment was stopped, so 
authors considered treatments to 
be almost complete for analytical 
purposes if GV was 2 cm or less over 
the last 6 months, or BA was ≥ 13 
years for girls, and ≥ 15 years for 
boys. Patients who had discontinued 
follow-up before reaching AH 
were contacted later for a final AH 
measurement. Those who had not 
reached AH were maintained in the 
analysis without correction
Characteristics of participants
Characteristic
Daily GH injections: 0.2 IU/
kg/day (0.067 mg/kg/day) 
(n = 102) Untreated (n = 47) p-value
Target height –1.2 ± 0.9 –0.9 ± 1.0
Duration of pregnancy (weeks) 39 ± 2 39 ± 2
Birth length (SDS) –2.8 ± 0.8 –3.1 ± 1.0 < 0.05
Birth WtSDS –1.8 ± 0.8 –1.9 ± 0.8
Age (years) 12.7 ± 1.4 12.8 ± 1.6
Height (cm)
HtSDS –3.2 ± 0.7 –3.2 ± 0.6
WtSDS –1.9 ± 0.7 –2.2 ± 0.6
GV (cm/year)
BA (years) 10.6 ± 1.4 10.8 ± 1.6
Pubertal (Tanner stage II) (%) 22 21
Comments
Four patients had Russell–Silver syndrome. GV and height (cm) were not detailed for the groups as a whole, but for boys 
and girls within the group separately.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Results
Outcomes
Daily GH injections: 0.2 IU/
kg/day (0.067 mg/kg/day) 
(n = 91) Untreated (n = 33) p-value
At inclusion: age (years) 12.6 ± 1.5 12.9 ± 1.4
At inclusion: HtSDS –3.2 ± 0.6 –3.2 ± 0.6
At inclusion: height (cm) nr for whole group nr for whole group
At end of treatment: age (years) 15.7 ± 1.5 nr
At end of treatment: HtSDS –2.1 ± 1.0 nr
At end of treatment: height (cm) nr for whole group nr
At AH measurement: age (years) nr nr
At AH measurement: HtSDS –2.1 ± 1.0 –2.7 ± 1.0 0.005
At AH measurement: height (cm) nr for whole group nr for whole group
At AH measurement: total height 
gain (cm)
26 ± 7 22 ± 6 0.005
At AH measurement: total height 
gain (SDS)
1.1 ± 0.9 0.5 ± 0.8 0.002
At AH measurement: difference from 
target HtSDS
–0.9 ± 1.2 –1.7 ± 1.2 0.005
Comments
A difference of 0.6 SDS was observed in FH between the control and treated groups (95% CI 0.2 to 0.9). (A difference of 
0.4 was observed at baseline, unclear if this is accounted for in finding the 0.6 result significant.) The measurements above 
that have not been reported for the whole group are reported in the paper separately for boys and girls.
Adverse effects
Overall, 44% of treated patients reported AEs, 10% having 4 or more events. The most frequently reported events 
involved the respiratory system (19%), osteomuscular system (14%), central nervous system (9%), and digestive tract (8%). 
Authors state that all of these were mild, reversible, benign conditions that were unlikely to be related to GH treatment. 
16 AEs recorded in 14 treated patients were considered severe: trauma, psychiatric symptoms, abdominal symptoms, 
otitis, asthma, varicocele, striae, and migraine. Again, authors state that these are unlikely to be related to GH treatment 
– two were causally related to treatment: one slipped capital epiphysis after 1.5 years of treatment and had one single 
seizure episode 10 minutes after first injection.
Methodological comments
Allocation to treatment groups: Allocation sequence generated centrally and faxed to participants.
Blinding: Group assignment was not masked, and the treated group was twice as large as the control group.
Comparability of treatment groups: There is a significant difference in birth length between the treated and untreated groups, 
with the treated group being longer than the untreated group (p = 0.04). On other characteristics the groups appear to be 
broadly similar.
Method of data analysis: Means and SD values are presented. Mann–Whitney U-test to compare groups. An α risk of 5% 
was set as the significance threshold. Not ITT.
Sample size/power calculation: Not reported.
Attrition/dropout: Four patients in the treatment group were excluded from analysis due to severe diseases interfering with 
growth (sickle cell anaemia, pulmonary hypertension, type 1 neurofibromatosis and severe prematurity). Five patients 
assigned to the treatment group refused GH treatment but remained in the study and were analysed as part of the control 
group; 15 patients left the study early (14 in control and one in the treated group). Treatment was completed in 4/102 
patients and almost complete in 64/102. The reasons for interrupting treatment early were: growth rates considered 
insufficient by patient/physician (n = 12), weariness with the treatment (n = 10), loss to follow-up (n = 5), satisfaction with 
height (n = 2), local intolerance (n = 1), and striae attributed to the treatment by the patient (n = 1). In addition, some of 
the investigators wrongly considered that the treatment duration was limited to 3 years and stopped the treatment early 
(n = unclear). 102 treated and 47 control patients are included in the analysis. Authors state that group reassignments or 
protocol deviations concerned 12 and 5 patients followed to AH in the treated and control groups respectively. Appear 
to have been significant problems with attrition for various reasons, appears to be fully described. Group assignment was 
not blinded and, despite the study being randomised and centrally allocated, the treatment group is twice as large as the 
control: either this was 2 : 1 randomisation (this is not reported) or large numbers of the control group dropped out after 
randomisation, or possibly swapped to the treatment group: this is unclear.Appendix 4
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Inadequate
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Reference and 
design Intervention Participants Outcome measures
De Schepper 
et al. 2007109
Country: Belgium
Study design: 
RCT
Number of 
centres: eight
Funding: Belgian 
Study Group 
for Paediatric 
Endocrinology/
Pfizer
1. High-dose GH: 
66 ± 3 µg/kg s.c. once 
daily, adjusted every 6 
months to body weight
2. Untreated (did 
not receive placebo 
injections)
Duration of treatment: 2 
years
Other interventions used: 
none stated
Target population: children born SGA
Number of participants: total: 40 (25)
1. 11
2. 14
Sample attrition/dropout: The trial cohort 
was reduced from 40 to 25 based on the 
availability of the same absorptiometry 
apparatus to assess body composition 
in a homogeneous fashion across eight 
centres. No anthropometric differences 
were detectable between the study 
population and the non-included 
subcohort (authors state, no data 
reported)
Inclusion criteria for study entry: birth 
weight, length or both < –2 SD for 
gestational age, current height < –2.5 
SDGV < +1 SD in the last 6–18 months, 
age between 3 and 8 years at study start
Exclusion criteria for study entry: premature 
birth (gestational age < 34 weeks); 
evidence for endocrine or bone disease; 
severe chronic disease; Turner, Noonan, 
Down or other genetic syndrome; 
irradiation treatment; current or 
previous glucocorticoid treatment; 
severe cognitive dysfunction (est. IQ < 50)
Primary outcomes: none clearly 
stated
Secondary outcomes: HtSDS and 
WtSDS, anthropometric and 
absorptiometric characteristics
Method of assessing outcomes: 
study participants seen every 3 
months, height measured with 
Harpenden stadiometer, and 
weight with electronic scale. 
Mid-upper arm circumference 
and four skinfolds were 
measured at study start and 
after 1 and 2 years
Length of follow-up: 2 years
Characteristics of participants
Characteristic High-dose GH (GH) (n = 11)a Untreated (n = 14) p-value
Age (years) 5.1 ± 1.6 5.1 ± 1.4
Gestational age (weeks) 37 ± 3 38 ± 2
Birth WtSDS –2.4 ± 0.8 –2.5 ± 0.8
Birth length (SDS) –3.1 ± 0.6 –2.9 ± 0.7
Mid-parental heightb –0.9 ± 0.8 –0.8 ± 0.7
HtSDS –3.3 ± 0.7 –3.2 ± 1
WtSDS –3.5 ± 1.2 –3.6 ± 1.5
Subscapular skinfold (mm) 5.4 ± 1.1 6.4 ± 2.1
Triceps skinfold (mm) 7.9 ± 1.4 8.3 ± 2.1
Subscapular/triceps 0.7 ± 0.2 0.8 ± 0.2
Sum skinfolds (mm) 22.1 ± 3 24.3 ± 6
Body fat fraction (%) 12.9 ± 2.1 14.1 ± 3.6
MUAMA (cm) 12.8 ± 2.5 14.1 ± 3.5
MUAFA (cm) 5.5 ± 1.1 5.7 ± 1.7
Lean mass (kg) 10 ± 3 9.9 ± 2.2
FM (kg) 2.3 ± 0.5 2.5 ± 0.9
Lean mass (%) 78 ± 4 77 ± 5
FM (%) 15 ± 3 20 ± 5
Trunk fat (kg) 0.7 ± 0.3 0.8 ± 0.4Appendix 4
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Limb fat (kg) 1.1 ± 0.3 1.2 ± 0.5
Trunk fat/limb fat 0.6 ± 0.2 0.6 ± 0.2
Trunk fat/leg fat 0.8 ± 0.3 0.8 ± 0.3
MUAFA, mid upper arm fat area; MUAMA, mid upper arm muscle area.
a  Not significant for baseline comparisons between groups.
b  [Father’s HtSDS + mother’s HtSDS]/2.
Results
Outcomes
High-dose GH (GH) (n = 11)a Untreated (n = 14)
p-valuea 1 year 2 years 1 year 2 years
HtSDS –2.1 ± 0.7b –1.7 ± 0.7b,e –3.1 ± 1c –3 ± 1c < 0.0001
WtSDS –2.4 ± 1.3b –1.8 ± 1b,e –3.5 ± 1.4 –3.4 ± 1.6c < 0.0001
Subscapular skinfold 
(mm)
4.7 ± 0.8c 5.1 ± 1 5.7 ± 1.8c 6 ± 2.1 ns
Triceps skinfold (mm) 4.9 ± 1.5b 5.5 ± 2.1b 8.2 ± 2.3 7.9 ± 2.4 < 0.001
Subscapular/triceps 1 ± 0.3d 1 ± 0.3b,f 0.7 ± 0.2 0.8 ± 0.2i 0.001
Sum skinfolds (mm) 16.6 ± 3.4b 18.1 ± 5d 22.4 ± 5.8c 22.9 ± 6.8 < 0.005
Body fat fraction (%) 9.1 ± 2.1b 10.1 ± 3d 13.3 ± 3.5 13.4 ± 3.5 < 0.005
MUAMA (cm) 15.2 ± 2.9b 17 ± 2.7b,g 13.3 ± 2.3d 14.1 ± 2.9b,h < 0.005
MUAFA (cm) 3.6 ± 1.2b 4.3 ± 1.9d,h 5.8 ± 2 5.7 ± 1.9 0.001
Lean mass (kg) 13.2 ± 3.4b 15.5 ± 3.4b,e 10.9 ± 2.4b 12.2 ± 2.5b,e < 0.0001
FM (kg) 2.4 ± 0.7 2.9 ± 1c,g 2.8 ± 1.1c 3.1 ± 1.1b,h ns
Lean mass (%) 82 ± 3d 82 ± 3c 77 ± 6 77 ± 5 < 0.05
FM (%) 15 ± 3d 15 ± 2c 20 ± 6 20 ± 5 < 0.05
Trunk fat (kg) 0.9 ± 0.3 1 ± 0.3c 0.9 ± 0.5 1 ± 0.6b ns
Limb fat (kg) 0.9 ± 0.5 1.3 ± 0.7g 1.4 ± 0.6c 1.5 ± 0.6 < 0.05
Trunk fat/limb fat 1 ± 0.5d 0.9 ± 0.3d,f 0.6 ± 0.2 0.7 ± 0.2i < 0.0001
Trunk fat/leg fat 1.5 ± 0.7d 1.3 ± 0.4d,f 0.8 ± 0.3 0.9 ± 0.3i < 0.0001
Comments
a  Difference between untreated and treated group (analysis of variance) unclear if this is totals over the 2 years of the 
study, including baseline measurements.
b  p < 0.0005 paired t-test or Wilcoxon rank test@ baseline – year 1, baseline – year 2.
c  p < 0.05.
d  p < 0.005.
e  p < 0.0005 paired t-test or Wilcoxon rank test: year 1 – year 2.
f  Elevated for age.
g  p < 0.005.
h  p < 0.5.
i  Normal for age.
GH treatment was accompanied by a gain of lean mass (p < 0.0001) and by a centripetal redistribution of FM (p < 0.0001) 
but not by an overall gain or loss of FM. The effects of high dose GH on adiposity are not readily detectable in the trunk 
and are essentially limited to the limbs.
Adverse effects
Authors state that ‘none had a noteworthy adverse event during the 2 years of study’.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Methodological comments
Allocation to treatment groups: States randomised, no information reported on allocation to groups. Original trial cohort 
was 40, this was reduced to 25 due to availability of equipment.
Blinding: No information on blinding reported, untreated group did not receive placebo injections.
Comparability of treatment groups: Groups appear comparable at baseline – authors state there were no detectable baseline 
differences in the subgroups.
Method of data analysis: Results are expressed as mean ± SD. Repeated measures analysis of variance was used to test for 
differences between subgroups. The level of statistical significance was set at p < 0.05.
Sample size/power calculation: None reported.
Attrition/dropout: 15 children from the original cohort were withdrawn due to issues with availability of measuring 
equipment – unclear at what stage this happened. No dropouts are reported from the 25 included in the study, apart from 
this.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
de Zegher et 
al. 2002113
Countries: UK 
and Belgium
Study design: 
RCT
Number of 
centres: two
Funding: 
Pharmacia Ltd
1. High-dose GH 
(100 µg/kg/day)
2. No treatment
Duration of treatment: 2 
years
Other interventions used: 
None stated
Target population: short children born 
SGA
Number of participants: total 13
1. 9
2. 4
Sample attrition/dropout: nr
Inclusion criteria for study entry: birth 
weight/length < –2 SD for gestational 
age, current height < –3.0 SD, GV 
below 0.0 SD, age between 2 and 8 
years
Exclusion criteria for study entry: 
identified syndrome other than 
Silver–Russell
Primary outcomes: not clearly stated
Secondary outcomes: growth response 
and its relationship to pretreatment 
GH secretion (not data extracted) 
HtSDS, WtSDS, BMI SDS, GV (cm/
year)
Method of assessing outcomes: 
Overnight GH profiles and GH 
stimulation tests at baseline (not 
data extracted), intravenous glucose 
tolerance tests were performed at 
baseline, yearly on GH treatment 
and 3 months post GH treatment. 
Height, weights and BMI converted 
to age- and sex- adjusted SDS using 
current UK reference data
Length of follow-up: 2 years
Characteristics of participants
Characteristic
High-dose GH (100 µg/kg/day) 
(n = 9) No treatment (n = 4)  p-value
Age (years) 6.3 (4.0 to 8.0) 4.7 (2.3 to 6.3)
HtSDS –3.6 (–5.5 to –2.8) –3.1 (–3.4 to –2.8)
WtSDS –4.5 (–7.2 to –2.6) –3.8 (–5.5 to –2.7)
BMI SDS –2.3 (–5.0 to –0.7) –2.0 (–4.2 to –0.1)
GV (cm/year) 5.1 (4.0 to 6.8) 6.4 (5.3 to 7.5)
Results (means and ranges)
Outcomes
High-dose GH  
(100 µg/kg/day) (n = 9) No treatment (n = 4) p-value
Age (years) (year 1) 7.2 (5.0 to 8.8) 5.7 (3.3 to 7.3)
Age (years) (year 2) 8.2 (6.0 to 9.9) 6.5 (4.3 to 8.3)
HtSDS (year 1) –2.4 (–4.6 to –1.4)a –3.0 (–3.3 to –2.7)
HtSDS (year 2) –1.8 (–3.9 to –0.5)a –3.0 (–3.3 to –2.5)
WtSDS (year 1) –2.9 (–4.7 to –1.7)a –4.0 (–5.4 to –3.2)
WtSDS (year 2) –2.1 (–3.6 to –0.9)a –3.8 (–4.8 to –3.2)
BMI SDS (year 1) –1.6 (–3.8 to –0.8)a –2.3 (–3.9 to –1.3)
BMI SDS (year 2) –1.2 (–3.4 to –0.4)a –2.1 (–2.9 to –1.4)
GV (cm/year) (year 1) 11.0 (7.4 to 13.3) nr
GV (cm/year) (year 2) 8.5 (6.3 to 10.2) 5.6 (4.4 to 6.8)
Comments
a  p < 0.0001 from baseline.
Authors state that GH-treated children showed significant increments in HtSDS, WtSDS and BMI SDS over 2 years (all 
p < 0.0001). Untreated SGA children remained on their height, weight and BMI SD levels.
Glucose and insulin metabolism markers not data extracted as reported for the treated group, no results reported for 
controls. Authors state that compared to baseline levels, children in the treated group showed significant increases in 
fasting levels of insulin (year 1, p = 0.003; year 2, p = 0.0002) and decreases in insulin sensitivity (year 1, p = 0.003; year 2, 
p = 0.0002).
Adverse effects
Not reported/discussed. No child showed impaired glucose tolerance.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
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Methodological comments
Allocation to treatment groups: Randomised on a 2 : 1 basis, no further details.
Blinding: No details given. No placebo used.
Comparability of treatment groups: Groups appear similar.
Method of data analysis: Means and ranges are presented. Changes in height/weight, glucose and insulin parameters analysed 
using paired t-tests. ITT.
Sample size/power calculation: Not reported.
Attrition/dropout: Not reported.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Unknown
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Adequate
10. Were withdrawals and dropouts completely described? AdequateAppendix 4
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Reference and 
design Intervention Participants Outcome measures
de Zegher et 
al. 1996112
Country: Belgium
Study design: 
open-label RCT
Number 
of centres: 
multicentre
Funding: support 
from Pharmacia 
Peptide 
Hormones
1. GH 0.2 IU/kg/day s.c.
2. GH 0.3 IU/kg/day s.c.
3. Untreated
Duration of treatment: 2 
years
Other interventions used: 
None stated
Target population: children born SGA
Number of participants: total 54
1. 20
2. 21
3. 13
Sample attrition/dropout: group 1, n = 2; 
group 2, n = 1; group 3, n = 1
Inclusion/exclusion criteria for study 
entry: birth weight/length < –2 SD for 
gestational age, HtSDS for age < –2.5, 
GV SDS for age < +1, CA between 2 
and 8 years, serum GH concentration 
> 10 µg/l after exercise, glucagon or 
insulin tolerance test, available growth 
data concerning the period preceding the 
start of the study
Exclusion criteria for study entry: endocrine 
disorders, Turner or Downs syndrome, 
previous or concomitant irradiation or 
anabolic steroid therapy, severe chronic 
disease, severe mental retardation
Primary outcomes: not clearly 
stated
Secondary outcomes: height, 
HtSDS, GV, GV SDS, WtSDS, 
weight gain, BMI and BMI SDS, 
serum IGF-1, IGF-II, IGFBP-3, 
osteocalcin
Method of assessing outcomes: 
study visits including history, 
auxological evaluation, BA 
determination, and dose 
adjustment were scheduled 
every 6 months. Biochemical 
examinations were performed 
yearly. All BAs were read 
according to Tanner–
Whitehouse II method, HtSDS 
for BA was used as an index of 
FH prognosis
Length of follow-up: 2 years
Characteristics of participants
Characteristic
GH 0.2 IU/kg/day 
(n = 20)
GH 0.3 IU/kg/day 
(n = 19) Untreated (n = 13)  p-value
Birth weight (g) 2082.0 ± 139.0 1842.0 ± 115.0 1996.0 ± 136.0 ns
Birth length (cm) 42.3 ± 1.1 42.5 ± 0.9 42.1 ± 1.1 ns
Chronological age (years) 5.4 ± 0.5 5.1 ± 0.4 4.9 ± 0.5 ns
BA (years) 4.5 ± 0.5 3.7 ± 0.5 3.7 ± 0.5 ns
HtSDS –3.5 ± 0.2 –3.7 ± 0.2 –3.4 ± 0.3 ns
GV (cm/year) 6.6 ± 0.4 7.0 ± 0.5 6.7 ± 0.7 ns
GV SDS –0.9 ± 0.2 –0.7 ± 0.3 –0.6 ± 0.3 ns
Weight (kg) 13.2 ± 0.9 12.3 ± 0.7 12.0 ± 0.8 ns
WtSDS –2.5 ± 0.2 –2.9 ± 0.2 –2.8 ± 0.2 ns
BMI 14.0 ± 0.4 13.8 ± 0.4 13.5 ± 0.4 ns
BMI SDS –1.8 ± 0.4 –1.8 ± 0.3 –2.0 ± 0.4 ns
Serum IGF-1 (µg/l) 107.0 ± 15.0 108.0 ± 14.0 108.0 ± 21.0 ns
Serum IGF-2 (µg/l) 557.0 ± 44.0 748.0 ± 60.0 699.0 ± 103.0 ns
Serum IGFBP-3 (mg/l) 3.34 ± 0.33 3.36 ± 0.38 3.35 ± 0.38 ns
Serum osteocalcin (µg/l) 69.0 ± 3.0 69.0 ± 2.0 63.0 ± 3.0 ns
Results are mean ± SEM. The 52 participating children were considered to have no specific syndrome (n = 33), Silver–Russell 
syndrome (n = 10), fetal alcohol syndrome (n = 4), Dubowitz syndrome (n = 3), 4p- syndrome (n = 1) or lacrimo-auriculo-
dento-digital syndrome (n = 1).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Results
Outcomes at 2 years, 
unless otherwise 
stated
GH 0.2 IU/kg/day 
(n = 20)
GH 0.3 IU/kg/day 
(n = 19) Untreated (n = 13) p-value
Gain in BA (years) 1.35 ± 0.16 1.33 ± 0.24 0.84 ± 0.07 < 0.001 treated vs 
untreated
GV (cm/year) (year 1) 11.5 ± 0.4 12.0 ± 0.4 nr
GV (cm/year) 10.2 ± 0.2 11.0 ± 0.4 5.7 ± 0.3 < 0.001 untreated 
vs treated; < 0.05 
group 1 vs group 2
GV SDS (year 1) 5.3 ± 0.3 5.8 ± 0.4. nr
GV SDS 4.3 ± 0.3 5.2 ± 0.4 –0.9 ± 0.3 < 0.001 untreated 
vs treated
Gain in HtSDS 2.1 ± 0.1 2.5 ± 0.1 0.2 ± 0.1 < 0.001 untreated 
vs treated
Gain in HtSDS for BA 1.0 ± 0.2 1.2 ± 0.4 0.0 ± 0.3 < 0.05 untreated vs 
treated
Weight gain (kg) 6.9 ± 0.6 7.8 ± 0.5 3.6 ± 0.4 < 0.001 untreated 
vs treated
Gain in WtSDS 1.3 ± 0.1 1.8 ± 0.1 0.4 ± 0.1 < 0.001 untreated 
vs group 1; < 0.01 
group 1 vs group 2
Serum IGF-1 (µg/l) (year 
1)
274 ± 30 392 ± 43 145 ± 23 < 0.01 group 1 vs 
untreated; < 0.05 
group 1 vs group 2
Serum IGF-1 (µg/l) 332 ± 29 655 ± 69 168 ± 46 < 0.0001 group 
1 vs group 2; 
< 0.01 group 1 vs 
untreated
Serum IGF-II (µg/l) (year 
1)
745 ± 72 944 ± 101 756 ± 108
Serum IGF-II (µg/l) 834 ± 53 966 ± 56 881 ± 125 ns
Serum IGFBP-3 (mg/l) 
(year 1)
5.37 ± 0.42 6.35 ± 0.44 3.88 ± 0.48
Serum IGFBP-3 (mg/l) 6.10 ± 0.35 6.50 ± 0.52 4.00 ± 0.58 ns for group 1 vs 2; 
< 0.001 untreated 
vs group 1
Serum osteocalcin (µg/l) 
(year 1)
89.4 ± 5.9 93.6 ± 9.9 59.9 ± 1.9
Serum osteocalcin (µg/l) 100.0 ± 8.6 102.7 ± 9.8 72.5 ± 7.3 < 0.05 untreated vs 
group 1, ns group 1 
vs group 2
Comments
Results are mean ± SEM. Compliance: Over 2 years less than 10 injections were said to be missed in 36/38 children. In 
two children, respectively, 3% and 8% of the injections were reportedly omitted. Children with and without specified 
syndromes appeared to present similar growth responses. The GV during the first year was higher than during the 
second year, both in group 1 (11.5 ± 0.4 vs 8.8 ± 0.2 cm/year) and group 2 (12.0 ± 0.4 vs 10.0 ± 0.3 cm/year). After 2 years all 
untreated children still had a HtSDS < –2.2, whereas this was no longer the case for 35/38 treated children. BMI and BMI 
SDS remained similar in the three groups after 1 and 2 years. BMI of the study population is reported, not separately for 
the groups, or treated vs untreated. Fasting serum insulin concentrations were twice as high (p = 0.01) in treated children 
compared with untreated children both after 1 year (20.3 ± 2.2 mU/l vs 10.6 ± 2.4 mU/l) and 2 years (18.9 ± 3.0 mU/l vs 
9.4 ± 1.3 mU/l) with no difference between the treated groups.Appendix 4
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Adverse effects
Four SAEs, which authors state conceivably not related to GH. One treated child received antibiotics for possible 
osteomyelitis of the distal tibia. Three children hospitalised in relation to viral diseases: one untreated and two treated. 
Treatment was not interrupted. Cutaneous eczema was aggravated in one child in group 1, no treatment interruption. 
Three treated children reported a possible increase in size or number of pigmented naevi, treatment was not interrupted. 
After 2 years, all HbA1c values were normal.
Methodological comments
Allocation to treatment groups: Stated to be weighted randomisation, no further details.
Blinding: Open label. Assessor for BA blinded to chronological age and treatment randomisation.
Comparability of treatment groups: No significant differences at baseline.
Method of data analysis: Wilcoxon rank-sum test used for differences between groups for growth variables, and Student’s 
t-test for biochemical markers. Statistically significant differences were considered to be obtained at p < 0.05. Results are 
mean ± SEM. Not ITT. Paper does not mention if there were any adjustments for multiple comparisons.
Sample size/power calculation: None reported.
Attrition/dropout: Two children allocated to 0.3 IU/kg did not start. Two children dropped out of the study for psychosocial 
reasons, one control after the start visit and one child from group 1 after 19 months.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Partial
6.  Was the care provider blinded? Unknown
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? AdequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Data extraction form for primary studies
Reference and 
design Intervention Participants Outcome measures
Phillip et al. 
2009114
Country: 
multinational
Study design: 
RCT
Number 
of centres: 
multicentre
Funding: Novo 
Nordisk
1. rhGH 0.033 mg/kg/day
2. rhGH 0.1 mg/kg/day
3. Untreated
Duration of treatment: 
2 years, but data only 
extracted for year 1 as 
control group received 
rhGH in year 2
Other interventions used: 
none
Target population: 3- to 8-year-olds 
with persistent short stature, born 
SGA
Number of participants: total n = 15
1. n = 51
2. n = 51
3. n = 47
Sample attrition/dropout: n = 2
Inclusion/exclusion criteria for study 
entry: birth weight/length ≤ –2 SDS; 
HtSDS ≤ –2.5 SDS; GV SDS ≤ 0 
during last 3 months; parental height 
≥ –2 SDS; normal response to GH 
test
Primary outcomes: measurement of 
height during 2 years. Treatment 
effect was additional height gain 
compared with untreated children
Secondary outcomes: HtSDS, IGF-1, 
IGFBP-3, glucose, insulin
Method of assessing outcomes: 
Harpenden stadiometer; sex-
adjusted target height calculated 
based on national references; BA 
assessed using radiograph; HtSDS 
calculated using appropriate 
population references by country
Length of follow-up: 1 year
Characteristics of participants
Mean ± SD
rhGH 0.033 mg/kg/
day (n = 51)
rhGH 0.1 mg/kg/day 
(n = 51)
No treatment 
(n = 47) p-value
Sex (m/f) (%) 55/45 47/53 51/49 nr
Birth length (cm) 44.3 ± 5.3 44.6 ± 4.3 43.9 ± 5.0 nr
Birth weight (kg) 1.9 ± 0.6 2.0 ± 0.6 2.0 ± 0.6 nr
Gestational age (weeks) 36.9 ± 3.6 37.6 ± 3.3 37.5 ± 3.2 nr
Target HtSDS –0.9 ± 0.6 –0.8 ± 0.6 –0.9 ± 0.8 nr
Height (cm) 99.0 ± 9.3 98.9 ± 9.0 99.2 ± 7.9 nr
HtSDS –3.1 ± 0.5 –3.2 ± 0.7 –3.1 ± 0.5 nr
Age (years) 5.5 ± 1.5 5.5 ± 1.4 5.6 ± 1.4 nr
BA (years) 4.7 ± 1.8 4.9 ± 1.8 5.0 ± 1.9 nr
BA–CA 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 nr
IGF-1 (ng/ml) 116.7 ± 59.4 145.9 ± 92.3 130.0 ± 84.1 nr
IGFBP-3 (µg/l) 3.2 ± 0.9 3.5 ± 0.9 3.4 ± 1.1 nr
IGF-1 SDS –1.4 ± 0.6 –1.1 ± 0.9 –1.2 ± 1.0 nr
Fasting glucose (mmol/l) 4.6 ± 0.6 4.7 ± 0.6 4.6 ± 0.4 nr
Fasting insulin (µIU/ml) 3.1 ± 2.8 2.7 ± 1.9 2.8 ± 3.3 nr
HbA1c (%) 5.2 ± 0.4 5.2 ± 0.3 5.1 ± 0.4 nr
Results at year 1 (mean ± SD)
rhGH 0.033 mg/kg/
day (n = 51)
rhGH 0.1 mg/kg/day 
(n = 51) 
No treatment 
(n = 45) p-value
HtSDS –2.3 ± 0.6 –1.8 ± 0.8 –3.0 ± 0.6 nr
Change in HtSDS 0.8 ± 0.3 1.4 ± 0.4 0.1 ± 0.3 nr
Additional height gain 
(cm)
3.3 ± 0.2 (95% CI 2.9 
to 3.7)
6.5 ± 0.2 (95% CI 6.0 
to 6.9)
n/a nr
IGF-1 (ng/ml) 345.6 ± 177 594.3 ± 221 176.3 ± 107 nr
IGFBP-3 (µg/l) 4.8 ± 1.1 6.1 ± 1.4 3.9 ± 1.1 nr
IGF-1 SDS 0.9 ± 1.9 3.3 ± 2.1 –0.9 ± 1.2 nr
Fasting glucose (mmol/l) 4.8 ± 0.5 5.0 ± 0.5 4.8 ± 0.6 nr
Fasting insulin (µ IU/ml) 5.3 ± 3.5 8.9 ± 5.0 4.1 ± 6.3 nr
HbA1c (%) 5.3 ± 0.4 5.3 ± 0.2 5.2 ± 0.4 nrAppendix 4
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Adverse events
Only reported for overall 2-year study, so treatment arms are different (no control arm). The majority (349/358, 73.5%) 
of AEs were mild to moderate in severity, and the most common events (57%) were childhood infections. 16 SAEs were 
reported, three of which were likely to be related to rhGH (convulsions, epilepsy, papilloedema – all stabilised/resolved 
after rhGH discontinued).
Methodological comments
Allocation to treatment groups: Randomised 1 : 1 to double-blind treatment in the two rhGH groups or to a control group 
that was untreated in the first year and received rhGH in the second. A computer-controlled, centralised system was used 
to assign treatment.
Blinding: BA assessed centrally by clinicians blinded to subject’s characteristics (other than gender) and treatment.
Comparability of treatment groups: Similar at baseline, but no p-values reported.
Method of data analysis: Mixed-effects model (ANCOVA) used where effects of age, sex and treatment duration were 
included. Tests were two-sided F-tests, performed at the 5% significance level.
Sample size/power calculation: At least 50 patients per group were required to detect a difference in height gain of 0.75 cm 
between the two rhGH groups with a power of 90% and a significance level of 0.05. To allow for comparison with the third 
group, and allowing for a dropout rate of 20%, 180 patients were required to be enrolled.
Attrition/dropout: Two randomised patients missing from analysis. Reasons not given.
Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Adequate
2.  Was the treatment allocation concealed? Unclear
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Partial
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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SHOX deficiency data extraction forms
Reference and 
design Intervention Participants Outcome measures
Blum et al. 
200749
Countries: 
international 
(14)
Study design: 
RCT
Number of 
centres: 33
Funding: Eli Lilly 
& Co.
1. Daily s.c.i. of 50 µg GH
2. No treatment
3. Daily s.c.i. of 50 µg 
GH
Duration of treatment: 2 
years
Other interventions used:
Target population: prepubertal children 
with SHOX-D
Number of participants: total 68 patients 
had SHOX gene deletions or mutations, 
of which 52 with SHOX-D enrolled. 
A further 26 (group 3) with TS were 
enrolled as an additional GH arm
1. n = 27
2. n = 25
3. n = 26 (not data extracted as not per 
protocol)
Sample attrition/dropout: one
Inclusion criteria for study entry: confirmed 
SHOX-D; age ≥ 3 years; prepubertal 
(Tanner stage 1); height < 3rd percentile 
or < 10th percentile with HV < 25th 
percentile; BA < 10 years (boys) or 
< 8 years (girls); < 9 years (TS girls); 
no GH deficiency or resistance; no 
chronic disease; no growth-influencing 
medications
Primary outcomes: First year GV
Secondary outcomes: comparison 
between treatment effects in 
SHOX-D and patients with TS 
(not data extracted as not per 
protocol); AEs
Method of assessing outcomes: 
height, IGF-1 and IGFBP-3 
measured at baseline, 3 months, 
6 months, then at 6-month 
intervals for remainder of the 
2 years; left hand and wrist 
radiographs for BA performed 
at baseline, 1 year and 2 year – 
assessed centrally using Greulich 
and Pyle method; glucose 
and routine blood analysis at 
baseline and first year. HtSDS 
calculated using a central 
European reference
Length of follow-up: 2 years
Characteristics of participants (mean ± SD, unless otherwise stated)
Characteristic
SHOX-D
p-value, 
group 1 vs 
group 2
Group 1: 50 µg GH 
(n = 27)
Group 2: no treatment 
(n = 25)
Complete deletion of SHOX gene (n) 18 16
Partial gene deletions (n) 2 2
Point mutations (n) 7 7
Female/male (%) 52/48 56/44
LWS/ISS phenotype (%) 56/40 44/56 0.689
Chronological age (years) 7.5 ± 2.7 7.3 ± 2.1 0.914
BA (years) 6.6 ± 2.8 6.5 ± 2.0 0.928
BA–CA –1.0 ± 0.9 –0.8 ± 0.8 0.809
BA SDS –1.2 ± 1.1 –1.0 ± 1.0 0.641
HtSDS –3.3 ± 1.0 –3.3 ± 0.8 0.111
Target HtSDS –1.3 ± 1.0 –1.5 ± 0.9 0.013
BMI SDS 0.2 ± 0.9 0.6 ± 0.9 0.147
IGF-1 SDS –0.8 ± 1.0 –0.9 ± 1.0 0.521
IGFBP-3 SDS 0.6 ± 1.3 0.1 ± 1.1 0.058
ISS, idiopathic short stature; LWS, Léri–Weill syndrome.Appendix 4
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Results (mean ± SD, unless otherwise stated)
Outcome
SHOX-D p-value 
group 1 vs 
group 2 Group 1: 50 µg GH Group 2: no treatment
Baseline HV (cm/year) 4.8 ± 0.3 (n = 18) 5.0 ± 0.5 (n = 14) 0.721
Baseline HV SDS –1.2 ± 0.3 (n = 12) –1.0 ± 0.6 (n = 10) 0.605
Baseline HtSDS –3.3 ± 0.2 (n = 27) –3.2 ± 0.2 (n = 24) 0.822
1st-year HV (cm/year) 8.7 ± 0.3 (n = 27) 5.2 ± 0.2 (n = 24) < 0.001
1st-year HV SDS 3.0 ± 0.3 (n = 25) –0.7 ± 0.2 (n = 22) < 0.001
1st-year HtSDS –2.6 ± 0.2 (n = 27) –3.1 ± 0.2 (n = 24) < 0.001
2nd-year HV (cm/year) 7.3 ± 0.2 (n = 27) 5.4 ± 0.2 (n = 24) < 0.001
2nd-year HV SDS 2.3 ± 0.3 (n = 27) –0.4 ± 0.1 (n = 22) < 0.001
2nd-year HtSDS –2.1 ± 0.2 (n = 27) –3.0 ± 0.2 (n = 24) < 0.001
2nd-year height gain (cm) 16.4 ± 0.4 (n = 27) 10.5 ± 0.4 (n = 24) < 0.001
Catch-up of BA 1.34 ± 0.07 1.1 ± 0.09 0.161
AEs
SHOX-D
p-value 
group 1 vs 
group 2
Group 1: 50 µg GH 
(n = 27)
Group 2: no treatment 
(n = 25)
At least 1 treatment-emergent AE 
(mostly common childhood illnesses) 
(%)
85 68
Arthralgia 3 2
Gynecomastia (males) 1 (n = 12 males) 0 (n = 12 males)
Increased number of cutaneous naevi 2 0
Recurrent otitis media 1 1
Scoliosis 1 0
Diabetes 0 0
Comments
Overall, 41% of GH-treated patients with SHOX-D reached a height within the normal range for age and gender (> –2.0 
SDS), compared with only one patient in the control group. For the GH-treated patients with SHOX-D, 1st year GV was 
somewhat greater for males (9.3 ± 0.5 cm/year) than for females (8.4 ± 0.5 cm/year), the baseline to second-year change 
in GV was very similar. Subgroup analysis for ISS phenotype vs LWS phenotype presented but not data extracted as not 
per protocol. IGF-1 SDS were in the low-normal range in each of the study groups at baseline and remained there for the 
untreated group. In the GH-treated group, values increased to the upper-normal range. IGF-1 concentrations exceeded 
two SDS at least once during GH treatment in 10 (37%) of patients and no untreated patients. IGFBP-3 SDS at baseline 
were closer to the normal mean than the corresponding IGF-1 SDS in both study groups and increased to the upper-
normal range in the treated group. There was a strong relationship between IGF-1 SDS and IGFBP-3 SDS values during 
GH treatment, such that no subject had an IGF-1 SDS in the upper tertile with an IGFBP-3 SDS in the lower tertile. No 
significant changes in thyroid function. No SAEs were reported for subjects with SHOX-D.
Methodological comments
Allocation to treatment groups: After stratification by sex and according to presence or absence of LWS, patients were 
randomised on a 1 : 1 basis. No further details given.
Blinding: Blood analyses were carried out in a central facility. Open label.
Comparability of treatment groups: Similar at baseline, although target HtSDS is statistically significantly lower in the rhGH 
group.
Method of data analysis: HtSDS calculated using a central European reference.
Sample size/power calculation: Not reported.
Attrition/dropout: One subject who discontinued with no postbaseline height data was excluded from the efficacy analyses; 
all patients were included in the safety analyses. ANOVA used for between-group differences.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Quality criteria for assessment of experimental studies
1.  Was the assignment to the treatment groups really random? Unknown
2.  Was the treatment allocation concealed? Unknown
3.  Were the groups similar at baseline in terms of prognostic factors? Reported
4.  Were the eligibility criteria specified? Adequate
5.  Were outcome assessors blinded to the treatment allocation? Partial
6.  Was the care provider blinded? Inadequate
7.  Was the patient blinded? Inadequate
8.  Were the point estimates and measure of variability presented for the primary 
outcome measure?
Adequate
9.  Did the analyses include an ITT analysis? Inadequate
10. Were withdrawals and dropouts completely described? InadequateDOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Appendix 7  
List of ongoing studies
Searches identified two relevant 
RCTs, which are ongoing
Study NCT00190658 aims to compare the mean 
first-year GV of somatropin-treated prepubertal 
patients with SHOX-D with the GV of a control 
group of untreated prepubertal patients with 
SHOX-D. Both groups will be compared to a 
somatropin-treated group of girls with TS.
•  Sponsor: Eli Lilly & Co.
•  Estimated end date: December 2010.
Study NCT00625872 focuses on the effect of a 
1-year somatropin treatment (0.035 mg/kg/day 
or 0.067 mg/kg/day) on neuromuscular function 
and cognitive performance in short children 
born SGA. Height gain and GV are included as 
secondary outcome measures. Inclusion criteria are 
birth length- and/or birth weight-SDS adjusted to 
gestational age < –2.0, current HtSDS < –2.5 and 
parental adjusted HtSDS below –1, GV SDS < 0 
during the last year before inclusion.
•  Sponsor: Pfizer.
•  End date: not reported.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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S
ix of the seven manufacturers submitted reports 
to NICE, and these are briefly appraised below. 
Please see Chapter 4 (Review of the manufacturers’ 
submissions) for a discussion of the economic 
models and results included in the MSs.
SHTAC review of clinical 
effectiveness in Eli Lilly’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  The MS uses the Novo Nordisk systematic 
review, which did not include SHOX. The 
MS states (p. 13) that the evidence for SHOX 
came from Lilly’s databases, i.e. there was 
no systematic review for this. The conditions 
listed as inclusion criteria for SGA include 
IUGR, which was not in the NICE scope. 
The comparator was clearly stated to be ‘no 
treatment’. However, the inclusion criteria also 
state that active-controlled RCTs were included. 
This is then contradicted by the exclusion 
criteria, which state that studies comparing 
somatropin with other treatments known or 
presumed to affect growth would be excluded.
•  The MS clearly reports search dates, search 
strategies and databases searched.
•  Enough detail was provided for the searches to 
be reproducible.
•  The MS does not present information on 
searches for ongoing studies.
•  Conference proceedings were excluded from 
the review.
•  The MS includes a separate search for QoL 
data in adolescents and adults.
Searches identified
The MS contains a summary of the included trials, 
but there is no tabulation of details such as study 
type, treatment arms, etc. The review included the 
following RCTs:
•  GHD  Five placebo/no treatment-controlled 
RCTs (mostly during transition phase): 
Jorgensen 2002 (excluded by SHTAC as 
mean age = 20), Underwood 2003 (excluded 
by SHTAC as mean age = 23.8), Drake 2003, 
Shalet 2003 and Mauras 2005 (all excluded 
by SHTAC as patients had completed linear 
growth). The manufacturer included six other 
studies that were either dosing studies or 
compared two different versions of somatropin.
•  TS  Nine RCTs (three placebo controlled: 
Gravholt 2002, 2005; Quigley 2002; all 
included by SHTAC) and six other studies 
[Bannick 2006, van Pareren 2003, Sas 2001 
(all excluded by SHTAC as dose studies), 
Davenport 2007, Johnston 2001, CGHAC 2005 
(all included by SHTAC)].
•  CRI  Four CTs: de Graaf 2003 (SHTAC 
excluded as this is analysis of body proportions 
in an RCT that we have already included for 
height and body composition outcomes – 
Hokken Koelega 1991), Hertel 2002 (SHTAC 
excluded as compares two doses, no placebo 
arm), Sanchez 2002 (included by SHTAC), Fine 
2002 (SHTAC excluded as includes pubertal 
children, with no separate data analysis).
•  SGA  Twenty RCTs identified, of which six 
had placebo or no treatment as control arm 
[Boguszweski 1998, Butenadt 1997, Arends 
2003 2004, Boonstra 2006 (SHTAC excluded 
these as patient group did not meet our 
criteria), van Pareren 2003 (SHTAC excluded 
as this is a follow-up of a dose–response study)].
•  PWS not relevant for this drug.
•  SHOX  not included in systematic review. 
Reported data comes from the GDFN study 
(n = 78), Blum et al. 2007 (SHTAC included 
this).
•  None of the additional studies met SHTAC’s 
inclusion criteria.
Clinical analysis
•  The MS also reports observational studies, in 
particular data from the KIGS database.
•  Given that the manufacturer included a range 
of studies that did not meet SHTAC’s inclusion 
criteria, it is not possible to compare their 
conclusions with those of SHTAC.
•  The MS did not include a meta-analysis or 
indirect comparison.
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•  The MS includes a short narrative summary 
of the included trials for each disease, but 
there is no overall tabulation of the included 
studies’ characteristics or results and no quality 
assessment of the trials.
•  The MS uses the same outcome measures as 
the SHTAC review.
•  The MS reports more detail on AEs from 
observational studies in addition to the limited 
information available in the RCTs.
Interpretation
•  The MS does not present any tabulated data 
from the studies included in the systematic 
review; there is simply a short narrative 
summary of each disease. It is therefore 
not possible to assess whether or not the 
manufacturer’s analysis is supported by data in 
the included trials.
Key issues
•  The manufacturer’s systematic review included 
a broad range of studies, for example dosage 
studies, which did not meet their own inclusion 
criteria.
•  Very little detail is presented for the 
included studies (e.g. patient characteristics, 
treatment arms, length of study) and there 
is no tabulation of data. The manufacturer’s 
conclusions seem to be based on both trials 
that met their inclusion criteria and those that 
clearly did not (e.g. dosage studies).
SHTAC review of clinical 
effectiveness in Novo Nordisk’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  Databases searched and the dates of searches 
are specified. Searches were conducted from 
the date of the original NICE appraisal – w/c 
28 August 2008, and from 1996 to w/c 28 
August 2008 for SGA (not included in the last 
review).
•  Search strategies are supplied in the 
appendices.
•  Search strategies are detailed and appear 
reproducible.
•  Novo Nordisk does not appear to have 
searched for other ongoing studies, but do 
report on two ongoing studies, specifically of 
Norditropin – NESGAS and NordiNet IOS.
•  Conference proceedings were not searched for 
and are listed in the exclusion criteria.
Clinical analysis
•  Novo Nordisk did not include PWS or SHOX. 
Uncontrolled trials were included. For long-
term effects of rhGH treatment, i.e. FH/AH/
near adult height, open-label extension studies 
were ‘deemed to be appropriate as the length 
of the RCTs was likely to be too short to capture 
the long term treatment effect’. Dose–response 
trials have been included. In the case of SGA, 
these form the majority of the submission.
•  SGA  Novo Nordisk have included 21 studies. 
None of these was included in SHTAC’s 
MTA. Exclusions in the SHTAC MTA were 
on the basis of patient group not meeting the 
inclusion criteria or on design, as 14 of the 21 
were dose–response studies. The five studies 
included in our MTA were not included in the 
Novo Nordisk submission. Novo Nordisk also 
included open-label extension studies.
•  GHD  Novo Nordisk have included 13 studies. 
One of these is the GHD study included in 
SHTAC’s MTA. Eight are transition-phase 
studies – these are not included in SHTAC’s 
systematic review. Four are dose–response 
studies and therefore are excluded from the 
MTA. Two are biosimilars compared with their 
reference product.
•  TS  Novo Nordisk discuss the Turner Cochrane 
Review. A total of 23 studies were included, 
including the six included in SHTAC’s MTA. 
The remaining studies were dose response, 
with the exception of one, which compared 
once-daily versus twice-daily injections.
•  CRI  Novo Nordisk have included nine studies, 
five of which were included in SHTAC’s MTA. 
Of the four excluded from the MTA, two were 
dose–response studies, one was excluded on 
patient group.
•  Nothing in the excluded reasons indicates 
why all of SHTAC’s included SGA papers are 
excluded.
Conclusions
•  SGA  It is not possible to compare the 
conclusions as the studies included in the two 
reviews are so different.
•  GHD  Again the conclusions are difficult to 
compare as Novo Nordisk include transition 
phase studies, which SHTAC excluded from 
the main systematic review as patients had 
completed linear growth; dose–response 
studies; and studies comparing biosimilars 
to their reference drug. Novo Nordisk’s 
conclusions tend to be based on dose–response DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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studies, and how far an outcome/result is dose 
dependent.
•  TS  Novo Nordisk concludes that height is 
improved in a ‘dose-dependent’ manner: The 
SHTAC MTA does not include dose–response 
studies or consider dose issues. SHTAC has 
concluded that there is evidence of improved 
body composition and height outcomes in girls 
with TS; this needs to be weighed against issues 
of quality of reporting and size of trials.
•  CRI  Height conclusions are dose related, 
and body composition ‘does not appear to be 
negatively influenced by rhGH therapy’.
•  Outcome measures are broadly similar.
•  Additional AE rates from KIGS and NCGS 
databases are included in an appendix.
Interpretation
•  SGA  Conclusions do not appear to fully reflect 
Novo Nordisk’s analyses, although the analysis 
contains few results and is a broad summary 
in itself. Very few of the points discussed in 
the analyses compare treated and untreated 
groups, predominantly focusing on dose–
response or differences in the treated group 
from baseline.
•  TS  Apart from height outcomes, few results 
are reported and, again, the focus is often on 
dose-related effects. The summary somewhat 
overstates the evidence presented.
•  CRI  Conclusions do appear to match analyses, 
although again few detailed results are 
presented. Novo Nordisk does not comment 
on the quantity/quality of research available to 
support their conclusions.
•  GHD  Novo Nordisk considered transition-
phase studies alongside non-transition phase 
studies for height and other outcomes, but 
separately for biochemical/body composition 
markers. The authors then summarise that 
the transition phase studies may lead to an 
underestimation of growth in children with 
GHD. Other conclusions appear to match the 
analyses.
•  Quality is discussed to a degree in the results 
sections – it is mentioned, for example, if trials 
are short, or low in patient numbers. However, 
this, or its possible effects on conclusions/
findings, is not referred to in the summary.
Key issues
•  The submission does not include the SGA 
papers included in SHTAC’s review, but does 
include studies whose patients do not meet 
the birth length/WtSDS criteria and/or current 
HtSDS criteria included.
•  Dose–response studies are included for all 
conditions.
SHTAC review of clinical 
effectiveness in Pfizer’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  The manufacturer supplied full details of 
the systematic review, specifying dates and 
databases searched.
•  Search strategies were supplied.
•  Enough detail was provided for the searches to 
be reproducible.
•  Inclusion criteria differed from that used by 
SHTAC in that cohort, observational, and 
retrospective studies were included. The 
manufacturer’s inclusion criteria defined 
children as being < 16 years old, whereas 
SHTAC included those up to 18 since they 
may still be growing and thus able to benefit 
from rhGH treatment. The manufacturer did 
not specify what the comparator should be 
(NICE’s final scope indicates that this should 
be treatment without somatropin).
•  The manufacturer restricted the review to 
only those studies which used Genotropin, 
or were sponsored by Pfizer. They excluded 
studies which used a competitor’s brand of 
somatropin. However, they also report the 
results of the Novo Nordisk full systematic 
review – see SHTAC assessment of the Novo 
Nordisk MS for more details.
•  The MS does not report ongoing studies.
•  The MS does not state whether or not they 
searched for conference proceedings.
Searches identified (studies for 
Genotropin)
•  GHD  Three RCTs and 17 observational 
studies. None of the three RCTs met our 
inclusion criteria. Coelho et al. (2008) 
compared two doses of Genotropin; Romer 
et al. (2007) compared omnitrope with 
Genotropin; Dorr et al. (2003) compared 
Genotropin delivered via two different devices.
•  TS  One RCT and eight observational studies: 
the single RCT by Johnston (2001) was also 
included in the SHTAC review.
•  PWS  Twelve RCTs (three from previous 
appraisal) and six observational studies. 
One of these (Festen 2007) is not included Appendix 8
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in our review as it is not a fully randomised 
study (children were stratified by age, and 
only the under-12s were randomized – older 
children were all given rhGH, but results were 
not reported separately for the randomised 
patients). Two of the studies included by the 
manufacturer have been combined by SHTAC, 
as they report data from the same RCT [Festen 
et al. 2008 and de Lind van Wijngaarden 2009 
(cited as Roderick et al. 2009 in the MS)].
•  CRI  No new RCTs, three observational studies. 
The submission discusses only the Broyer 
study from the previous review, and not the 
others that SHTAC included as these were not 
observing Genotropin.
•  SGA  Thirteen RCTs, 10 observational studies. 
Of the 13 RCTs, only five reported treatment 
versus no treatment/placebo. SHTAC excluded 
the review by Lagrou (2007) as its outcomes 
did not meet our inclusion criteria. We also 
excluded the reviews by Bundak (2001) and 
Carracosa (2006) as their patient groups did 
not match our criteria. We included the De 
Schepper (2008) study and the de Zegher 
(2002) studies.
•  None of the manufacturer’s included studies 
reported QoL as an outcome measure.
•  The MS also includes a summary of the Novo 
Nordisk systematic review. Please see SHTAC’s 
appraisal of that submission for further details.
Clinical analysis
•  The manufacturer has only included RCTs 
of its own brand of somatropin, so it is not 
possible to compare their findings directly with 
those of SHTAC.
•  GH and SGA RCTs  The MS and SHTAC 
reviews included different RCTs, so it is not 
possible to compare the evidence reported. 
The RCTs included for GHD were not placebo/
no treatment controlled.
•  PWS  The MS includes two studies (Roderick et 
al. 2009 and Festen et al. 2008), which appear 
to be the same RCT – SHTAC has treated these 
as one RCT to avoid double-counting.
•  Given that the manufacturer included a range 
of studies that did not meet SHTAC’s inclusion 
criteria, and focused only on studies of their 
own product, it is not possible to compare their 
conclusions directly with those of SHTAC.
•  The MS did not include a meta-analysis or 
indirect comparison. Results are presented 
in tables and there is a narrative synthesis for 
each disease area.
•  The MS uses the same outcome measures as 
the SHTAC review.
•  The MS includes data from the KIGS database, 
which is not included in the SHTAC review of 
clinical effectiveness as it is observational data. 
Additional adverse event data from the KIGS 
database is presented on p. 97 of the MS.
Interpretation
•  The manufacturer’s interpretation of the 
clinical data in the RCTs matches their 
analyses.
•  There are separate sections discussing the 
results of RCTs and of observational studies.
•  Data from observational studies have not been 
checked by SHTAC.
Key issues
•  The manufacturer’s systematic review included 
dose comparison studies for GHD, which 
SHTAC excluded.
•  Many of the studies included for the 
manufacturer’s review of SGA studies were 
excluded by SHTAC, as their patients did not 
meet our inclusion criteria.
SHTAC review of clinical 
effectiveness in Merck Serono’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  The MS uses the SHTAC review conducted in 
20026 and the systematic review conducted by 
Novo Nordisk for studies published since then 
(see Novo Nordisk critique) for the licensed 
indications for Saizen (GHD, TS, CRI and 
SGA).
Searches identified
•  Studies identified and reported are all those 
from the previous SHTAC report (RCTs and 
non-RCTs reporting FH) plus RCTs published 
since then identified by the Novo Nordisk 
review.
•  GHD  No additional RCTs were reported for 
GHD although an additional one is included in 
the SHTAC MTA (Mauras 2005).
•  TS  4 RCTs (Johnston 2001; CGHAC 2005; 
Quigley 2002; Davenport 2007). However, the 
MS did not identify two RCTs included in the 
SHTAC MTA (both Gravholt 2005).
•  CRI  Three RCTs (de Graaf 2003; Fine 2002; 
Sanchez 2002). Two of these (de Graaf and 
Fine) are not included in the SHTAC MTA 
review because they do not meet our inclusion 
criteria. One RCT (Fine 2004) is not included DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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in the MS but meets the SHTAC MTA inclusion 
criteria and is therefore included in that.
•  SGA  Four RCTs (Buttenandt 1997; 
Boguszewski 1998; Arends 2004; Van Pareren 
2003). These do not match the studies 
identified in the SHTAC MTA (from which they 
are excluded on the basis of patient group and 
study design).
•  The MS does not identify any RCTs that meet 
the inclusion criteria of the SHTAC MTA that 
are not already included.
Clinical analysis
•  Evidence reported is broadly similar to the 
SHTAC MTA in that it uses RCTs in the 
original SHTAC report; there are some 
discrepancies on RCTs since that time and on 
the extra indication SGA.
•  Narrative synthesis is somewhat selective. All 
included studies are tabulated, but only height 
results are reported.
•  Manufacturer’s submission also includes some 
non-systematic review data on psychological 
outcomes and body composition, and long-
term data from the KIGS observational 
database.
•  Conclusions are generally similar to the 
SHTAC MTA.
•  GHD  The MS has used the previous SHTAC 
review so conclusions on growth are similar but 
no data on LBM/biochemical markers.
•  TS  Conclusions are broadly similar to the 
SHTAC MTA in terms of growth and LBM.
•  CRI  Conclusions broadly similar to the SHTAC 
MTA in terms of growth; no statement on other 
outcomes.
•  SGA  Conclusions broadly similar to the 
SHTAC MTA in terms of growth; no statement 
on other outcomes.
•  Growth outcomes measures are same as the 
SHTAC MTA.
Interpretation
•  Overall MS interpretation of the clinical data 
matches the MS analyses, although the MS 
relies heavily on the previous SHTAC report. 
The new evidence is not really synthesised 
except for SGA, which includes studies that are 
not in the SHTAC MTA. Conclusions are based 
on selective statements and focus on height 
outcomes.
•  Manufacturer’s submission states that new data 
has ‘not materially changed the understanding 
of the efficacy of GH in children’.
Questions
•  The major areas of discrepancy compared with 
the SHTAC MTA relate to studies omitted from 
the MS (GHD 1, TS 2, CRI 1 and SGA 5).
SHTAC review of clinical 
effectiveness in Ipsen Ltd’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  The databases and dates searched are specified.
•  Search strategies were supplied and appear 
comprehensive enough to be reproducible.
•  Ongoing studies were not searched for or 
reported in this submission.
•  Conference proceedings were excluded.
•  This review includes CRI, GHD and TS, 
and ‘somatropin’ as intervention, including 
products from other manufacturers, and 
published and available in full studies in the 
English language. Exclusion criteria given but 
reasons for individual studies’ exclusions not 
stated.
•  Assessment of article quality looks at 
allocation concealment, patient blinding, 
investigator blinding, baseline differences of 
the experimental groups and ‘completeness 
of follow-up’. The MS did not appear to assess 
if there was an ITT analysis, or care-provider 
blinding.
Clinical analysis
•  For the results of the systematic review, we are 
referred to the submission prepared by Novo 
Nordisk. Studies are not referenced in the text. 
No conclusions in this submission, apart from 
on the limitations of RCTs for FH data, and 
the subsequent need to rely on observational 
studies (i.e. KIGS database) for this. The 
number of studies for each condition reporting 
certain outcomes is given, but the results are in 
the Novo Nordisk submission and not detailed 
in the Ipsen submission.
•  Manufacturer has included 11 GHD studies; 
most appear to be transition-phase studies.
•  MS states that nine TS studies were found.
•  MS states that four CRI studies were found.
•  Limited new data on FH from RCTs, so appear 
to have included observational studies for this 
outcome. However, no references are given in 
the text so cannot check.
•  The MS states that ‘there are limited data 
available on the effect of GH on height in Appendix 8
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RCTs [therefore] use of observational data from 
… KIGS was appropriate.’ This appears to have 
been used to inform the economic model.
•  A ‘rapid appraisal of the literature’ was 
undertaken by Eli Lilly for QoL ‘impact of 
short stature in adults’ due to lack of data on 
children and QoL.
•  No conclusions stated here: referred to Novo 
Nordisk submission.
•  There are no indirect comparisons included 
here.
•  No outcome results are reported here, but 
those outcomes reported in the included 
studies reflect those in the SHTAC review.
•  GHD  Four out of eight studies reporting AE 
‘found that a higher dose was associated with 
a greater incidence of AEs and/or serious AEs’. 
The remaining studies reported no differences 
between groups. Only one study in the SHTAC 
review reported AEs, with a slightly higher 
percentage in the GH group experiencing 
these. Only one event in each group was 
thought to be study drug related: oedema in 
GH and sluggishness in placebo. MS reports 
AEs that are thought to be related to study 
drug.
•  CRI  Three studies in the MS report AEs: 
one study reported a higher number of SAEs 
related to GH therapy compared with no 
treatment; another study reported SAEs that 
were ‘therapy-related’. SAEs related to therapy 
reported here include diabetes mellitus, 
hypertension and injection pain. This is not 
reflected in the studies included in SHTAC 
review. Difficulty with comparisons as there are 
no references in the text.
•  TS  A greater incidence of AE in the GH 
group was reported in two out of four studies 
reporting AEs in the SHTAC review. In the MS, 
one study showed GH to be associated with 
‘greater incidence of treatment emergent AEs’. 
No major differences between the groups were 
found in the other studies in the MS.
•  No references are given for these studies and 
AEs, and no proportions/means are reported – 
just these general results.
Interpretation
•  No interpretation included here – referred to 
the Novo Nordisk submission.
Key issues
•  Inclusion of observational data to inform FH 
differs from SHTAC review.
•  Studies not referenced here – cannot cross-
check with SHTAC review. See Novo Nordisk 
submission for further details.
SHTAC review of clinical 
effectiveness in Sandoz’s 
submission
Comprehensiveness of ascertainment of 
published studies
•  The submission did not include a systematic 
review, so there were no details of search 
strategies, databases or dates searched.
Searches identified
•  The MS includes details of two phase III 
studies: AQ-study and LYO-study. Neither 
meets SHTAC’s inclusion criteria; AQ-study 
compares different doses of omnitrope with 
a reference product and LYO-study is a non-
comparative trial.
Clinical analysis
•  The evidence reported in the Sandoz 
submission is from trials specific to their 
biosimilar product. The submission does not 
include any trials of rhGH versus no treatment. 
It is therefore not possible to compare their 
submission with the evidence presented in the 
SHTAC systematic review.
•  The submission uses the same outcome 
measures as the SHTAC review.
•  The submission includes a summary of AEs 
from the AQ-study and the LYO-study, neither 
of which was included in the SHTAC review. 
The manufacturer stated that the safety 
profiles of omnitrope and Genotropin were 
comparable.
Interpretation
•  The manufacturer’s interpretation of the 
clinical data matches their analyses.
Key issues
•  The manufacturer presents evidence for 
the use of omnitrope compared with other 
somatropin formulations, but does not present 
any information for its effectiveness compared 
with no treatment. The included studies did 
not meet SHTAC’s inclusion criteria.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Appendix 9  
Critical appraisal of manufacturers’ 
economic evaluation
TABLE 61  Critical appraisal checklist of economic evaluation (questions in this checklist based on Drummond and Jefferson, the NICE 
reference case, and the ISPOR checklist)
Item MSa
1 Is there a well-defined question? Yes
2 Is the patient group in the study similar to those of interest in UK NHS? Yes
3 Is the correct comparator used that is routinely used in NHS? Yes
4 Is the study type and modelling methodology reasonable? Yes
5 Is an appropriate perspective used for the analysis? Yes
6 Is the health-care system or setting comparable to UK? Yes
7 Is the effectiveness of the intervention established based on a systematic review? No
8 Is the model structure appropriate and does it fit with the clinical theory of the disease 
process?
Yes
9 Are assumptions reasonable and appropriate? Yes
10 Are health benefits measured in QALYs using a standardised and validated generic instrument 
from a representative sample of the public?
Yes
11 Are the resource costs used reasonable and appropriate for the NHS? Yes
12 Are the health states and parameters used in the model described clearly and are they 
reasonable and appropriate for the NHS?
?
13 Is an appropriate discount rate used? Yes
14 Has the model been validated appropriately? ?
15 Is sensitivity analysis undertaken and presented clearly? Yes
a  Yes/no/? (unclear or partially true).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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T
his appendix describes a critical appraisal of 
the cost-effectiveness section of the Sandoz 
MS. The submission attempts a cost-minimisation 
analysis comparing omnitrope with Genotropin 
(which was defined as the reference product) in 
patients with GHD and TS, rather than a cost-
effectiveness analysis. There is no indication 
that a systematic review of clinical evidence has 
been undertaken. The cost-effectiveness analysis 
according to NICE guidance138 was not presented.
Appraisal of the manufacturer 
cost-effectiveness analysis
A summary of the MS compared with the NICE 
reference case requirements is given in Table 62.
Summary of general concerns
The MS did not comply with NICE’s recommended 
structure138 and did not estimate QALYs or present 
cost-effectiveness analysis. The MS attempted a 
cost-minimisation analysis, implicitly suggesting 
that treatment with omnitrope is equally effective as 
treatment with Genotropin (in terms of additional 
height in children with GHD and TS), but is 
associated with less cost to the NHS. Due to the 
number of uncertainties it is not clear whether this 
assertion is justified. In particular, there was limited 
clinical efficacy data to support the non-inferiority 
of omnitrope compared with Genotropin. The only 
head-to-head RCT comparing omnitrope with 
Genotropin was of insufficient duration and might 
not have been designed as a non-inferiority trial. 
Appendix 10  
Critical appraisal of Sandoz 
MS (cost-effectiveness)
TABLE 62  Assessment of Sandoz submission against NICE reference case requirements
NICE reference case requirements Included in submission
Decision problem: as per the scope developed by NICE ×a
Comparator: no treatment alternative ×a
Perspective on costs: NHS and PSS b
Perspective on outcomes: all health effects on individuals ×c
Type of economic evaluation: cost-effectiveness analysis ×
Synthesis of evidence on outcomes: based on a systematic review No evidence synthesis
Measure of health benefits: QALYs ×
Description of health states for QALY calculations: use of a standardised and validated 
generic instrument
×
Method of preference elicitation for health state values: choice based method (e.g. TTO, 
SG, not rating scale)
×
Source of preference data: representative sample of the public ×
Discount rate: 3.5% p.a. for costs and health effects ×
 , yes; ×, no.
a  Scope states that rhGH (somatropin) be compared with no treatment alternative. The cost comparison includes only 
omnitrope and Genotropin.
b  Only costs of pharmaceuticals omnitrope and Genotropin are included in cost comparison.
c  The MS does not include an economic evaluation according to the NICE guidance. Patient outcomes (either observed 
or the final outcomes) are not included in the health economics part of the MS.Appendix 10
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The MS did not include any clinical evidence in 
relation to licensed indications other than GHD. 
Without clinical evidence that unequivocally 
demonstrated the non-inferiority of omnitrope in 
comparison with Genotropin, the results of a cost-
minimisation analysis cannot be confirmed.
The results of the cost comparison reported in the 
MS were not comparable with the results of cost-
effectiveness analysis reported in the submissions 
by Pfizer, Eli Lilly, Ipsen, Novo Nordisk and Merck 
Serono because Sandoz have not presented results 
either as an estimated incremental cost per QALY 
or as an incremental cost per extra centimetre 
gained, and the reported cost was neither a lifetime 
cost nor the cost per duration of treatment (until 
near-adult height is achieved).DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
203
T
he Health Survey for England database was 
reanalysed in a similar way to Christensen and 
colleagues for adults aged older than 18 years. 
The HSE 2003 contains variables for height 
(estht) and EQ-5D (eqmean). Incomplete records 
were omitted. For those with complete records 
(n = 13,321), the HSE 2003 data had mean AH for 
males of 175 cm (SD 7.2) and mean AH for females 
of 161 cm (6.8). There were 50 observations less 
than –3 SDS or greater than 3 SDS (i.e. 0.4%) and 
617 observations less than –2 SDS or greater than 2 
SDS (4.6%).
An analysis was completed to see the effect of 
different ages on QoL scores using a subset of 
people of age 18–49 years and over 50 years old. 
QoL score for all ages was 0.86; age 18–49 years 
QoL had mean 0.91 (SD = 0.18); and age 50+ 
years QoL had mean 0.8 (SD = 0.26). The QoL 
in the younger category was significantly better 
than for the older category and so it is logical to 
estimate the EQ-5D for each of these age groups.
There were few individuals in the SDS < –3 group 
and the estimates are highly variable. In addition, 
the majority of these individuals are in the older 
age group (mean age 72 years). It is therefore more 
logical to fit the distribution to all data and use this 
in the model.
Appendix 11  
Quality of life from HSE 2003
TABLE 63  Frequency of individuals at different ages and HtSDS 
in HSE 2003
SDS
Age 18–49 years Age 50+ years
n Eqmean n Eqmean
< –3.0 5 0.85 24 0.63
–3 to < –2.5 6 0.75 62 0.70
–2.5 to < –2.0 42 0.88 161 0.73
–2 to < –1.5 140 0.85 397 0.78
–1.5 to < –1.0 475 0.91 798 0.79
–1.0 to <–0.5 845 0.90 1133 0.78
–0.5 to < 0 1331 0.90 1288 0.82
0 to < 0.5 1485 0.91 1029 0.81
0.5 to < 1.0 1288 0.91 707 0.83
1.0 to < 1.5 837 0.91 368 0.84
1.5 to < 2.0 431 0.91 152 0.85
2.0 to < 2.5 201 0.92 41 0.84
2.5 to < 3.0 42 0.89 12 0.83
> 3.0 20 0.98 1 0.90
TABLE 64  Quality of life from fitted values
Age Fitted QoL score
18–49 years –0.0024x2 + 0.0177x + 0.9017
> 50 years –0.0054x2 + 0.0297x + 0.817
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FIGURE 9  Relationship between height (HtSDS) and EQ-5D score for adults aged 18 –50 years in HSE 2003.Appendix 11
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FIGURE 10  Relationship between height (HtSDS) and EQ-5D score for adults aged older than 50 years in HSE 2003.DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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T
he distribution assigned to each variable 
included in the PSA and the parameters of the 
distribution are reported in this appendix.
Health-state utility
The utility increments for HtSDS below –2.0, 
between –2.0 and 0, and above 0 were sampled 
using estimated standard errors. These were 
derived from an assumption that a variation of 
plus or minus 20% was an appropriate CI for the 
average utility gain. No other summary statistic 
was available. These were sampled using a normal 
distribution.
Compliance
The compliance of the model was based on the 
range of 69% to 95% compliance estimated in the 
compliance review conducted by Merck Serono. 
The estimated ‘standard errors’ for compliance 
was derived from this range, as this was thought to 
provide the best estimate of variability due to lack 
of other summary data.
Height standard deviations
The reported mean HtSDSs were taken from 
the applicable RCTs and KIGS data for both the 
treated and untreated groups consistent with 
the base-case analysis. The standard errors were 
calculated for each mean HtSDS, except for PWS, 
for which there was no mean reported; in this 
case a median value was assumed to adequately 
represent the mean. A SD of 1 was used to estimate 
the standard error for PWS. This is consistent 
with the level of dispersion reported for the other 
conditions. The HtSDS were simulated using the 
normal distributions. See Table 67 for mean and 
standard errors for each condition:
Starting age and treatment 
length
The starting age and treatment length were 
sampled using estimated ‘standard errors’. These 
were derived from CIs placed 2 years either side 
of the mean starting age and treatment length. 
This method was used instead of calculating the 
standard errors from the KIGS database. It was felt 
that the very small standard errors from KIGS did 
not reflect the possible variability in starting age 
and treatment length. These were sampled using 
normal distributions.
Childhood drug dose
The means for the childhood drug dose for all the 
conditions were the same as used in the base-case 
analysis. The estimated ‘standard errors’ attempted 
Appendix 12  
Input parameters for probabilistic 
sensitivity analysis
TABLE 65  Health-state utility parameters and distribution
Health-state utility Mean ‘Standard error’
95% CI
Distribution Lower Upper
Below –2 HtSDS 0.061 0.0061 0.049 0.730 Normal
Between –2 and 0 HtSDS 0.010 0.0010 0.008 0.120
Above 0 HtSDS 0.002 0.0002 0.0016 0.0024
TABLE 66  Compliance parameters and distribution
Mean ‘Standard error’ Alpha Beta Distribution
Compliance 0.85 0.085 14.150 2.497 BetaAppendix 12
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TABLE 67  HtSDS parameters and distribution
Condition HtSDS Mean Standard error Distribution
GHD Treated baseline –2.99 0.0134 Normal
Treated end –1.17 0.0216
Untreated baseline –2.99 0.0134
Untreated end –2.99 0.0216
TS Treated baseline –3.40 0.1152
Treated end –1.80 0.0206
Untreated baseline –3.40 0.1220
Untreated end –3.10 0.2294
PWS Treated baseline –2.00 0.2000
Treated end –0.50 0.2085
Untreated baseline –2.50 0.2132
Untreated end –2.60 0.2182
CRI Treated baseline –2.90 0.1214
Treated end –1.60 0.1925
Untreated baseline –2.90 0.0994
Untreated end –2.90 0.1525
SGA Treated baseline –3.10 0.0700
Treated end –2.30 0.0840
Untreated baseline –3.10 0.0729
Untreated end –3.00 0.0894
SHOX-D Treated baseline –3.30 0.1925
Treated end –2.10 0.0385
Untreated baseline –3.30 0.1600
Untreated end –3.00 0.0408
TABLE 68  Starting age and treatment length parameters and distribution
Mean ‘Standard error’
95% CI
Distribution Lower Upper
Starting age
GHD 9.0 1.020 7.0 11.0 Normal
TS 10.0 1.020 8.0 12.0
PWS 7.0 1.020 5.0 9.0
CRI 9.0 1.020 7.0 11.0
SGA 8.0 1.020 6.0 10.0
SHOX-D 8.0 1.020 6.0 10.0
Treatment length
GHD 7.0 1.0200 5.0 9.0 Normal
TS 6.0 1.0200 4.0 8.0
PWS 8.0 1.0200 6.0 10.0
CRI 5.0 1.0200 3.0 7.0
SGA 6.0 1.0200 4.0 8.0
SHOX-D 7.0 1.0200 5.0 9.0DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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TABLE 69  Childhood drug dose parameters and distribution
Childhood dose Mean ‘Standard error’
95% CI
Distribution Lower Upper
GHD 0.025 0.00255 0.020 0.030 Normal
TS 0.045 0.00255 0.040 0.050
PWS 0.035 0.00255 0.030 0.040
CRI 0.045 0.00255 0.040 0.050
SGA 0.035 0.00255 0.030 0.040
SHOX-D 0.040 0.00255 0.040 0.050
to express the appropriate variability of doses used 
in the KIGS database and also the maximum doses 
suggested in the BNF. These were sampled using 
normal distributions.
Proportion of males
The reported mean proportion of males for each 
condition was taken from the KIGS database for 
both the treated and untreated groups. This was 
consistent with the base-case analysis. The standard 
errors were calculated for each mean proportion of 
males and sampled using a normal distribution.
Costs
Costs included in the PSA were those related 
to outpatient visits, nurse visits and monitoring 
tests. Drug costs were not varied in the PSA, but 
were included at values quoted in the BNF. Costs 
derived from NHS Reference Costs were sampled 
using estimated ‘standard errors’. These assumed 
that a variation of plus or minus 25% was an 
appropriate CI for the average reference costs. The 
estimated standard errors are shown in column 3 
of the Table 71. Parameters for gamma distributions 
(shown in columns 4 and 5) were derived using 
the means and estimated ‘standard errors’. The 
simulated values were inflated to 2008–9 prices 
using appropriate inflation indices, as for the base-
case and deterministic sensitivity analyses.
TABLE 70  Proportion of males parameters and distribution
Proportion of males Mean Standard error Distribution
GHD 0.70 0.0100 Normal
TS 0.00 0.0000
PWS 0.50 0.0045
CRI 0.71 0.0040
SGA 0.596 0.0032
SHOX-D 0.48 0.0019
TABLE 71  Costs parameters and distribution
Item Mean ‘Standard error’ Alpha Beta Distribution
Outpatient (first) 206.28 24.57 126.07 1.64 Gamma
Outpatient (subsequent) 127.97 11.40 126.07 1.02
Specialist nurse 73.00 6.50 126.07 0.58
District nurse 64.00 5.70 126.07 0.51
Blood test 51.00 4.54 126.07 0.40
X-ray 28.64 2.55 126.07 0.23
Pituitary function test 246.50 21.95 126.07 1.96DOI: 10.3310/hta14420  Health Technology Assessment 2010; Vol. 14: No. 42
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Appendix 13  
Weight tables for males and females 
by age (Western Europe KIGS)
Age 
(years)
Weight (kg)
SGA GHD PWS CRI TS
Male Female Male Female Male Female Male Female Female
0 4.00 3.0 6.01 5.63 4.00 3.00 4.00 3.00 3.00
1 6.00 5.7 8.40 7.96 9.41 8.37 8.14 6.60 7.03
2 8.07 8.48 10.18 9.81 10.96 10.15 10.42 9.60 10.19
3 10.10 10.04 12.18 11.98 14.48 12.08 12.39 11.77 11.91
4 11.13 11.39 13.97 13.63 17.67 15.92 14.26 13.13 13.80
5 13.63 13.62 15.72 15.41 20.55 20.00 16.24 15.22 15.56
6 15.58 15.79 17.79 17.49 23.37 23.18 17.98 18.15 17.67
7 17.96 17.86 20.15 19.76 26.96 26.64 20.14 19.33 20.20
8 20.06 19.86 22.76 22.41 31.48 29.42 22.42 21.47 23.14
9 22.27 22.45 25.4 25.42 35.82 33.94 24.92 23.41 26.57
10 24.93 24.83 28.5 28.79 40.95 41.24 27.49 26.42 30.04
11 27.73 28.52 31.74 32.02 44.46 44.29 30.49 30.17 34.05
12 31.08 31.71 35.00 35.99 51.70 47.49 34.08 34.78 38.47
13 34.53 35.36 39.28 40.26 57.96 52.80 37.43 37.27 42.33
14 38.89 38.22 44.40 44.19 63.80 56.84 41.15 39.80 46.00
15 44.33 40.27 49.91 47.72 69.02 59.07 44.84 41.03 49.05
16 49.04 43.05 54.47 49.97 74.43 56.32 48.70 41.15 51.47
17 53.50 47.03 58.5 53.38 74.14 61.15 50.4 42.66 52.53Health Technology Assessment reports 
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Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.